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Best Full Member Abstract
Assessment of Complexity Among Cancer, Cardiovascular, General
Pediatric/Adult, and Prenatal Genetic Counseling at a Single
Institute: A Tool to Improve Efficiencies and Help Guide Patient
Volumes
A. Schreiber1, B. Heald Leach1, L. Rybicki1, D. Clements1, J.
Marquard1, J. Mester1, M. Nardini1, R. Noss1, J. Polk1, B. Psensky1,
C. Rigelsky1, A. Shealy1, M. Smith1, C. Eng1
1. Cleveland Clinic
Increasing demand for genetic counseling necessitates efficiency in prac-
tice. However, distinct differences exist between various disciplines of
genetic counseling, making it difficult to establish standardized practice
methods and patient volume expectations. Genetic counselors (GCs) at
Cleveland Clinic developed a data collection tool to track time and 69
activities related to pre-visit, in-person, and post-visit care as well as
referral indications. The practice provides cancer, cardiovascular, general,
and prenatal services. We hypothesized that the general practice had
greater complexity, and thus higher time requirements, than the other
three specialties. Over a 6 week period, 12 GCs prospectively tracked
data, encompassing 583 patient visits (252 cancer, 103 cardiovascular,
136 general, and 92 prenatal). Data were analyzed comparing general
versus specialist GCs. Variables were compared with hierarchical linear
models for ordinal or continuous data and hierarchical logistic models for
binary data. Descriptive statistics were also utilized. The number of pa-
tients seen weekly/1 FTE was: 14.7 (cancer), 8.6 (cardiovascular), 7.3
(general), and 11.8 (prenatal). General GCs completed more pre- and
post-visit activities (p=0.011) and spent more time (p=0.009). General
GCs reported higher case discussion with other providers (p<0.001), lit-
erature review (p=0.026), testing option research (p=0.041), electronic
medical record review (p=0.040), insurance pre-authorization (p=0.05),
and patient inquiries (p=0.003). Greater redundancy of referral indica-
tions was observed by specialty GCs; 66 % of cancer, 44 % of cardio-
vascular, and 50 % of prenatal patients were referred for 1 of 2 common
indications, compared to 16 % of general patients. Establishing patient
volumes is a balance between creating access and providing comprehen-
sive care and should include consideration of specialty and variety of
indications for referral. These data demonstrate that general GCs may
require lower patient volumes than other specialties to allow time for
additional pre-/post-visit activities.
Beth Fine Kaplan Best Student Abstract
Assessing Current Practices in Prenatal Genetic Counseling
Regarding a Prenatal Diagnosis of Down Syndrome. Phase II: What
Does Client-Centered Counseling Look Like in Practice?
A. Yragui1, M. Marvin2, E. Moe3, K. Berrier4, B. Yashar2
1. Perinatal Associates of New Mexico
2. University of Michigan
3. Children’s Hospital of Wisconsin
4. Duke University Medical Center
Recent discourse surrounding Down syndrome prenatal testing emphasizes
the need for communicating balanced, up-to-date information. The 2011
NSGC BPractice Guidelines for Communicating a Prenatal or Postnatal
Diagnosis of Down syndrome^ supported genetic counselors in this endeav-
or. Our group’s previous work found that counselors discuss the guidelines’
essential concepts almost always while frequency of discussion of lived
experience (LE) concepts was most variable. This follow-up study focused
on a deeper understanding of factors that contribute to practice guidelines
deviations, specifically related to LE discussions. Participants self-identified
at completion of our group’s 2014 quantitative survey (N=45) were stratified
into 3 groups according to their average discussion frequency (high, average,
low) of LE concepts. Semi-structured interviews (N=8) focused on 3 sce-
narios in which a patient was seen in-person for a prenatal diagnosis of
Down syndrome and was (1) unsure, (2) planning to terminate or (3) plan-
ning to continue the pregnancy. Questions focused on what counselors did/
did not communicate regarding the diagnosis and their rationale. Transcripts
were independently coded holistically by 3 group members in an iterative
process to identify process-related codes. The group coalesced the codes into
themes related to the study objective. Counselor considerations of patients’
needs and desires for information were the most significant contributors to
deviation from the guidelines during a prenatal Down syndrome diagnosis
session. In particular, counselors’ concerns about overwhelming the patient
and being perceived as unsupportive were recurrent. Our results suggest that
genetic counselors strive for a client-centered approach by prioritizing
both patients’ explicit and implicit informational wants and needs
over providing comprehensive information for a prenatal diagnosis
of Down syndrome. Deviations from the guidelines were a
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consequence of heightened counselor self-awareness regarding a
potential negative impact of information giving on the patient.
Platform Presentations
I. Access and Service Delivery I
Psychiatric Genetic Counseling: A Practice Model from the World’s
First Clinic
A. Inglis1, E. Morris2, D. Koehn1, E. Stewart2, A. Lehman2,3, J.
Austin2
1. Provincial Health Services Authority
2. University of British Columbia
3. Vancouver General Hospital
In February 2012, the world’s first specialist psychiatric genetic counseling
(GC) clinic opened in Vancouver, Canada as a direct result of research,
which had demonstrated the benefits of and the need for GC for this
population. Genetic counselors (GCl) and other healthcare professionals
(HCP) from around the world have come to train at this clinic, indicating
the emerging need for a practicemodel for psychiatric GC.Here, we define
the model of practice for psychiatric GC services that has been established
in British Columbia, based on prioritization of patient outcomes as the
benchmark metrics for value/success. The clinic’s one full-time GCl is
supervised by a PhD psychiatric geneticist/GCl, supported by a 0.2 full
time equivalent clinical secretary (who assists with bookings), and has
access to consult with a geneticist and a psychiatrist. The GCl: obtains
family histories prior to appointments (45min), provides GC by telephone,
telehealth or in person (at base location or at outreach sites, 100 min);
follows up with all patients 1 month after GC (20 min), completes detailed
consult reports to referring HCP, and participates in bi-weekly peer-super-
vision. Full case-load given these activities is 5 patients per week. Learners
are present at appointments for 5 months of the year. The clinic accepts
self-referrals and referrals from anyHCP.Medical records are not routinely
sought to confirm diagnoses, instead the GCl trained in psychiatric
interviewing to elicit high quality personal and family mental health his-
tories. For patients where a genetic syndrome is suspected, the GCl ad-
dresses psychiatric concerns before referring to a geneticist for an assess-
ment and possible genetic testing. An evaluation of patient outcomes after
the clinic’s first year demonstrated significant increases in empowerment
and self-efficacy 1 month post GC, showing that this practice model is
effective. In describing the practice model, we aim to allow other services
to be informed based on the model we have established.
A Novel Genetic Counseling Service Delivery Model
in a Pediatric/General Genetics Clinic Setting
C. Harper1
1. Beaumont Health, Royal Oak, MI
A novel genetic counseling service model in a pediatric/general genetics
setting is presented whereby the genetic counselor (GC) and the physician
(evaluation andmanagement [E/M]) portions of the visit are separated into
2 distinct visits (referred to as the GC visit and the E/M visit, respectively).
In this new model, patients are seen first by the GC with the E/M visit
occurring at a later date; a GC visit is required prior to any E/M visit. We
began incorporating this system in April of 2014, with full implementation
by the end of 2014. This newmodel has increased access to our services by
decreasing the wait times for an initial visit from 4 (or more) months to
2 months, allowed for triage at the GC visit rather than by phone, and
allowed more flexibility in scheduling appointments for both services. In
addition, physician time is used more efficiently, as some patients have
only required GC visits and the E/M visits are shorter in duration. This
change allows the physician to see more patients or attend to other clinical
activities without increasing the overall clinic time. Lastly, because the GC
visit does not involve a physical examination, minor patients do not need
to attend this visit; this has been especially helpful to families with young
children (who distract the parents) and in older children (whose families do
not wish to take them out of school). Disadvantages in this model include
added costs to the patient/family (since insurers generally have not covered
the GC visit) and the inconvenience of having 2 appointments rather than
one. Overall, this model has been well received by patients and providers
and provides a means to increase access and efficiency in genetics clinics.
Role for Genetic Counselors in Creating Clinical Decision Support
Messages for Genomic Results
S. Aufox1, M. Smith1
1. Northwestern University
It is anticipated that as the cost of genomic sequencing decreases, there will
be an increase in the use of genomic testing. While studies have shown that
many genetic counselors believe that they should be involved in pre/post-
test discussions as well as reporting genomic results, the current model for
providing genetic counseling for genomic testing is neither practical nor
scalable. Furthermore, it is speculated that most of these tests will be or-
dered by clinicians without the involvement of genetic counselors. There
are concerns about how genomic results will be used and understood by
clinicians, since many clinicians are not knowledgeable about, or comfort-
able with, conveying the issues surrounding genomic information to their
patients. Using Clinical Decision Support (CDS) messages in the electronic
health records (eHR) can assist clinicians with the clinical application of
genomic results. CDS messages, which are designed to improve clinical
decision making, are becoming a useful tool in patient care and are an area
where genetic counselors can assist clinicians to use and understand geno-
mic test results. Messages can be triggered based on specific test results or
patient characteristics, and have been shown to improve clinician perfor-
mance. Genetic counselors are perfectly positioned to create content and
recommendations for genomic-related CDS messages. Genetic counselors
at Northwestern University, together with a team that included eHR pro-
grammers, designed messages and recommendations tailored to specific
pharmacogenomic and genomic results. These messages triggered during
patient appointments or when prescribing medications, and were accessible
through a sidebar menu in the eHR. The genetic counselors monitored
issues that arose during the CDS rollout and made adjustments to help
clinicians better manage results. With the healthcare focus shifting to pre-
cision medicine and personalized patient care, genetic counselors can be a
key player in assisting clinicians to use genomic information by being
involved with CDS development and application.
Leveraging Data to Provide Financial Justification for Additional
GC FTE and Resources: Turning a Pilot into Reality
J. Conta1, D. Sternen1, S. Stasi1, M. Wellner1, L. Wick1, M. L.
Astion1,2
1. Department of Laboratories, Seattle Children’s Hospital
2. Department of Lab Medicine, University of Washington
As part of Seattle Children’s laboratory utilization management (UM)
program, an institutional policy requiring preauthorization for all genetic
tests was implemented in 2012. However, a clear process to carry out the
policy was not defined. Despite dedicated hospital resources, including
insurance processing specialists, genetic nurses, and clinical and
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laboratory genetic counselors (GCs), a typical test preauthorization request
takes many months to complete and involves unnecessary communication
hand-offs. We hypothesized that early involvement of a laboratory GC in
the preauthorization process would lead to improved turn-around time,
reduced staff/provider frustration, and would ensure the correct genetic
test variables were submitted with the authorization request, including
robust medical necessity documentation. A 5-week pilot was conducted
in October 2014 using an electronic preauthorization communication order
and laboratory GC involvement to facilitate efficient submission of neces-
sary and correct data to the insurance processing specialists. Time studies
were conducted to capture baseline and pilot metrics. The average request
turnaround time was halved for the 99 requests submitted during the pilot.
There were measureable reductions in collective provider and staff time
and rework related to the process. Using this data, we estimated staffing
requirements for pilot expansion. A business proposal submitted to hospi-
tal leadership included estimates of cost-savings associated with having
the right person doing the right work (optimize qualifications), cost-
avoidance of preauthorization work related to inappropriate/unnecessary
requests, and cost-avoidance related to prevention of inappropriate/
unnecessary tests. The improved efficiencies and quality related to use of
a laboratory GC in a standard process result in sufficient cost-savings to
justify the additional FTE required for pilot expansion. A phased expan-
sion of the new genetic testing preauthorization process is proposed, with
plans to hire additional FTE to support full expansion.
Partnering with Patient Services Associates to Streamline Insurance
Authorization Requests for Genetic Testing
W. Uhlmann1, K. Schwalm1, D. Grzeskowiak1, V. Raymond2
1. University of Michigan
2. Illumina
Introduction: Genetic testing insurance coverage varies by insurer,
plan, and hospital contracts. Ascertaining coverage is a multi-step
process, often requiring genetic counselors’ (GCs) input and time.
Given the increasing use of genetic testing, our goal was to de-
velop a streamlined work-flow for obtaining insurance authoriza-
tion, including delegation of tasks from GCs to patient services
associates (PSAs). Methods: The University of Michigan Cancer
Genetics and Medical Genetics Clinics partnered with an industri-
al engineer to map the genetic testing authorization process. The
industrial engineer observed and interviewed our clinics’ PSAs
and GCs and then together we brainstormed ways to increase
efficiency, decrease redundancy, and reassign tasks. Results: This
evaluation identified tasks that could be completed by PSAs and
the following work-flow changes were made: 1) instituted having
PSAs send a pre-clinic email to the GCs noting for each patient
whether genetic testing was a covered benefit, needed pre-
authorization or coverage would be decided after testing 2) creat-
ed a shared database where GCs enter genetic test information
needed by the PSAs to request authorization and the PSAs record
when the request was made and outcome 3) instituted including
the information needed by insurers to determine genetic testing
coverage in the clinic visit summary letter, eliminating the need
for a separate letter of medical necessity and 4) instituted PSAs
contacting patients about insurers’ decisions. As a result of these
changes, time is not taken during clinic to ascertain patients’
genetic testing coverage and the PSAs are responsible for insur-
ance authorization requests. Utilization of the shared database has
notably reduced GCs/PSAs emails and phone calls. Conclusion:
Workflow changes instituted through GC partnership with the in-
dustrial engineer and PSAs made it more efficient to request and
track genetic testing insurance authorizations, enhanced communi-
cation, and reduced tasks done by genetic counselors.
Genetic Counselors are Underutilized in Their Professional
Capacities
V. Raymond1, J. Everett2, J. Long3, K. Milliron2, M. Marvin2, S.
Gruber4
1. Illumina
2. University of Michigan
3. University of Pennsylvania Health System
4. University of Southern California
Introduction: The demand for certified genetic counselors (CGCs) con-
tinues to rise, especially with the increasing availability of genetic tests,
and recognition of the importance of genomic information in medical
care. As the genetic counseling workforce strives to meet these demands,
we must consider appropriate utilization of the skills and expertise of
CGCs. Methods: Five cancer CGCs in a large academic center underwent
a 4-week beeper time study with the goal of obtaining two work weeks of
data per CGC. Prior to initiation of the beeper time study, CGCs were
queried about daily tasks and a 29-item categorical task worksheet was
developed. Beepers were programmed for random alerts, multiple times
throughout the workday; for each alert, CGCs recorded the type of task
being performed. Results: 373 total hours were documented over the
study period. On average, full time CGCs recorded 89.5 hours each and
the part time CGC recorded 15.0 hours. Of the total recorded time, 11 %
was spent in Bpre-clinic work^ (related to next upcoming clinic day),
18 % was spent in clinic, and 22 % was spent in Bpost clinic work^
(related to most recent clinic day). The largest percentage of time,
49 %, was spent doing Boffice work^ which included organizing and
filing, printing/faxing and copying, triaging phone calls and patient
scheduling. Conclusion: This time study identified multiple areas of un-
derutilization of CGCs, with 49 % of time spent on Boffice work^ that
could be delegated to administrative staff, genetic counseling assistants,
or student workers. Offsetting these types of tasks to non-CGCs will
allow for more time in direct patient care and professional collaborative
roles, thus creating the potential to increase clinic volume and reduce
appointment wait time. Undertaking a time study provides systematic
collection of data which can successfully document the need for admin-
istrative staff in an effort to maximize efficiency and appropriate utiliza-
tion of CGCs.
II. Clinical Care: Cancer
Hereditary Hematological Malignancies: A Hereditary Leukemia
Clinic, One Year in Review
S. Bannon1, C. DiNardo1
1. The University of Texas MD Anderson Cancer Center
Introduction: Long considered sporadic, hematologic malignancies have
rarely been targets for genetic evaluation, even in familial cases. Evidence
suggests >10 % of individuals with blood cancers have >=1 first-degree
relative with blood cancer, suggesting familial predisposition. Surveil-
lance protocols for these likely under-diagnosed families are not well-
established. Many families with increased incidences of hematologic ma-
lignancies do not have currently described syndromes, suggesting addi-
tional causative genes remain to be identified. Methods: To identify these
individuals, a hereditary leukemia clinic was established. Staffed by a
leukemia medical oncologist and genetic counselor, the clinic offers ge-
netic counseling, clinical, and research testing for individuals suspected to
have predispositions to hematologic malignancy. Over 13 months, 56
individuals were evaluated. Skin biopsies were performed for those with
active hematologic malignancy or status-post bone marrow transplant.
Further evaluation of families was initiated utilizing next-generation se-
quencing on a whole exome sequencing protocol. Results: Genetic testing
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was performed in 35/56 individuals (62.5%). 19/56 (34%) were enrolled
in a whole exome sequencing protocol if negative for known susceptibil-
ity genes or not suggestive of a described syndrome. Two (3 %) did not
undergo any testing. 18/35 who underwent clinical testing (51 %) were
tested based on somatic alterations concerning for germline mutations.
Testing identified 9/56 (16%)with germline susceptibility to hematologic
malignancy. 6/56 (11 %) had RUNX1 mutations; one harbored a novel
mutation. One individual (2 %) with myelodysplastic syndrome and pul-
monary fibrosis was identified to have dyskeratosis congenita but did not
meet diagnostic criteria. Two (3.5 %) were identified to have Li-Fraumeni
syndrome. Conclusions: Individuals with hereditary susceptibilities to
hematologic malignancies are not as rare as previously thought. Clinical
evaluation of these patients through genetic counseling and testing is high
yield for identifying at-risk families.
Preliminary Results of Expanded Hereditary Cancer Panel Testing:
Is More Always Better?
J. Guiltinan1, J. Dolinsky1, R. McFarland1, J. Thompson1, H.
Laduca1, S. Li1, C. Horton1
1. Ambry Genetics
CancerNext (CN) includes 28 genes associated with hereditary melano-
ma, breast, ovarian, uterine, pancreatic, and colon cancer. CancerNext-
Expanded (CN-E) includes 15 additional genes, as it was developed to
also encompass paraganglioma/pheochromocytoma and renal cancer.
Here we sought to determine if the inclusion of these genes would im-
prove diagnostic yield of CN-E compared to CN and to assess the phe-
notypes of the CN-E positive patients. Between July 2014 and
March 2015, 1,270 individuals were tested with CN-E. Positive and var-
iants of uncertain significance (VUS) rates were compared to CN results
from 8,058 individuals tested between March 2012 and March 2015.
Clinical data reported by ordering providers was assessed for patients
with positive CN-E results. Out of the 1,270 individuals tested with
CN-E, 150 had a positive result and 547 had at least one VUS. 26 positive
individuals had alterations in CN-E only genes, 14 of whom did not have
a personal or family history that would have prompted further testing for
these genes. Five of 26 positive results represent atypical mutations in-
cluding one moderate risk RET mutation and 4 FH mutations associated
with autosomal recessive fumarate hydratase deficiency rather than can-
cer predisposition. The overall positive rate was similar for CN-E and CN
(11.8 % and 11.7 % respectively), however the VUS rate was significant-
ly higher for CN-E (43.1 % vs. 32.7 %; p-value = 2.16×10–13 using 2-
sample test for equality of proportions). The diagnostic yield of CN-E is
not improved compared to CN. This may be because the genes exclusive
to CN-E correspond to rare distinct tumor types, or may be a reflection of
a more complex phenotype in patients undergoing CN-E. The relatively
low number of individuals found to have mutations in CN-E only genes
without suggestive family history (1.1 % of total tested) indicates that the
utility of CN-E is most evident in individuals with a personal or family
history consisting of a broad spectrum of tumors, including those associ-
ated with genes excluded from CN.
Incidence and Spectrum of Germline Mutations
in Cancer-Predisposing Genes in Children with Cancer: A Report
from the Pediatric Cancer Genome Project
R.Nuccio1, J. Zhang1,M. F.Walsh1, G.Wu1,M.N. Edmonson1, T. A.
Gruber1, R. B. McGee 1, S. Hines-Dowell1, E. Quinn1, S. A.
Shurtleff1, D. W. Ellison1, C. H. Pui1, A. Gajjar1, A. Pappo1, K. E.
Nichols1, J. R. Downing1
1. St. Jude Children’s Research Hospital
Background: The incidence and spectrum of germ line mutations in
cancer-predisposing genes in pediatric oncology patients remains poorly
defined. The presence of these mutations has important implications that
influence cancer treatment and surveillance for patients and their families.
Methods: To gain insights into the frequency and range of cancer predis-
posingmutations, we analyzed the germ line and tumor genomes of 1,120
pediatric oncology patients by whole genome and/or exome approaches.
Mutations were assessed among 565 cancer-associated genes, including
60 clinically relevant autosomal dominant and 29 autosomal recessive
cancer predisposition genes. Mutations were classified as pathologic or
likely pathologic based on comparison to cancer gene and locus specific
mutation databases, in silico analyses and literature review. Results:
Across the clinically relevant cancer predisposition genes analyzed, path-
ogenic or likely pathologic mutations were identified in 96 patients
(8.6 %), with TP53 (n=48), APC (n=7) and BRCA2 (n=6) representing
the most frequently mutated genes. A single patient was identified with
bi-allelic ATM mutations. Four patients exhibited germline mosaicism
with a mutant allele fraction in normal tissue ranging from 10 to 30 %.
Fifty-eight of the 96 patients (60 %) had family history information avail-
able, with 21 (36 %) demonstrating a positive family cancer history.
Conclusions: Germ line mutations in 60 clinically relevant predisposition
genes were found in 8.6 % of pediatric cancer cases. Despite the known
association between germline mutations and familial transmission of can-
cer, family history alone fails to predict the presence of underlying
germline mutations in a substantial proportion (64 %) of patients.
Evaluating the NCCN Clinical Criteria for BRCA1/2Genetic Testing
in Breast Cancer Patients
C. Wu1, M. Daniels2, A. Woodson2, B. Arun2, C. Barcenas2, J.
Litton2, S. Noblin 1, D. Liu2, M. Park2,
1. The University of Texas Health Sciences Center
2. The University of Texas MD Anderson Cancer Center
Hereditary Breast and Ovarian Cancer (HBOC) syndrome predisposes
females with a BRCA1 or BRCA2mutation to an up to 85 % lifetime risk
for breast cancer and an up to 40 % lifetime risk for ovarian cancer. It is
crucial for individuals with HBOC to be identified to allow for proper
screening, management, and identification of at-risk family members in
order to reduce mortality. The National Comprehensive Cancer Network
(NCCN) has established clinical guidelines for when to recommend
BRCA1/2 testing. A retrospective chart review of 1,123 M.D. Anderson
Cancer Center breast cancer patients was performed in order to evaluate
the positive predictive values (PPVs) of 14 individual criterion for
predicting a BRCA1/2 mutation. Two criteria had PPVs significantly be-
low 10 %. Only 2 of 115 patients recommended for testing based solely
on the criterion of Bdiagnosed with breast cancer <=45 years of age^
tested positive for a pathogenic mutation at a PPV of 1.6 % (0.2–6 %,
95 % CI), which is significantly below the clinical utility cut-off of 10 %
(p=0.001). Additionally, 0 out of 37 individuals who underwent testing
based on the criterion, Bdiagnosed with breast cancer at any age with >=2
close blood relatives with breast cancer at any age^ tested positive (0–
9 %, 95 % CI). Overall, an individual who meets more than one criterion
has a PPVof 12 % while those who meet only one criterion has a PPVof
3.52 %, which is significantly below 10 % (p<.0001) for predicting
BRCA1/2 positivity. This data can help provide more personalized risks
and anticipatory guidance for patients in their decision to pursue genetic
testing.
High Frequency of Germline Mutations Among Unselected Patients
Enrolled in a Tumor/Normal Cancer Genomic Sequencing Project
J. Everett1, V. Raymond1, E. Stoffel1, J. Innis1, Y. M. Wu1, D.
Robinson1, P. Vats1, R. Lonigro1, R. Moday1, A. Chinnaiyan1
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1. University of Michigan
Introduction: The MI-Oncoseq project sequences tumor-normal pairs to
identify therapeutic targets. We aimed to understand the germline variant
spectrum in study participants. Methods: Adults (age 18+) with refractory
tumors and children (<= age 25) with all tumor types are study eligible.
Patients meet with a genetic counselor (GC) at the time of consent to the
IRB-approved protocols for discussion of potential secondary germline
findings and collection of a cancer focused pedigree. Germline results are
reviewed for 161 genes involved in cancer pathways, which are catego-
rized and reviewed by the study team, including a GC. Category 1 in-
cludes genes associated with autosomal dominant, high risk cancer syn-
dromes. Category 2 includes genes associated with autosomal dominant,
moderate risk cancer syndromes. Autosomal recessive genes are grouped
separately. Pathogenic/likely pathogenic (P/LP) variants in the 80 catego-
ry 1/2 genes are considered for disclosure. Results: Between August 2011
- October 2014, 463/500 enrolled patients (400 adult, 100 pediatric) com-
pleted sequencing (92.6 %). 1594 total variants (indels, single nucleotide
variants, copy number variants), 631 unique, were identified in category
1/2 genes in 431 patients (mean 3.7 variants/patient). 32 patients had no
category 1/2 gene variants. P/LP variants were identified in 20 category 1
genes in 20 patients (APC, BRCA1/2, BRIP1, DICER1, FH, MLH1,
MSH2, PDGFRB, SBDS, SMARCA4, TP53) and 23 category 2 genes in
23 patients (APC p.I1307K, BAP1, BARD1, CHEK2, HOXB13, MITF,
MYH, PALB2). One patient had P/LP variants in both categories. 255/395
category 1/2 variants of uncertain significance (VUS’s) were not previ-
ously reported in public databases. 1,159 variants were benign. Conclu-
sion: 9.1 % of patients with cancer referred to a tumor-normal sequencing
project, unselected for family history, had a P/LP germline variant asso-
ciated with a high/moderate cancer risk. This finding highlights the im-
portance of prior genetic counseling about potential germline findings in
tumor-normal sequencing and demonstrates the GC role in reviewing and
interpreting results.
The Angelina Jolie Boomerang Effect: How are Things Different
this Time Around?
J. T. Huang1, L. Kiedrowski1
1. UT Southwestern Simmons Comprehensive Cancer Center
The BAngelina Jolie effect^ refers to the rise in awareness and uptake of
genetics services after her 2013 New York Times op-ed about her deci-
sion to undergo genetic testing and (when positive for a BRCA1mutation)
preventive bilateral mastectomy (PBM). This year, Ms. Jolie wrote about
her preventive bilateral salpingo-oophorectomy (BSO). We sought to
explore how individuals made meaning of her decisions. We hypothe-
sized that the public would bemore supportive of her BSO than PBM and
have an increased awareness of genetic counseling and improved genetics
knowledge in 2015 vs. 2013.
We performed a content analysis of the online comments to Ms. Jolie’s
two op-ed pieces for the NewYork Times (2013,N= 624; 2015, N= 544).
Comments represented individuals from 42 states and 37 countries. Two
study team members coded comments for emerging themes (inter-rater
reliability 90 %).
More people reported a personal or family history of a gene mutation,
cancer, or similar surgery in 2013 than in 2015 (18% vs. 14%; p<0.001).
More individuals expressed direct support for Ms. Jolie’s PBM than her
BSO (7 % vs. 2 %, respectively; p<0.05). Consistent themes across both
op-eds included improved education, bravery, the importance of screen-
ing, choice, and not feeling alone or afraid anymore. More comments
discussed risk (p<0.001) and femininity (p<0.01) in 2013. More com-
ments equating knowledge with power appeared in 2015 (p<0.001). Al-
though proportions of comments on problems with access to healthcare/
resources were similar (13 % vs. 15 %), more comments expressed
insurance concerns in 2015 (p<0.001), specifically noting the Affordable
Care Act. Twenty comments mentioned gene patents in 2013, compared
to 1 in 2015 (p<0.001). These results indicate a need for genetic coun-
selors to be aware of overarching current events in healthcare. For each
op-ed, <2% of comments mentioned genetic counseling. There were also
comments demonstrating inaccurate genetics knowledge. This suggests
that there are still improvements to be made in educating the public about
cancer genetics and our profession.
III. Genetic/Genomic Testing
Genetic Testing for Hereditary Cancer Predisposition: The Impact
of the Number of Tests Presented and a Provider Recommendation
on Decision-Making Outcomes
M. Barr1, W. Klein2, C. Haakonsen3, D. Roter4
1. Genomics Medicine Institute, Geisinger Health System
2. National Cancer Institute, National Instutes of Health
3. The Harvey Institute for Human Genetics, Greater Baltimore Medical
Center
4. Johns Hopkins University Bloomberg School of Public Health
Objective: The abundance of genetic testing options raises questions for
genetic counselors when deciding which tests to offer and how to offer
them. The objective of this study was to examine how the presentation of
a choice can influence clients’ decisions about genetic testing for
inherited cancer predispositions. Specifically, we wanted to explore
how the number of options and the addition of a personalized clinician
recommendation might influence the likelihood of a client choosing to
undergo genetic testing, the genetic test chosen, and whether the test
chosen is consistent with a participants’ preferences about the informa-
tional tradeoffs of addingmoderate penetrance genes to a panel.Methods:
An online hypothetical vignette study was completed by 454 people from
the National Institutes of Health healthy volunteers database. Each par-
ticipant was randomized to receive one of two survey versions which
differed between a parallel or sequential presentation of testing options
and the timing of the provider recommendation. Regression analyses
were performed to determine the relationships between the choice pre-
sentation and participants’ test decisions. Wilcoxon rank-sign tests were
used to determine the impact of a provider recommendation on final
genetic testing choices. Results: Participants were more likely to choose
to undergo genetic testing when presented with three options instead of
two (OR: 2.00 p=0.014). This effect was no longer observed when indi-
viduals who had decided not to undergo testing were presented with a
third option (OR: 0.90 p=0.775). The addition of a provider recommen-
dation did not significantly change the options chosen at a group level
(p=0.746). However, individual participants were more likely to choose
the test most consistent with informational preferences after a personal-
ized recommendation (p<0.001). Conclusions: Participants are more like-
ly to undergo genetic testing when presented with more options. They are
also more likely to select an option in line with their own informational
preferences following a clinician recommendation based on this
preference.
Characterizing Personal Utility: A Systematic Literature Review
J. Kohler1, B. Biesecker2
1. Johns Hopkins University/National Human Genome Research Insti-
tute, National Institutes of Health
With the advancement of sequencing technologies that are faster and
more cost-effective, the landscape of genomic medicine has shifted from
a diagnostic to a preventive testing paradigm. One result of this shift is
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that researchers and clinicians have recognized patient benefits of geno-
mic testing results that are distinct from accepted clinical benefits. Non-
clinical benefits have been termed Bpersonal utility.^ Evidence of antici-
pated and experienced non-clinical benefits has been described in the
literature inconsistently. Clearer understanding of the concept of personal
utility will be important to evaluating the overall benefits of genome
sequencing. The purpose of this study was to systematically review the
literature to elucidate specific outcomes of genomic testing that comprise
personal utility. An initial search returned 332 abstracts: 49 papers were
read in full and 11 studies met the predetermined inclusion/exclusion
criteria. Studies were both quantitative and qualitative in design conduct-
ed on various types of genomic testing from single-gene disorders to
whole exome/whole genome sequencing for rare or complex disease.
Meta-analysis of the study outcomes identified eighteen distinct concepts
that fall into four domains: affective wellbeing, cognitive understanding,
practical application, and social effects. Three domains were comprised
of five concepts and the practical domain contained three concepts. Re-
sults from this review reveal a broader scope of patient-reported non-
clinical outcomes. Each concept was reported in an average of three of
the eleven studies (mean: 2.78, mode: 6). The concepts expand on previ-
ously reported outcomes of genetic testing, to include spiritual wellbeing
and change in identity, among others. In a future study, the 18 concepts
will be used to inform a Delphi study of participants in genome sequenc-
ing research to generate consensus data on the scope of personal utility.
The ultimate goal of these efforts is to generate a comprehensive defini-
tion of personal utility.
Variant Sign-out Practices for Exome and Genome Sequencing
Results: Current Roles of Genetic Counselors
L. Amendola1, J. O’Daniel2, V. Raymond3, H. McLaughlin4, G.
Jarvik5, R. Heidi6
1. University of Washington
2. University of North Carolina at Chapel Hill
3. Illumina
4. Partners Laboratory for Molecular Medicine
5. University of Washington
6. Harvard Medical School and Partners Laboratory for Molecular
The nature of diagnostic exome and genome sequencing necessitates
significant post-test variant interpretation to determine which variants, if
any, meet the threshold for disclosure. This process of variant interpreta-
tion, sign-out and subsequent reporting has resulted in new and evolving
genetic counselor roles. This work summarizes survey responses on var-
iant sign out practices for exome and genome sequencing tests at nine
CLIA certified research laboratories and ten clinical laboratories. At 4/10
clinical and 4/9 research laboratories, genetic counselors perform the
primary analysis of bioinformatically filtered variants to identify an eti-
ology of disease. Similarly, genetic counselors at both clinical (6/10) and
research (3/9) laboratories perform the initial evidence gathering and
review of individual variants. All 19 clinical and research laboratories
include genetic counselors in multidisciplinary committees to discuss
variants being considered for return. Genetic counselors are also involved
in the development of the test report. In general, more clinical laboratories
(7/10) than research laboratories (2/9) have genetic counselors write the
initial draft of the report; however, this difference is only marginally
significant (Fishers test p=0.07). When there is a second review of a case
prior to sign out, genetic counselors are involved in reviewing and editing
the report at both clinical (4/5) and research laboratories (2/4). The roles
of genetic counselors in the process of variant sign out of exome and
genome sequencing tests vary depending on the laboratory. The integra-
tion of genetic counselors throughout the genomic variant sign-out pro-
cesses suggests that laboratories value the input of counselors in these
efforts. With the continued growth of clinical and research applications of
genomic sequencing, there is a need and opportunity to prepare genetic
counselors to take on various roles in this process.
Estimating the Impact of Proposed FDA Regulation of Laboratory
Developed Tests
G. Hooker1, T. Murphy1, T. Hagelstrom2, J. Schneider1
1. NextGxDx
2. Human Genetics Laboratory, Monroe-Meyer Institute
In 2014, the U.S. Food and Drug Administration (FDA) issued a draft
guidance outlining a framework for the oversight of laboratory-developed
tests (LDTs), a policy which could have a significant impact on patients
seeking genetic tests and the providers who support them. The guidance
outlines a risk-based framework for regulation, prioritizing the regulation
of Bhigh-risk^ LDT’s tied to medical actionability. It remains to be deter-
mined which tests fall into this Bhigh-risk^ category, and how numerous
these products are. It is also unclear which tests will qualify for a rare
disease exemption with a proposed cutoff of < 4,000 orders per test per
year. Drawing from a database of more than 38,000 genetic testing prod-
ucts marketed byClinical Laboratory Improvement Amendments (CLIA)
certified U.S. laboratories, we set out to describe the industry-wide effects
by determining the number of labs and tests affected by these proposed
regulations. We defined high risk (Class III) as any test including a gene
from the American College of Medical Genetics and Genomics list of 56
genes associated with high penetrance, preventable conditions (as a proxy
for actionability) and any test tied to a specific drug or chemotherapeutic
agent. Our analysis determined that there are 3115 different genetic tests
available for clinical use that fall into this category, most of which would
be considered LDTs. These tests are represented across 380 categories of
tests and offered by 142 different CLIA-certified laboratories. Laboratory
estimates for a Class III test to be taken through the FDA approval process
are on the order of 1 million dollars per test. The remaining 35,533 tests
would either fall into Class I or Class II depending on how low risk tests
are defined, and how the rare disease exemption is applied. Laboratories
would likely be required to submit a Premarket Notification 510 (k)
before marketing a Class II test. Questions remain as to how the costs
of regulation will impact the large and rapidly growing genetic testing
market and ultimately patient access to testing. It is critical that policies be
developed to fit the scope and expanding, evolving nature of the genetic
testing marketplace.
The Importance of Carrier Screening in Individuals of Sephardic,
Mizrahi, and Persian Jewish Descent
S. Farner1, B. Swope1, C. Settler1
1. Progenity, Inc.
Background: In the United States, professional society guidelines for
Jewish carrier screening center on those of Ashkenazi Jewish ancestry.
However, people of Sephardic, Mizrahi, and Persian Jewish descent are at
increased risk for certain disorders as well. Very few laboratories offer a
Sephardic/Mizrahi/Persian Jewish carrier screening panel and there are no
published medical guidelines for carrier screening in patients of Sephar-
dic/Mizrahi/Persian Jewish ancestry.Methods: Community-based screen-
ing events were held at multiple sites between January 2014 and February
2015. Participants who self-identified as having at least ¼ Sephardic,
Mizrahi, or Persian Jewish ancestry were offered a panel of eight DNA
based carrier screening tests and a hemoglobinopathy evaluation. All
participants were provided pre-test information by a genetic counselor
and informed consent was obtained prior to blood draw. Positive test
results were called to patients by a genetic counselor. Results: Three
hundred five patients underwent carrier screening and 88 individuals
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(28.9 %) tested positive for at least one disorder. Five individuals tested
positive for more than one condition. Sixteen participants were identified
as affected with glucose-6-phosphate dehydrogenase (G6PD) deficiency
(15 males and 1 female). The most common conditions detected were
G6PD (27 carriers, 8.9 %: 16 affected 5.2 %), familial Mediterranean
fever (19 carriers, 6.2 %), and hereditary inclusion body myopathy type
1 (17 carriers, 5.6 %). Conclusions: Jewish individuals of non-Ashkenazi
ancestry are at risk for certain disorders, but clear screening guidelines do
not exist. As a result, access to testing may be more limited compared to
those of Ashkenazi Jewish descent. This small data set demonstrated that
about 1 in 4 individuals of Sephardi/Mizrahi/Persian Jewish ancestry are
positive for at least one condition on this panel. Further research is needed
to evaluate the most effective screening panel for this population.
Updates from the Canadian Open Genetics Repository (COGR):
A Unified Clinical Genome Database as a Community Resource
for Standardizing and Sharing Genetic Interpretations
S.White1, M.Wang2, K. R. Zakoor2, A. Girgis2, M. Lebo3, J. Lerner-
Ellis2,4
1. Partners HealthCare and GeneInsight
2. Mount Sinai Hospital
3. Laboratory for Molecular Medicine, Partners HealthCare
4. University of Toronto
The arrival of the genomics era has increased the quantity and complexity
of data produced by genetic laboratories. Initially, labs anticipated there
were a finite number of variants and increased adoption of sequencing
would lead to a declining number of novel and uncertain variants. This
has not been the trend thus far, prompting the critical need for data sharing
efforts. The Canadian Open Genetics Repository (COGR) is a collabora-
tive effort for the collection, sharing and analysis of variants reported by
diagnostic laboratories in Canada that can serve as a focal point for other
international data sharing efforts. The goals of the project are three-fold.
First, facilitate standardization of the assessment process via a freely
available Variant Assessment Tool (VAT). Second, each COGR lab re-
ceives a free instance of GeneInsight®, a database featuring versioning of
variant assessments and interpretations, plus functionality to enable real-
time sharing of this information between labs. Finally, curated variant
data will be presented to various stakeholder groups in appropriately
understandable formats and levels of summary. Here we present an up-
date to this initiative. To date, 20 institutions have a GeneInsight instance,
six are sharing variant data including over 6,000 intragenic and copy
number variants. Focus has now shifted to the last aim. The COGR
members are now identifying variant discrepancies through anonymous
discrepancy reports. Variants are proposed to reach consensus level if
three or more labs agree on an interpretation. Currently 37 variants match
this criterion. In cases where the reports are not sufficient to create con-
cordance, a majority vote will be sufficient to reach ‘majority level’
agreement. These consensus and majority level variant interpretations
will then be displayed on a publicly accessible site. As a continuing effort,
the COGR endeavors to increase genetic knowledge and standardization
through data sharing and consensus building, ultimately improving our
ability to diagnoses and treat genetic diseases.
IV. Professional Issues and Education
Transition Curriculum: An Educational Framework for Supporting
Genetic Counseling Students
C. Guy1, S. Hassed1, A. Darden1
1. University of Oklahoma Health Sciences Center
Genetic counseling students face the educational challenge of
transitioning from entry-level graduate students to practicing certified
genetic counselors in 2–3 years. Often students are also transitioning from
an undergraduate educational model to a professional graduate school
setting. Transition programs are well established both in educational
and clinical settings and have been shown to improve educational and
health outcomes. However, they have yet to be applied to genetic counsel-
ing education. We describe an educational framework to support genetic
counseling students’ professional development during their transition to
practicing genetic counselors. Learning outcomes of this curricular frame-
work focus on professional development in four main areas designed to
reflect the four domains of the Accreditation Council for Genetic
Counseling (ACGC) Practice Based Competencies. This framework is
structured to support students’ transition (I) from rote memorization to
independent clinical application of material; (II) to gradually increase
student independence and responsibility as a member of a clinical and
educational team; (III) to develop the educational skills required for clin-
ical and supervisory practice; and (IV) to establish self-reflective practice
as a foundation for professional development. Educational activities
based on this framework are described, including: transparency of edu-
cational design; near-peer mentoring; clinical supervision role-play; reg-
ular reflective writing practice; and discussion and self-evaluation of the
ACGC practice-based competencies. While many genetic counseling
programs have included similar educational activities as part of their
educational structure, there is little published on the educational theory
and tools utilized in these activities. This educational framework and
related educational activities are described with the goal of demonstrating
the application of the educational theory of transition to the professional
development of genetic counseling students.
Students’ Perceptions of Supervision Across a Year of Clinical
Rotations
I. MacFarlane1, K. Linthicum1, T. Truong1, B. Whalen1, M. Bagley1,
P. McCarthy Veach2, B. LeRoy2
1. Austin College
2. University of Minnesota
As increased focus is being paid to supervision of genetic counseling
students, it is vital to examine student perceptions of the process in addi-
tion to those of supervisors and educators. While the body of empirical
literature about student supervisees is growing, no research to date has
followed students longitudinally throughout their clinical rotations to de-
termine if and how their perceptions shift as they gain experience. To that
end, the current study sought to examine students’ perspectives on super-
vision near the beginning and end of clinical training. Phone interviews
with a national sample of 40 genetic counseling students beginning their
second year and follow-up interviews with 32 of these students at the end
of their second year were transcribed and analyzed using consensual
qualitative research methods. As students gained more experience, the
focus of their comments on supervision shifted from focusing on content
and evaluation (e.g., receiving feedback, clarifying expectations, manag-
ing feedback from multiple supervisors) to emphasizing process and re-
lationship aspects (e.g., connection, trust). For example, during the first
interviews, students highlighted the importance of type and frequency of
feedback from supervisors as the most important aspects of supervision.
During the second interviews, however, the support and encouragement
provided by supervisors was highlighted as most important. Additionally,
the quality of supervision interactions became more powerful influences
on students’ perceptions of their rotations as they gainedmore experience,
and students expressed less anxiety regarding supervision and their clin-
ical work in general. Training programs can leverage these findings to
help students understand their development and prepare for upcoming
challenges. Supervisors can also use the findings to better prepare for
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students’ expectations. Further research should investigate what factors
moderate this relationship and explore the relationship between supervi-
sion perceptions and actual performance.
A Sustainable Model for Blended Learning in Genetics
and Genomics
E. Edelman1, M. Dougherty2, T. Ingram1, K. Reed1
1. The Jackson Laboratory
2. ASHG, University of Colorado School of Medicine
Despite a recognized need in the medical community for improved inte-
gration of genetics into practice, significant barriers limit widespread
implementation. Key to successful implementation is a genetically edu-
cated and aware workforce. We describe a novel approach to genetics
education for the non-geneticist clinician that uses best practices in adult
education, is highly interactive and clinically relevant, and utilizes the
benefits of both in-person and digital delivery for maximum educational
impact. The Jackson Laboratory and the American Society of Human
Genetics developed and implemented an interactive educational program
to improve the clinical skills of primary care providers (PCPs) in
assessing and managing genetic risk for cancer. This blended learning
program consists of online pre-work, 6.5 hours of in-person content,
monthly communications, and access to digital resources. The approach
to in-person curriculum emphasizes skill-building by modeling a patient
interaction followed by immersing the participants in practice cases with
immediate expert feedback. The program includes presentation slides
with professional graphics and supporting key messages and notes, facil-
itator guides, and handouts (factsheets and tools) as well as reusable
digital educational activities. The program was initially piloted with 21
PCPs in 2014. Participants demonstrated significantly improved confi-
dence, attitudes, and knowledge related to genomic risk assessment.
These early results suggest that this innovative program can build PCP
skills in the assessment and management of hereditary cancer, supporting
improved patient care. This model of blended learning is easily reusable
and sustainable to implement again after the initial development is com-
plete. Based on this successful pilot, the program will be implemented
broadly and will serve as a framework for future programs and expanded
audiences to improve clinical integration of genetics into practice.
Interpreting for Genetic Counselors: Identifying Common Pitfalls
and Solutions
P. D.Hodges1, E. Simi2,M. Vandenberg2, S. Aufox1, D. Victorson1, G.
Steffen3
1. Northwestern University
2. NorthShore University HealthSystem
3. Northwestern Medical Faculty Foundation
In 2011, approximately 25.3 million individuals in the United States had
limited eEnglish proficiency. Communication issues due to language and
cultural diversity can significantly impact healthcare quality. To over-
come these obstacles, medical interpreters are used to facilitate commu-
nication between providers and patients. The goal of this study is to
identify challenges interpreters face during genetic counseling sessions
and provide insight in how genetic counselors and interpreters can effec-
tively collaborate to improve communication with patients. The study
targeted certified medical interpreters working at several hospitals in Chi-
cago to participate through an e-mail invitation distributed by their man-
agers. Participants were interviewed over the phone using a semi-
structured interview guide. Interviews were audio-recorded and tran-
scribed verbatim. Coding rules were established via exhaustive coding.
A joint codebookwas developed and assessed for inter-rater agreement (ĸ
= .85). All codes were reviewed for modification/relabeling. Following
open coding of the data, axial coding ensued, which consisted of identi-
fying relationships among concepts and categories. Fourteen in-house
medical interpreters discussed the process of interpreting, factors that
affect genetic counseling sessions, challenges that arise during sessions,
and provided feedback for genetic counselors. Challenges described in-
cluded the difficulty accessing genetic counseling materials, terminology
used, and the complexity of the information discussed. Interpreters rec-
ommended meeting for a pre- and post-session when possible and report-
ed the need for a reference that covers genetic counseling terminology
and common phrases to promote their proficiency. Participants voiced a
desire for an online tool that reviews basic genetics concepts to enhance
their overall understanding of the information discussed. Genetic coun-
selors could collaborate with interpreters in the creation of a reference aid
and an online tool in order to increase interpreter’s familiarity with the
genetic counseling field.
Design, Implementation, and Outcomes of a Psychiatric Genetics
for Genetic Counselors (PG4GC) Workshop in the UK
J. Austin1, A. Inglis1, K. McGhee2
1. University of British Columbia
2. Bournemouth UNiversity
Knowledge about the roles of genetic and environmental contributors to
the development of psychiatric disorders is accumulating rapidly, and
concurrently, the importance and urgency of translating this knowledge
into better health is increasing. The first specialist psychiatric genetic
counseling (PGC) service of its kind opened in Vancouver in 2012, gen-
erating interest from healthcare professionals from around the world who
wish to develop similar services. In responding to this interest, we noticed
that for many of these individuals, the barriers to their provision of high
quality specialist services for individuals with psychiatric disorders and
their families related to four core issues: lack of familiarity with specialist
(psychiatric and/or genetic) terminology, feeling out of touch with the
state of the art in psychiatric genetics, lack of confidence in discussing
psychiatric disorders – both in general, and their etiology (in lay lan-
guage) specifically, and uncertainty regarding how to discuss the risks
for illness recurrence amongst family members of affected individuals.
Therefore, with a target audience of genetic counselors in mind, we de-
veloped an intensive 2-day workshop (PG4GC) that aimed to address
these four core issues and form the foundation for the development of a
strategy for delivering PGC both within the United Kingdom (UK) and
globally. The workshop, which was delivered in the UK in Feb 2015,
incorporated didactic content, small and large group discussion, a prob-
lem based learning case, and individual reflective work. In total, 23 par-
ticipants from seven countries attended and completed pre- and post-
workshop surveys, which revealed that participants were more confident
with respect to all four core issues after the workshop. At the conclusion
of the workshop, participants founded the International Society for Psy-
chiatric Genetic Counseling (ISPGC, which interested counselors are
welcome to join). Members of this fledgling organization will meet at
the 2015 World Congress of Psychiatric Genetics, and plans are under-
way for a second PG4GC workshop in 2016.
Development of EMPOWER: Evaluation Model for Patient
Outcomes When Engaging in Reciprocal Communication as Part
of Genetic Service Delivery
H. Zierhut1, D. Cragun2
1. University of Minnesota - Twin Cities
2. Moffitt Cancer Center
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As healthcare reimbursement is progressively tied to value-of-service, it
is critical for the genetic counseling profession to systematically and
quantitatively demonstrate the value added by genetic counselors (GCs)
through outcomes research. To advance future research, a comprehensive
approach is needed to organize the broad array of potential outcomes and
to postulate relationships between genetic service delivery (GSD) pro-
cesses and outcomes. Methods: Through an iterative approach involving
literature review, thematic analysis, and consolidation, we categorized
GSD outcomes, processes, and strategies to create and define components
of a model and generate an illustrative example. Results: The resulting
model is termed EMPOWER: BEvaluation Model of Patient Outcomes
When Engaging in Reciprocal Communication^ and consists of multiple
constructs organized within the following seven domains: patient and
provider goals; GSD strategies; process constructs, stakeholder con-
structs, service system outcomes; patient outcomes (proximal, intermedi-
ate, health); and family outcomes. The utility and flexibility of the model
is illustrated through postulating mechanisms whereby GSD may influ-
ence outcomes. For example, process constructs hypothesized to influ-
ence family communication may include Beliciting communication facil-
itators and barriers^ and Bproviding informational resources for patients
to share with family.^ Proximal patient outcomes may include, Bpatient is
empowered to use resources to communicate with family.^ Family out-
comes could include, Bgenetic information is communicated to family
members^ and Bappropriate uptake of genetic services by family
members.^ Conclusion: This is the first conceptual framework that com-
prehensively defines a broad array of GC process and outcome constructs
and postulates general relationships between framework domains. Using
this type of theoretical model could provide a valuable resource that will
address three NSGC strategic objectives and be used to align quality
measures and promote necessary GC outcomes research and evidence-
based practice.
V. Access and Service Delivery II
The Beneficial Role of the Laboratory Genetic Counselor in Test
Utilization Management: Evidence and Opportunities
from a Multisite Study of Provider Satisfaction
J. Conta1, E. Leeth2, D. Sternen1, S. Stasi1, S. Wallace1, K. Leuer2, J.
Dickerson1
1. Pediatric Laboratory Utilization Guidance Services, Seattle Children’s
Hospital
2. Ann & Robert H. Lurie Children’s Hospital of Chicago
Seattle Children’s Hospital (SCH) and Lurie Children’s (LC) employ
laboratory genetic counselors (GCs) in active utilization management
(UM) programs to improve the value of laboratory tests for patients.
These programs are driven by similar goals of reducing incorrect or un-
necessary tests and avoiding excess financial liability for patients, fami-
lies and institutions. Approximately 50 % of PLUGS (Pediatric Utiliza-
tion Guidance Services) member institutions list provider culture as one
of the biggest challenges to implementing case review. To validate the
benefits of engaging laboratory GCs in UM case review, provider satis-
faction surveys were conducted at our respective institutions. The 10-
question survey was designed to capture the provider’s perspective using
a semi-quantitative scale where 50 % is a neutral response. At SCH, 216
providers were surveyed in 2013 and 182 providers in 2014, with a 46 %
and 40% response rate, respectively. At LC, 305 providers were surveyed
in 2014, with a 22 % response rate. A comparison of data between SCH
and LC showed strikingly similar responses across the questions, with
providers appreciating the support of the UMprograms and the support of
a laboratory genetic counselor in particular. The highest median satisfac-
tion (82 % at SCH and 88 % at LC) was related to the question, BI
appreciate knowing that the laboratory UM program supports me and
my patients (e.g. catching instances of duplicate orders, helping me stop
unnecessary patient-driven testing, etc.).^ The lowest median satisfaction
(50 % at SCH and 52 % at LC) was related to questions regarding
preauthorization support and processes. The results affirm each program’s
approach to case review and highlight the positive effect of the genetic
counselor in the UM process. The results also identified opportunities for
improvements. To that end, both SCH and LC have proposed algorithms
leveraging the laboratory GC to promote standard, efficient genetic test-
ing preauthorization coordination through the UM program and institu-
tional preauthorization teams.
Demonstrating Feasibility of a Collaborative Approach to Cancer
Risk Assessment Services in a Multi-System Community Hospital
S. Cohen1, D. Nixon1
1. St. Vincent hospital
Most board certified genetic counselors (CGCs) in Indianawho specialize
in cancer genetics are based in large cities. To provide improved access by
smaller rural communities, the St. Vincent Hospital Cancer Genetics Risk
Assessment Program designed a unique approach to cancer risk assess-
ment. This study reports on the experience with one collaborating hospital
over a 2-year period. Local, on-site nurse navigators received training
from the CGCs, including observation of genetic counseling sessions
and on-line courses. From August 2012-July 2014, 12,477 patient family
history questionnaires representing 8,937 unique patients having a
screening mammogram or new oncology appointment at the remote site
were triaged by CGCs. Of these, 8.2 % patients were identified at in-
creased risk for hereditary breast cancer with the offer to meet with a
nurse navigator for further risk assessment and potential BRCA1/2 testing,
while 4.2%were identified at increased risk for other hereditary causes of
cancer with an offer for evaluation with a CGC during a monthly outreach
clinic. A total of 171 patients reponded to a notification letter, resulting in
23 patient visits with the nurse navigator and 52 patient visits with a CGC.
An additional 30 patients were seen on-site by a CGC as a result of
referals from local physicians aware of the service, for a total of 105
patients. When coordinated by the nurse navigator, results of all genetic
testing were reviewed by a CGC to determine the need for additional
testing and risk interpretation. Efficiency of this model was assessed by
determining time spent by the CGC in all activities related to the collab-
oration, which amounted to approximately 16 hours per month. This
study demonstrates the feasibility of collaborating with trained and sup-
ported genetic counselor Bextenders^ to improve access to and efficiency
of a CGC without sacrificing quality or becoming overburdened.
Increasing Genetic Counseling Referrals for Women with Ovarian
Cancer: Utilization of a Best Practice Advisory in the Electronic
Medical Record
J. Marquard1, V. Radney1, D. Bijak1, C. Michener1, H. Mahdi1, C.
Eng1
1. Cleveland Clinic
Introduction: Genetic counseling is recommended for all women with
epithelial ovarian, fallopian tube, or primary peritoneal cancer. However,
many studies have shown that the majority of these patients are not re-
ferred to genetics. As targeted therapies emerge for women with ovarian
cancer due to mutations in BRCA1/2, genetic counseling and testing are
increasingly vital. Methods: We developed a Best Practice Advisory
(BPA) within the Electronic Medical Record (EMR) to prompt clinicians
to discuss genetic counseling with patients. The BPA was triggered for
healthcare providers in gynecologic oncology during a patient encounter
in the presence of ICD-9 codes for ovarian, fallopian tube, and primary
peritoneal cancer. Choices to acknowledge the alert were: order a consult
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to genetics, indicate testing was already performed, defer, or decline due
to patient choice. Results: Over 17 months, the BPA triggered for 328
patients with high grade epithelial cancer who had not had genetic
counseling or testing in the past. 192/328 (59%) were referred for genetic
counseling. Of those patients, 135/192 (70 %) had genetic counseling,
and 129/135 (96%) elected genetic testing. A deleterious mutation(s) was
identified in 27/129 (21 %) (12 BRCA1, 9 BRCA2, 3 BRIP1, 1 ATM, 1
TP53, and 1 BRIP1 and BARD1). Compared to the pre-implementation
period (1/2011-10/2013), significantly more patients were referred for
genetic counseling after implementing the BPA (192/328 (59 %) vs.
158/365 (43 %) p<0.0001). Limitations: Programming errors caused the
BPA to trigger inappropriately, causing user frustration. Conclusions: Use
of a BPA in the EMR for women with ovarian, fallopian tube, and peri-
toneal cancers significantly increases genetic counseling referrals and
identification of important mutations in a high percentage of patients that
could alter medical management. Edits to the programmay help decrease
rates of misfiring and make the advisory less intrusive to clinicians while
affording women the opportunity to pursue genetic testing.
Retesting Patients with Multi-Gene Hereditary Cancer Panels:
The Impact on a Genetic Counselors’ Patient Volume
C. Mauer1, L. Robinson1, T. Ross1
1. UT Southwestern Medical Center
The existence of hereditary cancer gene panels has led to providers
pinpointing which former patients should be offered reflex genetic testing
for Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Part of this
equation includes being aware of the effect this will have on clinic vol-
ume. To address this, we reviewed the histories of 9,854 patients to
determine a priori BRCAPro (ABP) risks, triple negative (TN) status,
and ovarian cancer (OC) diagnoses, as these patients have been deemed
as high-risk patients for finding a non-BRCA mutation. We analyzed
different ABP cutoffs for retesting and found an ABP >90 % results in
a 2.42% increase in patient volume; >60%ABP= 3.26%; >40%ABP =
5.47 %; >20 % ABP = 8.29 %; >10 % ABP = 11.71 %. These numbers
were similar between both the private (73.52 %) and underinsured
(26.48 %) clinic populations. 2.70 % of all patients would need re-
testing due to their diagnosis of TN breast cancer; 2.67 % of all patients
with OC would need re-testing. Although these three categories are not
necessarily independent of one another, these data help estimate the im-
pact of re-testing BRCA negative patients. A clinic of 300 patients annu-
ally would experience a 13.66 % (41 patients) increase in clinic volume
using the criteria of >20 % ABP, TN breast cancer, and OC patients; the
same clinic would experience a 16.77 % (51 patients) increase if the
criteria were >10 % ABP, TN breast cancer, and OC patients. Genetic
counselors need to be aware of the impact re-testing will have on their
clinic volume, be prepared to prioritize the highest risk patients for re-
testing, and educate their referral sources about appropriate patients for
re-testing.
Decision-Making Across Cultures: Cancer Counseling
of Low-Income Latina Women Using Medical Interpreters
D. Kamara1, J. Weil1, J. Youngblom1, G. Joseph2
1. California State University, Stanislaus
2. University of California, San Francisco
In cancer genetic counseling (CGC), a model of practice based on shared
decision-making (SDM) challenges communication with limited English
proficiency (LEP) patients, exacerbating existing health disparities. Lim-
ited research has examined the decision-making process of low-income
LEP patients in CGC. This study investigated the extent to which
communication was effective with low-income LEP Latina women in
CGC, how this communication affected decision-making, and identified
potential strategies leading to improve effective communication and
SDM with this population. We analyzed audio recordings, drawn from
a larger study, of CGC sessions with low-income LEP Latina women
conducted with professional medical interpreters via telephone in two
public hospitals. Audio files were coded directly by two bilingual
english-spanish speakers and analyzed using conventional content anal-
ysis through an iterative process. Twenty-four CGC sessions involving 13
patients and 6 genetic counselors were included. We identified two do-
mains that inhibited effective communication and SDM: the use of hypo-
thetical scenarios and misinterpretation by the medical interpreter. A third
domain, communication facilitators, involved strengths that enhanced
effective communication and SDM. Overall, there was an absence of
patient participation in the decision-making process. Our data suggest
that when counseling across language and culture via medical interpreter,
genetic counselors should present information in a way that clearly dem-
onstrates its utility for the patient, for example by explaining or modeling
how to integrate the information presented into the decision-making pro-
cess. Genetic counselors should also consider organizing information into
short-term and long-term goals to increase its utility, lessen information
overload, and improve comprehension for patient and interpreter. Further
research is needed to understand how applicable our findings are to other
populations.
Comparing Knowledge Gain Between in-Person and Telemedicine
Genetic Counseling for Hereditary Breast Cancer
M. Hallquist1, D. Thull1, N. Carter2, R. Huziak1, C. Lorenchick3
1. UPMC Cancer Genetics Program
2. GeneDx
3. UPMC Cancer Genetics Department
The demand for genetic counseling services for hereditary breast and
ovarian cancer has been rapidly increasing. In order to provide wider
access to these services across large geographic areas, the use of telemed-
icine has been expanding. Little is known, however, about the effective-
ness of telemedicine in increasing patients’ knowledge of cancer genetics.
Our study aimed to compare knowledge gain between in-person and
telemedicine genetic counseling sessions for hereditary breast cancer risk.
Using a seven item questionnaire adapted from previous studies, partici-
pants’ knowledge of hereditary breast cancer was assessed immediately
prior to and immediately following counseling sessions at an in-person
cancer genetics clinic and three telemedicine sites. We hypothesized that
there would be significant knowledge gain for both in-person and tele-
medicine groups and there would be no differences in final knowledge
between the two groups. There were 162 participants who received in-
person genetic counseling and 77 participants who received telemedicine
services. Knowledge level was measured by number of correct responses;
a general linear model was used to compare groups and control for patient
education level. Knowledge post-counseling did not differ significantly
by genetic counselor. For both groups, the number of correct responses on
the questionnaire was significantly higher after counseling, F(1,
233) = 171.95, p < .0001. While there were no significant differ-
ences in participants’ pre-counseling knowledge between in-person
and telemedicine groups, individuals who received counseling via
telemedicine had significantly fewer correct responses than those
who received in-person counseling when controlling for education
level, F(1, 233) = 3.87, p = .049. With genetic counseling ser-
vices continuing to expand using alternate models of care, it is
important to ensure that patients receive adequate knowledge for
decision making regarding genetic testing across all service deliv-
ery models.
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VI. Clinical Care: Counseling and Psychosocial Perspectives
Roles for Religion and Spirituality in Genetic Counseling
K. Salsbery1, W. Uhlmann2, B. Yashar2
1. Marshfield Clinic
2. University of Michigan
Religion and spirituality (R/S) can inform healthcare decisions and sup-
port patients when faced with medical issues. While a majority of genetic
counselors (GCs) believe that R/S should be addressed during a session,
they rarely or never inquire about patients’ R/S practices. This study
explored barriers GCs face performing a R/S assessment. A focus group
guide developed by the research team based on a literature review ex-
plored participants’ definitions of R/S, perceived value(s) in clinical care
and roles for non-spiritual care providers in R/S discussions. Following
an initial piloting with GC students, a focus group was held with six GCs
in a major medical center. Participants had an average of 8y GC experi-
ence (1–18 y) and represented cancer, prenatal, pediatric and ophthalmo-
logic genetic specialties. Two independent reviewers used an iterative
coding process based on content analysis and grounded theory to identify
26 codes (utilized 438 times) that coalesced into 5 themes. We found that
GCs are 1) generally passive when addressing R/S topics, relying on
patients to lead the discussion; 2) uncertain regarding how to perform a
R/S assessment, their responsibility, and relevance to the session; 3) re-
luctant to engage in R/S discussions due to fears including offending
patients or disclosing one’s own R/S practices; 4) concerned that R/S
inquiry could interfere with the genetic counseling process (e.g. patient’s
attributing conditions to BGod’s will^ may impact education and deci-
sion-making); and 5) have limited knowledge and experience with ser-
vices provided by chaplains. Participants expressed a willingness to part-
ner with clergy to learn about R/S assessments and support. While GCs
recognize R/S assessment as potentially relevant in some instances, utili-
zation is hampered by limited knowledge, discomfort in crossing bound-
aries and fears that R/S affects the GC process. Our results highlight the
complex barriers that limit a GC’s R/S assessments and opportunities for
partnerships with chaplains as a means of enriching patient care.
Spiritual Exploration in the Prenatal Genetic Counseling Session
K. Sagaser1, S. Hashmi2, R. Carter1, J. Lemons1, H. Mendez-
Figueroa2, S. Nassef3, B. Peery 4, C. Singletary1
1. University of Texas Graduate School of Biomedical Sciences
2. University of Texas Medical School at Houston
3. Baylor College of Medicine
4. Memorial Hermann - Texas Medical Center
Religion and spirituality (R/S) are important components of many indi-
viduals’ lives, and spirituality is often employed by women coping with
pregnancy complications. To characterize how prenatal genetic coun-
selors might address spiritual issues with patients, 283 English and Span-
ish speaking women receiving prenatal genetic counseling in Houston,
Texas were surveyed post-counseling using both the Brief RCope and
questions regarding interest in spiritual exploration. Counselors were
concurrently surveyed to identify religious/spiritual language used within
sessions and perceived importance of religion/spirituality. Counselors
were significantly more likely to identify R/S as important to a patient
when patients used religious/spiritual language (p<0.001). Conversely,
when no religious/spiritual terms were present, the counselor felt uncer-
tain about the importance of R/S 63 % of the time. Significant associa-
tions were found between patient desire to talk about faith in the session
and the use of the terms God, believe/belief, Christian, church, faith,
God’s hands, God’s will, pray, and religion (p<0.05). Overall, 67 % of
patients reported that they felt comfortable sharing their faith as it relates
to pregnancy, and 93 % reported using positive religious coping. Less
than 25 % reported a desire for overt religious actions such as prayer or
scripture exploration. Patients who desired overt religious actions had
significantly higher levels of positive religious coping (p<0.05) and neg-
ative religious coping (p <0.05) andmay benefit from a referral to pastoral
services. However, the majority of patients’ desires for spiritual explora-
tion centered around the decisionmaking and coping processes that are in
line with the genetic counseling scope of practice. Therefore, counselors
should feel empowered to incorporate spiritual exploration into their pa-
tient conversations. Genetic counselors may consider adding a question
about the impact of R/S in pregnancy on intake forms and/or inquiring
about R/S while taking a pedigree to inform the desire for exploration of
this topic.
Peering Down the Rabbit Hole: Living with von Hippel-Lindau
Syndrome from the Young Adult Perspective
L. Schmidt1, T. Cross2, S. Nylander3, E. Cross1, G. Chan-Smutko1
1. Brandeis University
2. University of Illinois at Urbana-Champaign
3. VHL Alliance
Von Hippel-Lindau (VHL) is a hereditary cancer susceptibility syndrome
that requires rigorous lifelong surveillance. Annual screening is age-
based, involving retinal exams after the first year of life and imaging of
the brain, spine and abdomen starting in adolescence. Surgical or other
interventions may become necessary to prevent secondary effects such as
vision loss or cancer metastasis. Given the young age at which symptoms
manifest, many patients undergo multiple screening and treatment proce-
dures by adulthood. Few studies have described the psychosocial aspects
of living with VHL and have not addressed issues specific to emerging
young adults. Accordingly, we conducted a qualitative study to explore
the experiences of ten young adults (18–26 years old) with VHL residing
in the United States. We recruited participants through the VHL Alliance
and administered semi-structured telephone interviews that addressed
five major topics: personal and familial experiences with VHL, support
systems, emotional well-being, effect of VHL on romantic and familial
relationships, and effect on life decisions. Thematic analysis of the inter-
view transcripts was performed in ATLAS.ti (v.7.5.4) and five themes
emerged: (1) living with uncertainty, (2) maintaining a positive attitude,
(3) family members as significant means of support, (4) polarizing effect
on relationships, and (5) impact on life decisions with respect to location,
career path, and childbearing. We conclude that living with VHL as a
young adult involves a considerable psychosocial component that ex-
tends beyond the well-studied physical aspects of the syndrome. Young
adults with VHL would likely benefit from establishing a long-term rela-
tionship with a genetic counselor, as they can help manage uncertainty,
connect patients with other young adults living with VHL, and provide
education regarding childbearing options. Further research with this pop-
ulation will likely help genetic counselors and other health professionals
provide better support and services to young adults living with VHL.
Development and Use of a Novel Scale: Parents’ Uncertainties
About Their child’s Health
E. Macnamara1, P. Han2, B. Biesecker3
1. Undiagnosed Diseases Program, National Human Genome Research
Institute, National Institutes of Health
2. Center for Outcomes Research & Evaluation, Maine Medical Center
3. Social and Behavioral Research Branch, National Human Genome
Research Institute, National Institutes of Health
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Uncertainty pervades all aspects of medicine and is specifically relevant
to those affected with rare and undiagnosed conditions. Research has
demonstrated that uncertainty can be a significant source of psychological
distress and of key importance in genetic counseling. The aim of the
current study was to assess the reliability and validity of a novel scale
designed to assess perceptions of uncertainty. Validated scales were used
to assess coping efficacy, tolerance for uncertainty, dispositional opti-
mism and resilience. Open-ended questions were used to explore re-
sponses to uncertainty. Ninety-four parents of children with undiagnosed
medical conditions, recruited from online advocacy groups, completed
the survey. Respondents were predominantly biologic mothers and aver-
aged 38.6 years old. The mean age of the children was 8.0 years and most
were female (57%). The Parents’Uncertainties about their Child’s Health
Scale (PUCHS) was designed to include seven domains of uncertainty.
Each domain was measured using two items that assessed the specific
source of uncertainty followed by two parallel questions about the per-
ceived importance of each item. The items for the scale originated from
the literature and our past studies. To capture parental priorities, each item
was weighted by importance. Exploratory factor analysis indicated con-
vergence into five factors: Medical (α=0.84), Future, Reproductive
(0.62), Social (0.81), and Existential (0.94). The Future factor consisted
of one item and was dropped from the scale, resulting in four final do-
mains. The greatest variance in the PUCHSwas accounted for byMedical
uncertainty. Initial evidence for discriminant validity data was established
by correlations of the PUCHS with measures of dispositional optimism
and resilience, such that individuals with higher dispositional optimism
and resilience tended to have lower levels of weighted uncertainty. These
results provide preliminary evidence to support the use of this scale in
future studies of parental coping and adaptation to having a child with an
undiagnosed disease.
Psychological Impact of Exercise Restrictions in Recreational
Athletes with Hypertrophic Cardiomyopathy
R. Luiten1, K. Ormond2, I. Asif3, M.Wheeler4, L. Post5, C. Caleshu4
1. Stanford University
2. Department of Genetics, Stanford University
3. University of South Carolina Greenville
4. Stanford Center for Inherited Cardiovascular Disease
5. Department of Psychiatry and Behavioral Sciences, Stanford
University
Individuals with hereditary cardiovascular conditions, like hypertrophic
cardiomyopathy (HCM), are recommended to restrict their athletic activ-
ities in order to reduce their risk of sudden cardiac death. Clinical expe-
rience and prior studies suggest that these restrictions can be a source of
psychological distress for some individuals; however, this has not been
specifically studied. We used semi-structured telephone interviews to
explore the psychological effect of exercise restrictions on athletes with
HCM and the adaptive and maladaptive techniques used to adjust to the
restrictions. To obtain a rich sample, we performed purposive selection of
self-identified recreational athletes who had difficulty adjusting to their
exercise restrictions. Sixteen (9 men, 7 women) individuals participated,
with a mean age of 52. Data was analyzed using a modified grounded-
theory approach, which included thematic coding. The majority of indi-
viduals could not identify positive effects from their restriction, but could
report various long-term negative effects including weight gain and feel-
ings of uncertainty surrounding exercising safely. Participants experi-
enced a shrinking of the role of exercise from a myriad of functions
(social, stress relief, fitness) to solely health maintenance. The majority
expressed a desire for more concrete and individualized exercise recom-
mendations. Adaptive coping strategies included getting educated; com-
munication with support network surrounding restrictions; and having
family and friends participate with them in lower intensity exercise. Lack
of understanding from family or friends about the emotional difficulty
associated with reducing athletic involvement was hurtful. Many reported
that avoiding exercise completely was detrimental. These findings sug-
gest that clinicians can help athlete’s adapt to exercise restrictions by
using an individualized approach that includes discussing the emotional
impact, addressing methods to fill the void of exercise, creating a specific
exercise plan and helping the patient activate their support network.
Knowledge and Self-Esteem of Individuals with Neurofibromatosis
Type 1
K. Vaughn1, S. Hashmi2, H. Northrup2, J. Slopis3, S. Noblin4, M.
Ashfaq2
1. University of Texas Health Science Center of Houston
2. Department of Pediatrics, UTHealth
3. Department of Neuro-Oncology, UT MD Anderson Cancer Center
4. Departments of OB/GYN and Pediatrics, UTHealth
Neurofibromatosis Type 1 (NF1) is a progressive genetic disorder char-
acterized by café-au-lait macules, Lisch nodules, as well as neurofi-
bromas among other traits. Learning and social problems are also more
prevalent in this population. Due to the visible and nonvisible manifesta-
tions of the condition, it has been observed that individuals with NF1
have lower self-esteem (SE) when compared to the general population.
Additionally, a study published over 20 years ago found that overall
knowledge of NF1 was poor in individuals affected with the condition.
The goal of our study was to reassess knowledge in this population and
investigate whether it is related to SE. Furthermore, we explored the
impact of other factors on knowledge and SE. A survey comprised of
knowledge-based questions and the Rosenberg Self-Esteem Scale was
distributed to individuals with NF1 through the Texas NF Foundation.
Overall, the 49 respondents (13 to 73 years old) had higher than expected
knowledge of NF1 (mean score = 77.9 % correct answers) across various
aspects of the condition. Consistent with previous studies, the SE of our
study population was lower when compared to general population norms.
Although no correlation between knowledge and SE was observed, SE
scores were on average higher if a person reported to have friends with
NF1 (p=0.009), attended an NF1 support group (p=0.006), attended an
NF clinic (p=0.049), or received genetic counseling (p=0.008). Having
friendships with people who have the same condition as well as attending
support groups may help those affected by NF1 to feel less isolated and
increase their SE. Additionally, genetic counseling provides an opportu-
nity for these individuals to identify positive coping strategies such as
educating peers about NF1 and therefore may help boost SE.
VII. Clinical Care: Pediatrics and Adults
Predispositional Genome Sequencing in Healthy Adults: First
Findings from the PeopleSeq Study
M. Helm1, T. Hambuch2, M. Ball3, G. Church3, M. Linderman4, N.
Pearson5, J. S. Roberts6, S. Sanderson4, E. Schadt4, R. Green1,3
1. Brigham and Women’s Hospital
2. Illumina Inc.
3. Harvard Medical School
4. Icahn School of Medicine at Mount Sinai
5. New York Genome Center
6. Department of Health Behavior and Health Education, University of
Michigan School of Public Health
Introduction: Several clinical and research programs offer whole genome
(WGS) or whole exome sequencing to ostensibly healthy adults, for ed-
ucation and prognostic purposes. Though such personal/predispositional
genome sequencing (PGS) may prove to be a valuable tool for improving
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health, the outcomes of providing PGS remain poorly documented. Pur-
pose: As part of the Personal Genome Sequencing Outcomes (PeopleSeq)
Study, we sought to understand participants’ motivations for obtaining
PGS, and their attitudes on sharing PGS results. Methods: We piloted our
survey with participants from Illumina’s Understand Your Genome
(UYG) program, which offers WGS to ostensibly healthy, paying adults,
and returns a clinically focused report to each participant via her/his
ordering physician. Online, we uniformly surveyed 292UYGparticipants
about their motivations for PGS, perceived utility of their results, and
attitudes on sharing results. We used descriptive statistics and chi-
square tests to examine data from 70 (24 %) UYG individuals. Results:
Reported motivations for seeking PGS included personal interest in ge-
netics (100 %), and curiosity about their own genetic make-up (99 %).
Respondents motivated by family history of a possible or confirmed
genetic condition (31 %) were likelier than others to report learning
something from PGS that they believed would improve their health
(p=0.006). As a result of receiving their PGS results, 21% of respondents
made appointments with a medical professional, 11 % had a medical
exam/procedure, and 4 % had a genetic test to confirm a variant in their
PGS results. Respondents reported discussing their results with family
members (87 %), co-workers/colleagues (80 %), friends (70 %), and
healthcare practitioners (60 %). Conclusions: Survey respondents report-
ed high genetic curiosity, and willingness to discuss their results with
others. Respondents who sought PGS for family history concerns were
likeliest to report receiving useful health insight. PGS results motivated
many, though not all, respondents to obtain additional medical care.
ACMG Recommended Secondary Findings are Identified in only
2.25 % of Pediatric Patients Undergoing Exome Sequencing
Z. Powis1, C. Alamillo1, L. Shahmirzadi1, K. Farwell1, J. Song1, W.
Alcaraz1, R. Baxter1, E. Chao1, S. Tang1
1. Ambry Genetics
Background: Diagnostic exome sequencing (DES) is a powerful diagnos-
tic tool to provide a molecular diagnosis for patients with undiagnosed
genetic disease and may result in identification of secondary findings
(SF). Following the publication of American College ofMedical Genetics
and Genomics’s (ACMG) BRecommendations for Reporting of Inciden-
tal Findings in Clinical Exome and Genome Sequencing,^ genetic coun-
selors are integral to providing patients with clear expectations. Pre-test
counseling is especially important for pediatric patients, as many of the
genes on the ACMG list are adult onset conditions or cancer susceptibility
syndromes. Methods: We performed a retrospective analysis of the SF
results identified in the first 400 pediatric patients undergoing DES,
electing ACMG minimum secondary findings gene results. SF reports
were only offered for the proband and included part of the DES testing.
Clinicians were re-contacted following a positive SF report to determine
if additional family history of the condition had been obtained. Results:
Overall, 9 (2.25 %) of the 400 patients were identified to carry a patho-
genic mutation in one of the ACMG recommended genes. Of these re-
ported mutations, 5 (55.6 %) were in cancer genes (2 - BRCA2, 1 -
BRCA1, 1 - APC, 1 - TP53), 3 (33.3 %) in cardiac associated genes
(DSC2, KCNQ1, MYBPC3), and 1 (11.1 %) a mutation causing suscep-
tibility to malignant hypothermia (RYR1). A family history of cancer
meeting the NCCN guidelines for testing an affected family member
was not reported in 3 of the 5 positive cases (60 %). Additionally, indi-
viduals that tested positive for cardiac genes and malignant hypothermia
did not have a reported family history consistent with the diagnosis.
Conclusions: Despite initial concerns regarding reporting of ACMG sec-
ondary findings, the number of positive cases is low in pediatric patients.
An important observation was that the majority of patients who tested
positive did not have reported family histories of these conditions. These
findings underscore the importance of pre and post-exome counseling in
order to aid in the interpretation of SF results.
Research Participation in the Duchenne Muscular Dystrophy
Community: Parent Perceived Barriers and Their Impact
on Families
K. Clinard1, L. Morgenroth2, R. Bendixen1, R. E. Grubs1, D.
Finegold1
1. University of Pittsburgh
2. Children’s National Health System, Cooperative International Neuro-
muscular Research Group
Purpose: Duchenne Muscular Dystrophy (DMD) is a degenerative neu-
romuscular disorder causing severe progressive muscle loss and prema-
ture death. While research in DMD is critical to advance treatment and
care it also presents many challenges for families, which can affect re-
search recruitment. Poor recruitment constrains the ability to achieve and
measure progress in clinical research, and consequently affects how well
new therapies perform. The purpose of the present study was to identify
barriers to research participation in DMD research and to explore how
these barriers impact families. Methods: In collaboration with the Coop-
erative International Neuromuscular Research Group (CINRG) academic
clinical research network and associated Muscular Dystrophy Associa-
tion (MDA) clinics, parent-centered focus groups were conducted at five
sites: Pittsburgh, PA; Washington, DC; Minneapolis, MN; Houston, TX;
and Sacramento, CA. A total of eight guided focus groups attended by 28
parents of boys with DMD were audio-recorded and transcribed. Quali-
tative thematic analysis of focus group transcripts was conducted to iden-
tify themes. Results: Major themes identified as barriers to research par-
ticipation included: 1) commitments; 2) fighting a new battle; and 3) the
gamble. Participating in research was shown to affect many aspects of
participants’ lives and additionally had an impact on the entire family.
Conclusions: Identifying barriers to research participation and under-
standing how these barriers impact families can provide information to
improve research protocols and facilitate development of strategies to
encourage greater research involvement. These findings highlight the
need for greater support and appropriate resources to alleviate potential
barriers faced by families. Genetic counselors are well suited to commu-
nicate research opportunities, address the specific needs of families, edu-
cate families on complex research issues, and explain study eligibility
criteria due to mutation-specific approaches in many DMD research
studies.
Sleep Disturbances in Children with Phelan-McDermid Syndrome
and Their Caregivers
D. Bro1, R. O’Hara1,M. Primeau1, A.Hanson-Kahn1, J. Hallmayer1,
J. Bernstein1
1. Stanford University
Backg round : Phe l an -McDe rm id synd rome (PMS) i s a
neurodevelopmental disorder caused by haploinsufficiency of the
SHANK3 gene. Sleep problems in children with PMS are anecdotally
common but not well characterized. Study objectives were: 1) to describe
parent-reported sleep disturbances in children with PMS, 2) to investigate
whether children with PMS are routinely assessed for sleep disorders, and
3) to examine the correlation between child and caregiver sleep distur-
bances. Methods: Data were collected via an online survey comprising
two questionnaires: the Children’s Sleep Habits Questionnaire and the
Parents’ Sleep Habits Questionnaire. Results: Caregivers who completed
the survey (n=193) were 86 % female and had a median age of 40 years.
Children of respondents were 54%male and had a median age of 8 years.
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Ninety percent of child total sleep disturbance scores were above the
clinical cutoff score (>=41), for marked sleep disturbance. However, only
22% of children had undergone a formal sleep assessment, and only 17%
had been diagnosed with a sleep disorder. Mean child scores for all
subdomains (bedtime resistance, sleep onset delay, sleep duration, sleep
anxiety, night wakings, parasomnias, sleep disordered breathing, and day-
time sleepiness) were elevated above those of a large historical commu-
nity sample. Caregiver total sleep disturbance scores and daytime sleep-
iness scores were significantly correlated with child total sleep distur-
bance scores (r=0.544, p<0.001 & r=0.413, p<0.001, respectively). Con-
clusions: Clinically significant sleep problems are present in childrenwith
PMS; however, most children have not been formally evaluated for sleep
disorders. Further research utilizing objective sleepmeasures is warranted
to identify the underlying sleep disorders present in children with PMS.
When properly diagnosed, many sleep disorders can be alleviated with
intervention. Addressing sleep disorders may not only improve the child’s
health and well-being, but also the quality of life of their caregivers.
The Clinical Utility of a Multi-Gene Panel for Neuromuscular
Disorders
M. Bradbury1, A. Lindy1, D. Copenheaver1, S. Suchy1
1. GeneDx
Objective: To assess the clinical utility of a multi-gene panel for diagnos-
ing a neuromuscular disorder (NMD). Background: NMD encompass
over 200 clinically and genetically heterogeneous disorders that primarily
affect the peripheral nervous and musculoskeletal systems. Overlapping
clinical features can make a clinical diagnosis challenging and may lead
to a diagnostic odyssey while potential health risks associated with the
condition go unmonitored. Molecular testing using a large multi-gene
next generation sequencing (NGS) panel is a newly available diagnostic
tool for providing a genetic diagnosis. Methods: In this retrospective
study, molecular testing was performed on 150 individuals with NMD
using NGS and exon-level copy number analysis of NMD 76 genes.
Confirmed test results and clinical information were evaluated to assess
the positive rate and concordance with the patient’s suspected diagnosis.
Positive results were defined as a pathogenic or likely pathogenic muta-
tion in an autosomal dominant or X-linked disorder, or two mutations in
an autosomal recessive disorder. Results: The positive rate for the panel
was 34 % (49/146). We found that 55 % (27/49) of positive cases were
concordant with the clinical diagnosis at the time of testing, while 35 %
(17/49) showed discordant results and an alternate diagnosis was
established. Examples include limb girdle muscular dystrophy (LGMD)
to hypokalemic periodic paralysis, type1 or FSHD to a dystrophinopathy.
In 10 % (5/49) no prior clinical diagnosis was provided. Of the positive
cases, 38 % had mutation in genes associated with LGMD, and 18 % in
genes for congenital muscular dystrophies or myotonias, consistent with
the high frequency of these disorders. Counclusion: Our results demon-
strate that multi-gene panels for NMD are an effective diagnostic tool and
in this series provided an unexpected diagnosis in one-third of cases.
Pursuing a multi-gene panel may allow identifying phenotypic outliers,
for which potentially therapeutic interventions exist; hence, targeted long-
term management of patients can be improved.
VIII. Clinical Care: Pre/Perinatal
Something Extra on Chromosome 5: Couples’ Understanding
of Positive Prenatal Chromosomal Microarray Analysis Results
B. Bernhardt1, A. Russell2, S. Walser1, R. Wapner2
1. University of Pennsylvania
2. Columbia University
Chromosomal microarray analysis (CMA) identifies copy number vari-
ants (CNVs) associated with known syndromes, risk for neuro-cognitive
disorders, an uncertain phenotype, or normal development. When diag-
nosed prenatally, couples’ understanding of the nature and consequences
of CNVs impacts decision-making and coping. To assess understanding
of positive prenatal CMA results, we conducted phone interviews with 28
women (2 terminating pregnancies and 26 continuing) and 13 male part-
ners 4–8 weeks after receiving positive CMA results from genetic coun-
selors. Transcript analysis assessed how CNVs were described,
interpreted and understood phenotypically. We compared this with labo-
ratory interpretation (pathogenic, likely pathogenic, variant of uncertain
significance (VOUS), or likely benign). We found nearly all the women,
but fewmen, accurately described the chromosome involved, whether the
CNV was a deletion or duplication and the range of possible phenotypic
effect; all participants knew if it was inherited or de novo. Most partici-
pants initially interpreted results as abnormal or uncertain, but couples
told a parent carries the same CNV as the fetus re-interpreted results as
normal or benign even if classified by the lab as likely pathogenic or
VOUS. Some couples receiving VOUS results were reassured by lack
of definitive information suggesting a problem, while others wanted prob-
abilities and experienced ongoing concern. When considering possible
clinical involvement, couples assessed their threshold for parenting a
child with a particular problem, most frequently mentioning learning
disabilities and autism risk. These findings suggest women, but not part-
ners, generally understand the nature and clinical implications of prenatal
CMA results. Couples feel reassured, perhaps sometimes falsely so, when
a CNV is inherited from a Bnormal^ parent. When a CNV is de novo
without ultrasound findings, even when some phenotypic information is
available, couples experience considerable uncertainty. Research is need-
ed to identify counseling approaches to aid understanding and adjustment
to uncertain results.
Patient Responses to cfDNATesting for Aneuploidy in a General
Pregnancy Population: Preliminary Results of the Rhode Island
Experience
E. Kloza1, B. O’Brien1,2, G. Messerlian1, E. Eklund1, G. Palomaki1
1. Women & Infants Hospital of Rhode Island
2. Department of Obstetrics and Gynecology, Alpert Medical School of
Brown University
Introduction: Several studies support the ability of cell free DNA
(cfDNA) to screen for aneuploidy in the general risk population. Howev-
er, evidence is still sought to support the feasibility of offering this
through primary care obstetrical providers. Purpose: To develop a mech-
anism to educate primary care office staff and to determine if validated
educational materials for the general risk patient support informed deci-
sion making. Methods: In September, 2014, Women & Infants Hospital
of Rhode Island began offering a cfDNA test (DNAFirst) to general
prenatal practices. Office education was developed, and patient materials
were validated by a focus group. Testingwas offered at no charge through
an arrangement with Natera, Inc. (San Carlos, CA). One hundred women
with negative cfDNA test results were selected for a telephone survey to
measure satisfaction, their knowledge of cfDNA testing, and characteris-
tics of their experience. Results: Sixty-six patient surveys were completed
to date. Surveys were administered by an experienced genetic counselor,
consisted of 36 questions and took 10 minutes to complete. Women
responded favorably (89–98 %) to 5 questions regarding the amount of
information provided and time allowed to decide. Questions focusing on
satisfaction revealed 97 % of women scoring 4 or 5 out of 5 regarding
their decision to have the test. All 66 women would recommend the
DNAFirst test to others, and 62 (94 %) would choose it again themselves.
Responses to knowledge questions were more variable. Around 80 %
knew what the test screened for and that there was a small chance of an
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affected fetus with a negative screen; 70% knew that a positive result was
not diagnostic. Of 58 women opting for sex aneuploidy testing, 40 (69%)
chose it to learn fetal sex. Conclusions: cfDNA testing can be an accept-
able alternative to conventional serum screening. Women express satis-
faction with the information they receive from providers and supplemen-
tal material. While most women understand test benefits and limitations,
there are opportunities to improve knowledge.
NIPS + FTS = ?: A Consideration of the Next Steps of Prenatal
Screening
E. Suskin1, L. Hercher2, K. Aaron2,3, K. Bajaj3
1. Sarah Lawrence College
2. Albert Einstein College of Medicine
3. Montefiore Medical Center
Introduction: Since its introduction less than 4 years ago, cell-free DNA
screening, also referred to as noninvasive prenatal screening (NIPS), has
been widely adopted as a screening tool for women at a high risk for fetal
aneuploidy. As use expands into the general population, questions arise
concerning the integration of NIPS into preexisting screening paradigms.
Hypothesis/Purpose: This study aims to examine the use of NIPS in
current practice, predominantly in the United States and Canada, in order
to inform strategies for the optimal use of both new and existing screening
techniques. Methods: We electronically surveyed 208 practicing mem-
bers of the National Society of Genetic Counselors to ascertain howNIPS
is currently being used. Genetic counselors were queried as to the advan-
tages and disadvantages of offering NIPS to all patients regardless of a
priori risk. Results and Conclusions: Results indicate substantial variation
in practice regarding which patients are offered NIPS and how counselors
have incorporated NIPS into existing screening routines. The majority of
participants report offering NIPS in conjunction with another method of
screening for fetal aneuploidy, indicating that NIPS is being used as an
addition rather than as a replacement. These screening methods primarily
include nuchal translucency (NT) and maternal serum alpha-fetoprotein
(MSAFP) (45.1 %, n=78) or first trimester serum screening, with or
without an NT, and MSAFP (19.7 %, n=34). Further, the majority report
that they would be concerned about losing the clinical value of an NT in a
complete transition to NIPS (85.4 %, n=164). Counselors are evenly split
on the merits of expanding the use ofNIPS to the general population (con:
55.3 %, n=105; pro: 44.7 %, n=85). The lack of consensus among re-
spondents suggests that practice guidelines might be a benefit to coun-
selors at this time. In addition, the respondents emphasize the significance
of better educating providers about the risks, benefits, and limitations of
the test.
Smith-Lemli-Opitz Syndrome is as Common in Caucasians
and Ashkenazi Jewish as Spinal Muscular Atrophy: Accurate
Carrier Frequencies Identified Through Expanded Carrier
Screening
G. Lazarin1, I. Haque1, E. Evans1, J. Goldberg1
1. Counsyl
Objective: Smith-Lemli-Opitz syndrome (SLOS) is a profound autosomal
recessive disease caused by mutations in the DHCR7 gene. Individuals
with the disease may exhibit a wide of phenotypic abnormalities, includ-
ing multiple congenital malformations, facial abnormalities, metabolic
errors, intellectual disability or developmental delay and behavioral ab-
normalities. Fetal demise is also thought to be a common outcome (up to
90 %) in affected fetuses. Having performed carrier screening for SLOS
in a large unselected cohort, here we compare the frequencies of SLOS
and spinal muscular atrophy (SMA), a disease currently recommended
for pan-ethnic screening based on severity level and high prevalence.
Methods: Targeted DHCR7mutations were analyzed in 174,156 individ-
uals presenting for routine carrier screening. We compared the resultant
carrier frequencies to those published for SMA. Results: SLOS carrier
frequencies were 1 in 56 in all combined Caucasians and 1 in 42 Ashke-
nazi Jewish. By comparison, the published SMA carrier frequency is 1 in
47 Caucasians and 1 in 67 Ashkenazi Jewish.
In other groups, SLOS frequency was less than 1 %, though it did exceed
0.5 % in Hispanics (1 in 168) and African Americans (1 in 175). The
SMA carrier frequency in these two latter groups is approximately
0.75%. Conclusion: SLOS and SMA are similarly severe diseases. SLOS
causes intellectual disability and congenital defects, though fetal demise
occurs in up to 90 % of conceptuses. SMA results in neurodegeneration
and infant death in most cases. Our data show that SLOS is common in
Caucasians and Ashkenazi Jewish, relative to SMA frequency. The
American College of Medical Genetics and Genomics recommends
pan-ethnic SMA carrier screening, due in part to frequency and severity.
Given the similar incidence and severity of SLOS and SMA, consider-
ation should be given to routine carrier screening for SLOS, at minimum
in the Caucasian and Ashkenazi Jewish populations.
The Experience of Vulnerable Patients Participating in Prenatal
Research Following a Diagnosis of Down Syndrome
B. Crissman1, K. Berrier1, B. Smith1, P. Kishnani1
1. Duke University
A prenatal diagnosis of Down syndrome (DS) brings a range of emotional
responses for expectant parents. Given that this is a vulnerable time,
medical professionals are met with historical, ethical and practical diffi-
culties for conducting prospective, large-scale studies with the prenatal
population. Following completion of an anonymous, web-based ques-
tionnaire which explored patients’ experiences and needs after a prenatal
diagnosis of DS, patients were subsequently asked to complete a self-
assessment of their experience with research. The 8-item post-study ques-
tionnaire, adapted from a previous bereavement study, aimed to assess the
emotional impact, perceived benefits and negative outcomes of the re-
search experience. A convenience sample of 232 respondents, 21–
54 years old, from 47 US states and 5 countries, included patients who
chose to terminate, continue and parent the child or create an adoption
plan. At the time of participation 30 % were currently pregnant. Results
showed that 95 % found participation in research to be beneficial, 95 %
agreed it provided an opportunity to share their feelings and 96 % felt
their participation could potentially help others. While 9 % felt research
participation was stressful, 91 % did not. While most agreed their partic-
ipation had some effect on them, and 28 % experienced unanticipated
emotional responses, only 1 % rated the overall research experience as
negative or regretted the decision to participate. Furthermore, the majority
(72 %) of patients provided personal contact information to learn about
future research opportunities regarding their prenatal diagnosis experi-
ence. Results support existing literature: even those who experience dis-
tress positively evaluated research on sensitive topics and their participa-
tion in it. We conclude that the potential altruistic and cathartic benefits of
participating in research outweigh the potential risks of psychological
distress for patients with a prenatal diagnosis of DS and suggest that
research opportunities may be considered as a resource even during vul-
nerable times.
Prenatal Diagnosis of Down Syndrome: Genetic Counseling
as a Significantly Unique Service
K. Berrier1, B. Crissman1, P. Smith1, P. Kishnani1
1. Duke University Medical Center
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Current literature is limited to retrospective accounts of patients with a
prenatal diagnosis (PNDX) of Down syndrome (DS). With increasing
popularity of noninvasive prenatal screening (NIPS), the need for further
investigation of patients’ diagnostic experiences is more important than
ever. This exploratory study aimed to assess patients’ experiences follow-
ing a PNDX of DS. Participants voluntarily completed an anonymous
web-based questionnaire to characterize the genetic counseling (GC) pro-
cess and define the role of GC as well as information provided. A con-
venience sample included 187 men and women, ages 19–49, with a
PNDX of DS in 2013 or 2014 via amniocentesis (n=68), chorionic villus
sampling (n=28) or NIPS (n=87) in an ongoing or recent pregnancy.
Responses were stratified and compared by logistic regression based on
whether there was interaction with GC. Most patients (n=120) had some
interaction with and 59 % (n=71/120) were initially told the PNDX by a
GC. The GC role was more frequently considered to be Beducator,^
providing mostly genetic or medical facts about the diagnosis (63 %)
and less often Bcounselor^ (31 %) or emotional Bsupporter^ (41 %).
Compared to various other healthcare providers (HCPs), patients with
GC interactions were significantly more likely to receive information
about the genetics, associated physical features and intellectual disability,
future reproductive options and recurrence risks, potential impact on the
family, web-based and printed informational resources including support
groups and organizations, and the option to create an adoption plan.
Patients with GC interactions were more likely to discuss personal knowl-
edge or beliefs about DS and were also significantly more satisfied with
the information and emotional support received. Results represent a novel
and current look into patients’ PNDX experience and evince GC as a
significantly unique service compared to other HCPs. Findings may be
useful for demonstrating utility of and justification for the inclusion of GC
for a PNDX, with application to other clinical settings.
Posters
I. Access and Service Delivery
A Glimpse into the Future: Disclosure of Genomic Sequencing
Results by Non-Genetics Physicians
C. Blout1, J. Krier1,2, J. Robinson3,M.Helm1,2, K. Lee3, D. Perry4, R.
Green1,2,5
1. Brigham and Women’s Hospital
2. Harvard Med School
3. Center for Medical Ethics and Health Policy, Baylor College of
Medicine
4. Illumina Clinical Services Laboratory
5. Broad Institute
Introduction: Experts have raised concerns about a shortage of genetics
professionals to interpret/communicate genome sequencing (GS) results,
but little data exist regarding GS disclosure competency by non-genetics
physicians. The MedSeq Project explores the incorporation of GS into
clinical medicine, enrolling primary care physicians (PCPs) and cardiol-
ogists to return genome reports (GR) to patients without the mediation of
genetic counselors (GCs).
Purpose: Our goals were to assess physicians’ intended and actual use of
an on-call Genome Resource Center (GRC), staffed by GCs and clinical
geneticists, to support their GR interpretation and implementation and to
monitor for errors and miscommunication about GS results during GR
disclosure.
Methods: At study start, physicians completed a genomics education
module. Prior to patient enrollment, physicians were asked about their
anticipated use of the GRC. Interviews were consensus coded and ana-
lyzed and GRCutilization tracked. Disclosure sessions were recorded and
transcripts reviewed for the accuracy of genetic information shared with
the patient. If miscommunications were identified, physicians were
contacted immediately or at the end of the study depending upon the
perceived urgency and safety impact of the miscommunication.
Results: Of 18 physicians asked, 13 articulated an intention to utilize the
GRC. Six physicians contacted the GRC in the first 28 months of the
study. Of the first 45/100 GS disclosure transcripts reviewed, 20 minor
miscommunications were identified for end-of-study educational follow-
up, and 3 for real-time intervention (2 related to carrier risk, 1 to inheri-
tance pattern mis-interpretation).
Conclusion: Non-genetic physicians who participated in MedSeq ac-
knowledged the value of the GRC, but only a minority utilized it. While
the genetics information provided by non-geneticists contained some er-
rors, serious errors were infrequent. When provided with genetic educa-
tion and resources to easily query experts, non-genetics providers may be
able to correctly and safely convey GS results.
A Unique Service Delivery Model for Genetic Counseling Services
E. Denne1, M. Gilats1, G. Lazarin1, J. Goldberg1
1. Counsyl
The recently published joint statement, BExpanded Carrier Screening in
Reproductive Medicine - Points to Consider^ highlights the importance
of post-test genetic counseling in helping patients understand their carrier
screening results. Counsyl, a laboratory which has performed expanded
carrier screening on over 400,000 patients since 2009, has integrated
genetic counseling into expanded carrier screening services since incep-
tion, and developed a unique service delivery model in order to scale this
service with mass population utilization. Upon results availability, pro-
viders are first notified; then, patients are contacted by email and are
requested to view their results. Patients log into their secure account
online to view results, watch tailored informational videos and request
immediate genetic counseling with our on-call service. Patients may also
opt to schedule a consult at a later point if preferred. This systemmay help
overcome barriers such as limited access to in-person genetic counseling
in certain geographic areas, employment conflicts, long wait times for
scheduling an in-person genetic counseling appointment, and appoint-
ment times outside of normal business hours. We recently issued 16,
306 laboratory results via this unique system, and greater than 90 % of
reports were for expanded carrier screening. Currently 79 % of all indi-
viduals view their results within 2 weeks after availability. Most that do
not view results have no abnormal findings. 99 % of individuals with
abnormal results scheduled counseling, declined a consult or received
manual follow-up from our support team within 2 weeks. We will present
further data to discuss the efficiency of this protocol and the differences in
consultation goals compared with a Btraditional^ model. Understanding
these differences will highlight how alternative service delivery models,
such as the one we have implemented, help to extend genetic counseling
services to an expanded patient population.
Evaluating the Impact of Group Genetic Counseling Sessions
in the BRCAcommunity Study
B. Georges1, R. Lebor1, C. Wiesman2,3, E. Rose2,3, N. Schreiber-
Agus2
1. Sarah Lawrence College
2. Program for Jewish Genetic Health, Albert Einstein College of
Medicine
3. Montefiore Medical Center
The purpose of this study was to design, implement, and evaluate the
utilization of a group genetic counseling tool and pre-counseling
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education among Blow risk^ Ashkenazi Jewish (AJ) individuals being
offered population screening for BRCA founder mutations. Screening is
offered through an ongoing IRB approved study called the
BRCAcommunity Study, an initiative of the Program for Jewish Genetic
Health and Montefiore Medical Center. Methods of pre-test genetic
counseling in large groups of low risk individuals are not well defined
and have not been previously studied. The counseling tool developed is a
PowerPoint presentation containing education about BRCA mutations,
two facilitated discussion components, the genetic testing consent process
and information about the BRCAcommunity Study. Broad educational
themes included the role of BRCAmutations in cancer development, risk
assessment challenges in low-risk families, risk-reducing options for
BRCA carriers, and risks, benefits and limitations of BRCA testing.
Self-administered pre- and post-group counseling surveys were used to
determine the effects of the pre-counseling educational materials and
group genetic counseling on gains in knowledge and patient comfort.
Approximately half of participants indicated they utilized the pre-
counseling educational materials 6/11 (55 %). The average pre-
counseling knowledge score was 79.5 % while the average post-
counseling score was 95.5 %. When asked if they would prefer meeting
with a genetic counselor one-on-one: 4/9 (44 %) felt neutral; 5/9 (56 %)
disagreed/strongly disagreed. None of the participants preferred to meet
with a genetic counselor one-on one. In terms of the interactive elements
of the session, 7/9 (78 %) reported feeling comfortable, but only 1/9
(11 %) felt it enhanced the session. This study reveals a broadly positive
patient experience using group genetic counseling as an effective service
delivery model for population based pre-test genetic counseling in low
risk individuals in terms of knowledge gain, patient comfort, and patient
perceptions of efficacy.
Facilitating the Continuum of Care: A Model for Utilization
of the Electronic Medical Record to Transition Patients
from Perinatal to Pediatric Genetics
C. Grabarits1, M. Dudek1, L. Fairbrother1, J. Nichols1
1. Vanderbilt University Medical Center
With the rapid technological advancement in prenatal ultrasonography,
patients are increasingly being identified in the perinatal period as need-
ing postnatal genetic evaluation or testing.With this ever-growing need, it
is imperative to improve communication between genetic colleagues in
the departments of obstetrics and pediatrics. More specifically, providing
and reviewing patient-specific information with the postnatal genetics
team so that the patient Bhandoff^ can be successful between depart-
ments. At Vanderbilt Children’s Hospital genetic counselors in the De-
partments of Obstetrics and Pediatrics have collaborated to create a com-
munication tool within the electronic medical record (EMR) called the
Fetal Center Panel (FCP). The FCP is a list of expecting mothers whose
unborn babies have an indication for postnatal genetics evaluation. The
panel grants electronic access to the mother and newborn charts and has a
brief summary of prenatal information including pertinent labs, ultra-
sound findings, EDD, delivery plan, and psychosocial information for
review by the postnatal team. The providers from the two departments
have established the criteria for which patients should be added to the
FCP. The prenatal genetic counselors consult with the indicated families
and make them aware of the involvement of genetics at delivery while
obtaining consent for genetics involvement. Typically these patients have
ultrasonography findings consistent with a possible genetic disorder, a
pertinent family history, or the need for postnatal testing coordination,
including pathology and specialty testing. Both teams monitor the FCP
for anticipated and impending deliveries. Having the FCP and summaries
electronically accessible facilitates the coordination of care by the pedi-
atric genetic counselors. Consultations are triaged and the pediatric ge-
netic counselors expedite critical labs ensuring they are sent
appropriately. The development and use of the FCP within the EMR
provides a communication bridge between prenatal and postnatal genetic
services and continuity of patient care.
Community-Based Cancer Genetics: Evaluating the Planned
Parenthood System
S.Greenberg1, B. Yashar1, D. Duquette2,M. Pearlman1, K.Milliron1,
M. Marvin1
1. University of Michigan
2. Michigan Department of Community Health
Well-documented health disparities exist in the provision of cancer genet-
ics services. In response, Planned Parenthood (PP) developed a novel
breast cancer risk screening program (BRSQ) to identify clients that could
benefit from genetic services. This research evaluated the BRSQ’s effica-
cy as a community-based high-risk cancer screening program. A mixed
method approach was used to evaluate clinician knowledge, confidence
and utilization of the BRSQ. Novel surveys probing these topics were
administered to Mid/South Michigan PP providers (n=14). Descriptive
statistical analysis formed the basis for follow-up semi-structured inter-
views (n=6). An iterative coding process with 3 coders identified themes
describing facilitators and barriers to BRSQ and genetic service utiliza-
tion. The survey and interview results found that all providers knew how
to administer the BRSQ and most (83 %) could accurately describe ge-
netic counseling/testing, however they were least confident discussing
genetic services with their clients (p<0.01). 6/6 interviews identified lim-
ited knowledge of client’s family history as a barrier to BRSQ-risk as-
sessment, with specific concerns regarding client awareness of ovarian
cancer family histories (6/6) and genetic testing (5/6). Barriers including
affordability (6/6), client attitudes towards genetic knowledge (6/6), and
background genetic knowledge (5/6) were similar to those in hospital
settings. The client population’s young age (70 % under age 30) was
described in 83 % of interviews as a unique challenge. However, family
experiences with cancer was reported as a predictor of clients’ interest in
seeking genetic services (4/6 interviews). Effective use of a community
based cancer screening program depends on both provider and patient
characteristics. Provider training should include education about genetic
counseling to build confidence and encourage patients to seek genetic
services. Understanding the traditional and unique barriers identified in
a community setting allows for targeted interventions to improve utiliza-
tion of genetic services.
BeCarefulWhat youWish For: TheDownstream Impacts ofGenetic
Counseling Licensure
M. Hardy1, T. Page1
1. JScreen, Emory University
Efforts to pass licensure legislation for genetic counselors have proven
successful in over twenty states. Licensure protects the public interest,
and has led to improved recognition of the profession and reimbursement
for genetic counseling services. However, further consideration of the
downstream impact is warranted. JScreen is a small, non-profit public
health initiative at Emory University dedicated to promoting preconcep-
tion reproductive carrier screening. The telegenetics approach allows us
to reach individuals in remote or underserved areas across the United
States. Post-test genetic counseling, provided using phone or secure vid-
eo-conferencing, is an important part of the service we offer. Our goal is
to have at least 2 genetic counselors licensed to provide counseling in
every state at all times. Initial application fees and associated costs have
totaled over $2,000 per counselor and involved over 40 hours of work to
fulfill requirements, many of which are common between the states.
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Regular renewal of licenses is similarly cost-prohibitive. These costs do
not include those related to continuing education and board certification.
Licensure requirements disproportionately hurt smaller non-profit com-
panies over for-profit companies with many genetic counselors on staff.
As genetic counselors in additional states succeed in obtaining licensure,
the burden in terms of cost and time may lead to reduced ability to serve
states with smaller populations and limit telehealth opportunities for the
genetic counseling profession as a whole. Reciprocity and other solutions
to reduce this growing burden must be a larger part of the licensing
conversation.
Greater Professional Autonomy and Recognition with use of a Novel
Genetic Counseling Service Delivery Model in a Pediatric/General
Genetics Clinic Setting
C. Harper1
1. Beaumont Health
A novel genetic counseling service model in a pediatric/general genetics
setting is presented in which patients are seen first by the genetic
cousnelor (GC) with the physician evaluation and management (E/M)
visit occurring a later time. A GC visit is required prior to any E/M visit.
Although GCs in other clinical areas have provided independent GC
services for some time, this type ofmodel in the pediatric/general genetics
setting is novel.We began incorporating this model in April of 2014, with
full implementation by the end of 2014. Professional advantages to the
GC have included increased autonomy and recognition of the genetic
counselor as a distinct and unique provider. Traditionally, the services
of the GC is included as part of the E/M visit. The GC, although consid-
ered to be integral to the service, not been recognized as an independent
provider and generates no separate revenue. Furthermore, a large portion
of the GC’s time is spent triaging cases by phone, activities that require
separate documentation and are usually not reimbursed. In this new mod-
el, the GC is independently responsible for the GC visit including written
documentation, correspondence, follow-up, and billing. Most of the
triaging is now performed as part of the GC visit so that the documenta-
tion is included as part of the GC clinic note and part of a billable service.
Because the documentation of the GC visit is separate from that of the E/
M visit, other providers are more likely to recognize the GC as an inde-
pendent provider rather than support staff. Importantly, since the billing of
the GC visit is under the GC’s national provider identifier number, the
revenue cycle at our institution has begun to recognize GCs as a separate
source of revenue, which we hope will lead to increased valuation of the
GC and genetic counseling services by the institution.
Texas Physicians’ Awareness and Utilization of Genetic Services
C. Jenevein1, J. Hoskovec2, B. Stevens2, C. Sullivan3, S. Hashmi4, J.
Refuerzo2
1. University of Texas Health Science Center at Houston
2. University of Texas Medical School
3. Baylor College of Medicine
4. Department of Pediatrics, University of Texas Medical School
The number of disorders for which genetic testing is available has in-
creased nearly 500 % in the past 15 years. Access to the majority of
genetic tests and services hinge on physicians’ ability to identify patients
at risk for genetic disease and provide appropriate testing and counseling
or refer to genetics specialists. Recent research demonstrates the need for
referrals to genetics specialists by showing that many physicians lack
skills required to perform appropriate genetic services, such as making
proper risk assessments, providing genetic counseling, ordering genetic
testing and interpreting results. However, little research exists on
physicians’ awareness and utilization of genetic services. In this study,
an electronic survey evaluating practicing physicians’ awareness of, uti-
lization of, and perceived barriers to genetic services in Texas was dis-
tributed via state physician organizations. Of the 157 participants, approx-
imately half reported they were moderately or very aware of genetic
testing and services in their area. Very few reported awareness of tele-
medicine services. Over two-thirds reported never or rarely referring to
genetic counselors or other genetic specialists, despite 75 % reporting
they had noticed an increased impact of genetics on their field and
61 % reporting they had discussed genetics more in their day-to-day
practice in the last 5–10 years. Only 20 % reported genetics was very
integral to their specialty. Over three-fourths of all participants indicated
interest in learning more about genetics, genetic testing and genetic ser-
vices. Among the most frequently chosen barriers to genetic counselors
were awareness-related barriers such as not knowing how to refer
to a genetic counselor. Responses to many items varied signifi-
cantly by medical specialty. The results identify a need to in-
crease awareness of genetic services and referral logistics. Specif-
ic findings can help direct outreach efforts to educate clinicians,
such as developing clinically meaningful, specialty-specific educa-
tional objectives.
Next-Generation Counseling: Increased Efficiency and High Patient
Satisfaction Utilizing Web Technology and Telephone
for Post-Carrier Screen Counseling and Education
G. Lazarin1, M. Gilats1, E. Denne1, I. Haque1
1. Counsyl
Post-test patient followup is integral to carrier screening programs. How-
ever, there are 4M pregnancies each year and expanded carrier screening
(ECS), which confers high test-positive rates, is being increasingly uti-
lized. Thus, efficient allocation of genetic counselors’ (GCs) time is a
necessary step to large-scale implementation. Our laboratory has offered
iterations of direct-to-patient results delivery. Here we compare three
models’ effects on GCs’ time spent: V1 (every patient speaks to a GC),
V2 (results are systematically triaged, and most patients are given results
online, with web education and immediate GC consultation option), and a
Btraditional^ model (the clinic delivers results and GC consultation is
available when initiated by the patient).We analyzed consultation uptake,
duration and satisfaction for 304,108 carrier screening results issued by
our laboratory, identifying the following trends: (1) In all versions, more
serious results (e.g., a carrier/carrier couple) were associated with longer
consultation times. (2) In V2 and the traditional model, more serious
results were also associated with higher consultation uptake rates. (3)
Consults were longer on average for V1 results than for V2. E.g., an
individual carrier consult was 12 min (9–17 min, interquartile range) for
V1 and 10 min (7–15 min) for V2. The shorter consult times may derive
from pre-consult web education issued through V2. (4) Illustrating opti-
mal GC allocation, the V2website education provided for negative results
enabled lower consultation rates compared with V1. (5) Patient satisfac-
tion was high (4.9 / 5.0 rating) in all models. We demonstrate time utili-
zation benefits by a results-delivery model that combines web education
and counseling. Time saved by efficient delivery of simpler re-
sults offsets time used due to increased positives. In one example,
2 minutes per consult were saved. As a laboratory issuing multi-
ple thousand results per week, with concomitant GC availability,
this translates to hours saved enabling feasibility of post-test fol-
low up for widespread ECS.
Participant Perspectives and Efficiency of iPads in Pedigree
Construction and Assessment
A. McCarty1, K. Valverde1, L. Conway1, H. Fecteau2, L. Kessler1
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1. Arcadia University
2. HCA Healthcare
Many medical institutions have converted to using electronic health re-
cords (EHR). Numerous programs have been created to draw pedigrees,
yet integration of these programs into EHRs remains limited. Anecdotal-
ly, many counselors still construct pedigrees using pen and paper, while
others use available commercial software. To date, there has been little
research comparing methods. The goal of this study was to assess the
experience of participants when having their family histories taken with
pen and paper compared to a digital method (Proband©) on the iPad.
Forty-eight participants were recruited from a university student and fac-
ulty population and were randomized to a pen and paper group or iPad
group. Outcomes assessed included: time needed to draw the pedigree,
plans for sharing the information, perceived accuracy, and satisfaction
with the process. Pedigrees were recorded by the primary author. There
was no statistically significant difference found on any outcomes mea-
sured between the two groups, as analyzed by two-tailed Fisher’s exact
test. Specifically, no difference was found in the amount of time needed,
and 94 % of participants reported being satisfied with the experience. In
spite of providing education about the importance of family health history
information, only fourteen participants (29.2 %) indicated that they would
share the pedigree with family members. All in the iPad group (24/24)
and 22/24 in the pen and paper group reported satisfaction with accuracy
of the pedigree. Although this difference was not statistically significant,
the perception of increased accuracy in the iPad group may be an area for
future study. Recording pedigrees using an electronic method may in-
crease efficiency in clinical care if the method can be seamlessly integrat-
ed with EHR. Results from this research show use of the iPad application
does not negatively impact perceived accuracy, rapport during the pedi-
gree, or overall satisfaction. This study provides evidence to support use
of iPad applications for collection of family health history in clinical
settings.
Cancer Genetic Counseling by Videoteleconferencing
Along the Texas-Mexico Border
L. Mette1, A.M. Pulido1, N. Poullard1, I. Torres1, S. Seth1, B.
Pollock2, G. Tomlinson1
1. University of Texas Health Science Center at San Antonio
2. University of California, Davis
Breast and colorectal cancers are two common cancers for which genetic
risk assessment and counseling are available. However these services are
often limited to major metropolitan areas and not frequently accessed by
underserved populations. Multiple ethnic and racial disparities exist with
regards to identification of high-risk individuals, screening, and treatment
outcomes; these socioeconomic factors are frequently seen in minority
and new immigrant populations. We provided cancer genetic risk assess-
ment and counseling via telemedicine, as well navigation to breast and
colorectal cancer screening, education, and outreach to the south Texas-
Mexico border region. This population shares many of the barriers iden-
tified in other minority populations, including lack of resources and health
insurance, distrust of the medical system, and family and employment
obligations that preclude access to care. In order to determine the accept-
ability of this alternate service model, program participants were mailed a
20-item questionnaire to assess their level of satisfaction with the pro-
gram.With a completion rate of 34%, the overall level of satisfactionwas
very high (4.715 out of 5), and nearly half reported decreased concerns
about developing cancer after genetic counseling. These findings demon-
strate the acceptability of a cancer genetic risk assessment program heavi-
ly reliant on telemedicine in an underserved minority community. Despite
the challenges previously noted in the literature about serving minority
populations and barriers to cancer genetic risk assessment for Hispanics,
we were able to provide these services in line with traditional genetic
counseling services while maintaining a high level of participant
satisfaction.
Making Sense of a Primary Care Role in Genomic Medicine: Views
of Genetics Health Professionals
S. Morrison1, J. Allanson1,2, F. Miller3, B. Wilson2, J. Permaul4, J.
Carroll3,4
1. Children’s Hospital of Eastern Ontario
2. University of Ottawa
3. University of Toronto
4. Mount Sinai Hospital
Developments in genomic medicine (GM) are expected to implicate pri-
mary care providers (PCPs), who, as first contact professionals with a
foundational role in most health care systems, will need to be equipped.
Yet public policy efforts to enhance the relationship between primary care
(PC) and genetics are inconsistent or non-existent. Purpose: To explore
the role of genetics health professionals (GHPs) in building relationships
with the PC community. Methods: Qualitative methodology. GHPs at
centers across Ontario, Canada were invited to participate in semi-
structured focus groups or telephone interviews. Purposeful sampling
was used to ensure diversity by type of GHP and of center (academic,
community). Transcripts were analyzed using a qualitative interpretive
approach. Results: 5 focus groups and 2 interviews were conducted (6
clinical geneticists, 24 genetic counselors, 4 nurses, 4 lab staff, 3 admin-
istrators) from 5 of 10 regional genetics centers and 2 of 5 northern
outreach clinics. Participating GHPs expect PCPs to play a role in GM
and describe the relationship between GHPs and PCPs as key to the
provision of quality GM.However through interactionswith their patients
and very limited direct interactions with PCPs, GHPs expressed limited
understanding of PC scope of practice and acknowledged uncertainty
about howGMmight fit into primary care practice. GHPs voiced concern
about a perceived lack of knowledge of GM, as reflected in under- and
over- referral, and in PCPs ’ ability to incorporate new genomic discov-
eries. GHPs also reflected on whether existing communication methods
with PCPs were effective, and recognized a need to understand PCPs’
need for support in this area. Conclusions: GHPs recognize an important
role for PCP in GM, but in the absence of policy direction or organiza-
tional support, they struggle tomake sense of how this might work. In this
context, in addition to identifying knowledge and capacity deficits, pa-
rameters of a productive collaboration between PCPs and GHPs need to
be developed.
AGenomic Education/Decision Support Tool for Clinical Sequencing
B. O’Connor1, K. Owens1, J. Schuette1
1. University of Michigan
Genomic medicine challenges health care providers to communicate
complex information. Of particular importance is the task of obtaining
informed consent (IC) for clinical sequencing (whole genome/ whole
exome sequencing (WES)), which has relevance for the diagnostic eval-
uation as well as implications for additional health considerations known
as secondary findings. Tools for facilitating IC and decision-making in
this context are limited. We therefore developed an education/decision
support tool in a personal narrative/video format to enhance communica-
tion, IC, and to assist with identifying patient preferences for the return of
results. The experience of a family undergoing clinical sequencing, deci-
sion making and receipt of both diagnostic and secondary test results was
used to highlight issues for consideration during the IC process. The 8-
minute video is viewable prior to a patient’s appointment or in clinic via
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an iPad. Family specific questions and concerns are addressed by the
genetic counselor when the video has ended. Forty-six families (n=81)
completed an anonymous, novel 8-item Likert scale survey examining
knowledge, self-rated understanding, clarity, and ease of choice. The
validated Traditional Decisional Conflict Scale (DCS) was used to exam-
ine the factors of certainty, values clarity, knowledge, and confidence in
decision making, with scoring from 0 to 100. The majority (60 %) report-
ed the video tool assisted with decision making, while 32 % were neutral.
Total average score on the decisional conflict scale (7.16) was consistent
with minimal conflict. The average length of time for WES counseling
and informed consent was 21½minutes (range 15–40), not including time
for viewing the video. Our findings show that an education/decision
support tool can be invaluable as an adjunct to counseling and informed
consent for genomic sequencing. Understanding of sequencing-specific
issues and test outcomes, and confidence in decision making with mini-
mal conflict are achievable within the clinical setting.
Genetic Telecounseling: Ensuring Quality Patient Care
by Examining Initial Experiences
N. Paolino1, S. Yarnall1, S. Rodriguez1, N. Kumar1
1. Recombine
As the technologies andmethodologies for genetic testing evolve, somust
the careers surrounding it. With a welcome push from the larger medical
community to integrate genetic testing into routine care, genetic coun-
selors in particular find themselves providing patient care in new and
different environments. With an increasing number of genetic counselors
employed by laboratories, the practice of telecounseling is becoming
more commonplace. Limited literature exists in regards to strategies or
recommended practices for a successful genetic telecounseling session.
Just as standards of care were constructed in the past for clinical genetic
counseling, the same must now occur for telecounseling.
Important aspects of a clinical counseling session, such as establishing
rapport, explaining complex genetic concepts, obtaining a detailed family
history, and coordinating follow-up care will need to be successfully
incorporatedwithout the added benefit of face-to-face interaction. A num-
ber of laboratories currently offer post-test telecounseling following ex-
panded carrier screening, noninvasive prenatal testing, and hereditary
cancer screening. These sessions vary greatly in their structure and the
incorporation of the aforementioned clinical elements. It is important that
counselors with vast experience performing genetic counseling via tele-
phone and other communication technologies discuss what works, what
could be improved, and what inherent issues cannot be eliminated. In
doing so, practice guidelines that prove successful universally can be
established. By examining the initial experiences of a team of laboratory
genetic counselors conducting genetic telecounseling for both expanded
carrier screening and noninvasive prenatal testing, our aim is to start a
dialogue to lay the groundwork for the establishment of telecounseling
practice guidelines.
Partnering with Industrial Engineering to Obtain Critical
Programmatic Resources
V. Raymond1,2, K. Schwalm2, J. Everett2, T. Ellies2, W. Uhlmann2
1. Illumina
2. University of Michigan
Problem: The increasing demand for clinical genetics expertise, specifi-
cally in regards to the growing patient volumes and the institutional goal
of decreasing patient appointment wait time, placed stress and strain on
the genetic counselor and physician resources at the University of Mich-
igan Medical and Cancer Genetics Clinics. We partnered with an
industrial engineer (IE) to identify ways to streamline workflows and
delegate specific tasks in an effort to meet these demands. Intervention:
Between March and March 2014, the IE mapped clinic workflows,
interviewed GCs, support staff and scheduling teams. Data from a previ-
ous GC time study was also utilized. The goal was to propose streamlined
workflows that respect unique clinical requirements, and determine the
full time effort (FTE) requirements for execution. Solution: The IE pro-
posed: 1) centralizing intake to a single individual supporting the two
clinics, ensuring individuals speak with a knowledgeable person and
patients are scheduled appropriately. 2) Delegating insurance authoriza-
tion for the clinic visit and genetic testing to a single individual 3) order-
ing pre-assembled appointment packets for patients and 4) Delegating
administrative tasks including, mailing/collecting clinic forms, obtaining
outside medical records and patient no-show/cancellation follow-up. The
IE recommended 1.5 FTE Bintake coordinators^ and 0.75 FTE for insur-
ance authorization. The IE provided the institution with detailed docu-
mentation and this proposal was approved with an additional 0.5 FTE
granted (2.75 FTE) to accommodate for anticipated growth.
Outcome: Since implementation, both clinics have experienced increased
patient volume and decreased wait times. The physicians and GC’s report
that the daily clinic operations have improved and streamlined with ap-
propriate patient scheduling and the upfront work of gathering medical
records and insurance information. Partnering with the IE allowed for the
collection of systematic, detailed data demonstrating needs and obtaining
necessary resources.
Fetal Center web Directory Provides Easy Access to Fetal Center
Genetic Counselors
S. Reichert1, M. Dudek2
1. Children’s Hospital of Philadelphia
2. Vanderbilt University
Since the publication of the results of the Management of
Myelomeningocele Study (MOMS) in 2011, there has been a surge in
ultrasound units rebranding and reinventing themselves as Fetal Centers.
Fetal Centers typically utilize a multidisciplinary approach for the evalu-
ation and management of women with pregnancies diagnosed with a fetal
anomaly by ultrasound. Some centers offer fetal interventions.
Genetic counselors have worked in the area of obstetrics and ultrasound
for decades and are experts at providing education and discussing testing
options to families receiving news of a potential fetal anomaly by ultra-
sound. However, it has been difficult for patients and providers to easily
identify Fetal Centers which employ genetic counselors as part of their
multidisciplinary team. With grant funding from the Prenatal Special
Interest Group (SIG) of the NSGC, the REDCap web application was
used to create an online database of Fetal Centers. Patients and providers
will find 53 Fetal Centers listed in 26 states at www.NSGC.org/
fetalcenterdirectory. Links to the centers’ websites are provided as
well as their contact information. All contributing centers were
polled for the fetal anomalies for which they provide evaluation
and fetal interventions. These data are listed as well as the diag-
nostic procedures offered. Data regarding support services avail-
able (social work, housing assistance, perinatal palliative care) and
if patients are being recruited for fetal intervention studies are
also provided. Members of NSGC have the exclusive ability to
download contact information for genetic counselors working at
each Fetal Center. This online directory is an excellent resource
for those seeking Fetal Center services. It highlights the value of
Genetic Counselors in this growing area of expertise. The website
will be maintained by the NSGC and updated annually by the
Prenatal SIG prior to the educational conference to keep the in-
formation current and inclusive of all Fetal Centers with genetic
counselors.
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Barriers and Motivators for Genetic Counseling Services:
A Physician Survey
C. Rigelsky1, D. Clements1, M. Doerr1
1. Cleveland Clinic
The practice and billing of genetic counseling services have evolved in
recent years with the hope of providing greater access. Referral practices
of physicians to genetics have been previously studied with the greatest
emphasis on referrals to genetic services in general or to cancer genetics.
Primary care physicians have most commonly been surveyed with a few
surveys including specialists. The objective of this study was to gain a
better understanding of what influences physicians to utilize genetic
counseling services at Cleveland Clinic as well determine the obstacles
in referring to genetic counseling in order to increase patient referrals. An
electronic survey was distributed to 934 physicians in the Heart and
Vascular Institute, Pediatric Institute, Neurological Institute, Cancer Insti-
tute and OB/GYN and Women’s Health Institute of the Cleveland Clinic
Health System. The survey consisted of a maximum of 36 questions
regarding knowledge and awareness of genetic services, existing referral
practices, motivators and obstacles to referring patients. Descriptive sta-
tistics were used to analyze and summarize the study responses. Ninety-
four percent of physicians from select institutes indicated they were aware
of genetic counseling services and 75 % of physicians who have referred
to genetic counseling services were Bvery satisfied.^ Fourteen percent of
respondents indicated a Bcompletely sufficient^ understanding of how
genetics can meet their current practice needs. The greatest barrier to
referring to genetic counseling services was the cost of tests (51 %) and
genetic counseling (43 %). Following cost, 27 % of physicians agree that
patient willingness is a barrier to genetic counseling services. Thirty per-
cent agreed that accessibility of services was a barrier. The results of this
study indicate the need for ongoing education of physicians and patient
groups and to provide services in locations that are convenient for the
patient.
What We Have Learned and What We Need to Change: Two-Year
Experience of a Newly Established Prenatal Genetics Clinic in Japan
C. Tamura1, H. Arakawa1, Y. Chiba1, C. Kihira1, M. Song1, Y.
Nakamura1
1. Fetal Medicine Clinic Tokyo
Since 2013, we have established a new prenatal clinic in Tokyo. Founding
members were a fetal medicine specialist as well as a clinical geneticist,
and a genetic counselor, and both studied in Europe and the U.S.We have
practiced according to the European and American standard, providing
full-spectrum of prenatal testing/diagnosis, including first and second
trimester screening, detailed sonogram, chorionic villus sampling, amnio-
centesis, and genetic testing when needed, with sufficient individual and
group genetic counseling sessions. Although it has been reported that
prenatal testing is not commonly practiced in Japan, we have seen more
than 3,000 people over 2 years, and have learned many things from their
statements. In this presentation we would like to describe what we have
learned. First of all, there is a short supply of prenatal testing in Japan, and
equal access for people is not guaranteed. Many have faced difficulty to
have prenatal testing because there are not many providers, and obstetri-
cians often try to stop them undergoing prenatal testing because it is an
unethical thing. Second, prenatal practice seems not to be standardized in
Japan. Different providers have different procedures, and many use dif-
ferent risk assessment calculations. Third, complexity of genetics seems
not to be understood by most of Japanese practitioners, as they tend to
ignore people’s family histories and genetic backgrounds. Fourth, as we
experience that information provision through our genetic counseling has
been greatly appreciated by clients, it seems that information about pre-
natal options is very limited among pregnant women and couples, as well
as among medical professionals. Although there are many challenges in
Japan in this field, the first thing we need to do seems to be introduction of
the idea of people’s right to obtain information, right to choose, and
guaranteed equal access to the prenatal testing options. We would like
to promote people’s self-determination and informed choices, and expand
our online information provision, in addition to genetic counseling at our
clinic.
Genetic Testing BPain-^Perwork: Improving the Collection
and Submission of Clinical History for Genetic Test Orders
S. Stasi1, D. Sternen1, J. Conta1, G. Londre2, C. Zaleski2
1. Seattle Children’s Hospital and the Pediatric Laboratory Utilization
Guidance Services
2. PreventionGenetics
Clinical history is critical for accurate and meaningful genetic test result
interpretation. Despite reference laboratories’ requests for this informa-
tion, it is not routinely submitted.When omitted, laboratory directors may
be limited in their ability to pre-analytically review test requests for ap-
propriateness, interpret results, or produce a report that offers meaningful
interpretation and recommendations. When reference laboratories spend
time eliciting this information from ordering providers, test delays may
result. We identified several barriers to consistently submitting clinical
history on genetic test requisitions, including unique requisitions across
labs and limited provider/staff time to locate and complete requisitions.
The purpose of this study was to outline the current landscape and devel-
op and implement a standard clinical history form to be included with test
requisitions. We hypothesized that use of a standardized, simplified form
would increase the number of requests that include clinical history and
enable reference laboratories to better review orders, ultimately improv-
ing the value of test request and interpretation. A 1-month retrospective
review was completed to determine how often clinical history was pro-
vided on genetic test requisitions. Of 74 requisitions, 8 were excluded due
to explicit clinical history requirements (e.g., exome sequencing) and the
proposed form would not apply. Only 29 % (19/66) of the requisitions
included clinical history. Genetics providers’ orders included clinical his-
tory on 42 % (19/45) of requisitions; non-genetics providers’ on 0 %
(0/21). The value of clinical history for genetic test interpretation is gen-
erally recognized. A standard clinical history form may improve the in-
clusion of this information with genetic test orders. We created a form
modeled after the International Collaboration for Clinical Genomics pa-
tient history form, reviewed it with several reference laboratories who
affirmed that it would satisfy their needs. The standard form is being
piloted with our institution’s genetics providers with a plan to expand
use by other providers.
Developing a Cancer Genetic Counseling Service at an Institution
Serving Minority Populations: The Howard University Cancer
Center Experience
N. Thompson1, L. Wilson2, C. Williams1, C. Spencer1, A. Mahan3, L.
Ricks-Santi4
1. Howard University Cancer Center
2. Howard University College of Medicine/Hospital
3. Howard University Health Sciences
4. Hampton University Cancer Research Center
Washington, D.C. has one of the highest breast cancer mortality rates in
the country – 26.3 per 100,000 compared to a national rate of 21.5 per
100,000, and higher breast cancer incidence rates for women under age
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50 versus the U.S. average. Of note, evidence shows that African Amer-
ican (AA) women with triple negative breast cancer (TNBC), an aggres-
sive subtype of breast cancer, have worse clinical outcomes than Cauca-
sian women. U.S. Census data for D.C. shows that nearly 60% of its 649,
111 residents are AA or non-White Hispanic, making D.C. one of the
most diverse populations in the U.S. and a unique location for cancer
genomic activities. At this institution, over 50 % of minority women with
breast cancer and/or a family history of cancer participating in research
studies met the National Comprehensive Cancer Network’s guidelines for
further genetic evaluation/testing. Due to the high breast cancer mortality/
incidence rates in young, ethnically diverse women, the prevalence of
TNBC, and the collection of family health history at this institution, the
need for genetic counseling and testing was identified. We will discuss
how this new service was developed at an institution providing care for
minority populations. Acquiring a culturally-competent minority genetic
counselor was vital, as data suggests that minority genetic counselors and
health care providers (HCPs) increase the uptake of genetic services
amongst minorities. Educating HCPs on the importance of genetics as it
pertains to patient management-of-care has assisted with referrals, patient
compliance, and the overall implementation of the genetic counseling
service. As a result, this institution has increased the uptake of cancer
genetic counseling services by nearly 40-fold, from 2 to 3 patient encoun-
ters per year to over 200 patient encounters within a 21-month time span.
Furthermore, referrals continue to increase from outside institutions due
to community engagement and outreach.
Benchmarking the Process of Genetic Testing Insurance
Authorization in a Large Academic Medical Center
W. Uhlmann1, K. Schwalm1, D. Grzeskowiak1, V. Raymond2
1. University of Michigan
2. Illumina
Introduction: The rapid expansion of available genetic tests (GT), increas-
ing number of testing laboratories, and differences in insurance coverage
has led to a complicated, time-consuming GT insurance authorization
(IA) process. This process is confusing to patients and clinicians and is
a barrier to obtaining appropriate genetic services. We aimed to bench-
mark the GT IA process and ascertain optimal work-flows. Methods:
Baseline surveys and follow-up interviews were conducted by an indus-
trial engineer and patient services associate (PSA) with representatives
from 8 genetics and 4 specialty clinics at the University of Michigan.
Questions regarding each clinic’s scope of GT and current IA process
were developed by the industrial engineer, genetic counselors (GCs),
and PSA. Results: Clinics surveyed order 1 to >20 GT each week. None
of the clinics routinely obtain GT IA prior to the appointment. Seven
clinics write letters of medical necessity, while three clinics include GT
IA information in the clinic note. In seven clinics, the clinician is respon-
sible for determining insurance coverage, accomplished by asking the
patient/hospital billing staff/other administrative staff, checking the elec-
tronic medical record, or calling the insurance company. In eleven clinics,
patients must return for sample collection following IA. Sample collec-
tion is only done the same day if patients have IA or are having DNA
extracted and held by the testing laboratory pending IA. In nine clinics,
the physician or GC is responsible for submitting the necessary IA doc-
umentation, following-up on pending IAs, and notifying patients
of GT coverage decisions. Conclusion: The results of this
benchmarking study showed that GCs and physicians are respon-
sible for several of the tasks associated with the IA process.
Delegation of IA tasks to non-clinicians and improving work-
flows is necessary to reduce clinicians’ time spent on insurance
authorization and facilitate patients having genetic testing in a
timely manner.
II. Adult
Communication Strategies Utilized by People with NF2 and Hearing
Loss
A. Bergner1
1. Johns Hopkins University
The hallmark of neurofibromatosis 2 (NF2) is bilateral vestibular
schwannomas (VS), which cause hearing loss (HL) that progresses to
deafness typically beginning in early adulthood. Incomplete auditory re-
habilitation following the onset of HL can lead to significant interruption
in communication across multiple spheres of life. There is little known
about the strategies for communication utilized by people with NF2 and
HL, or the adequacy of these methods. A 14-question online survey was
advertised to individuals with NF2 and HL through NF2 support groups
with an online presence and several NF2 clinical centers in the United
States. Survey responses were collected and analyzed. 187 participants
from 5 continents were eligible for inclusion in data analysis. The mean
age of respondents was 39 years. The average duration of HL at the time
of the survey was 13.6 years (SD=9.6). Most individuals reported using a
combination of strategies for communication. The majority (125/187)
utilize lip reading. 41 % (76/187) use manual signing, such as a formal
sign language, cued speech, fingerspelling, or Bhomemade^ signs. Only 4
respondents rely solely on a formal sign language to communicate. 14 %
(27/187) use written language to supplement their communication. De-
spite the numerous strategies employed, 95 % of respondents report on-
going communication difficulties in one or more daily settings.
Auditory rehabilitation in the NF2 population is currently inadequate
even in the context of improved rates of hearing preservation following
surgery, moderate success with medical therapies, and amplification op-
tions (e.g. hearing aids, cochlear implants, auditory brainstem implants).
Importantly, the uptake of sign language as a primary means of commu-
nication in the NF2 population is very low. Clinicians should be aware of
the range of communication strategies employed in this population, as
well as the reported inadequacy of these options. This data also speaks to
the need to develop alternative methods of enhancing communication for
people with NF2 and HL.
The Diagnostic Process of Ehlers-Danlos Syndrome
and the Symptoms Leading to the Diagnosis: A Pilot Study of 25
Rheumatology Patients
M. Chuldzhyan1, A. Weinberger2, M. Weisman3, M. Ishimori3, B.
Greenspan2, N. Frye1, N. Steinberg-Warren1
1. Long Island University, CW Post
2. Alan Weinberger, MD Private Practice, Los Angeles, CA
3. Cedars-Sinai Medical Center
Ehlers-Danlos syndrome (EDS) is a collagen deficiency disorder that
affects multiple organ systems, including the cardiovascular, skeletal,
and integumentary systems. Due to the different multisystem presenta-
tions of at least six major subtypes, other studies have shown that EDS is
commonly underreported, misdiagnosed, and that a true diagnosis can be
delayed by decades. The purpose of this study was to comprehensively
explore the difference between the signs for diagnosis and symptoms
presented by participants leading to the diagnosis of EDS in a group of
patients followed by rheumatologists for joint pain or other rheumatologic
reasons. Twenty-five, english-speaking participants (18-years-old or
older) diagnosed with EDS were recruited from rheumatology clinics at
one medical center and were interviewed in person or by phone by the
first author. The interview included a survey of 108-dichotomous ques-
tions on symptoms associated with EDS. Patients were also asked age of
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onset of their symptoms, which medical specialties they had seen, and
what symptoms led to their diagnosis of EDS. Study participants identi-
fied as having EDS subtypes hypermobile (48 %, n=12) or classic (20 %,
n=5). Mean age of diagnosis was 33.5 years (range 20–63 years) and
duration from onset of symptoms to diagnosis averaged 24.6 years. Par-
ticipants reported being diagnosed by a rheumatologist (64 %, n=16) or
geneticist (44 %, n=11), citing hypermobility (72 %, n=18), skin findings
(64 %, n=16), and pain (44 %, n=11) as critical to making a diagnosis of
EDS. Diagnoses prior to a diagnosis of EDS included depression/anxiety
(72 %, n=18), acute abdominal pain (60 %, n=15), and fibromyalgia
(60 %, n=15). Participants reported the reasons for seeking medical care
included orthopedic issues (80 %, n=20) and gastrointestinal problems
(52 %, n=13). The manifestations participants sought medical care for
were not part of the current diagnostic criteria for EDS (hyermobility, skin
extensibility and fragility), resulting in diagnostic delays.
The Relationship Between Delayed Diagnosis and Quality of Life
in Individuals with Fabry Disease
L.A. McCoy1, D. Bernstein2, J. M. Fischer1, N. Frye1
1. Long Island University - Post
2. GenoPheno, LLC
Fabry disease (FD) is a rare progressive genetic disorder marked by a
wide range of variably expressed clinical features including initial symp-
toms of debilitating neuropathic pain, chronic fatigue, anhidrosis, extreme
temperature intolerance, gastrointestinal problems and angiokeratomas
(benign skin lesions). Cardiac disease, renal impairment, and cerebrovas-
cular accidents typically emerge later in the course of the disease andmay
lead to early mortality in the 4th or 5th decade of life. Fabry disease often
falls outside the scope of most physicians’ knowledge, with symptoms
ranging across many areas of medical specialization and overlapping with
other disorders. Patients are commonly misdiagnosed, have their pain
attributed to psychosomatic causes and spend years with uncertainty
about their medical condition before an accurate diagnosis is made. A
delay in diagnosis prevents appropriate treatment, specifically the initia-
tion of enzyme replacement therapy, which can improve pain and overall
prognosis, yet is more effective when initiated earlier in the course of FD.
This study proposed that the length of diagnostic delay was inversely
correlated with health-related quality of life (HRQOL). A survey
consisting of FD-specific questions and the Medical Outcomes Study
SF-36 questionnaire to assess HRQOL was distributed by email to mem-
bers of the National Fabry Disease Foundation and the Fabry Support and
Information Group. Respondents included 164 individuals, of which 45
were males, 118 were females and 1 without gender specified. Results
confirmed the relationship between longer diagnostic delay and lower
HRQOL. Furthermore, the mean diagnostic delay was 19.8 years, which
is more than 6 years longer than previous research suggests. The long
diagnostic delay, reduced quality of life and the potential for adverse
consequences in undiagnosed and untreated FD patients highlight the
need for increased physician awareness to enable earlier diagnosis and
may also be relevant to newborn screening initiatives for FD.
An Exploration of the Approach to Family Planning Among Adult
Siblings of Individuals with Undiagnosed Conditions
H. Porter1, S. Kalia2, C. Perry3, M. Campion1
1. Boston University School of Medicine
2. Icahn School of Medicine at Mount Sinai
3. Boston Children’s Hospital, Division of Genetics and Genomic
The current study’s goal was to gain a general knowledge on the factors
that impact the approach adult siblings of individuals with an
undiagnosed genetic condition take when planning a family. Reviewing
past studies on family planning or siblings of individuals with disabilities,
we identified two gaps in the literature. First, adult’s knowledge for what
their sibling’s condition meant for their reproduction was not clearly
communicated to them in childhood and second, sibling life experiences
were typically evaluated in childhood. The study explored the factors
involved in the decision-making process in the context of an unknown
recurrence risk. The study population was identified via the NSGC email
list-serve and snowball recruitment. Potential participants were screened
and five eligible respondents were interviewed by phone. A semi-
structured interview guide was used; 15 standard questions were asked
to each participant and unique questions were asked when clarification
was needed. The interviews were recorded and transcribed. Salient
themes were uncovered using modified-grounded theory after the tran-
scripts were hand-coded by the Principal Investigator. Themes included
topics on information and control, reflections on the participants’ life
experiences, and social support. Modifying factors in the decision-
making process included age, finances, timing constraints, and caretaker
expectations. Participants reported evaluating different family planning
possibilities such as adoption, biological children, egg donor/surrogacy,
and no children. All participants conveyed that current decisions were
subject to change. This exploration established that the decision-making
process is flexible and that the uncertainty in recurrence risk and adult
siblings’ future caretaker status may play major roles in the decisions
individuals make when planning a family. The research indicated that
genetic counselors can be a source of balanced information and can pro-
vide guidance, acceptance, and support throughout the decision-making
process.
Absence of Genotype-Phenotype Correlations inRPE65: Implication
for Identification of Patients Suitable for Gene Therapy
K. Trzupek1, D. Chung2, J. Wellman2, K. High2
1. InformedDNA
2. Spark Therapeutics
In many inherited disorders, genotype-phenotype correlations provide
insight into onset of disease, rate of progression, and degree of severity.
Both Leber congenital amaurosis type 2 (LCA2) and autosomal recessive
retinitis pigmentosa (RP) type 20 (RP20) are caused by mutations in the
RPE65 gene. We performed a retrospective chart review of patients with
known RPE65mutations to determine the spectrum of clinical diagnoses
associated with this gene. We also examined the RPE65 mutations iden-
tified in individuals enrolled in the phase 1/2 and phase 3 RPE65 gene
therapy clinical trials at The Children’s Hospital of Philadelphia,
and compared those with RPE65 mutations reported in the litera-
ture. Over 125 discrete mutations were identified in the RPE65
gene in individuals with inherited retinal disease. These include
missense and nonsense point mutations, frameshift mutations
resulting from small insertions and deletions, and splice site mu-
tations. Patient diagnoses included LCA2, early onset retinal dys-
trophy (EORD), and RP20. Missense, nonsense, splice site, and
frameshift mutations were described in patients across all diagno-
sis groups. In the cohort of subjects reviewed in this study, no
clear genotype-phenotype correlations emerged. The distinction
between RP20, LCA2, and other clinical diagnoses given to those
with autosomal recessive RPE65 mutations appears to be based
primarily on clinical symptoms and age of onset, and unrelated to
underlying genotype. These data have important implications for
the identification of patients suitable for RPE65 gene replacement
therapy, and suggest that RPE65 should be considered in not only
patients with LCA, but also early onset severe forms of retinal
dystrophy and autosomal recessive RP.
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The Diagnostic Odyssey in the Young Adult Population: A Case
Perspective of Desminopathy
J. Stone1, J. Ganesh1
1. Cooper University Healthcare
We present the case of a 27 year old woman who came to genetics after
several years of a diagnostic journey involving multiple specialists and
invasive procedures. She was developmentally on target and a well-
trained athlete before onset of symptoms approximately 7 years ago.
Initial symptoms included gradual onset fatigue that was attributed to life
style changes. Hypothyroidism was diagnosed and treated, however
symptoms persisted. At the age of 23 she had a syncopal episode and
was found to have cardiac arrhythmia with complete heart block. She now
has class III congestive heart failure with cardiomegaly and ventricular
dysfunction. A unifying diagnosis was not apparent initially, and she had
multispecialty evaluation over the next several years, including skeletal
muscle biopsy. Muscle histology suggested possible metabolic myopathy
with non-specific histology. An inflammatory myopathy could not be
excluded, and glycogen storage disease was also considered due to pres-
ence of glycogen deposition in muscle. Genetics work up included met-
abolic screening and molecular testing for cardiomyopathy. This patient
was shown to have a heterozygous c.1216C>Tmutation in the DES gene,
consistent with an autosomal dominant myofibrillar myopathy. DES
codes for the protein desmin, which is important for maintaining the
structures of sarcomeres in skeletal and cardiac muscle. Myofibrillar my-
opathy is a muscular dystrophy with variable features, including progres-
sive weakness and cardiomyopathy. This case illustrates the importance
of establishing an accurate genetic diagnosis for at least two reasons. Due
to progressive skeletal and cardiac disease, establishing a definitive diag-
nosis was urgent as this patient was being considered for a cardiac trans-
plant. Secondly, after several years, this young woman can move toward
knowledge and acceptance of her life-limiting diagnosis.
Increasing Diagnosis and Treatment in Hereditary Angioedema
K. Trzupek1, K. Steenblock1, R. Sutphen1
1. InformedDNA
Hereditary angioedema (HAE) is a rare, life-threatening and frequently
disabling disease characterized by episodic subcutaneous and submucosal
swelling. HAE is an autosomal dominant condition with significant clin-
ical variability. Over the last 10 years, several new treatments have been
approved for the treatment of HAE, improving the prognosis of individ-
uals affected with this condition. Consensus guidelines support early and
accurate diagnosis to reduce disease morbidity and mortality, but signif-
icant barriers reduce effective diagnosis in this patient community. We
initiated a program to provide subspecialty level genetic counseling to
patients and family members in the HAE community. Patients were given
the choice of telephone-based, video/Web-based, or in-person genetic
counseling appointments; the overwhelming majority chose telephone-
based services. Over 200 individuals registered for the program; 69 %
followed throughwith appointments. On average, each unrelated proband
reported a family history in which 7 at-risk relatives were identified.
Although the genetic counselor offered to provide follow-up counseling
sessions to those individuals, few at-risk family members made genetic
counseling appointments. We sought to understand the barriers to family
outreach, and provide meaningful solutions. Reported reasons for not
reaching out to family include uncertainty in personal diagnosis, stigma
attached to HAE diagnosis, and lack of confidence in answering family
members’ questions. To help address these issues, we provide family
outreach letters, physician support, and social media outreach. We devel-
oped a Facebook page with updates about diagnosis, inheritance, disease
management, and support. To date, more than 325 individuals follow the
Facebook page. Utilization of telephone genetic counseling services has
the potential to significantly increase diagnosis and quality of care for
patients and at risk family members in the HAE community. Patient
satisfaction data, collected anonymously, has supported the success of
this program.
Knowledge and Patient Satisfaction Following Genetic Counseling
for Patients with Inherited Retinal Dystrophy
K. Zajo1, M. Marino2, S. DeBrosse3, R. Darrah1, A. Matthews1
1. Case Western Reserve University
2. Cleveland Clinic Foundation Cole Eye Institute
3. University Hospitals Case Medical Center
Introduction: Few studies have characterized the baseline knowledge of
patients with Inherited Retinal Dystrophies (IRD) and none have directly
addressed the impact of genetic counseling on patient understanding in
this population. This study assessed the baseline knowledge of patients
receiving specialized ophthalmic genetic counseling and evaluated the
impact of counseling on their understanding of IRD genetics as well as
patient satisfaction. Methods: Adults with IRD or parents of pediatric
patients (n=10) seen at the Cole Eye Institute were surveyed. Prior to
genetic counseling, participants met with the researcher, and were read
a baseline questionnaire which included IRD-related knowledge ques-
tions and beliefs about the etiology of their condition. Two weeks after
the counseling session, participants completed a post-counseling tele-
phone survey which included the same knowledge items as the pre-
counseling survey in addition to the Genetic Counseling Satisfaction
Survey. The impact of genetic counseling, prior beliefs about the etiology
of their visual impairment, and demographic factors on knowledge scores
were assessed. Results: Nine participants completed all parts of the study.
Patients demonstrated significant increases in IRD-related genetics
knowledge 2 weeks after genetic counseling (78.1 % correct) compared
to baseline knowledge scores (48.6 % correct, p<.001). Participants who
had previously attributed their IRD to non-genetic causes demonstrated
lower baseline knowledge scores compared to those who endorsed a
genetic cause (37.5 % vs. 57.2 %, p=.077). All patients reported high
levels of satisfaction with genetic counseling (avg 4.67/5). Conclusions:
These results suggest that genetic counseling improves knowledge for
patients with IRD and that patients are highly satisfied with these services.
This IRD knowledge survey may be a useful clinical and research tool for
assessing patient understanding provided during counseling for
IRD and potentially promote patient satisfaction with the genetic
counseling process.
III. Adult/Cardiology
Genetic Testing Experience in a Large Cardiovascular Genetics
Referral Program
L. Dellefave-Castillo1, E. McNally1
1. Northwestern University
Background: We performed a retrospective review of cardiac genetic
testing performed at a large cardiovascular genetics referral center in
Chicago, IL where clinical gene testing has been performed with an
experienced genetic counselor since 2004. This period encompassed the
growth in gene panel testing for cardiovascular disease. Methods: Cardiac
gene testing performed between 2004 and 2015 was queried within a
Progeny database and retrospectively analyzed. Clinical diagnosis of hy-
pertrophic (HCM), dilated (DCM) and arrhythmogenic right ventricular
(ARVC) cardiomyopathy were delineated. Patient populations with
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significant arrhythmia burden of unknown origin and sudden cardiac
arrest were analyzed individually. In all cases, pathogenic mutations as
reported by the clinical lab were counted excluding variants of uncertain
significance. Results: Detection rates for pathogenic mutations were:
HCM 33.9 % (21 individuals with mutations (+); n=62); DCM 31.9 %
(37+; n=116); and ARVC 18.2 % (2+; n=11). In DCM, panels of 18 or
fewer genes yielded a detection rate of 28.6 % (18+; n=63); an LMNA
only gene test accounted for 13 of the 18+ (38.2 %). DCMpanels over 18
genes yielded a detection rate of 34.0 % (18+; n=53). Addition of the titin
(TTN) gene into cardiomyopathy panels in 2012, the pathogenic mutation
detection rate prior to TTNwas 31.7 % (26+; n=82) versus after TTNwas
32.4 % (11+; n=34). Gene testing of those with significant arrhythmia
burden (without sudden cardiac arrest or LongQT diagnosis, n=9) yielded
a pathogenic mutation in 1 (11.1 %). Aborted sudden cardiac arrest since
2009 (n=12) tested by large gene panels (typically over 50 cardiomyop-
athy and arrhythmia genes) yielded a pathogenic mutation in 2 (16.6 %).
Conclusions: DCM gene testing has yielded pathogenic mutation detec-
tion rates of 32 %. Cardiac genetic testing in those with significant ar-
rhythmia burden of unknown etiology and aborted sudden cardiac arrest
have comparatively lower yield despite larger gene testing panels. Gene
testing is essential to better assess arrhythmia risk for surviving family
members.
Diagnostic Exome Sequencing with Inheritance Model-Based
Analysis: Results from a Cohort of 81 Probands Referred
with Cardiac Indications as Compared to the Group of 500
Unselected Families with Undiagnosed Genetic Conditions
M. Bunnell1, K. Farwell2, B. Tippin Davis2, Z. Powis2
1. Northwestern University Medical School Graduate Program in Genet-
ic Counseling
2. Ambry Genetics
Purpose: Diagnostic exome sequencing has been shown to have definite
utility in cases of undiagnosed genetic conditions. This paper presents
data from 81 referrals with a cardiac indication, as compared to the entire
population of 500 unselected referrals. Methods: Family-based exome
sequencing included whole-exome sequencing followed by family
inheritance-based model filtering, comprehensive medical review, family
co-segregation analysis, and analysis of novel genes. Comparisons in
diagnostic exome sequencing results were made between the population
of 419 unselected families with undiagnosed genetic conditions without a
cardiac indication and the cohort of 81 patients referred with a cardiac
indication in addition to the other indications for referral. Results: Refer-
rals madewith a cardiac indication comprised 16.2% (81/500) of the total
referrals. All referrals made for patients with a cardiac indication also
included at least one other indication for referral. A positive or likely
positive result in a characterized gene was identified in 23.5 % (19/81)
of patients with a cardiac indication. This rate is not significantly different
from the group of referrals made without a cardiac indication 133/419
(31.7 %) (p= 0.1378). A novel gene finding was identified in 4.3 % of
patients (3/70) which is not statistically different from the 8.1 % (28/346)
in patients with a novel finding in the non-cardio group. The
novel findings within the cardiac indication cohort all occurred
in genes associated with cell adhesion protein production. Con-
clusion: Overall, this paper presents results from a large clinical
cohort of diagnostic exome sequencing. These data demonstrate
similarities between individuals referred for exome sequencing
with and without a cardiac indication. This paper illustrates a
number of interesting findings in the types of genes discovered
within the population of exome sequencing patients. The results
suggest opportunity for follow-up in the population of patients
presenting with a cardiac indication within the spectrum of an
undiagnosed genetic condition.
Pulmonary Arterial Hypertension: Specialists’ Knowledge,
Practices, and Attitudes of Genetic Testing and Genetic Counseling
J. Jacher1, L. Martin2, W. Chung3, J. Loyd4, W. Nichols2
1. University of Cincinnati
2. Cincinnati Children’s Hospital and Medical Center
3. Columbia University
4. Vanderbilt University
Background: Pulmonary Arterial Hypertension (PAH) is a disease that is
characterized by obstruction of pre-capillary pulmonary arteries which
leads to sustained elevation of pulmonary arterial pressure. Early inter-
ventions can help to mitigate the disease course if those at risk are iden-
tified throughmethods such as genetic testing. Current practice guidelines
from the American College of Chest Physicians in addition to other liter-
ature have been in existence for more than 10 years and recommend
genetic counseling and offering genetic testing to individuals with heri-
table PAH, idiopathic PAH, and their family members. However, it is
unclear if PAH specialists follow these recommendations. Thus, the ob-
jective of this research was to determine the knowledge, utilization, and
perceptions about genetic counseling and genetic testing of PAH special-
ists. Methods: A survey was custom designed and distributed to PAH
specialists’ in order to assess their knowledge, practices, and attitudes
about the genetics of PAH. Parametric and non-parametric statistics were
used to analyze responses with comparisons of groups performed using
the Wilcoxon rank sum test. Results: PAH specialists had low perceived
and actual knowledge of the genetics of PAH with 13.2 % perceiving
themselves as knowledgeable and 27 % actually being knowledgeable.
Although these specialists have positive or ambivalent attitudes about
genetic testing and genetic counseling, they have poor utilization of these
genetic services with almost 80 % of participants never or rarely ordering
genetic testing or referring their patients with PAH to a genetic counselor.
Physicians, who would be the primary specialist to utilize these genetic
services, have both lower utilization of and perceptions of the value of
genetic testing and genetic counseling compared to non-physicians
(p=<0.05). Conclusion: Taken together our results suggest that increased
education and awareness is needed about the genetics of PAH as well as
the benefits of genetic testing and genetic counseling for individuals who
treat patients with PAH.
MicroRNAs as a Marker of Cardiovascular Disease in Marfan
Syndrome and Marfan-Related Disorders
T. Nguyen1, C. Coughlin II2, A. Karimpour-fard2, K. Chatfield2
1. University of Colorado Denver
2. University of Colorado School of Medicine
Introduction: Marfan syndrome affects many body systems, but
aortopathy is the most common cause of death, and predicting the cardio-
vascular complications in any given individual remains difficult. In sev-
eral diseases, micro RNAs (miRNAs) have emerged as a promising bio-
marker to indicate the presence of pathology. This study explores the use
of miRNAs as biomarkers in predicting onset and severity of aortopathy
for patients with Marfan syndrome and Marfan-related disorders. Hy-
pothesis: The hypothesis was that circulating miRNA profiles are unique
in individuals with Marfan syndrome as compared to controls. A second-
ary aim of the study was to determine whether unique miRNA profiles
will aid in identifying those at high risk for aortic aneurysm. Methods:
Subjects were recruited with a clinical diagnosis of Marfan syndrome.
The subject’s demographic information, diagnosis, skeletal features and
aortic measurements were also documented. An array for 754 miRNAs
and real time polymerase chain reaction confirmation of select miRNAs
were performed. Results: Nine subjects were enrolled (7/9 subjects with
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Marfan syndrome and 2/9 with Loeys-Dietz Syndrome). Two miRNAs
were up-regulate (miR-298 andmiR-342) and twenty-nine weremiRNAs
were down-regulated in subjects with Marfan syndrome or Marfan-
related disorders. Conclusions: This study provides preliminary evidence
that circulating miRNA profiles are distinct in patients with Marfan syn-
drome. This provides further evidence for the utility of miRNAs as a
biomarker for aortopathy inMarfan syndrome. Further studies are needed
to investigate whether miRNAs can differentiate between patients with
high risk and low risk of developing aortic disease progression. Uncer-
tainty surrounding the prognosis of aortopathy inMarfan syndrome raises
the question of whether a personalized risk assessment using miRNAs
would benefit the family and could be incorporated into the genetic
counseling process.
Familial Hypercholesterolemia: Characterization of a Pediatric
Population and Evaluation of Parental Knowledge and Attitudes
J. Phetteplace1, R. Hinton2, M. Myers2, A. Parrott2, V. Pilipenko2, A.
Shikany2, E. Urbina2, E. Miller2
1. University of Cincinnati, College of Medicine
2. Cincinnati Children’s Hospital Medical Center
Familial hypercholesterolemia (FH) is a dominant condition estimated to
affect 1 in 500 individuals. If untreated, FH leads to premature coronary
heart disease and death. Despite the high prevalence, screening guide-
lines, and effective treatment, FH remains underdiagnosed and
undertreated. Current guidelines recommend universal cholesterol
screening in adolescence and genetic testing for individuals with
suspected FH. We sought to identify the prevalence of FH at a pediatric
medical center and to characterize the population with a retrospective
chart review. A survey was used to assess parental beliefs and attitudes
towards genetic counseling and testing and to assess knowledge of FH.
The prevalence of FH was calculated as the proportion of children who
have FH compared to all individuals seen at the institution. A mean
knowledge score was reported and analyzed using a Wilcoxon test. The
prevalence of FH was 4/10,000 with only 1 % of individuals between the
ages of 9 and 11 receiving cholesterol screening. Of the 180 individuals
with suspected FH, 28 (16 %) had been prescribed a statin and none had
received genetic counseling or testing for FH. The survey response rate
was 44 %. Forty-eight (63 %) respondents reported interest in genetic
counseling about FH and 42 (55 %) reported they had never discussed
FH with relatives. Mean knowledge scores trended higher among partic-
ipants who reported speaking about FH with a healthcare provider
(p=0.061). To our knowledge, this is the first prevalence estimate for
FH in a pediatric medical center and demonstrates suboptimal diagnosis
and adherence to cholesterol screening and genetic testing guidelines.
Results suggest that families are interested in genetic counseling for FH
and that less than half of families discuss FH with relatives. Genetic
counseling has previously been associated with increased disease knowl-
edge, family communication and heightened adherence to recommenda-
tions for at risk family members. Research regarding barriers to choles-
terol screening and the impact of genetic counseling and testing on FH is
needed.
Patient Recall, Interpretation and Perspective Regarding an
Inconclusive Result in Long QT Syndrome Genetic Testing
S. Predham1, G. Hulait2,3, J. Hathaway4,5, L. Arbour3,4 , A.
Lehman2,3
1. Memorial University of Newfoundland
2. Provincial Medical Genetics Programme, BC Women’s Hospital,
3. Department of Medical Genetics, University of British Columbia
4. BC Inherited Arrhythmia Program
5. St. Paul’s Hospital
5. Department of Medical Genetics, University of British Columbia
Introduction: Patients’ perceptions of inconclusive genetic testing results
have been investigated in the cancer setting, however little to no data are
available on patient perspectives to these results in inherited heart disease.
We explored how receiving an inconclusive result can affect patient re-
call, perception and interpretation. As well, we studied a possible rela-
tionship between their personal circumstances and recall accuracy. We
report qualitative results of 16 telephone interviews with individuals who
received a negative or variant of unknown significance (VUS) result from
Long QT syndrome (LQTS) testing between 2008 and 2013. Methods:
Semi-structured telephone interviews were conducted with individuals
with an inconclusive LQTS result. Analysis of interviews was conducted
through grounded theory by two coders. Results: The type of genetic
testing result does not affect patient recall. When receiving a negative
result, a large proportion of participants perceived no change in the out-
look on their diagnosis, while the perception of influence on family was
varied. A proportion of participants felt relief, perceiving that their fam-
ilies were no longer at risk. Conversely, majority of participants felt they
maintained an awareness of their condition after the result disclosure.
Many participants found they consulted a results letter following the
appointment as a source of information, and the language used by partic-
ipants reflected that of the patient letters. Some participants noted a need
for more tailored information. Conclusions: This study demonstrates that
a negative result suggests to some patients a non-genetic etiology to their
diagnosis. As well, the reasoning for testing and understanding of their
result informed three main reactions of disappointment, relief or
questioning their diagnosis. These findings highlight the importance of
a patient letter as an educational tool. This study also highlights the need
for tailoring counseling sessions to individual patient needs and situation
and explicitly addressing topics of confusion for patients.
Preimplantation Genetic Dianosis in Familial Dilated
Cardiomyopathy: Potential Limitations and the Continued Role
of Medical Genetics
B. Psensky1, R. Moran2
1. Cleveland Clinic
2. MetroHealth Medical Center
Introduction: Familial dilated cardiomyopathy (DCM) is a genetically
heterogeneous cardiac disorder, most commonly with autosomal domi-
nant transmission. Current genetic testing panels analyze up to about 50
genes; however, disease causingmutations are identified in only 25–40%
of families with DCM, arguing that the genetics of this disorder are still
not fully understood. Preimplantation genetic diagnosis (PGD) technolo-
gy allows for individuals with certain genetic disorders to undergo in vitro
fertilization (IVF), with implantation of embryos that do not harbor the
familial mutation, and genetic counseling should be an important compo-
nent of this process. Case Report: A 5 month old girl was diagnosed with
heart failure necessitating cardiac transplant at 9 months; her paternal
half-brother was then diagnosed with DCM at 5 months and required
transplant at 8 months. Their father had a history of cardiomyopathy
diagnosed at age 18. Genetic testing identified presumed pathogenic
MYH7mutation and variant of unknown significance (VUS) inMYBPC3
in both affected children in 2009. In 2013, the family returned to genetics
after having undergone IVF with PGD, resulting in monozygotic male
twins. Genetic counseling was not pursued during IVF. Echocardiogram
at 3 months identified left ventricle dysfunction in both twins, and LV
trabeculations in one. Genetic testing confirmed neither MYH7 nor
MYBPC3 variant was present. In the interim, the MYH7 mutation had
been reclassified to a VUS. Neither of the affected twins has required
cardiac transplantation, but continue to be closely followed and treated
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for cardiomyopathy. The family has not yet elected to pursue additional
clinical or research testing. Discussion: Dilated cardiomyopathy is a com-
plex genetic disorder, and the limitations of clinical testing can make
genetic counseling difficult even in families with known or suspected
mutations. This case identifies the challenge of utilization of PGD for
DCM, and also highlights the importance of continued involvement of
medical genetics in patient care.
Goal Achievement in Young Adults with Asperger Syndrome
and High Functioning Autism
M. Racobaldo1, C. Hill-Chapman2, S. McDermott1, S. Ravan3
1. University of South Carolina
2. Francis Marion University
3. University of South Carolina School of Medicine
Purpose: This study aimed to evaluate perspectives of young adults with
Asperger syndrome (AS) and high functioning autism (HFA) regarding
supports, services, future goals, and confidence in their success. The goal
was to identify valuable supports and areas in which this support was
lacking. Identifying areas of support for AS/HFA young adults
transitioning to adulthood aids in providing services for successful goal
achievement. The study has value among genetic counselors as under
covering genetic etiologies of autism has led to referral of families with
ASD to genetic clinics. Methods: AS/HFA young adults were invited to
participate via online questionnaire, telephone or in-person interview.
Email invitation letters were sent to local and national support groups
and colleges in South Carolina, and on social media sites. The question-
naire and interviews included questions regarding receiving a diagnosis,
education, supports, services, future goals, feelings towards the DSM-5,
and demographics. Results: Of the total respondents, (N=12), eight met
inclusion criteria; four completed online questionnaires, two completed
telephone interviews, and two completed in-person interviews. Partici-
pants felt their diagnoses provided a self-identity and explanation for
differences. A family member, teacher, or peer who understood the diag-
nosis or was similar to the participant was the greatest source of support.
Current services were minimal, and participants lacked confidence in
achieving future goals, feeing they would benefit from help in social skills
or goal planning. Participants did not favor the newDSM-5 change due to
their identification with the diagnosis. No participants reported meeting
with a genetic counselor. Conclusions: AS/HFAyoung adults are lacking
in support during the transition to adulthood and pursuit of future goals,
particularly in the area of social communication. The findings of this
study allow genetic counselors to be better prepared in identifying the
areas of need and directing families to appropriate resources when they
present in clinic.
Psychological Effects of a Positive Test Result in a Cardiomyopathy
Gene: A Comparison of Symptomatic and Asymptomatic Mutation
Carriers
N. Salvatore1, J. Wynn2, N. Frye3, J. Fischer3, W. Chung2
1. Meridian Health
2. Columbia University Medical Center
3. Long Island University - Post
The psychological implications of genetic testing have been well studied
in populations such as BRCA1 and BRCA2 mutation carriers, presymp-
tomatic Huntington disease carriers and APOE mutation carriers. How-
ever, genetic testing for cardiac disease is a new and growing area and, as
such, the psychological implications of testing in this population are not
well understood. Using a subpopulation of the Columbia UniversityMed-
ical Center’s study regarding psychological implications of cardiogenetic
testing, this study assessed how a positive gene test result in a cardiomy-
opathy gene affects psychological well-being. This study reviewed and
compared the psychological effects of genetic test results for 46 symp-
tomatic and asymptomatic mutation carriers for hypertrophic cardiomy-
opathy and dilated cardiomyopathy using a unique survey, which includ-
ed an adapted Multidimensional Impact of Cancer Risk Assessment
(MICRA) scale for cardiac disease, Impact of Events scale and Satisfac-
tion with Decisions scale. This study found most positive mutation car-
riers of a cardiomyopathy gene to be satisfied with their decision to
pursue genetic testing and felt informed about the process. However,
the symptomatic subset of the study population reported signifi-
cantly higher levels of distress and avoidance tendencies due to
their positive genetic test results. This could be due to the com-
bination of the physical manifestation of the disease and the im-
plications of a mutation in a cardiomyopathy gene. A significant
portion of the population also reported their positive genetic test
results to affect lifestyle and family decisions, such as having
children, changing careers and purchasing life insurance. This
shows the importance of pre- and post-test counseling to address
the psychological impact of genetic testing. Genetic counselors
need to address these issues to ensure patients understand the
implications and should be customized based on the medical sta-
tus of the patient.
Moving Beyond the 1 %: Incorporating the Exome Aggregation
Consortium Data into Variant Interpretation and Classification
J. Tahiliani1, J. Garcia1, A. Daly1, S. Topper1
1. Invitae
The availability of population frequency data on sequence variants
has increased exponentially over the past decade. The Broad In-
stitute recently released the Exome Aggregation Consortium
(ExAC) database, which includes sequence data of more than
60,000 individuals from various studies. In this study, we review
the interpretation of variants of uncertain significance in genes
associated with hypertrophic cardiomyopathy (HCM), which had
conflicting clinical and population data. Specifically, p.Arg495Gln
and p.Val28Met in the MYBPC3 gene were reanalyzed using the
ExAC data. The p.Arg495Gln variant has been reported in multi-
ple cases of HCM, as have other changes affecting this residue,
arguing towards pathogenicity. However, this variant also had
been reported to have a population frequency of 0.17 % (1/569
European alleles, dbSNP), suggesting p.Arg495Gln may be benign
since it approaches the incidence of HCM. This conflict is re-
solved in the ExAC data, where the frequency is 0.0015 %
(1/67,000 European alleles). p.Arg495Gln is now reclassified as
pathogenic. The p.Val28Met variant in the MYBPC3 gene had
been reported in an individual with suspected HCM and was
absent from control and population databases, evidence which
suggest pathogenicity. However, p.Val28Met is present in ExAC
in 14/12,646 (0.1 %) alleles from a South Asian subpopulation,
and one homozygote is also present. As a result, p.Val28Met is
now reclassified as likely benign. The reclassification of these
variants emphasizes the benefit of large population variant data-
bases. Smaller databases provide insufficient power for confidence
in low frequency variants and have the potential for misinterpre-
tation. ExAC is a powerful tool as its large sampling minimizes
the effect of sampling bias. Variants present at frequencies less
than 1 %, a historical threshold for benign classifications, in a
large dataset may now be classified as benign in genes associated
with autosomal dominant conditions. In conclusion, larger popu-
lation variant databases significantly improve the accuracy of var-
iant classification.
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IV. Cancer
End of Life Discussions: Exploring How to Talk About Hereditary
Cancer at the End of Life
L. Bailey1, T. Albrecht1, H. Creswick2, D. Noreika2, J. Quillin2
1. Virginia Commonwealth University
2. Virginia Commonwealth University Massey Cancer Center
The discussion of hereditary cancer can be difficult to understand and
cope with emotionally. In order to best provide family members of termi-
nally ill cancer patients the information about hereditary cancer risk, it is
important to assess how receptive the population is to the information, as
well as to identify the best method of delivery. Therefore, the aims of the
study were, 1.) to identify potentially effective and appropriate methods
of delivery of cancer genetic information to family members of patients
with terminal cancer, and 2.) to assess the impact that the exploration of
hereditary risk of cancer has on the family members of the dying patients.
This was a descriptive qualitative study using phenomenological ap-
proach. Audiotaped semi-structured interviews were conducted with sev-
en blood relatives of patients diagnosed with terminal cancer and admit-
ted to an inpatient palliative care unit at an academic medical center.
Participants included six females and one male. Their relationship to the
patient was sibling, child, aunt or mother. The audiotapes were tran-
scribed verbatim and loaded into Atlas.ti for analysis. Common emerging
themes were verified prior to dissemination. Participants expressed opin-
ions about open communication with health care professionals, as well as
communication among family members. Participants indicated preferred
methods of communicationwith health care professionals, includingwrit-
ten, in person, and electronic/telephone communication. Emotional re-
sponses regarding the topic of hereditary risk discussion in this popula-
tion, and feelings about obtaining genetic information were revealed.
Emotions expressed included apprehension, reluctance, worry, hostility
and stress. Overall, this study suggested that open communication is an
important aspect of a hereditary cancer risk discussion, and the best meth-
od of delivery is situational; however, this needs to be explored further.
Due to the wide range of emotions, it is important to be cognizant of these
emotions and adapt the discussion of hereditary cancer appropriately.
The Impact of a Clinic-Based Pancreatic Cancer Research Registry
in Identifying Actionable Germline Mutations
C. Bascunana1,2, A. L. Smith1,2, A. Hall1,2, Y. Zhang1,2, G. Chong3, E.
Saloustros4, W. D. Foulkes5, G. Zogopoulos1,2
1. Research Institute of the McGill University Health Centre
2. Goodman Cancer Research Centre, McGill University
3. Molecular Diagnostics Laboratory, Sir Mortimer B. Davis-Jewish
General Hospital
4. Hereditary Cancer Clinic, University Hospital of Heraklion
5. Program in Cancer Genetics, Departments of Oncology and Human
Genetics, McGill University
Approximately 10 % of pancreatic cancer is estimated to be hereditary.
Despite the recognized hereditary fraction of pancreatic cancer, we hy-
pothesized that individuals affected with pancreatic cancer or with family
histories of pancreatic cancer are under-referred for genetic assessments.
In this study we evaluated the value of a clinic-based research registry in
identifying actionable germline mutations. Through Quebec Pancreas
Cancer Study (QPCS), a clinic-based research registry, 278 individuals
were evaluated between April 2012 and April 2015 by a genetic counsel-
or for hereditary risk.We identified 154 individuals with potential risk for
genetic predisposition based on family histories, young-onset of disease,
multiple primary cancers, ancestries with recurrent predisposing gene
mutations, and chemotherapeutic responses suggestive of an underlying
DNA repair gene mutation. Of these cases, 16 were referred to QPCS by
clinical genetics. 9 of these cases had been found to carry germline pre-
disposing variants and 7 had negative genetic testing results. These cases
were referred to QPCS for pancreatic cancer screening, penetrance, and
gene discovery studies. An additional 11 cases referred to QPCS inde-
pendently of clinical genetics (i.e., by surgical or medical oncology for a
pancreatic lesion) were found to have had a previous clinical genetics
assessment, of which 4 individuals were found to be carriers of known
predisposition genes. These genetic assessments may have beenmissed in
routine surgical or medical oncology consultations. The remaining 127
cases considered at increased risk for pancreatic cancer predisposition had
not undergone prior genetic evaluations. These individuals were
counseled and underwent genetic testing on a QPCS research platform,
including recurrent mutation testing and next generation sequencing.
Even though testing was limited to opportunities available through the
QPCS research initiatives, we identified actionable BRCA2 and PALB2
mutations in 7/127 individuals (5.5 %).
The Ever Changing Role of Genetic Counseling in Oncology
C. Benson1, J. Schwab1, L. Massingham1, K. Perez1
1. Rhode Island Hospital
In the world of genetics, nothing is static. The question is: are best prac-
tices being developed to keep stride? Somatic tumor testing is becoming a
routine aspect of oncology care and genetic counselors have the potential
to play an important role in the education and counseling of patients and
providers.We compare and contrast two cases that involved tumor testing
and genetic counseling, with differences in pre-test counseling and out-
comes. Case One: 57-year old male with metastatic colon cancer, initially
referred for genetic counseling for his personal and family history. At the
initial session, the family met National Comprehensive Cancer Network
Guidelines for BRCA genetic testing based on multiple individuals with
early onset breast cancer. Tumor testing was discussed, as well as BRCA
testing for an affected relative. Tumor testing revealed a BRCA2mutation
that had previously been reported as a germline mutation. Follow up
counseling ensued and this patient underwent germline testing for the
same BRCA2mutation, which confirmed a diagnosis of hereditary breast
and ovarian cancer in this family. The family was appropriately prepared
for the outcome because of appropriate pre-test counseling. Case Two:
57-year old female with metastatic colon cancer. Genetic counseling oc-
curred after tumor testing revealed somatic APC and TGFBR2mutations.
The oncologist misinformed the patient that the findings were
likely hereditary. She was anxious and expected germline testing
despite a negative family history. The genetic counselor explained
that the personal and family history was not consistent with a
hereditary cancer syndrome. Nevertheless, the patient requested
targeted germline testing, which was negative. She was relieved
not have a hereditary cancer syndrome, but was upset about the
unnecessary anxiety created by her oncologist’s remarks. Genetic
counselors play an important but challenging role in the setting of
somatic testing. This is a potential area for consideration of de-
velopment of best practices for genetic counselors.
Assessing Documentation of Cancer Family History in the Pediatric
Oncology Setting
K. Bergstrom1,2, S. Scollon1,2, R. Kerstein1,2, S. Gutierrez1,2, U.
Ramamurthy2, M. Naik2, D. Parsons1,2, S. Plon1,2
1. Texas Children’s Hospital
2. Baylor College of Medicine
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Background: Well described adult cancer predisposition syndromes, such
as hereditary breast and ovarian cancer syndrome, have illustrated the
importance of obtaining family history (FH) in comprehensive oncology
care. Given the rare nature of pediatric cancer predisposition syndromes
and their associated cancers, it is unclear how often FH details are record-
ed in the pediatric oncology setting. We report findings of a FH survey
analysis and medical chart review of 182 pediatric oncology patients
enrolled in the BASIC3 clinical trial. Methods: The National Human
Genome Research Institute/National Cancer Institute-funded BASIC3 tri-
al examines the clinical utility of tumor and germline whole exome se-
quencing (WES) in the care of childhood cancer patients at the time of
solid tumor diagnosis. Upon enrollment, participant families are asked to
complete FH surveys, which include targeted FH cancer questions. Study
genetic counselors review surveys and the patient’s electronic medical
record (EMR) for personal and family medical history and report relevant
findings to the WES laboratory. FH details may also be reported by the
family at the results disclosure. Results: Of 182 families, 60 (33 %) had at
least one parent complete the FH survey. Of this group, 33 (55 %) of
patients had missing FH details in the EMR, including three to four
generations of family members with cancer diagnoses or the age of cancer
diagnosis. There were germline diagnostic WES results in 16 patients
relevant to their tumor diagnosis, and 56 % (9) had relevant FH details
that were not noted by their provider. Conclusions: FH information nec-
essary for genetic cancer risk assessment, referral for genetic evaluation,
and determination of the need for genetic testing is not reliably recorded
in the medical record of pediatric oncology patients. Improved FH assess-
ment is needed to provide optimal genetic evaluation in this population.
A Population-Based Sample of Breast Cancer Survivors Who
Accessed BRCATesting Recalled Greater Adherence to Cancer
Genetic Counseling Practice Guidelines when a Genetic Healthcare
Provider was Involved
D. Bonner1, D. Cragun2, L. Camperlengo2, T. Pal2
1. Johns Hopkins University/National Human Genome Research Insti-
tute, National Institutes of Health
2. Moffitt Cancer Center
Background: Although any physician may order BRCA testing, many
professional organizations endorse genetic counseling (GC) prior to ge-
netic testing (GT). Differences in GC services delivered by board-
certified genetic healthcare providers (GHP) versus non-genetic
healthcare providers (non-GHP) have been identified in a high-risk cohort
of BRCA carriers, but it is important to confirm this in a population-based
sample. Methods: Women diagnosed with invasive breast cancer <= age
50 in 2009–2012 were recruited through the Florida cancer registry. Par-
ticipants completed a baseline questionnaire and provided BRCA test
reports. Summary statistics and chi-square tests were used for analysis.
Results: Of 495 women who reported having GT prior to enrollment, 153
(31 %) had returned their test report at the time of analysis. Of these 153,
84 % were white and 10 % were BRCA carriers. Those without GHP
involvement (n=123) did not differ significantly from those with GHP
involvement (n=30) by sociodemographic factors. Although having a
pretest discussion was high in both GHP and non-GHP subgroups, those
with GHP involvement were significantly more likely to report adherence
to 6 of 8 recognized elements of GC. Compared to the non-GHP sub-
group, those with GHP involvement more often recalled: (1) having a
pedigree collected (85 % vs. 51 %; p=0.005); (2) receiving a summary
letter (60 % vs. 22 %; p<0.001); (3) discussing other hereditary cancer
syndromes (45 % vs.15 %; p=0.003); (4) discussing uninformative test
results (95 % vs. 74 %; p=0.04); (5) discussing risks to life and disability
insurance (35% vs. 8%; p=0.002) (6) discussing laws that protect against
genetic discrimination (65% vs. 17 %; p<0.001); and (7) that their doctor
encouraged them to share their test results with relatives (73 % versus
58 %; p=0.1). Conclusions: Our results suggest that GHP involvement
was associated with increased patient recall of adherence to nationally
recognized cancer GC practice guidelines. Future studies should assess if
these differences influence whether women share GT results with at risk
relatives.
Personal and Family Cancer History in Li-Fraumeni Syndrome
Diagnosed on Multi-Gene Testing
J. Brzosowicz1, L. Barton1, C. Lewis1, A. Cantor1, T. Pal1
1. Moffitt Cancer Center-Screening and Prevention
Introduction: The emergence of next-generation sequencing with multi-
gene testing has led to unexpected TP53 results in families who may not
meet recognized clinical criteria for Li-Fraumeni Syndrome (LFS) over a
one year period. Methods: A chart review was performed to determine
personal and family history characteristics of patients who tested positive
for a deleterious TP53 mutation on pan-cancer (broad spectrum) multi-
gene testing for twenty five or more genes. Results: Between April 1,
2014–March 31, 2015, 441 patients received results from pan-cancer
multi-gene testing. Five patients tested positive for a deleterious TP53
mutation of whom: 1) four did not meet recognized clinical diagnostic
criteria (classic or Chompret) for a diagnosis of LFS at the time of testing;
and 2) three met National Comprehensive Cancer Network (NCCN) clin-
ical testing guidelines for LFS. Two patients did not meet clinical diag-
nostic criteria or NCCN clinical testing guidelines. Discussion: This se-
ries highlights the high variability in expressivity of what is historically
considered a highly penetrant inherited cancer syndrome. Given the ma-
jority of our families did not meet clinical diagnostic criteria for LFS, it is
clear that multi-gene testing is leading to widening of the disease pheno-
type. Identification of families who do not meet clinical diagnostic criteria
presents many unanswered questions such as the existence of genotype/
phenotype correlations, the presence of genetic or environmental modi-
fiers, and the refinement of quantifying cancer risks (particularly given
that cancer risk estimates are based on the classic highly penetrant fam-
ilies). Consequently, this series emphasizes the need to more broadly
assess genotype/phenotype correlations, cancer risks, risk modifiers,
and ultimately be able to advise these patients about cancer risk
management.
Characteristics of Li-Fraumeni Syndrome in a CHEK2Multi-Gene
Panel Cohort
L. Bucheit1, C. Mason2, H. LaDuca3, R. McFarland4, S. Li5, E.
Chao1,2
1. Ambry Genetics
2. University of California, Irvine
Pathogenic mutations in CHEK2 have been implicated in some TP53-
negative patients with Li-Fraumeni Syndrome (LFS) cancer histories.
Literature is conflicting regarding LFS phenotype of CHEK2+ patients.
With the use of multi-gene panel testing, CHEK2 is investigated in this
population more frequently. The purpose of this study was to describe
LFS characteristics amongst CHEK2 mutation carriers (CHEK2+). Clin-
ical histories of 594 patients who underwent panel testing between 3/2012
and 12/2014 and harbored pathogenic/likely pathogenic CHEK2 muta-
tions were queried. Where personal and family cancer history (hx) were
available, the cohort was analyzed for TP53 testing criteria met including
classic LFS, Chompret, and breast cancer <36 criteria per National Com-
prehensive Cancer Network guidelines (v1.2015). The cohort was ana-
lyzed to determine who met LFS-like (LFL) criteria (Birch or Eeles). The
prevalence of LFS cancers including breast (BR), sarcoma (SAR), adre-
nocortical carcinoma (ACC) and others was also reviewed. CHEK2
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mutations were identified in 594/23555 patients (2.5 %). Patients with
biallelic mutations inCHEK2 (n=7), or with additionalmutations in genes
other than CHEK2 (n=52) were excluded from analysis. No CHEK2+
patients met criteria for classic LFS; 30/464 (6.5 %) met Chompret; 3/468
(0.6 %) met Birch; and 306/494 (61.9 %) met Eeles. CHEK2+ patients
who met Chompret criteria (CHEK2+ LFS) included 12 1100delC mu-
tation carriers and 18 non-1100delC mutations. No CHEK2+ LFS pa-
tients reported personal/family hx of ACC. No SAR was reported in
non-1100delC carriers. Four patients had multiple LFS cancers: 2/18
(11 %) non-1100delC and 2/12 (16 %) 1100delC carriers. 6/12 (50 %)
CHEK2+ LFS patients with 1100delC mutations reported BR diagnosed
< 36 compared to 6/18 (33.3 %) non-1100delC carriers. 6/12 (50 %)
CHEK2+ LFS patients with 1100delC mutations reported family hx of
more than one LFS cancer compared to 7/18 (38 %) for non-1100delC
carriers. This study confirms the presence of LFS/LFL phenotypes in a
subset of CHEK2+ patients with both 1100delC and non-1100delC
mutations.
Referrals to Genetic Counseling in Patients with Breast Cancer
Based on National Comprehensive Cancer Network Guidelines
S. Carroll1
1. Hartford HealthCare Cancer Institute
Indications for referring to cancer genetic counseling and considering
genetic testing for BRCA1/2 are provided by the National Comprehensive
Cancer Network (NCCN)Guidelines. This study is a retrospective review
over a 5 year period of patients diagnosed with breast cancer who are
found to have at least one of three characteristics that would qualify for
genetic counseling and BRCA testing according to NCCN guidelines: 1)
diagnosed <=45 years of age; and/or 2) triple negative breast cancer
(TNBC) <=60 years of age; and/or 3) those who are male. Data was
collected from the tumor registry at The Hospital of Central Connecticut
and was compared to our genetic counseling patient database. From 2010
to 2014, there were 100 diagnoses <=45 years of age, 37 diagnoses of
TNBC <=60 years of age and 2 males, for a total of 126 distinct patients
meeting criteria for genetic counseling and genetic testing. Overall, 55 %
of patients in this study were referred to genetic counseling. Of the eligi-
ble patients diagnosed in 2010, 2011, 2012, 2013, and 2014 the referral
rates to genetic counseling were 30 %, 54 %, 44 %, 75 % and 61 %,
respectively. Our findings in 2010 are comparable to other studies on
women with early-onset breast cancer; however, a notable increase in
referrals occurred over the 5 year time period. Of the 69 patients who
were referred to genetic counseling, 96 % were seen. Of those 66 that
were seen for genetic counseling, 97 % elected to proceed with genetic
testing. One female with non-TNBC diagnosed <=45 years of age was
found to carry a deleterious BRCA2mutation resulting in an incidence of
1.6 % in the cohort who had genetic testing (n=64). Based on these
findings, our cancer committee has implemented a policy to add a notifi-
cation to the pathology reports of all cases of triple negative breast cancer
regarding the NCCN guideline recommendation to refer the patient to
genetic counseling for consideration of genetic testing.
Determining the Clinical Significance of aMSH2 Variants
of Unknown Significance in a Family with Lynch Syndrome
D. Collins1, A. Philp2, N. Doyle3, J. Bell3, H. Ji3
1. University of Kansas Cancer Center
2. Northwestern University
3. Stanford Genome Technology Center
We report a family of Ashkenazi Jewish descent with a history consistent
with Lynch syndrome. The proband initially presented in his early 40’s
with stage II adenocarcinoma in the transverse colon and underwent
surgical resection without additional adjuvant treatment His oncology
evaluation identified multiple paternal relatives with cancers consistent
with Lynch syndrome. His tumor was found to be microsatellite instabil-
ity (MSI) high with immunohistochemistry (IHC) loss of expression of
MSH2 and MLH1. His younger sister was diagnosed during the same
time period with tubulo-villous adenoma in the sigmoid colon. His pater-
nal uncle was diagnosedwith bladder and prostate cancer at age 63, with a
history of colon polyps. The prostate carcinoma was notable for IHC loss
of MSH2. The paternal grandmother was diagnosed in her 40’s with
uterine carcinoma, two metachronous occurrences of colon carcinoma
in her 60’s and ureteral carcinoma in her 60’s as well. The proband’s
initial clinical sequencing of MSH2 and EPCAM deletion results were
inconclusive. As part of a research genetics study, six of the family mem-
bers underwent combined exome and low fold coverage whole genome
sequencing. This included the unaffected mother of the proband. Exome
and whole genome sequencing analysis identified a MSH2 variant
[c.1784 T>G, p.L595R] common to all the affected individuals compared
to other germline coding variants. Per whole genome sequencing, no
large genomic deletions were present in other causative genes of Lynch
syndrome. In silico pathogenicity analysis (MAP-MMR) indicated a high
likelihood of deleterious impact. Clinical diagnostic sequencing was re-
peated and the MSH2 mutation was reclassified as causative. This case
highlights the challenge of variant classification in the clinical setting and
illustrates the diagnostic utility of variant of uncertain significance
(VUS)-related segregation analysis in the era of clinical whole genome
and exome sequencing, as well as genetic counselor involvement in var-
iant reclassification.
Forget the Guidelines? Atypical Presentations of Well-Defined
Hereditary Cancer Syndromes
V. Costello1, J. Schwab1, L. Massingham1
1. Rhode Island Hospital
The landscape of cancer genetic testing has changed dramatically in re-
cent years due to the cost-effectiveness of next-generation sequencing
technologies and overturning of gene patenting. Clinical testing has large-
ly shifted towards the use of multigene panels. It has been demonstrated
that multigene panel testing identifies actionable gene mutations in pro-
bands with atypical presentations who may not meet classical testing
criteria. The current case series reports three such patients. Proband 1 is
a 69-year old male with 3 primary cancers: gastroesophageal junction
adenocarcinoma, renal cell carcinoma and gastric adenocarcinoma. A
29-gene panel identified a pathogenic BRCA1 deletion. This patient did
not meet National Comprehensive Cancer Network (NCCN) testing
criteria for BRCA1/2. Proband 2 is 67-year old female with bilateral breast
cancers. The patient met NCCN criteria for BRCA1/2 testing only. A 9-
gene panel revealed a pathogenic PMS2mutation. Proband 3 is a 44-year
old female with a history of breast cancer diagnosed at age 43, with a
negative family history. A 25-gene hereditary cancer panel revealed a
pathogenic PMS2 deletion. The patient met NCCN criteria for BRCA1/
2 testing only. These cases add to the growing body of evidence that high-
risk cancer predisposition genes may have a wider phenotypic spectrum
than previously appreciated. This raises two questions for genetic
counseling practice. First, should actionable cancer predisposition
genes with established management guidelines be considered a
single entity for diagnostic genetic testing? Reanalysis of testing
criteria may be necessary to provide appropriate patient care and
risk-reduction in patients with hereditary cancer syndromes. Sec-
ond, what screening and management guidelines should be used
for patients with atypical presentation? Guidelines for hereditary
cancer syndromes have been developed based on risk figures
gleaned from high penetrance families. These recommendations
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may need to evolve as we learn more regarding the phenotypic
spectrum of these conditions.
Pedigree Modeling Demonstrates that Family History Performs
Poorly for the Identification of Women with Inherited Risks
for Breast Cancer
H. Cox1, E. Rosenthal1, R. Wenstrup1, B. Roa1, K. Bowles1
1. Myriad Genetic Laboratories, Inc.
Hypothesis/Purpose: Women with an estimated >20 % lifetime risk of
breast cancer are candidates for more aggressive clinical management
including screening at younger ages, at more frequent intervals, and with
more sensitive technologies. We utilized pedigree simulation to test the
hypothesis that the majority of patients carrying pathogenic variants
(PVs) of moderate to high penetrance in breast cancer-associated genes
cannot be identified by family history analysis. Methods: We utilized
computerized pedigree simulation and statistical modeling to estimate
the probability that a female proband carrying a PV conveying a
moderate or high increase in breast cancer risk, will be identified
as having at least a 20 % lifetime breast cancer risk using the
Claus model. Moderate penetrance and high penetrance were de-
fined as a 24 % or 50 % female breast cancer risk to age 79,
respectively. Simulated pedigrees were one-sided and limited to
either the maternal or paternal side segregating the disease allele.
Pedigrees were moderate in size, spanning 3 generations with
sibships comprised of 2 or 5 individuals. Results: Simulated anal-
ysis of moderately and highly penetrant pathogenic breast cancer
variants failed to identify >75 % and >91 % of appropriate pa-
tients by family history analysis, respectively, in sibships com-
posed of 5 individuals. When considering sibships composed of
2 individuals, this result increased to >88 % and >95 % for
moderate and high penetrance models. Conclusions: Pedigree sim-
ulation demonstrates that family history analysis alone fails to
identify the majority of patients carrying PVs in breast cancer
risk genes. Therefore, genetic testing is critical for identifying
women who are candidates for modified medical management
under current professional society guidelines. Although questions
remain about the feasibility of population screening this study
demonstrates a potential benefit of broad pan-cancer testing over
family history based cancer-specific testing for patients who have
been targeted for evaluation of inherited cancer risk.
Utilizing Kentucky Cancer Registry Data to Evaluate Cases
Appropriate for Referral to Genetic Services for Hereditary Breast
and Ovarian Cancer Syndrome and Lynch Syndrome, 2009–2012
A. Durst1, J. Holsinger Jr.2, E. Durbin3, R. Nagarajan2, A. Carman2
1. University of Pittsburgh
2. University of Kentucky
3. Kentucky Cancer Registry
Background: It is estimated that over 1 million people in the U.S. have
Hereditary Breast and Ovarian Cancer syndrome (HBOC) or Lynch syn-
drome (LS). However, most of these individuals remain undiagnosed.
This study utilizes Kentucky Cancer Registry (KCR) data to estimate
the number of cases of breast, ovarian, fallopian tube, colorectal and
endometrial cancers diagnosed between 2009 and 2012 that would meet
select guidelines for referral to genetic services. Methods: Breast, ovarian,
fallopian tube, colorectal and endometrial cancers diagnosed between
2009 and 2012 were obtained from KCR. Evidence-based guidelines
from National Comprehensive Cancer Network, Evaluation of Genomic
Applications in Practice and Prevention, and the American College of
Medical Genetics and Genomics and NSGC were used to determine the
number of cases that met specific criteria for referral to genetic services.
Descriptive statistics were performed and referral groups were compared
using chi-square statistics. Geo-spatial distribution of the cases
across counties and Area Development Districts in Kentucky
was subsequently determined for 2012. Results: Of the 28,109
cancer cases diagnosed in Kentucky between 2009 and 2012,
15,270 (54.3 %) were determined to meet guidelines for referral
including 4,022 cases of breast cancer, 1,057 cases of ovarian and
fallopian tube cancers, 9,815 colorectal cancers and 376 endome-
trial cancers. Review of cases by county for 2012 showed that
cancer cases appropriate for referral occur in every county, but
only 10 % (12/120) of Kentucky counties and 60 % (9/15) of
ADDs were equipped with genetic counseling services. Discus-
sion: This study represents the first analysis of Kentucky Cancer
Registry data to identify cancer cases appropriate for referral to
genetic services. Identification of patients with HBOC and LS
allow planning for cancer prevention, screening, and treatment
in index cases and their relatives. Population-based programs for
the identification of patients that would benefit from genetic ser-
vices should be considered in Kentucky. In order to accommodate
additional genetic counseling referrals from such programs, efforts
should be made to expand the genetic counseling workforce in
Kentucky.
Clinical Impact of Multi-Gene Testing for Hereditary Breast
and Ovarian Cancer in a Large Representative Population
L. W. Ellisen1, K. Shannon1, A. Kurian2, A. J. Desmond1, M. J.
Gabree1, Y. Kobayashi3, M. J. Anderson3, S. Yang3, M. A. Mills2,
S. E. Lincoln3, J. M. Ford2
1. Massachusetts General Hospital Cancer Center
2. Stanford University Cancer Institute
3. Invitae
The practice of genetic testing is rapidly evolving with the recent intro-
duction of multi-gene panels, however the clinical impact of these tests is
not yet fully understood. For patients without BRCA1/2 mutations man-
agement is traditionally guided by personal and family history, although
additional (non-BRCA1/2) genes can contribute additional information.
We sought to understand how often this informationwould change patient
management recommendations in a large representative clinical cohort.
We used similar 25 or 29 gene panels to test more than 1,000 patients, all
of whom were enrolled prospectively at three academic medical centers
and all met National Comprehensive Cancer Network guidelines for he-
reditary breast and ovarian cancer evaluation. We established a uniform
algorithm based on current practice guidelines to recommend manage-
ment actions for the non-BRCA1/2-positive individuals, and we evaluated
which of these recommendations would represent changes in manage-
ment over and above any recommendations based on personal and family
history alone. In total, 63 patients were identified with pathogenic or
likely pathogenic mutations in non-BRCA1/2 genes, consistent with pub-
lished prevalence studies in similar cohorts. We found that the majority of
these findings (55 %) would result in consideration of additional screen-
ing and/or prevention measures for the patient. Moreover, we found that
genetic testing of first-degree family members would also be warranted
given that 70 % of mutation positive relatives would also have a recom-
mended management change. We conclude that in appropriately-referred
patients, multi-gene panel testing yields clinically relevant findings with
potential management impact for substantially more patients than does
BRCA testing alone. Thus, this approach may improve care for many
mutation-affected individuals in the short term, and in the long term
should lead to the development of additional evidence-based guidelines
for at-risk individuals.
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Testing Relatives of Moderate Penetrance Breast and Ovarian
Cancer Gene Mutation Carriers: Current Practices of Genetic
Counselors
E. Fassi1, K. Vogel Postula2, D. Euhus3, P. Hulick4, J. Stoll5, H.
LaDuca6
1. Northwestern University
2. GeneDx
3. Johns Hopkins Medicine
4. NorthShore University HealthSystem
5. University of Chicago Medicine
6. Ambry Genetics
Although moderate penetrance cancer genes are commonly used in the
evaluation of hereditary breast and ovarian cancer susceptibility, their
relevance to the cascade testing and medical management of at-risk rela-
tives is less certain at present. We report current practices of genetic
counselors regarding testing relatives of moderate penetrance breast and
ovarian cancer gene mutation carriers. As part of an online survey con-
ducted through NSGC, participants were asked about their counseling of
family members through a series of closed- and open-ended questions.
Eligible participants consisted of healthcare providers who had provided
genetic counseling to at least one patient who tested positive for a path-
ogenic or likely pathogenic germline mutation in one of the following
genes through a hereditary cancer panel: ATM, BARD1, BRIP1, CHEK2,
FANCC, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51C, RAD51D,
and XRCC2. A total of 124 respondents were included in the final anal-
ysis. For most genes (10/13), the majority of respondents offered testing
for the known familial mutation to relatives. If a family member tested
negative, most respondents explained that it was unknown whether that
individual’s cancer risk was elevated above that in the general population
and continued to offer high-risk cancer screening. Major themes identi-
fied in free-text responses included: (1) making the decision of whether
testing would be relevant for a particular family member on a case-
specific basis, (2) emphasizing the importance of pre-test counseling for
family members, and (3) exercising caution regarding management rec-
ommendations for family members who tested negative for the known
familial mutation. These data provide insight into how moderate pene-
trance cancer gene mutations are being incorporated into family-level
testing and medical management despite uncertain cancer risks.
Familial Cancer Syndromes in African American Women
with Ovarian Cancer
R. Gold1,2, M. Cote1,2, A. Alberg3, E. Bandera4, J. Barnholtz-Sloan5,
M. Bondy6, E. Funkhouser7, E. Peters8, P. Terry9, F. Wang10, S.
Crankshaw10, P. Moorman10, J. Schildkraut10, A. Schwartz11
1. Wayne State University
2. Karmanos Cancer Institute
3. Hollings Cancer Center and Department of Public Health Sciences,
Medical University of South Carolina
4. Cancer Prevention and Control Program, Rutgers Cancer Institute of
New Jersey
5. Case Comprehensive Cancer Center, Case Western Reserve University
School of Medicine
6. Cancer Prevention and Population Sciences Program, Baylor Univer-
sity School of Medicine
7. Division of Preventive Medicine, University of Alabama at
Birmingham
8. Epidemiology Program, Louisiana State University School of Public
Health
9. Departments of Public Health and Surgery, University of Tennessee-
Knoxville
10. Duke Cancer Institute, Department of Community and Family Med-
icine, Duke University Medical Center
11. Wayne State University School of Medicine, Department of Oncology,
Population Studies and Disparities Research
Ovarian cancer (OVCA) has the highest mortality rate of all gynecologic
cancers in the United States, particularly among African American wom-
en. Familial syndromes are associated with 10–15% of OVCA; however,
these syndromes have not been well-characterized in African American
families. We describe cancers seen in Hereditary Breast and Ovarian
Cancer (HBOC), Lynch Syndrome (LS), Cowden Syndrome (CS), and
germline p16 mutations (p16) in African American women with and
without OVCA. African American women with OVCA (ovarian, perito-
neal and fallopian tube cancers) and healthy age-matched controls were
identified from 10 sites between 2010 and 2014. These sites comprise the
African American Cancer Epidemiology Study, and include 469 cases
and 705 controls. A structured telephone questionnaire was administered
to collect information on demographics, reproductive history, medical
conditions, and family history of cancer (parents, full and half-siblings,
children). Unconditional logistic regression models were created to esti-
mate odds ratios and 95 % confidence intervals. Individuals with OVCA
were about 40 % more likely to have a family history of HBOC-related
cancers in a first degree relative than those without OVCA, after adjusting
for study site, age, body mass index, education, age at menarche, number
of live births, and number of first degree relatives (OR=1.41, 95 % CI:
1.04, 1.91). Cases were also more likely to have a family history of LS-
related cancers (OR=1.32, 95 % CI: 1.00, 1.73), CS-related cancers
(OR=1.51, 95 % CI: 1.11, 2.04) and p16-mutation-related cancers
(OR=1.56, 95 % CI: 1.18, 2.07) after adjustment. For all syndromes,
the association was strengthened as the number of affected relatives in-
creased (p-trend: 0.01, 0.08, 0.04, and 0.003, respectively). This study
documents for the first time that African American women with OVCA
are more likely to have first degree relatives with cancers associated with
known cancer syndromes, and their unaffected relatives may benefit from
enhanced surveillance.
Pathogenic Mutations Identified in Patients with 6 or More Colon
Polyps
K. Grace1, B. Leach2, J. Kidd1, J. Saam1, J. Lancaster1
1. Myriad Genetic Laboratories, Inc.
2. Genomic Medicine Institute, Cleveland Clinic
Hypothesis/Purpose: Testing patients at risk for hereditary colorectal can-
cer has traditionally posed a challenge for clinicians. Personal and family
histories do not always meet the testing guidelines, even when the history
appears suggestive to a clinician. At other times, criteria may be met for
multiple syndromes. This analysis reviewed results from a hereditary
cancer panel test to explore the how well polyp count might have pre-
dicted genetic diagnosis. Methods: Pathogenic mutations, as identified by
a 25 gene hereditary cancer panel, were noted for all patients for whom a
minimum of six polyps had been documented on the laboratory test
request form. The polyp count, personal and family cancer history were
reviewed for each patient. The panel included BRAC1, BRAC2, MLH1,
MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, CDKN2A (p16INK4A
and p14ARF), CDK4, TP53, PTEN, STK11, CDH1, BMPR1A, SMAD4,
PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C and RAD51D.
Results: In total, 1017 patients were identified as having six or more
polyps and, of these, 145 patients (14 %) were found to carry pathogenic
mutations. The majority of the mutations were identified in the APC gene
(54 patients) and biallelic MUTYH (15 patients). However, of these 69
patients, 24 (35 %) had less than 20 polyps. Eight of 25 patients (32 %)
identified with a mutation in a Lynch syndrome gene had greater than 20
polyps. Of these patients with Lynch syndrome, all met Revised Bethesda
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criteria and half met Amsterdam II. Eleven patients hadmutations in other
polyposis genes and 40 had mutations in genes unrelated to colon
cancer with BRCA2 (13 patients) being most common in this
group. Conclusions: Although a thorough personal and family
history are very important when selecting hereditary cancer testing
among patients at risk for colon cancer syndromes, this sample of
patients with polyposis illustrates an advantage of a multigene
panel since polyp count may not indicate the single most appro-
priate hereditary colon cancer test.
Outcomes of Cancer Patient-Oncologist Interactions
Concerning Familial Risk of Cancer andReferral to Cancer Genetics
Services
E. Henson Daugherty1, A. Trepanier2, R. Tkatch3, T. Foster3, L.
Penner3, R. Chapman4, T. Albrecht 3, S. Eggly3
1. Henry Ford Hospital
2. Wayne State University
3. Karmanos Cancer Institute
4. Josephine Ford Cancer Institute, Henry Ford Hospital
Background: Little is known regarding patient-oncologist communica-
tion about cancer genetics.We aimed to better understand cancer patients’
interest in discussing familial cancer risk with an oncologist and commu-
nications on this topic. Methods: The parent study, BImproving Patient
Doctor Communication (IPDC),^ included 137 African Americans aged
25–85 with newly diagnosed breast, colorectal, or lung cancer. Data from
participants randomized to receive an interventionwith a question prompt
list (QPL) and a visit with a communication coach prior to seeing a
medical oncologist to discuss treatment (n=36) were analyzed in this
study. Audio recordings of coaching sessions were reviewed to assess
patients’ interest in discussing familial risk with their oncologist. Video
recordings of the patient-oncologist encounter were reviewed for patients
indicating interest in discussing familial risk and for whom a video was
available (n=14). Videos were coded to identify and describe conversa-
tions about familial risk, family history, features of hereditary cancer,
cancer screening, tumor testing, previous genetic counseling, and referral
to genetics. Results: Most patients (n=22, 61.1 %) indicated interest in
discussing familial risk; reasons included concerns about relatives’ risks
or wanting to increase awareness in the family. Lack of interest was due to
having already discussed familial risk with another provider or previous
referral to genetics. Familial risk was discussed in just over half of oncol-
ogy visits (n=8/14, 57%); most discussions (n=5, 63%) were initiated by
the patient. Oncologists asked about family history in half of the visits.
Six patients were appropriate for genetics referral; of these, 4 were re-
ferred. Conclusions: Most patients in this study were interested in
discussing familial cancer risks with their oncologist. However, during
the oncology appointment, only about half of those interested actually
discussed the topic. Most oncologists discussed familial risks when the
subject was raised and often made appropriate referrals for genetic
counseling.
Impacts of Targeted Population Screening Program Implementation
on a Cancer Genetics Clinic
L. Kiedrowski1, J. Huang1, L. Robinson1
1. University of Texas Southwestern Medical Center
There has been a recent call for broader hereditary cancer screening. Our
cancer genetics program implemented a screening process to identify
individuals at increased risk for hereditary cancer. We hypothesized that
implementing the screening program would significantly increase num-
bers of patients seen, genetic tests ordered, and mutations detected. A
family history-based screening tool developed by the Centers for Disease
Control and Prevention (CDC) was modified and used to identify high-
risk patients receiving mammograms starting in October 2011. Our can-
cer genetics department staffs both private (insured) and public
(underserved) clinics. From 2011 to 2014, >35,000 insured and >62,
000 underserved patients were screened, with those identified as high-
risk being navigated to the cancer genetics clinic. Numbers of patients
seen, tests ordered, and mutations detected were tracked across all sites
from 2007 to 2014 to compare pre- and post-screening. The number of
patients seen almost doubled after implementing population screening (1,
401 in 2011 vs. 2,679 in 2014), and the proportion of patients tested
increased (68% vs. 80%, on average). The absolute number of mutations
identified increased, but proportion of positive tests decreased, with a pre-
screening average rate of 16 % versus a post-screening average rate of
12 %. These effects are observed more clearly in the underserved popu-
lation, in which a large proportion of patients seenwere identified through
the screening program. In this group, total patients seen increased over 3-
fold (279 vs. 893). On average, the proportion of patients tested increased
after program implementation (68 % vs. 78 %), and mutation identifica-
tion rate decreased (18 % vs. 9 %). Our population screening program
substantially increased clinic and testing volumes but decreased the mu-
tation positive rate. Implementing such screening will increase the num-
ber of at-risk patients receiving genetic counseling services but also likely
require the addition of both genetic counselors and ancillary staff to take
on the significant increase in volume.
An Investigation ofWomen atHighRisk forHereditary CancerWho
do not Utilize Genetics Services: What are They Communicating
to Their Families?
M. Kieke1, B. LeRoy1, K. Niendorf1, P. Veach1, S. Petzel1
1. University of Minnesota
Research exploring genetic risk communication in families often focuses
on families that have already had genetic counseling and/or testing. For
this study, women who were informed that they are at high risk for
hereditary cancer based on family history but did not utilize genetics
services were interviewed regarding their communication of hereditary
cancer risk to other family members. Telephone interviews (n=12) were
conducted using a semi-structured guide with open-ended questions. In-
ductive and cross-case methods were used for data collection and analysis
to identify themes. Communication of cancer risk primarily involved
first-degree family members and often involved other women in the fam-
ily. Females played an important role in information dissemination. The
interviewees’ knowledge of hereditary cancer was limited; therefore risk
communication focused mostly on lifestyle and environmental factors
rather than inherited risk. Communication was more frequent around
the time of diagnosis or was triggered by diagnosis of other friends/
family members. Intentions for communicating risk included increasing
family cohesiveness, increasing family members’ awareness of cancer
risk, and advocating for health of the family. Barriers to uptake included
interviewee having an inaccurate perception of hereditary cancer risk,
having a good outcome after diagnosis (thus less concerned about cancer
recurrence or diagnosis in other relatives), and feeling less urgency for
being tested due to interviewees’ lack of biological children who
could inherit a cancer susceptibility mutation from them (n=3).
When asked about genetic counseling, interviewees were interest-
ed and thought such services might be useful, but lacked the
knowledge to appreciate value or personal relevance. These find-
ings suggest the importance of continued education related to
hereditary versus sporadic cancer, and increasing general aware-
ness about genetic counseling. Since communication is frequent
around the time of cancer diagnosis, this may be the optimal time
to refer patients to a genetic counselor.
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Pontocerebellar Hypoplasia Type 6: A Diagnostic Odyssey
and Genetic Counseling Dilemma
C. Kiss1, J. MacKenzie1, D. Hull1, A. Acker1, E. MacDonald1, A.
Guerin1
1. Kingston General Hospital
Pontocerebellar hypoplasia represents a group of autosomal recessive
disorders characterized by progressive neurological degeneration, infan-
tile encephalopathy and defects in the mitochondrial respiratory transport
chain. Pontocerebellar hypoplasia type 6, (OMIM # 611523), is caused by
mutations in the nuclear encoded RARS2 gene. We present a patient with
mitochondrial dysfunction, secondary to pontocerebellar hypoplasia type
6. In reaching this diagnosis, familial cancer predisposition was an inci-
dental finding. The patient presented with encephalopathy, hypoglycemia
and lactic acidosis. Muscle biopsy showed mitochondrial complex IV
deficiency. The patient passed away due to respiratory failure at the age
of 18 months. Genetic testing included a comprehensive mitochondrial
disease panel, which revealed two mutations in RARS2, in addition to a
paternally inherited pathogenic mutation in the FH gene. In the homozy-
gous formmutations in FH cause fumerase deficiency (OMIM #606812);
in the heterozygous form hereditary leiomyomatosis and renal cell cancer
(OMIM#150800). The disclosure of these incidental results demonstrated
the importance of pre-test counseling, the principle of autonomy and
recognizing differing coping styles and defense mechanisms amongst
family members. In testing a sick child, parents may not expect to find
out information that may have a direct impact on their own health and the
health of relatives. It may also be difficult to balance the desire to learn the
cause of a child’s illness against the possibility of learning health infor-
mation one may not wish to know about oneself. In this case, the auton-
omy of the family was impacted as they may not have wanted to be aware
of their increased risk for cancer. Coping styles and defense mechanisms
illustrated by this family included Bplan^, Bdenial^ and Bself-
controlling^. Overall, this incidental finding created additional stress
and anxiety in the family, in the midst of an already stressful situation.
One Clinic’s Experience with CHEK2Mutations Other than
c.1100delC
R. Koff1, L. Puryear2, K. Kingham1, N. Chun1, C. Rowe-Teeter1, A.
Lebensohn1
1. Stanford Health Care
2. Stanford University
Cell cycle checkpoint kinase 2 (CHEK2) is a checkpoint kinase important
for DNA damage signaling and repair. Current data estimates heterozy-
gous mutations in CHEK2 increase risk for breast and colon cancer and
possibly prostate, thyroid and kidney cancer. Here we describe the out-
comes from approximately 15 months of germline testing for CHEK2 in
families with breast, colon and other cancers at the Stanford Cancer Ge-
netics Clinic. Data was collected from January 2014-March 2015. 786
individuals with personal or family history of breast and other cancers
were offered a panel that included CHEK2. 22 individuals (3 %) were
found to carry a heterozygous germline CHEK2 mutation. 17 (77 %) of
these were mutations other than c.1100delC. The only recurring non-
c.1100delC mutation was p.Ile157Thr. Six individuals in our cohort were
found to carry this variant (27 %). All of these individuals had a personal
or family history of breast cancer; two had a personal or family history of
colon cancer. Our six unrelated families also reported a history of pancre-
atic, uterine, ovarian, thyroid, melanoma and prostate cancer, although for
most cases the origin of the mutation is unknown. There is discordance in
the classification of this variant by testing laboratories. Functional studies
have demonstrated that this alteration interferes with DNA damage re-
sponse and epidemiological data support pathogenicity, however this
variant is found in NHLBI control populations and some data support
lower cancer risk, suggesting this is a lower penetrance mutation. Our
recommendations for patients with CHEK2 mutations include high risk
breast cancer screening with mammogram andMRI for women, colonos-
copy every 3–5 years and additional screening tailored to an individual’s
personal and family history. Continuing data collection with panel testing
and identification of non-c.1100delCCHEK2mutations will contribute to
understanding of the CHEK2 phenotype and will help clarify guidelines
for cancer screening.
Coordinating Laboratory and Clinical Data to Incorporate
Endometrial Tumor Testing into the Universal Lynch Syndrome
Screening Program at Geisinger Health System
A. Kulchak Rahm1, N. Sertac Kip1, A. Fan1, S. Guha1, D. Davis1, J.
Williams1, H. Kaspar1, R. Gogoi1, Z. M. Chen1, M. Williams1
1. Geisinger
Background: Universal Lynch Syndrome screening (ULS) is defined as
tumor screening of all individuals newly diagnosedwith colorectal (CRC)
or endometrial cancer (EC). ULS screening has been implemented in
multiple health systems and is part of the Healthy People 2020 initiative.
ULS was instituted at Geisinger Health System (GHS) in 2012 for CRC.
Current ULS for CRC includes immunohistochemistry (IHC) screening
of all CRC resected tumors regardless of age, with reflexive BRAF and
promoter hypermethylation (PHM) testing as appropriate through pathol-
ogists. EC tumor screening was limited to age <=60 or age >60 with
specific tumor histology. No protocols were in place for reflexive PHM
testing in EC tumors. Methods: Two genetic counselors and a molecular
pathologist evaluated all EC patients with IHC testing since 2012 to
identify care gaps and presented results to pathologists, genetics services,
gynecologic oncologists and ethics to facilitate inclusion of EC in the
ULS program. Results: Since 2012, 161 EC patients were screened by
IHC (N=152 <=60 and N=19 >60); of whom 30 (18 %) had loss of
MLH1/PMS2 and 11 (7 %) had MSH2 or MSH6 loss. Only 10 patients
with MLH1 loss (33 %) had PHM testing to differentiate between
germline vs. somatic etiology. Of the 20 remaining EC patients, 6
(30 %) were referred to genetics without determination of tumor etiology
and 14 (70%) had no additional follow-up. 91% of patients (10 out of 11)
withMSH2 orMSH6 losswere referred to genetics. Based on the benefits
identified through the ULS program for CRC previously adopted, multi-
ple stakeholders worked together to develop protocols and facilitate pol-
icy change to include EC screening in the ULS program. Conclusion: We
determined that limited EC tumor screening potentially creates missed
opportunities to identify LS patients. Engagement of multiple stake-
holders was required to reach agreement that adding EC tumor screening
to the existing ULS program with reflexive PHM testing by pathologists
will result in improved identification of LS patients and facilitate appro-
priate care.
Phenotype ComparisonBetween Founder andNon-FounderCHEK2
Mutation Carriers
T. Leedom1, H. LaDuca1, R. McFarland1, S. Li1, E. Chao1,2
1. Ambry Genetics
2. University of Irvine
The phenotype of individuals and families with CHEK2 mutations is
currently not well defined, particularly for those harboring non-founder
CHEK2 mutations. The purpose of this study was to assess the pheno-
types and molecular characteristics of CHEK2 mutation carriers in a
multi-gene cancer panel cohort with a focus on comparing phenotypes
of founder and non-founder mutation carriers. Clinical histories of
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patients with CHEK2 pathogenic mutations or likely pathogenic variants
reported on multi-gene panel testing from March 2012-December 2014
were reviewed, including personal and family history of breast (female
and male), multiple primary breast, colorectal, ovarian, thyroid, prostate,
kidney, and endometrial cancers. Clinical history information was obtain-
ed via clinician-report through test requisition forms. CHEK2 mutations
were detected in 594/23,555 individuals (2.5 %). Individuals with addi-
tional mutations in non-CHEK2 genes (n=52) or with biallelic CHEK2
mutations (n=7) were excluded from analysis, as were those for whom no
personal or family history information was provided by the clinician
when appropriate (n=11). Family members known or inferred to be neg-
ative for the familial CHEK2mutation were also excluded from analysis.
CHEK2mutations were further categorized as founder mutations (n=422)
or non-founder mutations (n=113). Founder mutations were classified as
c.1100delC (n=223), c.1283C>T (p.S428F) (n=46), c.444+1G>A
(n=12), c.470T>C (p.I157T) (n=125), and CDS8_9del (EX9_10del)
(n=16). Clinical histories of non-founder mutation carriers were com-
pared against founder mutation carriers using Fisher’s exact test. No
significant differences were observed between clinical histories of
CHEK2 non-founder and founder mutation carriers. These data suggest
that cancer risks reported in founder populations may be generalizable to
all CHEK2 mutation carriers.
Assessment of Constitutional Mismatch Repair Deficiency
Syndrome Testing Criteria in a Pediatric Cancer Genetics Clinic
R. McGee1, E. Quinn1, R. Nuccio1, S. Hines-Dowell1, K. Nichols1
1. St. Jude Children’s Research Hospital
Introduction: Constitutional mismatch repair deficiency syndrome
(CMMRD) predisposes to pediatric-onset cancers and is caused by
biallelic defects in mismatch repair (MMR) genes. CMMRD diagnostic
criteria have been proposed to guide the testing of patients with cancer.
Using these criteria, a score of 3 points is theminimumneeded to consider
CMMRD testing. As the clinical utility of this system is yet to be deter-
mined, a preliminary assessment was performed.Methods: Twelve cancer
patients referred to the Cancer Predisposition Program at St. Jude Chil-
dren’s Research Hospital were assessed for CMMRD. All patients had a
testing criteria score of >=3. After clinical assessment and genetic
counseling, MMR gene testing was performed. Reason for referral, can-
cer diagnosis, demographics, MMR immunohistochemistry (IHC) results
and family history information were collected. Descriptive statistics were
used to evaluate the relationship between testing criteria score and the
likelihood of having a CMMRD diagnosis. Results: The most common
primary tumor types were brain (n=5; 41.6 %) and hematologic (4; 25%).
Eight (75 %) patients were referred for signs of NF1 (café au lait spots or
neurofibroma). Only 1 family history met Lynch syndrome Amsterdam
criteria. Testing revealed 4 patients (33.3 %) with a molecular diagnosis
of CMMRD (testing criteria scores: 3, 6, 6, 8). One (8.3 %) patient
(testing criteria score: 4) had a single MMR variant of unknown signifi-
cance. The remaining cases had noMMR gene alterations (testing criteria
scores: 3–5). Discussion: Although the current CMMRD testing criteria
scoring system lacks specificity, these results suggest that they should be
integrated into the evaluation of children with cancer, given that one third
of patients in this small group were diagnosed with the condition. Larger
cohorts with complete clinical and genetic evaluation will improve our
ability to assess and optimize the testing criteria. Future blood-based
functional assays to assess MMR deficiency may also assist in guiding
testing.
Comparing Yields and Referral Criteria for the Lynch/Colorectal
High Risk Panel and the Colorectal Cancer Panel
A. McGill1, S. Hiraki1, R. Nusbaum1, R. T. Klein2, K. S. Hruska1
1. GeneDx
2. GenPath/BioReference Laboratories, Inc.
Introduction: The growing availability of multi-gene panels for inherited
cancer susceptibility can present clinicians with difficult decisions
concerning the type of panel to order, especially for patients with atypical
clinical presentations. In addition, some of the less well-described genes
included on many panels may not have standard management guidelines
and therefore present a challenge to translating results into clinical care.
Purpose: The aim of this study was to compare the yield of pathogenic/
likely pathogenic variant (PV/LPV) results from a seven-gene Lynch/
Colorectal High Risk Panel (high-risk panel) with well-established phe-
notypes and management guidelines versus a Colorectal Cancer Panel
(CRC panel) consisting of these genes and nine more that have recently
been associated with increased colon cancer risk. Methods:We retrospec-
tively reviewed our data for individuals who underwent testing with a
seven gene high-risk panel or a 16-gene CRC panel, to identify those
patients with a PV/LPV. We then assessed the clinical histories of those
individuals carrying a PV/LPVin a gene in the CRC panel not included in
the high-risk panel. Results: Of 679 high-risk panel tests, 93 had PV/LPV
(13.7%) results, while 107/885 (12.1%) had PV/LPVresults on the CRC
panel. Of these 107 cases with a PV/LPV result on the CRC panel, 41
(38.3 %) had findings in genes not included in the high-risk panel;
CHEK2 (20), ATM (7), PTEN (6), SMAD4 (4), STK11 (2), CDH1 (2),
BMPRIA (2). Of the 41 cases with a PV/LPV in the aforementioned
genes, 35 (85.4 %) met at least one well-established CRC testing guide-
line. Two individuals met Amsterdam criteria, 19 had a personal or family
history that met Bethesda guidelines/endometrial cancer <50 and 18 had
>10 colon polyps. Conclusions: Many of the PV/LPV identified on the
CRC panel would have been missed if the high-risk panel had been
ordered. Therefore, a broad panel might be considered, even in cases with
a clinical history consistent with published testing guidelines for well-
established genes, in order to capture unexpected findings.
Complex Counseling Issues Regarding Cancer Panels: Genetic
counselors’ Experiences Regarding Communication of Reproductive
Risks Associated with Autosomal Recessive Conditions
S. Mets1, R. Tryon2, P. McCarthy-Veach1, H. Zierhut1
1. University of Minnesota
2. Fairview Health Services
Objectives: The development of hereditary cancer genetic testing panels
has altered genetic counseling practice.Mutations within certain genes on
cancer panels pose not only a cancer risk, but also a reproductive risk for
autosomal recessive conditions such as Fanconi anemia, constitutional
mismatch repair deficiency syndrome, and ataxia telangiectasia. This
study aimed to determine if genetic counselors discuss reproductive risks
for autosomal recessive conditions associated with genes included on
cancer panels, and if so, under what circumstances these risks are
discussed. Methods: An online survey composed of 10 open and 14
closed ended questions was emailed through the NSGC listserv. The
survey assessed cancer genetic counselors’ experiences discussing repro-
ductive risks with patients at risk to carry a mutation or variant of uncer-
tain significance (VUS) in a gene associated with both an autosomal
dominant cancer risk and an autosomal recessive syndrome (N=189).
Results: Over half (n=82, 55 %) reported having discussed reproductive
risks; the remainder (n=66, 45 %) had not done so. Overall, genetic
counselors who reported discussing reproductive risks primarily did so
when patients had a positive result and were of reproductive age. Reasons
for not discussing these risks included when a patient had completed
childbearing, or when a VUS was identified. Genetic counselors with
more years of experience, and those spending a greater percentage of time
in cancer genetic counseling, were more likely to discuss reproductive
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risks (p<0.05). Most counselors discussed reproductive risks after
obtaining results and not during the informed consent process.
Conclusions: There is inconsistency in if and when the discussion
of reproductive risks is taking place. The wide variation in these
reproductive risk discussions suggests a need to develop profes-
sional guidelines for when and how discussions of reproductive
risks for autosomal recessive conditions identified through cancer
panels should occur with patients.
A Rare Presentation of Familial Adenomatous Polyposis
J. Mikkelson1, M. Merzianu1, H. Arshad1, A. Bain1, S. Nurkin1, N.
Voian1
1. Roswell Park Cancer Institute
Familial Adenomatous Polyposis (FAP) is a well-known multi-system
hereditary cancer susceptibility syndrome which predisposes individuals
to significant colonic polyposis; without intervention, colon cancer is
virtually inevitable. Additionally, these individuals are at increased risk
for several extraintestinal cancers, including papillary thyroid cancers,
which, in rare occasions, may be the presenting manifestation of the
disease. A significant proportion of individuals with a rare subtype of
papillary thyroid cancer, cribriform-morular (CMPTC), have an underly-
ing diagnosis of FAP. Due to its rarity and heterogeneity, the CMPTCmay
be either missed or misinterpreted as a more aggressive tumor. Our pro-
band, a 19-year-old female was referred to our Institute for additional
evaluation of a suspicious thyroid nodule. Previous thyroid biopsies noted
atypical cells of indeterminate significance; re-review raised concern of a
medullary thyroid cancer. Additional biopsies performed were consistent
with a papillary thyroid cancer. Subsequent total thyroidectomy ultimate-
ly confirmed a multifocal papillary carcinoma, cribriform-morular type.
Based on this pathology, the patient was referred for colonoscopy and
clinical genetics consultation. Colonoscopy identified innumerable colon
polyps; representative biopsies were consistent with an adenomatous pa-
thology. Genetic testing of the APC and MUTYH genes ultimately con-
firmed the patient to have a deleterious APC genemutation. Although the
reported family history was negative for individuals known to have colon
polyps and/or cancer, this mutation was confirmed to be maternally
inherited. Based on this, her first-degree relatives had genetic counseling
and subsequent testing, which confirmed a diagnosis of FAP in three
more of these relatives. This case raises genetic counselor awareness of
unusual presentations of FAP, demonstrates the importance of correctly
identifying this rare thyroid cancer and supports the recommendation that
individuals with CMPTC be referred for genetic counseling and assessed
for FAP.
Recontacting Patients in the Age of Panel Testing: Cancer Genetic
Counselors’ Practice and Perspective
A. Mueller1, E. Dalton2, D. Enserro1, C. Wang1, M. Flynn1
1. Boston University
2. Ambry Genetics
The duty to recontact patients is an acutely pertinent topic in cancer
genetics given the recent availability of hereditary cancer panels that
allow for rapid analysis of multiple genes associated with cancer devel-
opment. The development of practice recommendations on recontact in
cancer genetics requires understanding the practice and perspective of
cancer genetic counselors. From December 10, 2014-January 7, 2015
we conducted an online anonymous survey of cancer genetic counselors
in the United States and Canada. Questionnaire domains included scope
of recontact practice, factors influencing recontact practice, method of
recontact, attitudes about recontact, and demographic characteristics. A
total of 127 counselors responded to the survey, with 52 % (66) of re-
spondents reporting that they have recontacted patients to offer updated
diagnostic testing. Of those who reported recontact and continued the
survey, 75 % reported recontact to offer hereditary cancer panel testing
and 80 % to offer BRCA1 and BRCA2 rearrangement testing. Factors
influencing recontact include Bavailable resources/staff for recontact^
(80 %), Bavailable systems for recontact^ (75 %), and Bpotential impli-
cations for the patient’s family^ (65 %). Respondents indicated that re-
contact for updated diagnostic testing is a shared responsibility between
the provider and patient (43 %), or, mostly patient responsibility (49 %).
A minority indicated that recontacting patients about updated diagnostic
testing should be the standard of care for genetics providers (4 %). Out-
side of patient recontact, education of other providers was the most re-
ported alternativemethod (57%) to increase patient awareness of updated
diagnostic testing. This empirical data offer insight into possible practice
recommendations on recontact for updated diagnostic testing in cancer
genetics.
Lifestyle Risk Factors Among Cancer Genetic Testing Patients
J. Quillin1
1. Virginia Commonwealth University
Lifestyle influences cancer risk. Genetic counselors help clients under-
stand and manage their risks. Traditionally genetic counseling has fo-
cused on medical interventions like screening, risk-reducing surgery,
and medication. Lifestyle changes may be cheaper, more accessible,
and helpful for multiple diseases. This study assessed cancer risk-
relevant lifestyle factors for people who have had cancer genetic testing.
Data came from the Health Information National Trends Survey (HINTS
4), with nationally representative phone and mail data, collected through
2013. The presented analyses selected variables relevant for American
Cancer Society nutrition and physical activity guidelines. Lifestyle factors
were assessed for people who had undergone testing for BRCA1,
BRCA2, or Lynch Syndrome genes. Analyses used SAS v.9.3 SURVEY
procedures. In exploratory analyses, lifestyle was compared with people
who had not had genetic testing, adjusted for potentially associated
(p<0.10) demographic factors. Among 3,016 HINTS respondents, 135
had cancer genetic testing. Average body mass index (BMI) for people
who had testing was 27.8 (SE=0.62) kg/m2. 57.6 % were overweight or
obese. 17.6 % did no physical activity of at least moderate intensity. On
average, they reported sedentary behavior (e.g., watching TV) 3.4
(SE=0.472) hours daily. 62.6 % drank non-diet soda, and 22.6 % of these
people drank soda every day. They most commonly ate 1–2 cups fruit
(33.5 %) and 1–2 cups vegetables (34.8 %) daily. 23.8 % were current
smokers. There were no differences in age, race, or education between
those who did and did not have testing. People who had testingwere more
likely to be female and have higher income. Controlling for gender and
income, having genetic testing was not a predictor of lifestyle. In conclu-
sion, most people who have genetic testing for cancer susceptibility have
at least one modifiable risk factor. Genetic counselors have opportunities
to impact a client’s cancer risk not only through risk-tailored medical
procedures, but also through lifestyle modification recommendations.
Managing Uncertainty: Lessons Learned from Utilizing a Biallelic
MSH6 Variant of Uncertain Significance to Alter Clinical Care
E. Quinn1, R. McGee1, R. Nuccio1, S. Hines-Dowell1, A. Pappo1, A.
Broniscer1, K. Nichols1
1. St. Jude Children’s Research Hospital
Introduction: Variants of uncertain significance (VUS) continue to be a
significant challenge for providers and patients alike; no consensus exists
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regarding what to do with these results. The value of communication
between the laboratory and provider cannot be underestimated; it is in-
deed a two-way conversation with each source of information facilitating
interpretation of the other. Here, we report a case where an MSH6 VUS
was used to guide clinical management, ultimately leading to the detec-
tion of asymptomatic tumors in the patient and eventual variant reclassi-
fication. Care Report: Our patient is of Palestinian ancestry and presented
at age 12 with anaplastic astrocytoma. Constitutional Mismatch Repair
Deficiency syndrome (CMMRD) was suspected due to the high grade
nature of the brain tumor, presence of café-au-lait spots, and parental
consanguinity. Results from a MMR gene panel test revealed a homozy-
gous MSH6 VUS: c.3701_3706dupAACTTG. Although the impact of
this variant was unclear, based on the high level of clinical suspicion,
CMMRD-related tumor surveillance was added to the patient’s care plan.
Upon colonoscopy, numerous polyps were identified, including 1 that
was determined to be a mucinous adenocarcinoma. As a result, the patient
underwent a total colectomy. The patient’s sister, age 9 and with multiple
café-au-lait spots, also tested positive for the homozygous MSH6 VUS.
She was subsequently noted to have extensive colonic polyps as well as
lesions consistent with a diagnosis of gliomatosis cerebri. Discussion: In
specific family and/or medical contexts, a VUS may have clinical utility.
With our patient, wewere able to detect and remove colon cancer before it
metastasized and/or became inoperable. For our patient’s sister, testing for
the familial VUS enabled us to justify CMMRD-related tumor surveil-
lance which detected many asymptomatic lesions. Sharing the aforemen-
tioned clinical information with the testing laboratory facilitated the ulti-
mate reclassification of this variant as likely pathogenic.
Congenital Wilms Tumor in a Father and Daughter Found to Carry
a Novel Truncating Mutation in the WT1 Gene
L. Rhodes1, N. Pinto1, E. Sokol1, K. Onel1
1. The University of Chicago
Inherited mutations in theWT1 gene are associated with predisposition to
syndromic and isolated Wilms tumor, genitourinary abnormalities, and
nephrotic syndrome. Here, we describe a family with a novel WT1 mu-
tation located 5’ to any other WT1 mutations previously reported in the
literature. The father of the proband had a history of bilateralWilms tumor
diagnosed in his first couple days of life in addition to unilateral cryptor-
chidism. He had a left nephrectomy at 3 days of age followed by preop-
erative chemotherapy with vincristine and dactinomycin, and a partial
right nephrectomy at 7 months. In adolescence he went into renal failure
and underwent renal transplant. Shortly after discovering his wife was
pregnant with his first child, he was evaluated in a general genetics clinic
and found to have a novel c.144C>G truncating mutation in WT1. The
couple declined prenatal genetic testing, but underwent serial prenatal
ultrasound surveillance that was unremarkable. On day of life one, ab-
dominal ultrasound revealed a right renal mass. Postnatal genetic testing
confirmed that the proband, a daughter, had inherited the familial WT1
mutation. She was treated with vincristine alone and later with added
dactinomycin. She underwent a partial right nephrectomy at 3 months
of age, which confirmed the diagnosis of Wilms tumor. Both paternal
grandparents tested negative for the familial WT1 mutation; intriguingly,
the paternal grandfather was affected with glomerulonephritis of un-
known etiology at age 35. It remains uncertain whether the father’s ne-
phrotic syndrome was due to the WT1 mutation, unrelated factors that
also contributed to the grandfather’s history of glomerulonephritis, or
other factors, such as exposure to chemotherapy. This report of congenital
Wilms tumor in a father and daughter supports the idea that early trun-
catingWT1mutations can be highly penetrant andmay be associatedwith
a very early age of Wilms tumor development, as well as nephrotic syn-
drome and genitourinary abnormalities.
Hereditary Cancer Testing for Patients of Ashkenazi Jewish
Ancestry in the Era of Panel Testing
J. Rinsky1, M. Landon1, J. Kidd1, K. Brown1, E. Rosenthal1, S.
Manley1
1. Myriad Genetic Laboratories, Inc.
Hypothesis/Purpose: Due to the high prevalence of 3 founder mutations
in BRCA1/2 among patients of Ashkenazi Jewish (AJ) ancestry, current
National Comprehnsive Cancer Network guidelines recommend founder
mutation testing for all AJ women with a personal history, or close rela-
tive diagnosed with breast or ovarian cancer at any age. A subset of AJ
individuals with additional history are candidates for full analysis of
BRCA1/2 and current data suggests that this results in approximately a
10 % increase in mutations detected. However, with the advent of panel
testing for multiple additional genes, we hypothesized that Breflexing^AJ
patients to a panel following negative founder mutation testing would
significantly increase the number of pathogenic variants (PVs) identified
relative to BRCA1/2 testing alone. Methods: We analyzed results from
clinical testing of AJ patients with negative results for the 3 BRCA1/2
founder mutations, whowere then tested with a 25-gene hereditary cancer
panel including BRCA1, BRCA2, MLH1,MSH2, MSH6, PMS2, EPCAM,
APC, MUTYH, CDKN2A, CDK4, TP53, PTEN, STK11, CDH1,
BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1,
RAD51C, and RAD51D. All patient information was obtained by health
care provider report on the test requisition forms. Results: 2,667 patients
of AJ ancestry underwent genetic testing. Of those, 4.8 % (129) tested
positive for one of the 3 founder mutations. 2,217 patients went on to
testing with the 25-gene panel and 2.4 % (54) were identified as having at
least one pathogenic mutation, 22.2 % (12) of which were non-founder
mutations inBRCA1/2mutations, and 77.8% (42) in 14 other genes. This
included mutations in CHEK2 (16.7 %), ATM (11.1 %), and MSH6
(7.4 %). Conclusions: An AJ patient in this cohort is 3 times more likely
to carry a pathogenic mutation in a different inherited cancer gene com-
pared with a non-founder mutation in BRCA1/2. This supports the hy-
pothesis that the yield from multi-gene panel testing is significantly
higher compared with comprehensive analysis of BRCA1/2 alone for
patients of AJ ancestry.
Outcomes of Multi-Gene Testing for Inherited Cancer Risk
in Patients of Varied Ancestries
E. Rosenthal1, H. McCoy1, J. Kidd1, K. Brown1, S. Manley1
1. Myriad Genetic Laboratories, Inc.
Hypothesis/Purpose: Genetic testing outcomes can vary by patient ances-
try, due to founder mutations, knowledge about variants, other biological/
environmental risk factors, and disparities in access to services. We in-
vestigated the impact of patient ancestry on utilization and results from
clinical testing with multi-gene panels that have recently emerged as an
alternative to single gene/syndrome testing for assessment of inherited
cancer risk. Methods: Results are from 74,095 female patients tested
clinically with a 25 gene hereditary cancer panel. Clinical information
was obtained from test request forms completed by ordering healthcare
providers. Pathogenic variants (PVs) are those classified as deleterious or
suspected deleterious. Results: Almost 50 % of the female sample report-
edWhite/Caucasian ancestry. Excluding patients with no specified ances-
try (19.8 %), or multiple reported ancestries (11.3 %), the next three
largest groups were Latin American/Caribbean (7.2 %), African (6.0 %)
and Asian (2.6 %). The positive rate in the four most common ancestries
for one or more PVs was 7.6 %, 7.4 %, 6.6 % and 7.6 %. Although there
were differences in the prevalence of PVs in different genes by ancestry,
the highest number of PVs in all groups was in BRCA1 and BRCA2,
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followed by the moderate penetrance breast cancer genes, ATM, CHEK2
and PALB2. CHEK2 mutations were notably more common in patients
reportingWhite/Caucasian ancestry, due largely to the 1100del European
founder PV. Evidence is emerging for the presence of additional founder
mutations in other panel genes. Conclusions: There is evidence for under-
utilization of the hereditary cancer panel for non-White/Caucasian wom-
en based on the ancestry distribution in the U.S. population. Among the
women tested, the positive rate for detection of one or more PVs was not
strikingly different in any ancestry, and although there were differences in
the distribution by gene, there is no evidence to suggest that the panel
approach has benefits that are ancestry-specific.
Urologists’ Current Practices in Screening and Treating Men
with a Family History of Prostate Cancer
L. Rudichuk1, K. Vogel2, C. Wang3, B. Helfand3, C. Selkirk3
1. Northwestern University
2. GeneDx
3. NorthShore University HealthSystem
Background: Family history is one of the fewwell-defined risk factors for
prostate cancer (PC). Guidelines for PC screening are variable for high-
risk men, and guidelines for treatment do not change in the setting of
familial PC. There is limited data whether family history of PC is used in
clinical urological practice. Therefore we surveyed urologists to assess
whether current practice takes family history into account and affects their
PC screening and treatment recommendations. Methods: Surveys were
handed out to members of the Chicago Urological Society at the Novem-
ber 2014 meeting on prostate cancer. Survey questions explored urolo-
gists’ frequency of family history collection and utilization of family
history for screening and treatment recommendations for PC. Data were
summarized and compared using descriptive statistics. Results: A total of
87 responses were included in the analysis, for a response rate of 60 %
(87/145). The majority reported that they always collect family history
when discussing risk (95 %) or screening (87 %), and recommended
earlier screening for men with family history of PC in comparison to
men with no family history. Although only 57 % reported always
collecting family history when discussing treatment, it was evident more
definitive treatment plans were adopted when presented with various
family history scenarios. Eight percent of urologists would recommend
prostatectomy for men diagnosed with low grade, low risk PC and no
family history of PC versus 52%whowould recommend the same course
of treatment when the patient had at least 1 first degree relative (FDR)
who died of the disease. Conversely, 91 % of urologists would recom-
mend active surveillance for men with low grade, low risk PC versus
47 % for those with at least 1 FDR who died of the disease. Conclusion:
Despite the lack of literature to support familial PC patients needing more
aggressive treatment, urologists were more likely to recommend defini-
tive therapies, with their inherent side effects possibly contributing to the
overtreatment problem in prostate cancer.
Identification of a Recurrent Pathogenic Variant in BRIP1
S. San Roman1, E. Rosenthal1, J. Kidd1, S. Manley1
1. Myriad Genetic Laboratories, Inc.
Purpose: Pathogenic variants in BRIP1 are known to be associated with
an increased risk of breast and ovarian cancer; however, little is known
about the spectrum of pathogenic variants seen in this gene.
Methods:We identified patients positive for pathogenic variants inBRIP1
through clinical testing with a 25-gene hereditary cancer panel from Sep-
tember 20, 2013 to March 13, 2015. Patients were referred for panel
testing due to a personal and/or family history of cancer. Results: 230
patients were found to have a pathogenic variant in BRIP1, 85 (37.0 %)
had a personal diagnosis of breast cancer, 38 (16.5 %) had a personal
diagnosis of ovarian cancer, and 100were unaffected at the time of testing
(43.5 %). Of the 230 patients identified to carry BRIP1 pathogenic vari-
ants, 67 (29.1 %) were heterozygous for the variant c.2392C>T that
truncates the protein at amino acid position 798. 31/67 (46.3 %) had a
personal diagnosis of breast cancer, 6/67 (9.0 %) had a personal diagnosis
of ovarian cancer, and 32/67 (47.8 %) were unaffected. The majority of
patients positive for c.2392C>T reported to be of Western/Northern Eu-
ropean ancestry (56.7 %), compared to 50.9 % in all patients with BRIP1
pathogenic variants. Interestingly, the common Icelandic and Spanish
variants (c.2040_2041insTT and c.1702_1703del) were not detected.
Conclusions: A single truncating variant has been identified that consti-
tutes 29.1 % of the total pathogenic variants in BRIP1. The types of
cancer associated with c.2392C>T are similar to those seen with other
BRIP1 pathogenic variants. In this cohort, these findings highlight the
importance of BRIP1 as a breast and ovarian cancer predisposition gene.
Predispositions to Lymphoma: A Practical Guide for Genetic
Counselors
M. Similuk1, J. Peters2, K. Rao1, M. Lenardo1
1. National Institute of Allergy and Infectious Disease, National Institutes
of Health
2. National Cancer Institute, National Institutes of Health
As with almost all cancers, the majority of lymphomas are sporadic yet
rare hereditary predispositions exist. Identifying families with a predispo-
sition to lymphoma has potential to decrease morbidity and mortality
while also helping the individuals understand and adapt to the medical,
psychological, and familial implications of disease. Cancer genetic coun-
selors are aware that genomic instability syndromes, such as Li-Fraumeni
syndrome, can predispose to lymphoma. In addition, recent technological
advances have ushered in the identification ofmany new germline genetic
syndromes predisposing to lymphoma, particularly in the area of immune
dysregulation. Immune-mediated lymphoma predisposition has histori-
cally been sparsely discussed in the cancer genetic counseling literature
but the integration of genetic counseling into immunology is bridging the
two specialties. We aim to increase the awareness among genetic coun-
selors and colleagues in oncology about familial lymphoma susceptibility
and facilitate critical thinking in the face of a lymphoma risk assessment.
We provide a synopsis of major concepts of lymphoma predisposition
including genomic instability, role of oncogenic viruses, autoimmunity,
proliferation/apoptosis imbalance, and chronic antigen stimulation. Syn-
dromes typifying each of these mechanisms are discussed and a summary
table with empiric risk estimates is provided. Clinical translation of this
knowledge is aided by recommendations for targeted collection of per-
sonal and family history to guide risk assessment and testing. Lastly,
genetic counseling issues including perceptions of the context, nature,
and magnitude of lymphoma risk, as well as special issues in coping with
lymphoma susceptibility are highlighted.
Cancer Incidence in First and Second Degree Relatives of BRCA
Mutation Carriers
H. Streff1, J. Profato2, D. Nebgen2, Y. Ye2, S. K. Peterson2, C.
Singletary1, J. Litton2
1. University of Texas Health Science Center at Houston
2. University of Texas MD Anderson Cancer Center
Purpose: Mutations in the BRCA1 or BRCA2 genes are associated with
increased risks for breast, ovarian, and several other cancers. The purpose
of this study was to evaluate the incidence of cancers in first and second
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degree relatives of BRCA mutation carriers compared to the general
population. Methods: A total of 1,086 pedigrees of BRCA mutation car-
riers was obtained from a prospectively maintained, internal review board
approved study of persons referred for clinical genetic counseling at The
University of Texas MD Anderson Cancer Center. We identified 9,032
first and second degree relatives from 784 pedigrees which demonstrated
a clear indication of parental origin of mutation. Standardized incidence
ratios (SIRs) were used to compare the observed incidence of 20 primary
cancer sites to the expected incidence of each cancer based on calculated
risk estimates according to a subject’s age, sex, and ethnicity. Results:
BRCA1 families had increased SIRs for breast and ovarian cancer
(p<0.001) and decreased SIRs for kidney, lung, Non-Hodgkin’s lympho-
ma, prostate, and thyroid cancer (p<0.001). BRCA2 families had in-
creased SIRs for breast, ovarian, and pancreatic cancer (p<0.001) and
decreased SIRs for kidney, lung, Non-Hodgkin’s lymphoma, thyroid,
and uterine cancer (p<0.0025). Analysis of only first degree relatives
(n=4,099) identified no decreased SIRs and agreed with the increased
SIRs observed in the overall study population. It also identified an in-
creased SIR for prostate cancer in BRCA2 families trending towards
significance (p=0.003). Conclusion: We confirmed previous reports of
an association between breast, ovarian, and pancreatic cancers with
BRCA mutations as well as an association between prostate cancer with
BRCA2 mutations. Additional research to quantify the relative risks of
these cancers for BRCA mutation carriers can help tailor recommenda-
tions for risk reduction.
Evaluating the Appropriateness of Hereditary Breast and Ovarian
Cancer Genetic Referrals by National Comprehensive Cancer
Network Guidelines and Predictive Risk Models
C. Tallo1, C. Stanislaw2, A. Eppolito3, C. Bellcross4
1. Emory University
2. Winship Cancer Institute of Emory University
3. Piedmont Healthcare
4. Emory University School of Medicine
Introduction: As awareness of Hereditary Breast and Ovarian Cancer
(HBOC) syndrome continues to grow, so has the demand for genetic risk
assessment and testing. These services can be utilized most effectively by
ensuring that referrals for cancer genetic counseling are appropriate based
on a personal or family history suggestive of HBOC. Purpose: We inves-
tigated whether referrals for cancer genetic counseling were appropriate
by determining if patients met National Comprehensive Cancer Network
(NCCN) Guidelines® Version 1.2014 for Breast and/or Ovarian Cancer
Genetic Assessment and HBOC syndrome testing criteria, as well as their
scores on the Breast Cancer Genetics Referral Screening Tool (B-RST)
and BRCAPRO model. Methods: We conducted a retrospective chart
review to collect information on patients seen within the Emory Depart-
ment of Human Genetics (DOHG) and theWinship Cancer Institute High
Risk Assessment Clinic (HRC) from 2008 to 2013. Full pedigrees and
BRCA1/2 test results were evaluated. Results: Of 367 patients analyzed,
94.8 % met NCCN risk assessment criteria and 92.4 % met testing
criteria. In contrast, 42.2 % screened positive on B-RST while 13.1 %
had a BRCAPRO score of >=10 % and 22.1 % had a score of >=5 %. Of
the 214 patients who underwent BRCA testing, 14 (6.5 %) had a muta-
tion. Among mutation carriers, 6 had a BRCAPRO score <5 % and 10
scored positive on B-RST. The specificities of BRCAPRO cutoffs of 5 %
and 10%, B-RST, and NCCN testing criteria were 79%, 88%, 52%, and
4%, respectively. Conclusions:While a largemajority of patients referred
met NCCN Guidelines®, most were not considered at high risk for
HBOC by B-RST or the BRCAPRO cut offs of 5 % and 10 %. The
guidelines did not appear to discriminate individuals at low risk to carry
a BRCAmutation. Further studies evaluating the clinical usage of NCCN
criteria and predictive risk models, along with more studies on HBOC
penetrance in families with limited cancer histories, can help guide
healthcare professionals in referring patients within this rapidly changing
landscape of cancer genetic testing.
Yield ofGenetic Testing for Hereditary Cancer AmongMale Patients
K. A. Theobald1, L. Andolina1, S. Knapke1, L. Susswein1, P.
Murphy1, R. Nusbaum1, K. S. Hruska1, R. T. Klein1
1. GeneDx
Background: Historically, genetic testing guidelines for hereditary breast
and ovarian cancer (HBOC) focused on female probands with a clinical
history. Despite recognition of prostate and pancreatic cancer as features
of HBOC, published guidelines have only recently included these in
testing criteria. Next generation sequencing has expanded cancer genetic
testing, but testing of men remains limited. We sought to quantify testing
in men and to determine the yield of pathogenic/likely pathogenic vari-
ants (PV/LPV) in men with breast, prostate or pancreatic cancer.
Methfods: We reviewed the results of 1,635 men genetically evaluated
for BRCA1/2 and up to 27 additional high/moderate risk genes, including
184 with breast cancer, 116 with pancreatic cancer and 144 with prostate
cancer. Results: In an unselected series of 25,755 inherited cancer genetic
tests, 1,635 specimens were received from men (6.3 %). Among men
tested, 259/1,635 (15.8 %) had a PV/LPV compared to 2,076/24,120
(8.6 %) women. Of 184 men with breast cancer, 24 (13 %%) had a PV/
LPV in the following genes: BRCA2 (10), CHEK2 (8), BRCA1 (2),
PALB2 (2), ATM (1), and TP53 (1). Of 116 men with pancreatic cancer,
17 (14.6 %) had PV/LPV: BRCA2 (6), ATM (4), BRCA1 (2), PALB2 (2),
TP53 (2), and CDKN2A (1). Among 144 with prostate cancer, 22 had a
PV/LPV (15.2 %) and of these 22 men, 17 (77 %) had at least one
additional primary cancer: BRCA2 (7); CHEK2 (5); BRCA1 (4); MSH2
(2); ATM (1), MLH1 (1), PALB2 (1), and TP53 (1). Conclusion:In this
series, men were nearly twice as likely to have a PV/LPV compared to
women. This could be attributed to clinicians using more stringent
personal/family history criteria before offering testing to men. Although
guidelines have often focused on BRCA1/2, 51 % (32/63) of men had a
PV/LPV in genes other than BRCA1/2. PV/LPV were most commonly
identified in BRCA2, CHEK2 and ATM in this population. Consideration
should be given to genetic testing by inherited cancer panels in men with
breast, pancreatic or prostate cancer, particularly in the context of a pos-
itive family history.
Characterizing the Clinical Cancer Presentation of Individuals
with Pathogenic Variants in NBN
K. A. Theobald1, S. Jackson1, S. Knapke1, L. Susswein1, L. M.
Cremona2, R. T. Klein2, K. S. Hruska1
1. GeneDx
2. BioReference Laboratories
Background: The NBN protein is a component of the MRN (MRE11/
RAD50/NBN) complex integral to DNA double strand break repair. Het-
erozygous pathogenic variants in NBN confer a 3-fold risk for breast
cancer and are associated with melanoma, non-Hodgkin lymphoma,
and prostate cancer. Our aim was to review the clinical characteristics
of patients with pathogenic/likely pathogenic variants (PV/LPV) in
NBN. Methods: We retrospectively queried our series of 10,000 Com-
prehensive and Breast/Ovarian Cancer panels, excluding patients with a
PV/LPV in high or moderate risk cancer genes such as BRCA1/2, ATM,
CDH1, CHEK2, PALB2, PTEN, STK11 and TP53. Personal and family
history was extracted from pedigrees and requisition forms of individuals
with a NBN PV/LPV and evaluated against NCCN testing criteria. Re-
sults: In this series, 23 patients had a PV/LPV inNBN. Of the variants, 16
were frameshift (most often c.657_661del5 (8 patients) and
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c.698_701delAACA (3 patients)), 4 splicing, 2 nonsense and one multi-
exon deletion. Pedigree review revealed that 21/23 (91 %) mutation car-
riers had cancer: 17 patients with breast (mean age at diagnosis 48), 3
patients with ovarian (mean age at diagnosis 56) and one patient with
colorectal cancer at 52 and basal cell carcinoma. In the series, 20/23
(87 %) met NCCN genetic testing criteria (19 for HBOC, 1 for Lynch).
Five patients with breast cancer also reported a second primary cancer
(glioblastoma, thyroid, breast, lung, basal cell). All but two patients re-
ported multiple first- and second-degree relatives with cancer such as
melanoma, lymphoma and most commonly breast, colon, prostate and
pancreatic cancer. Conclusion: The inclusion of NBN in multi-gene can-
cer panels will identify hereditary cancer risk in a small population of
patients with breast and ovarian cancer. Factors such as multiple primary
cancers and a family history of cancer, especially breast, colon or prostate,
increase the likelihood of identifying a PV/LPV in NBN. Patients with a
PV/LPV in NBN will most often meet NCCN clinical criteria for genetic
testing.
Physician Views on Genetic Testing and Cancer Surveillance
in Asymptomatic Minors at Risk for Li-Fraumeni Syndrome
K. Wolfe Schneider1, J. Nazario2, R. Casey1,3
1. University of Colorado Denver
2. Invision Sally Jobe
3. Center for Cancer and Blood Disorders Wellness Program
Genetic testing an asymptomatic minor with a parent with Li-Fraumeni
syndrome (LFS) has, historically, been controversial due to the lack of
universal management recommendations for medical interventions dur-
ing childhood. Recent guidelines, however, have suggested medical sur-
veillance protocols for children with LFS and ethical guidelines now
recognize circumstances in which testing minors may provide psychoso-
cial benefits to families. An online survey targeting oncologists and clin-
ical geneticists, physicians who work in specialties most likely to care for
patients with LFS, assessed their (1) experiences with LFS; (2) views
regarding testing minors at risk for LFS; (3) perceptions regarding factors
which are important to consider prior to testing; and (4) screening recom-
mendations for minors with, or at risk for, LFS. Respondents reported a
general lack of experience in working with families with LFS (5.3% (N =
4) of oncologists and 8.1 % (N = 3) of geneticists had followed more than
10 families with LFS). The majority of respondents (60.5 % (N = 46) of
oncologists and 75.7 % (N = 28) of geneticists) reported a high likelihood
to test a child when a parent had a TP53mutation. Geneticists were more
likely than oncologists to view certain factors as important when deciding
about genetic testing (such as published surveillance recommendations
for children or whether current surveillance regimens would change
based on the test result). Interestingly, respondent’s recommendations
for surveillance were more aggressive for children with a confirmed
TP53 mutation than for those children not tested, but with a parent with
a TP53 mutation. Responses suggest that molecular confirmation of a
TP53 mutation in the child impacts medical management recommenda-
tions, which contrasts the standard of treating at risk individuals as pos-
itive until proven otherwise. While testing minors at risk for LFS con-
tinues to be controversial, physicians are likely to test children despite an
observed general lack of knowledge with LFS and screening recommen-
dations inconsistencies.
Assessment of Current Practices in Post-Visit Written Patient
Communication Amongst Genetic Counselors
E. VandenBoom1, A. Trepanier1, E. Carmany1
1. Wayne State University
Providing patients with post-visit written communication is a long-
standing tradition in genetic counseling, however characterization of this
practice in today’s clinical landscape is limited. Our study aimed to char-
acterize the current practice of providing post-visit communications to
patients by format, time spent writing and perceived purpose of providing
communications following a typical new patient visit. A novel, online
mixed methods survey was sent by E-blast to NSGC members. Genetic
counselors in clinical practice were asked if they send post-visit commu-
nications and if so, which of 7 different types they send and average time
spent writing. They were also asked open-ended questions about the
perceived purpose for providing written summaries to patients, if/how
the practice has changed over time and factors they believed influenced
the practice. Eighty three percent (233/280) of respondents reported send-
ing post-visit patient communications. Using pair-wise comparisons by
chi-square analysis, we found that the type of communication sent varies
based on specialty, with prenatal counselors less likely to send out patient-
specific letters or copies of consultation notes than cancer (p=0.010,
p=0.048, respectively) or pediatric counselors (p=0.001, p=0.001, respec-
tively). Between-group Bonferroni post-hoc analysis showed that prena-
tal counselors spend less mean time writing post-visit communications
(19.0 min) relative to cancer and pediatric counselors (30.6 min, p=0.027
and 37.7 min, p=0.001, respectively). Using conventional qualitative
content analysis, the most commonly cited purpose for sending a post-
visit written communication was to provide the patient with a formal
account of what was discussed during the visit. Counselors reported that
they currently send fewer and shorter patient-specific letters than they did
in the past, primarily as a result of having less time due to increased
patient volumes. These data suggest post-visit written patient communi-
cation practices are variable amongst specialties and are changing as the
profession evolves.
V. Counseling/Psychosocial Issues
An Exploration of the Genetic Counselor-Patient Relationship
Following a Life-Limiting Prenatal Diagnosis
S. Anderson1, J. Edwards1, K. Berrier2, K. Redlinger-Grosse3
1. University of South Carolina
2. Duke University Medical Genetics
3. University of Minnesota Educational Psychology/Counseling and Stu-
dent Personnel Psychology
The proposed Reciprocal-Engagement Model of genetic counseling is
comprised of five core tenets with the relationship between the genetic
counselor and patient being central to the process and success of genetic
counseling. This study sought to explore the relationship between the
genetic counselor and patient during and after a prenatal diagnosis of a
Blife-limiting^ diagnosis that resulted in a major loss (termination, still-
birth/miscarriage, or neonatal death). Eight genetic counselor and patient
pairs were individually/separately interviewed about their mutual rela-
tionship and asked about the development and maintenance of the rela-
tionship, the contributing factors, and the long-term effects on both the
genetic counselor and patient. The length of these relationships ranged
from 4 months to 14 years following their initiation. All clinical relation-
ships established required extensive follow-up via multiple modes of
communication with more frequent communication in the beginning
and less as the relationship evolved with more equal initiation of commu-
nication over time. The content of conversations expanded to include
more personal elements from both the genetic counselor and the patient
perspectives. Most participant pairs fell somewhere on a spectrum of
professional relationship to deeply personal relationship as one pair main-
tained an exclusively personal relationship. The support offered by the
genetic counselor during the time of crisis was both essential and unique
to the patient compared to other healthcare providers and family/friends.
Strategies employed and/or characteristics of the genetic counselor and
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patient did contribute to the development and maintenance of the rela-
tionship as did the life-limiting nature of the diagnosis, whichwas thought
to overall strengthen the connection. The long-term effects on participants
reveal clinical implications for genetic counseling. This exploratory study
highlights the unique service of support offered by genetic counselors, as
well as potential avenues for future research and training implications.
The Effect of Room Environment on Patient Experience
in a Prenatal Genetic Counseling Session
E. Baack1, S. Hashmi2, A. Harbison3, S. Peterson4, B. Rech2, C.
Singletary1, R. Carter1
1. UT Health Science Center at Houston
2. University of Texas Medical School at Houston
3. Sequenom Laboratories
4. Univeristy of Texas MD Anderson Cancer Center
An important facet of aesthetic design, a topic of increasing interest in
healthcare, is the concept of using positive distractions to promote well-
ness. This concept has largely been explored in long-term, inpatient care,
and findings suggest these positive distractions decrease patient anxiety.
However, little research exists regarding this concept in short term, out-
patient care, such as prenatal genetic counseling. This study evaluated the
change in anxiety levels from pre- to post-counseling between prenatal
genetic counseling patients who were randomly assigned to one of two
room environments: an experimental room which incorporated positive
distractions, such as a window, plant, art depicting a nature scene, and
full-spectrum lighting, or a control room lacking such features. Partici-
pants (n=98) were English-speaking patients at a Houston Maternal Fetal
Medicine clinic who completed the State-Trait Anxiety Inventory (STAI)
pre- and post-genetic counseling and open-ended questions regarding the
room environment post-counseling. State anxiety scores decreased in
both groups from pre- to post-counseling (p = 0.011); however, average
changes in anxiety scores from pre- to post-counseling did not differ
between the room designs (p =0.530). In addition, patients who chose
not to pursue testing or screening post-counseling experienced a greater
decrease in anxiety from pre- to post-counseling than those patients who
did pursue testing or were undecided (p = 0.007). Unlike prior research,
these findings suggest the room environment may not significantly im-
pact patient anxiety levels in an outpatient setting. However, these find-
ingsmay highlight the benefits of genetic counseling in decreasing patient
anxiety. Lastly, several themes were identified from responses to open-
ended questions, suggesting patients may value certain aesthetic features
of clinic rooms, such as having a window.
An Exploration and Analysis of the Reproductive Decision-Making
Process in Parents of Children with Wolf-Hirschhorn/4p Deletion
Conditions
L. Baldwin1, R. C. Stewart1, A. Lortz2, M. Sdano3,
1. University of North Carolina Greensboro
2. 4p- Support Group
3. Lineagen, Inc.
Background: Wolf-Hirschhorn syndrome/4p deletion syndrome (WHS/
4p-) is characterized by developmental and growth delays, intellectual
disabilities, distinctive facial characteristics and seizures. While previous
studies have focused on the genetic cause and variation in symptoms,
there is a lack of information regarding the effects of this complex etiol-
ogy and variability. The goal of this study was to explore factors involved
in the reproductive decision-making process in parents of children with
WHS/4p-. Methods: Members of the 4p- Support Group were recruited
for personal interviews and an anonymous online survey. Participants had
a biological child with WHS/4p- and were at least 18 years old. Eight
parents or parent couples participated in personal interviews and 95 par-
ticipants completed the survey. Data were analyzed using descriptive
statistics and thematic analysis. Results: 61 % of survey participants felt
that they had not received balanced information during the initial diagno-
sis and 47 % did not feel emotionally supported by the medical commu-
nity. Six of 9 survey participants that were carriers of a balanced translo-
cation agreed that carrier status influenced their reproductive decisions.
The most frequently utilized reproductive option among survey respon-
dents in subsequent pregnancies was prenatal diagnosis via amniocentesis
or chorionic villus sampling (21 %); the majority did not consider preg-
nancy termination. Emotional burden of care was reported to be more
significant than financial burden of care. Parental perception of severity of
child’s phenotype and religious beliefs did not appear to influence deci-
sion making. The majority agreed that having a sibling, either typically
developing or with WHS/4p-, would benefit other sibling(s). Discussion:
Reproductive decision-making is a complex process in the WHS/4p-
community. Many families reported a desire for more emotional support
from healthcare providers and balanced information at diagnosis. Future
studies can expand upon reproductive decision-making of balanced trans-
location carriers or fathers.
Telling the Truth About Turner Syndrome: Disclosure of a Diagnosis
and Infertility to a Romantic Partner
N. Carroll1, M. Gittess2, I. Chilton3,4, J. Ungerleider5, E. Cross1, G.
Schneider6
1. Brandeis University
2. Houston Eating Disorders Specialists
3. Columbia University Medical Center
4. New York Presbyterian
5. Boston IVF
6. Brandeis University
Women with Turner syndrome (TS) often struggle with shyness, social
anxiety, and low self-esteem, and as a result, may have trouble forming
romantic relationships. Studies have identified concerns about infertility
as a primary issue for women with TS. Little research however, has
looked at how women discuss their diagnosis of TS and infertility with
others and none exists that has focused specifically on disclosure to ro-
mantic partners. The purpose of this study was to explore the experiences
of women who disclosed their diagnosis of TS and infertility to romantic
partners. We performed semi-structured interviews with 10 women re-
cruited through the Turner Syndrome Society of the United States, Turner
Syndrome Support Group of Boston and by word of mouth. Questions
focused on life with TS and infertility, disclosure to romantic partners,
and advice for others.We coded and analyzed interview transcripts, using
ATLAS.ti software, and identified emergent themes. The women in our
study ranged in age from 23 to 38 years and the number of partners they
had varied from one to ten. Participants emphasized the importance of a
strong sense of self, and those who were confident and accepting of TS
typically had more positive disclosure experiences. Often, their confi-
dence came from supportive parents, yet regardless of upbringing, all felt
that infertility caused isolation. Participants perceived a benefit to being in
control of disclosure conversations and felt that discussions with
romantic partners present unique challenges, due to issues sur-
rounding having children, and the impact the condition has on a
partner. Advice to others with TS included seeking guidance from
women who have previously disclosed to partners, disclosing in a
comfortable manner, being proud of yourself, and creating a
strong support network. Future studies should focus on partners’
perspectives to gain additional insight on how women with TS
can best have these discussions.
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The Impact of Online Images of Neurofibromatosis Type 1
on the Parents of Newly Diagnosed Children
M. Cushing1, S. Ellingwood2, C. McGowan3, E. Cross1, M. Corral1,
G. Schneider1
1. Brandeis University
2. Maine Medical
3. Boston Children’s Hospital
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a
de novo rate of 50 %. As a result, many affected children are born to
parents with no prior knowledge of NF1. Internet searches for informa-
tion about NF1 typically uncover pictures depicting the most severe end
of the disease spectrum. Therefore, parents encountering these images
may not get an accurate representation of what the disorder means for
their child. This study aimed to gather insights from parents of children
with a new diagnosis of NF1 and no prior knowledge of the disease who
viewed internet images of affected individuals. We performed semi-
structured interviews with seven mothers recruited from the Children’s
Tumor Foundations NF Registry. Discussions focused on diagnostic
stories, first encounters with internet images of NF1, sharing of pictures
with other individuals and advice for future parents of children with NF1.
Participants ranged in age from 30 to 40 years and their children were
between 2 and 3 years old. Mothers felt parents should be advocates for
their children when a medical concern arises, with four proactively seek-
ing out NF1 information online. Viewing internet images caused every
participant to have negative feelings such as worry or heartbreak.Mothers
also felt that online photos misrepresent their child’s diagnosis and the
NF1 population as a whole and that the most memorable images repre-
sented very severe cases of NF1. All participants viewed sharing NF1
images with friends or family as a personal choice, and felt they would
introduce images to their children at an appropriate time when they were
older. Advice for future parents of children with NF1 included seeking
information from reputable sources and being aware that NF1 is not
usually as severe as the images online. Future studies should focus on a
larger sample size that includes fathers, parents of older or more severely
affected children and individuals with varying levels of health literacy, to
gain broader insights about the effects of viewing NF1 images on the
internet.
Secondary Finding Preferences in Whole Genome Sequencing:
Experiences with a Large Developmental Delay Cohort
K. East1, K. Brothers2, K. Bowling1, S. Simmons3, M. Bebin4, E.
Lose4, W. Kelley1, G. Barsh1, R. Myers1, G. Cooper1
1. HudsonAlpha Institute for Biotechnology
2. University of Louisville
3. North Alabama Childrens Specialists
4. University of Alabama Birmingham
Developmental delay, intellectual disability, and related congenital de-
fects (DD/ID) affect ~1–2 % of children born and have a large impact
on affected individuals and their families. Though many cases are attrib-
uted to an underlying genetic cause, identification of the specific variation
often proves elusive. As part of the Clinical Sequencing Exploratory
Research Consortium, we are conducting whole exome/genome sequenc-
ing in ~450 affected probands and their parents to establish a genetic
diagnosis for DD/ID and better understand the utility and impact of large
scale sequencing in a pediatric neurology clinic. To date, we have en-
rolled 210 families, and have completed sequencing and analysis for 123.
We have successfully identified DD/ID pathogenic or likely pathogenic
variants in ~25 % of our probands and have identified potentially patho-
genic secondary findings in ~10 % of parent participants. Participants are
randomized to provide preferences for secondary finding disclosure either
at time of study enrollment or at result return. Preferences are gathered
through a novel instrument developed to illicit preferences on the types of
risk information an individual would like to receive with categories de-
fined by disease type (diabetes, cancer, alzheimer’s disease). When path-
ogenic variants are identified, these preferences are used to determine
whether a result is returned. Analysis of preferences solicited to date show
that the overwhelming majority (>80 %) of parents in this study elect to
receive all types of secondary findings. However a minority of parents
elects not to receive one or more categories of results. The categories
declined vary with the most common category declined being risk of
developing obesity. Reasons for decline include a lack of interest,
perception of low risk status, or anxiety surrounding a specific
category or type of disease. Reported secondary findings to date
include genetic variation leading to an increased risk for malig-
nant hyperthermia, cancer, and heart disease as well as carrier
status for select recessive diseases.
Assessing the Perception of Fertility Preservation Within the Turner
Syndrome Community
R. Gaber1
1. Stroger Cook County Hospital
Background: Turner syndrome (TS) is the most common sex chromo-
some disorder. A hallmark clinical feature of TS is early ovarian failure,
which severely decreases a woman’s chances of achieving natural preg-
nancy. Ovarian tissue cryopreservation (OTC), an experimental fertility
preservation process, may provide women with TS another reproductive
option. This study explored the attitudes of the Turner syndrome commu-
nity regarding possible issues surrounding fertility preservation.Methods:
Each individual participated in one semi-structured phone interview. The
interview was developed using grounded theory and was based on the
current reproductive issues in TS. Participants were asked to reflect on
their attitudes and possible experiences with infertility as well as their
interest in fertility preservation. Interviews were audio recorded and tran-
scribed; responses were coded and categorized into higher order themes.
Results: Eleven participants were interviewed. The issue of infertility was
an emotional burden for most, which was not always adequately ad-
dressed by doctors. Participants also expressed desire for a woman with
TS to have her own biological children. Participants had considered al-
ternative reproductive options, namely adoption. Reactions to experimen-
tal fertility preservation by OTC were mainly positive, but there were
some concerns about the surgery. Some parents believed the daughter
should autonomously make the decision whether to undergo the process
once she is of adult age. Conclusions: Literature supports families’ desire
to have personalized, in-depth discussions on fertility (options); genetic
counselors can help meet this need. A pediatric genetic counselor can
discuss reproductive options with families of girls with TS before it is
too late to preserve fertility. By understanding the experiences of parents
andwomen livingwith TS that create the psychosocial issues surrounding
reproductive issues, clinicians can better anticipate and appreciate how
the TS community will respond to the prospect of experimental fertility
preservation.
Impact of Huntington’s Disease Gene Positive Status on the Lives
of Presymptomatic Young Adults and Recommendations for Genetic
Counselors
P. Gong1, J. Fanos2, L. Korty3, C. Siskind4, A. Hanson-Kahn1,5
1. Department of Genetics, Stanford University School of Medicine
2. Department of Pediatrics, Geisel School of Medicine at Dartmouth
3. Department of Pediatrics, Division of Genetics, University of Califor-
nia, San Diego School of Medicine
Presented Abstracts from the Thirty Fourth Annual Education 1085
4. Department of Neurology, Stanford Health Care
5. Division of Medical Genetics, Stanford University Medical Center
Introduction: Predictive testing for Huntington’s disease (HD) has been
available for over 20 years to asymptomatic at-risk individuals. Young
adults (<=35 years old) make up approximately half of the population
who has undergone predictive testing. Studies targeting young adults’
predictive testing experiences have focused on the time period immedi-
ately surrounding testing. Little is known about the long-term impact of
being gene positive. Purpose:We aimed to explore how the knowledge of
HD gene positive status influences various aspects (career and education,
romantic relationships, family planning, etc.) of the lives of presymptom-
atic young adults, and young adults’ experiences with the predictive test-
ing process and suggestions for genetic counselors. Methods: Adults <=
35 years who had tested positive for >= 6 months were recruited via
support groups, HD Society of America National Youth Alliance, and
HD Youth Organization. Participants (N=14) completed a semi-
structured interview via telephone or Internet. An iterative coding process
was used to identify major themes. Results: (1) Knowing one’s gene
positive status helped participants Bmature faster^ and Bbecome better
people^. Greater appreciation of time led to clearer priorities for life,
living in the moment and letting go of trivial worries. Participants planned
to obtain career and family planning goals faster due to limited healthy
years. (2) Concerns included fears and experiences of discrimination,
loneliness, and uncertainty about how much to disclose about gene pos-
itive status in personal relationships. (3) Some appreciated the pre-test
counseling process whereas others saw it as a hurdle. Many expressed
appreciation or desire for a follow-up plan. Conclusions: Results demon-
strate that young adults are well equipped to handle a positive result.
Opportunities exist for genetic counselors to more carefully address
young adults’ concerns identified in this study. In the future, ways to
make the predictive testing process more concise and accessible with
follow-up plans in place should be considered.
Does a Negative Prenatal Genetic Screen Result Impact
Maternal-Fetal Bonding?
C. Hippman1, J. Austin1
1. University of British Columbia
Background: The maternal-fetal bond (MFB) is the affectionate relation-
ship between mother and fetus. There is a little evidence suggesting that
prenatal screening for fetal aneuploidy – regardless of result –may have a
negative impact on MFB. Given the rapidly increasing options available
for prenatal genetic screening, it is crucial to improve our understanding
of the impact of these tests on MFB. Purpose: To explore the impact of
negative prenatal genetic screening results on MFB. Methods: Women
were recruited from healthcare providers’ offices and community events
to participate in semi-structured (45–60 minute) interviews in person or
by telephone. Data analysis informed data collection using the constant
comparative method. Interviews were recorded and transcribed verbatim.
Constructivist grounded theory was used in data coding to generate cat-
egories and a cohesive theoretical model. Reflexive journaling and peer
debriefing were used to enhance credibility, confirmability, and depend-
ability of results. Results and Discussion: Interviews were conducted until
saturation was reached (N=9). Participants (mean age: 32.78) all con-
ceived naturally, had a romantic partner, and received care from a variety
of prenatal providers. This was a planned pregnancy for seven women
(78%), and first pregnancy for five (56 %). Four women had noninvasive
prenatal testing (NIPT) and five had maternal serum screening. Women
described an instant instinct to protect (Theme 1) and saw bonding as
imagining life with a baby (Theme 2). For women who trust their gut
(Theme 3), genetic screening didn’t impactMFB, but for women who felt
the need for information and saw planning as love (Theme 4), genetic
screening was a time for holding their breath (Theme 5), and a negative
result brought a sigh of relief (Theme 6) and let them give themselves
permission to relax into the pregnancy (Theme 7) and connect more
deeply. Findings from this study provide insight into patients’ experiences
that can enhance clinicians’ ability to empathize with and empower pa-
tients as they engage in prenatal testing for fetal aneuploidy.
Conception Through Gamete Donation: Unique Counseling
Considerations in the Era of Genome-Wide Testing
L. Isley1, P. Callum1
1. California Cryobank
Individuals conceived through egg, embryo, and sperm donation are in-
creasingly and openly presenting for medical care in the United States.
Their methods of conception present unique counseling issues when these
individuals present for genetic evaluation and the use of genome-wide
technology is considered. Triad testing when ordering genome-wide tests,
including chromosomal microarray (CMA) or whole genome/exome se-
quencing (WGS/WES), on a donor-conceived proband is complex. Ge-
netic counselors who are involved in evaluation and testing of these
individuals need to be familiar with the current trends in assisted repro-
ductive technologies so that they can accurately educate these patient
populations to aid in the decision-making process and achieve informed
consent. Failure to consider these circumstances and limitations of testing
can lead to patient distress and poor outcomes. The following counseling
considerations will be described: (1) Donor-conceived individuals are
openly presenting for genetic evaluation in an increasing number of med-
ical settings and genetic counselors and other healthcare providers need to
be prepared for appropriately managing their care. The use of donor
gametes is more frequently disclosed to healthcare providers than in pre-
vious generations due to shifts in recipient populations and greater open-
ness and acceptability of these practices in society. (2) The gamete donor
facility may decline to facilitate testing or be unable to accommodate
requests due to the limited scope of services offered by these organiza-
tions. (3) The donor may be unavailable for testing. (4) Interpretation of a
variant of unknown clinical significance or an incidental finding is com-
plex when many healthy offspring exist from that donor. Counseling
should establish the family’s understanding of the benefits and limitations
of these testing options as well as the potential for complex outcomes.
The Patient Experience Matters: Emotional Reactions to Expanded
Carrier Screening
N. Kumar1, S. Bristow1, S. Rodriguez1, S. Yarnall1, K. Lee1, C.
Pascale2, S. Chen2
1. Recombine
2. Institute for Reproductive Medicine and Science
Introduction: Expanded carrier screening (ECS) is now routinely used in
the clinical setting for patients planning or early in pregnancy. To date, no
study has investigated patients’ reactions to ECS.We aimed to understand
patients’ perceived utility of expanded carrier screening results. Our ini-
tial analysis focused on how patients identified as carriers vs. non-carriers
for included diseases felt about their screening results. Methods: Patients
receiving ECS through a laboratory were sent a survey approximately
3 weeks after results were returned. The survey included a modified
version of the validated BREVEAL Impact of Genetic Testing in
Alzheimer’s Disease^ measure, recommended for use in monitoring pa-
tients who receive genetic information. Results from this measure were
analyzed and compared between carriers vs. non-carriers. Consent was
obtained for all participants. Results: A total of 76 participants completed
the survey. Carriers and non-carriers reported a significant difference
between how often they felt the following: sad (p=0.0092), surprised
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(p=0.038), and anxious (p=0.0011) regarding their results and worried
about their children developing disease (p=0.045). Carriers and non-
carriers did not report a significant difference (p>0.05) between how often
they felt the following: relief, happiness, loss of control and re-
gret. Discussion: As expected, carriers and non-carriers had dif-
ferent feelings towards their results. Carriers more often felt anx-
ious and worried about their results. Interestingly, carriers did not
feel relief or happiness about their results less often than non-
carriers, though this may be the result of post-test genetic
counseling provided. This highlights the importance of genetic
counseling. Our results also show that 90 % of patients reported
they did not feel regret regarding their results. This data suggests
that expanded carrier screening is not detrimental to patients.
Analyses of other measures such as impact on decision-making
and communication about results are necessary to fully evaluate
perceived utility.
The Importance of Social Support in the Undiagnosed Diseases
Community
E. Macnamara1, S. Caldwell2, B. Biesecker2
1. Undiagnosed Diseases Program, National Human Genome Research
Institute, National Institutes of Health
2. Social and Behavioral Research Branch, National Human Genome
Research Institute, National Institutes of Health
Previous work related to parental uncertainty has highlighted the impor-
tance of social aspects of uncertainty; identifying parents in similar situ-
ations who can offer empathic support. The purpose of this analysis was
to explore the social uncertainty perceived by parents of children with
undiagnosed medical conditions. Parents were recruited through online
support groups to complete a cross-sectional, mixed methods study ex-
ploring the domains of uncertainty. The current analysis was conducted
on the qualitative data from 96 parents’ responses on perceptions of
uncertainty. Responses were coded and analyzed looking for common
themes by two investigators with close agreement; residual discrepancies
were reconciled. Many parents conveyed the challenges in finding sup-
port through other parents leaving them without a sense of community.
They also described feeling a lack of understanding from those who did
not share similar parenting experiences. Parents further discussed social
uncertainty including strong feelings of isolation, the need for validation
of their concerns, and feeling as though they lacked the words to describe
their experiences and their child to others, including medical profes-
sionals. One parent stated that uncertainty has caused the Bloss of friend-
ships and relationships because people don’t understand and you can’t
make them understand^. Another explained, BI don’t feel like I can ex-
plain what’s happening to medical professionals or that they always be-
lieve me^. Lacking the words to describe your child and feeling ignored
by medical professionals are likely to exacerbate feelings of isolation and
impede adaptation. Genetic counselors are in a unique position to help
families mitigate aspects of social uncertainty by identifying potential
sources of social support and providing families with easily understood
vocabulary about their child’s condition. This study contributes to our
understanding of uncertainty and its broad effects on parents. It also
identifies an opportunity for genetic counselors to use their skills to pro-
mote healthy adaptation.
Genetics Education and Counseling of Incarcerated Women:
Beginning the Conversation
J. Miller1, E. Balkite2
1. Recombine
2. Genetics Education Consultant, Durham, NC
Genetic counselors periodically see incarcerated patients. However, there
is virtually no research on genetic counseling in this population. This
research was intended to initiate a conversation on the genetic counseling
of incarcerated women. It was also designed to assess the effectiveness of
different techniques that genetic counselors may use to better reach their
incarcerated patients. Six guest lectures on the science and ethics of hu-
man genetics were prepared and delivered to a select group of 19 students
in the Bedford Hills College Program at the Bedford Hills Correctional
Facility for women in Bedford Hills, New York. Vocabulary lists and
visual aids were distributed for each lecture. Each lecture was analyzed
for its effectiveness and impact. Additionally, 12 participating students
were administered a course evaluation wherein they shared their thoughts
on the lectures and handouts. The student inmates’ responses suggested
that prenatal genetics issues, such as age-related risks during pregnancy,
were most relevant and valuable to them. Three respondents specifically
indicated that they are planning to conceive upon release from prison.
Additionally, the information gleaned through a review of the literature,
the participants’ responses, and the lecture series itself identified key
issues to address as genetic counselors attempt to better serve incarcerated
patients. The students who participated in this lecture series benefited
from simple explanations and visual aids, as would most genetic counsel-
ing patients, incarcerated or not. They also expressed significant distrust
of the medical system. Results show that genetic counselors should strive
to build rapport with incarcerated patients, use visual aids, and be pre-
pared to address sensitive subjects such as substance abuse, domestic
violence, and mental illness with them. Furthermore, educating more
incarcerated women about genetics may help them establish more faith
in genetic counseling as a valuable health service.
Experiences with Whole Exome Sequencing
D.Mouhlas1, M.Merrill2, A.Matthews1, L. Konczal2,M.McGowan3
1. Case Western Reserve University
2. University Hospitals Case Medical Center
3. The Pennsylvania State University
Whole exome sequencing (WES) is a complex genomic test involving
sequencing of the protein-coding regions of the genome. Interpreting and
reporting WES results involves complex counseling, medical and ethical
issues. This qualitative study explored parental perspectives on the pro-
cess of WES; assessed parental knowledge and understanding of their
child’s WES results in comparison to the WES laboratory report and
genetics evaluation; and analyzed the similarities and differences between
the parents’ and clinicians’ perspectives regarding the WES process.
Most previous WES research has centered on discovering genetic causes
for disease and professional opinions. There has been limited research on
perspectives of patients and families undergoing clinical WES. Four fam-
ilies were interviewed, along with a corresponding chart review of WES
documents, and interviews with the genetics providers involved. A col-
lective case study methodology was utilized, which involved in-depth
description and analysis of the application ofWESwith triangulating data
from multiple sources - parents, genetics professionals and laboratory
data. Following the collective case study approach, four cases were indi-
vidually assessed followed by a between-case analysis. Major themes
included a Bmotivation to end the diagnostic odyssey^ as the primary
reason to pursue WES for both parents and genetics professionals;
Blearning through genetic testing^ as parents described their experiences
with previous genetic testing as having helped them to learn to cope with
stress and uncertainty in WES; Bvaluing simplicity and honestly in WES
counseling^ was important for both parents and genetic professionals;
Breturning results in person^ was essential to the parents’ understanding
of the test results; and parents felt empowered by the support from genet-
ics professionals. This study adds rich description to the WES process.
Moreover, it highlights the importance and necessity of thorough and
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transparent genetic counseling and its ability to empower patients regard-
less of WES outcome.
Family History: Separating Truth from Fiction. Cancer Risk
Assessment’s Unique Vulnerability to Munchhausen Syndrome
K. Murray1
1. Women’s Care
Taking a medical and family history is an integral part of a Cancer Risk
Assessment (CRA). CRA is one of the few areas of medicine in which a
person may have a surgical procedure, with significant risks, without any
diagnostic test. Through a real life case scenario, I came face to face with
the reality of Munchhausen syndrome and my responsibility to Bdo no
harm^ as a genetic counselor. Upon reflection andwith a thorough review
of the literature, I developed an original scale from which genetic coun-
selors can assess the client’s family Bstory .^ This original continuum
(truth, misinformation, misunderstanding, misrepresentation, to lying)
will be thoroughly explored and applied to an illustrative case. An indi-
vidual’s perception of risk is also an integral part of their family Bstory .^
Utilizing a framework of a comprehensive literature review, the factitious
disorder (aka Munchhausen syndrome) will be explored. The perception
of one’s risk and the seeking of attention are vastly different. However, in
this discussion one will see how they overlap and conflict. Finally, the
Genetic Counseling Code of Ethics will be examined with respect to the
responsibilities of a genetic counselor: to myself, to my client, to my
colleagues, and to society. This lecture is sure to raise many ethical ques-
tions and a framework from which to debate Cancer Risk Assessment’s
unique vulnerability to Munchhausen Syndrome.
Patients’ Opinions on Genetic Counseling on the Increased Risk
of Parkinson’s Disease Among Gaucher Disease Carriers
M. Mulhern1, L. Bier1, M. Balwani1, R. Alcalay2
1. Icahn School of Medicine at Mount Sinai
2. Columbia University Medical Center
Carrier screening for Gaucher disease (GD) is routinely offered to couples
during or prior to pregnancy. Carriers for GD have been found to have an
increased lifetime risk of developing Parkinson’s disease (PD); however,
patients are not generally informed about this increased risk. This study
aims to determine if patients prefer to learn about this correlation and if
learning this information would affect carrier screening uptake, and to
characterize the potential psychological impact of learning this informa-
tion. A survey was administered to individuals who screened negative for
GD. Of the 75 participants, 86.7 % indicated that everyone should be
informed about the increased risk of PD prior to having GD carrier
screening, and 93.3 % responded that they would still have had carrier
screening had they received this information beforehand. These results
indicate that healthcare providers should counsel patients on this topic in
order to align care with patient preferences.
Parents’ Experience Having a Child Diagnosed with more than One
Genetic Disorder
P. Nassab1, J. Youngblom1, K. Weisiger2, L. Abrams3
1. California State University, Stanislaus
2. University of California, San Francisco
3. East Bay Genetic Counseling and Consultation
While the effect of having a child diagnosed with a single genetic disorder
has been extensively studied, to our knowledge, no published studies
have described the psychosocial impact that having a child diagnosed
with co-occurring, yet unrelated, genetic disorders has on parents. In the
presented study, semi-structured interviews were conducted with four
mothers and one father of children diagnosed with two distinct genetic
disorders. These interviews explored the experiences of the parents and
the challenges that arise as a result of this unique situation. Interview
transcripts were analyzed using the qualitative method of interpretative
phenomenological analysis. Results indicated that these parents share
some experiences similar to those previously reported by parents of chil-
dren with a single genetic condition, such as emotions around the diag-
nosis, impact on relationships with family and friends and changes in
values and view on life. However, the findings also elicited some novel
experiences and challenges faced by these families. The challenges in-
cluded frustration toward health care providers who dismissed parents’
input on the effective management of their child’s two conditions, delay
in the diagnosis of the second condition due to misattribution of addition-
al symptoms to the first diagnosis and difficulty balancing the medical
management of two seemingly distinct conditions. These findings sug-
gest that healthcare providers should encourage greater collaborative in-
volvement of parents in the care of their child, as there are significant
challenges in managing two conditions. Additionally, parents may be
more of the expert in this unique situation due to their intimate and
extensive experience caring for their ill child as compared to the pro-
viders’ limited expertise on the combination of rare genetic disorders.
Sharing the experiences of parents raising a child with multiple unrelated
genetic disorders may help to provide guidance for healthcare profes-
sionals to better understand and effectively address some of the unique
issues faced by these families.
Parental Disclosure of Familial Amyotrophic Lateral Sclerosis
Diagnosis and Mutation Status to Children: Perceptions
of Young-Adult Offspring
S. Neumann1, L. Kinsley2, N. Siddique3, S. Magasi4, S. O’Neill5, L.
Fieldman6
1. Northwestern University
2. Neuromuscular Disorders Program at Northwestern University
3. Division of Neuromuscular Medicine, Northwestern University
4. Deptartment of Occupational Therapy University of Illinois Chicago
5. Center for Genetic Medicine, Northwestern University
6. Les Turner ALS Foundation
Background: This qualitative study examined parents’ communication
with their children about the diagnosis of amyotrophic lateral sclerosis
(ALS) and the genetic component of the disease, and to explore if there
was a relationship between the disclosure experience and decision-
making about genetic testing options. Methods: We spoke with 8 individ-
uals utilizing a semi-structured interview. Participants had a parent with
an SOD1 or C9orf72 familial ALS (FALS) mutation, and were ages 20–
33 years. Interviews attempted to identify whether timing and content of
disclosure of parental FALS influences the outlook of young adult off-
spring on FALS genetic testing. Results: Participants were most likely to
prefer open honest communication during the disclosure process, but they
also acknowledged that everything changes the moment the diagnosis is
disclosed and that Bignorance is bliss.^ Communication was dictated by
disease awareness within the family. Participants each had a unique ex-
perience with the presence of ALS in their lives once the diagnosis was
made; yet this was often tied to a sense of loss of control of their own
futures. Most participants referred to a duty to protect their family from
the emotional pain and anxiety experienced from the knowledge of the
diagnosis. Conclusion: Opinions about testing were determined by want-
ing to gain back control over their lives, or an avoidance of the stress
testing would cause them. In conclusion, information obtained from this
study may help genetic counselors guide their patients in the disclosure
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process and assist at-risk young adult family members during the genetic
testing decision-making process.
Paternal Adaptation to a Child’s Diagnosis of Fragile X Syndrome:
Predictors of Individual and Family Well-Being
K. Partynski1 J. Sheldon2, K. Owens3, A. Giordimaina4, B. Yashar5
1. Division of Metabolic Disorders, Children’s Hospital of Orange
County
2. University of Michigan-Dearborn
3. Pediatric Genetics, University of Michigan
4. Institute for Social Research, University of Michigan
5. University of Michigan
A family’s ability to positively adapt to a child’s diagnosis of Fragile
X Syndrome (FXS) depends on individual family members’ resil-
ience. Previous work on adaptation in FXS families has predominate-
ly focused on mothers. Few have studied fathers’ resilience and con-
tributions to family well-being, the focus of this research. We ex-
plored predictors of personal well-being and family quality of life
(FQoL) from a paternal perspective. An online survey using validated
measures of coping strategies (problem & emotion-focused), rela-
tionship satisfaction, parenting stress, family communication, per-
sonal well-being, and FQoL (i.e., Family Interaction, Parenting Sat-
isfaction, Emotional Well-Being, Physical/Material Well-Being, Dis-
ability Support) was distributed nationally via support groups to fa-
thers of children with FXS (N=110). We used hierarchical linear
regressions to assess predictors of personal well-being and subscales
of FQoL. The three predictors blocks were: 1) family environment
(income, education, number of affected children), 2) fathers’ personal
attributes (coping styles, perceived FXS knowledge, perceived sever-
ity of child symptoms), and 3) family dynamics (marital satisfaction,
parenting stress). While personal well-being and FQoL were signif-
icantly correlated (r=.20, p=.03), different variables predicted these
outcomes. Problem-focused coping and parenting stress significantly
predicted fathers’ personal well-being (p<.01). Relationship satisfac-
tion and parenting stress were significant predictors for 3 of 5 FQoL
subscales (Family Interaction, Parenting Satisfaction, Emotional
Well-being) (p<.01). Our findings show that paternal coping strate-
gies in FXS families differ from previously-reported, maternal
emotion-focused approaches and also suggest that the partnership
between spouses is important for positive family adaptation. Genetic
counselors should consider gender differences in individual adapta-
tion, work to engage fathers in sessions (especially by bolstering
marital partnerships), and consider a family-centered counseling
approach.
Social Connections in Families with Li-Fraumeni Syndrome: A
Preliminary Report
J. A. Peters1, R. Kenen2, R. Bremer1, S. Givens1, S. A. Savage1, P. L.
Mai1
1. National Cancer Institute, National Institutes of Health
2. The College of New Jersey
Introduction and Purpose: Li-Fraumeni Syndrome (LFS) is a rare
inherited disorder with the only known cause being germline muta-
tions in the TP53 gene. Mutation carriers have an exceedingly high
(>90 %) lifetime chance of developing one or more malignancies.
Although there are multiple publications of assessment of psycholog-
ical status of families with hereditary cancer predispositions such as
LFS, there are few examples of social assessments. This study pre-
sents findings of a mixed method study for the purpose of filling this
knowledge gap by describing the role of friends and spirituality/
religiosity in easing the burden of families with LFS. Methods: We
evaluated 66 members of LFS families attending National Cancer
Institute LFS Study clinic at the National Institues of Health Clinical
Center between 2011 and 2015. During the first clinical visit we
assessed distress with the BSI-18, and several types of social ex-
changes among the study participants using an established interactive
research tool called the Colored Eco-Genetic Relationship Map
(CEGRM). We performed both quantitative and qualitative analyses
of social relationships with LFS family members and close non-kin.
Results: Of the 59 BSI-18 Distress measures completed by adult
participants, the Global Symptom Inventory mean was 46, i.e., low-
normal, with a few outliers at +/− 1 standard deviation. Anxiety,
depression and somatization sub-scale means were similar. We found
that reported friendships varied widely in number and type, that the
friendships were often deep and enduring, and were important
sources of informational, tangible, emotional and spiritual support.
Confidantes tended to be best friends and/or spouses. Organized re-
ligion was important in selected families, typically from mainstream
traditions. However, a number of other people identified themselves
as Bspiritual-but-not-religious^ and reported spiritual and humanist
explorations. Conclusions: Our results shed preliminary light on
how people in families with LFS cope in the face of overwhelming
medical, social and emotional challenges.
Prenatal Genetic Testing and Screening for Consanguineous
Couples: Is Clinical Practice Consistent with Practice Guidelines?
N. Reddy1, K. Sheets2, R. Bennett3, J. Tsipis1, E. Cross1
1. Brandeis University
2. Vibrant Gene Consulting
3. University of Washington Medical Center
Our study assessed the preconception and prenatal genetic counseling
services offered to consanguineous couples in North America. We sur-
veyed prenatal genetic counselors who have worked in a prenatal setting
at any point between the years 2010 and 2015. Our online survey
contained both quantitative and qualitative questions and we received
132 completed surveys. We analyzed quantitative responses using Statis-
tical Package for the Social Sciences (version 22) and used thematic
network analysis to identify common themes in open-ended responses.
Respondents in our study had an average of 7.5 years of experience in a
prenatal setting and they have counseled an average of 19 consanguine-
ous couples since the start of their career. The mean baseline risk respon-
dents quoted for consanguineous couples to have a child with a genetic
disorder or congenital anomaly ranged from 5.02 to 10.55 % depending
on the degree of relatedness while counselors cited a 3.57 % mean base-
line risk for unrelated couples. The common psychosocial concerns per-
ceived by respondents when counseling consanguineous couples were
stigma, discrimination, fear, and blame as well as some arising from a
couple’s cultural and religious beliefs. Fifty-four percent of counselors
reported that they refer to some guideline, the majority referring to the
NSGC guideline for genetic counseling and screening of consanguineous
couples and their offspring, published in 2002. When asked if they have
recommendations for revising the NSGC guidelines, a number of respon-
dents suggested they be revised to include information on offering new
technologies such as expanded carrier screening, noninvasive prenatal
testing (NIPT), chromosomal microarray and exome sequencing to con-
sanguineous couples and their offspring as well as strategies for
discussing incidental/secondary findings with consanguineous couples.
This study, although limited in size, demonstrates that the genetic
counseling practices for consanguineous couples is more consistent than
observed in the previous study in 1999.
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The Role of Counseling in Facilitating Parent–Child Communication
about Genetic Breast Cancer Risk
K. Tercyak1, D. Mays1, A. Johnson1, S. Murphy1, T. DeMarco2
1. Georgetown Lombardi Comprehensive Cancer Center
2. Inova Translational Medicine Institute
Women at genetic risk for breast cancer are urged to tell their adult rela-
tives about cancer-causing mutations in the family. In the case of BRCA1/
2, informing relatives can be lifesaving. High risk women often collabo-
rate with their genetic counselors to follow this advice. However, women
may also want to tell their minor-age offspring about BRCA in the family,
despite the lack of medical implications in childhood. There is very little
empirical data to gauge how commonly these issues are or are not raised
during genetic counseling sessions, or ways to support family communi-
cation about cancer risk with young people. As part of a multi-site ran-
domized controlled trial, we conducted post-genetic counseling
debriefing interviews (separately with counseled women and their coun-
selors) to ascertain the frequency of how often women (N=231) and/or
counselors addressed issues in-session pertaining to BRCA and
childrearing. In the majority of coded counseling episodes (N=356), dis-
cussions between women and counselors about disclosing BRCA test
results to children were fairly common (54–85 %), including discussion
of pediatric BRCA testing (32–64 %). In 77 % of sessions overall, and
88 % of sessions among BRCA+ women only, women requested more
information about communicating genetic breast cancer risk information
to their children: women were also 4.7x more likely to ask counselors for
support in talking with children about BRCA than counselors were to
recognize this need in their own clients, X2(1)=16.9, p<.001. After ge-
netic counseling, we queried women about what specific resources were
needed to help them make more informed choices about communicating
BRCA risk information to their offspring: 83 % desired a decision guide,
83 % wanted convenient access to an interactive experience (i.e., tele-
phone conversation), and 79 % wanted peer support/connection with
experienced BRCA previvor/survivor. Our data highlight key interactions
between women and genetic counselors about BRCA and childrearing,
and insights into supporting open parent–child communication about ge-
netic breast cancer risk in families.
From Projection to Empathy: Characterizing Genetic Counselors’
Countertransference Experiences
R. Reeder1, P. McCarthy Veach2, I. MacFarlane3, R. Willaert4, B.
LeRoy2
1. Ohio Health
2. University of Minnesota
3. Austin College
4. GeneDx
Introduction: Countertransference (CT) refers to conscious and uncon-
scious emotions, fantasies, behaviors, perceptions, and psychological de-
fenses genetic counselors experience in response to any aspect of genetic
counseling situations (Weil). Some authors discuss the importance of
recognizing and managing CT, but no studies have explored genetic
counselors’ experiences of CT. This study investigated how clinical ge-
netic counselors define CT, the nature of their CT experiences, and their
strategies to effectively manage CT. Method: An anonymous online sur-
vey, sent to NSGC members yielded usable data for 142 participants.
Participants indicated agreement with the provided definition of CT and
completed 28 Likert-type items rating their CT propensities (1=Little/not
characteristic, 4= Very characteristic); 57 participants also provided ex-
amples of CT they experienced in their practice. Results: A large majority
agreed with the CT definition (88.85 %). Factor analysis of CT items
yielded four factors: Control, Conflict Avoidance, Directiveness, and
Self-Regulation, accounting for 38.5 % of response variance. Thematic
analysis of CT examples yielded common triggers: general similarity to
the patient, medical/genetic similarity, angry patients, patient behaves
differently from counselor expectations, and disclosing bad news. Com-
mon manifestations were: being self-focused, projecting feelings onto the
patient, intense emotional reaction to patient, overly invested, disengaged,
and physical reaction. CT Effects were: empathic break, increased empa-
thy, boundary crossing, conversation does not reach fullest potential, and
counselor is drained emotionally. Management strategies were: recogniz-
ing CTas it occurs, self-reflection, and consultation. Conclusion: Genetic
counselors experience CT for various reasons and CT can manifest in
different ways. Training programs, continuing education, and peer super-
vision might include discussion of CT, informed by examples from this
study, to increase genetic counselor skills for managing this phenomenon
with patients.
Understanding Psychosocial Outcomes Among Couples Affected
by Genetic Breast Cancer Risk: Counseling Implications
K. Tercyak1, S. O’Neill1, T. DeMarco2, F. Marcus Lewis3
1. Georgetown Lombardi Comprehensive Cancer Center
2. Inova Translational Medicine Institute
3. University of Washington
Over 1M women have undergone genetic testing for BRCA1/2
mutations–which carry an 85 % lifetime risk of breast cancer. Although
this genetic test is essential to help women make more informed decisions
to protect their health, genetic discoveries far outpace the programs and
services that are available to aid these women and their spouses/partners
(Bpartners^) to manage the uncertainty of familial risk of breast cancer
together. This includes managing the psychosocial toll on each of them as
individuals, but also as a couple/family. Women withBRCA1/2mutations
and their partners face high uncertainty and stress about this substantial
cancer threat, yet lack tailored resources to collaborate together to con-
front multiple, complex treatment decisions. Genetic counselors are ap-
propriate sources of patients’ short-term support, but partners are the main
source of enduring support and shared decision making. Because we
recognize that partners cannot effectively perform this role without ade-
quate preparation, the purpose of this session is to inform the genetic
counseling community about the state-of-the-science in understanding
psychosocial outcomes among couples affected by genetic breast cancer
risk. We will do so by providing a clinical rationale for focusing on
couple-level outcomes, define them and describe their typology, and re-
view existing evidence generated from empirical studies in this area of
work. Where appropriate, we will address core principles of couples-
focused intervention, metrics of successful engagement, and challenges
encountered in clinical settings and outcomes research/lessons learned
addressing this topic. Specifically, we will cover partners’ need for access
to genetic information, stress management and coping skills, and ways to
communicate openly and compassionately with women facing genetic
breast cancer threats and diagnoses. This evidence base includes our
own work and the works of others on the development, implementation,
and evaluation of counseling support services and resources.
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Purpose: There are over 250 known genetic immune disorders, yet the
subspecialty remains relatively uncharted territory for genetic counselors.
In order to better understand the challenges faced by these families and
special opportunities for genetic counselors and other allied health pro-
viders working in this area, a systematic review of research on psycho-
social dimensions of primary immune disorders was conducted.Methods:
A systematic review was conducted via PubMed and Scopus to include
original research on psychological, social, or behavioral aspects of illness
published between 1999 and 2015. ATitle/Abstract search was conducted
using disease specific keywords (for example: Bprimary immune
deficiency^ OR Bcommon variable immune deficiency^ AND
Bpsychosocial^ OR Bquality of life^ etc.). The resulting 225 candidate
article abstracts were manually reviewed, forward/backward reference
searches were completed, and findings were synthesized. Results:
Twenty-nine studies met inclusion criteria. Half of the studies focused
on mixed primary immunodeficiency, primary antibody deficiency or
common variable immune deficiency patient populations; the remaining
studies focused more specifically on patient populations such as X-linked
agammaglobulinemia, severe combined immune deficiency, etc. The
studies illuminate themes such as the potential for negative psychosocial
impact from disease; adaptation over time; the complex assessments of
quality of life; familial impact; the important roles of hope, developing a
sense of control, social support; and addressing anxiety/depression in our
patients and their families. Methodological considerations (e.g., parent
proxy- vs. child self-report) and areas for improvement are discussed.
Conclusion: We propose the research agenda focus on study creativity
and rigor, with improved engagement with existing empirical and theo-
retical literature and critical study design (e.g., methodology with ade-
quate statistical power, creative variable selection, etc.). Additionally, we
highlight special clinical and research opportunities.
VI. Education
The Relationship Between the Supervisor Role and Compassion
Fatigue and Burnout in Genetic Counseling
K. Allsbrook1, K. Wusik1, H. He1, C. Engelhard2, G. Yager2, C.
Atzinger1
1. Cincinnati Children’s Hospital Medical Center
2. University of Cincinnati
The majority of genetic counselors provide supervision to students at
some point during their career. Previous studies have shown that genetic
counselors, in general, are at moderate to high risk for compassion fatigue
and that certain factors such as inherent anxiety increase this risk. How-
ever, no studies have explored the relationship between job duties such as
supervision and the development of compassion fatigue and burnout in
genetic counselors. The purpose of this study was to determine if there
was a difference in compassion fatigue and burnout levels in genetic
counselors who supervise compared to genetic counselors who do not.
Genetic counselors who currently practice in a clinical setting (N=391)
completed an online survey containing demographic questions, the Pro-
fessional Quality of Life Scale, the State-Trait Anxiety Inventory, and
questions specific to the genetic counselor’s experiences with supervi-
sion. Results indicated that genetic counseling supervisors had signifi-
cantly lower levels of compassion satisfaction as compared to non-
supervisors (p=0.026). However, no difference was found between the
two groups when controlling for levels of trait anxiety. Within supervi-
sors, those with more supervision experience reported less secondary
traumatic stress. Those supervisors reporting greater confidence in super-
vision roles had increased compassion satisfaction and decreased burnout
and secondary traumatic stress. The findings of this study indicate that
there is no difference in burnout or compassion fatigue between supervi-
sors and non-supervisors when controlling for anxiety. However, less
experience or less confidence in their supervision role were related to
burnout and compassion fatigue among supervisors. Therefore, we rec-
ommend training in supervision and support for dealing with compassion
fatigue and burnout for supervisors with less experience and less confi-
dence in their role as a supervisor.
Training Methods for Delivering Difficult News in Genetic
Counseling and Genetics Residency Training Programs
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Introduction: Genetic counselors and geneticists are often in the position
of delivering difficult news (DDN) to patients. Many studies state that
healthcare providers need to improve DDN in a manner that is satisfac-
tory to their patients. The purpose of this study was to assess the amount
and methodology of DDN training received by genetic counselors and
geneticists in their training programs. Hypothesis: We hypothesize that
genetic counseling (GC) programs utilize multiple effective methods in
training students to deliver difficult news and that they utilize more strat-
egies than genetics residency programs. Methods: We invited all GC and
genetics residency program directors to participate in an online survey
assessing coursework and clinical experiences dedicated to teaching
DDN. Results: Eight-five percent of GC program directors and 26 % of
genetic residency program directors completed the survey. GC and genet-
ic residency directors unanimously agreed it is important for genetic
counselors and geneticists to be able to deliver difficult news effectively.
They agreed that training programs should include formal instruction on
this important skill. The majority (75 %) of GC programs employed a
wide variety of teaching methods including role plays, reviewing articles,
and attending lectures while most genetics residency programs used only
two common training methods. Seventy-eight percent of genetic counsel-
ing program directors and 93 % of genetics residency program directors
agree there should be recommendations for how to teach students to
deliver difficult news. Conclusions: Our results show that techniques
for DDN are integrated more fully into GC program curricula than genet-
ics residency curricula. Both groups of program directors agree that DDN
is an important aspect of student training and as a result, desire standard-
ized recommendations for training students to deliver difficult news
effectively.
Exploring Communication Patterns in the Discussion of Maternal
Phenylketonuria Syndrome Between Parents and Daughters
H. Andrews1, E. Jordon2, L. Baggett3, R. Singh4
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Maternal phenylketonuria (PKU) syndrome is the collection of features
and birth defects that arise from uncontrolled phenylalanine levels in a
pregnant woman with phenylalanine hydroxylase (PAH) deficiency, pre-
viously known as phenylketonuria. Currently, the literature is lacking in
exploring what young women are being told about maternal PKU syn-
drome. In this study, communication patterns between parents and their
daughters about maternal PKU syndrome were investigated through an
online survey completed by parents. The survey assessed parents’ level of
comfort with this topic, the information they discussed with their daughter
and the resources they accessed. Follow-up interviews were conducted
with participants to elaborate on survey responses. The majority of par-
ticipants were very comfortable discussing maternal PKU syndrome
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(51 %); however, 21 % reported being very uncomfortable with the dis-
cussion. Parents most often discussed health concerns associated with
maternal PKU syndrome (94%) and least frequently discussed unplanned
pregnancies (58 %). The most frequently used resource was a metabolic
doctor (73 %); however, parents included mothers with PAH deficiency
among the most helpful resources. Themes from open-ended responses
and interviews emphasized qualities of parents’ discussion with their
daughters. Parents commented on the timing and how they presented
the information to their daughters. They described challenges such as
the emotional impact of the conversation as well as their daughter’s
decision-making and consequences of her actions. Lastly, they discussed
advice for treatment compliance, resources, and ways to normalize the
topic of maternal PKU syndrome. These results can help genetic coun-
selors better understand the parent- daughter conversation so that
healthcare professionals can better assess and inform families about ma-
ternal PKU syndrome.
Lessons Learned from the Development of an Educational
Curriculum for Potential and Confirmed Female Carriers
of Hemophilia
R. Butler1, D. Deery1, M. Alabek2, S. Cutter3, K. Miller4
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Background: Hemophilia is an X-linked, inherited bleeding disorder,
characterized by the deficiency or absence of a clotting protein in plasma,
leading to prolonged bleeding in affected individuals. Priority has histor-
ically been on treatment of affected individuals, with less emphasis on
identification and education of female relatives who may be hemophilia
carriers. Carriers can sustain complications from injuries and surgery and
they and their newborns are at risk for serious bleeding without appropri-
ate care around childbirth. Women with a family history of hemophilia
may be unaware of their potential carrier status or may not understand the
implications for themselves and their offspring. Carrier identification and
education helps promote optimal health outcomes and allows women and
their partners to make informed family planning and healthcare decisions.
Methods: A curriculum was developed for female relatives of individuals
with hemophilia to provide accurate information about hemophilia, its
inheritance, current care, and potential health concerns for carriers and
their children. Curriculum materials were developed to assist health care
providers in conducting educational programs for potential carriers. Ma-
terials include flyers, forms, agendas, slides, and a facilitator guide. The
materials can also be used separately to provide genetic education for
carriers and potential carriers. Results: Two pilot programs were held,
with a total of 24 participants. Evaluations contained positive feedback
and 23 attendees rated the program as Bvery good^. Complete pre-post
test results are evaluable for 19 participants; three had perfect scores on
pre and post-tests, 12 improved their scores, and 4 had a drop in post test
scores. The test and materials are under review to determine needed
changes. Conclusions: Women were very satisfied with the program
and learning took place overall. Final revisions will be made. The curric-
ulum will be distributed nationally as a resource for education of female
relatives of individuals with hemophilia.
An Assessment of College Students’ Knowledge of the Importance
and Awareness of Family Health History
E. Cox1, B. Harrison2
1. Howard University
2. Howard University Hospital
Background: In 2013, the Center for Disease Control (CDC) reported that
96 % of Americans believed family history was important to health.
However, only about 30 % of Americans have tried to collect and orga-
nize their family history information. Purpose: This study assessed the
importance of knowing family health history (FHH) amongst a college
student population in the United States (U.S.). This study also explored
factors that influence how FHH is disseminated and collected among the
families of the students. Methods: 57 college students from Howard Uni-
versity inWashington, D.C. completed a 30 item survey; quantitative data
was analyzed using a Fisher exact test. Results: Natural science students
were more likely to know the components for an appropriate FHH. Stu-
dents who agreed that knowing FHH could be beneficial in the prevention
of cancer understood the importance of FHH, but there were no differ-
ences in the age and year of classification, and if the student had a genetic
condition in regards to understanding the importance of FHH. Of the 41
participants that scored highly on the FHH importance scale, eight were
not familiar with the genetic counseling profession. The majority selected
their mothers as the relative most knowledgeable of FHH and felt that
FHH should be discussed between ages 13 and 19. Popular barriers in
collecting FHH included having a large family, differences in understand-
ing medical information amongst relatives, and no one being diagnosed
with a hereditary condition. Of those, a larger percentage of international
students (versus U.S. born) selected spiritual beliefs, shame of having a
condition, and guilt of passing the condition down to offspring as barriers.
Conclusions: Students viewed FHH as important but noted significant
barriers to collecting this information. As public educators regarding ge-
netics, genetic counselors can play a critical role in reducing these
barriers.
A Content Analysis and Readability Assessment of Websites
for Lynch Syndrome
K. Davis1, L. Erby1, D. Roter3
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Finding clearly written, accessible, high quality genetic information for a
lay audience is challenging. Commercial testing sites may not be objec-
tive, health professional sites are complex, and blogs and Wikipedia are
not authoritative. However, the U.S. government provides genetic infor-
mation via the National Institutes of Health (NIH) and the Centers for
Disease Control and Prevention (CDC). President Obama signed the
Plain Language Act to improve clarity in government communication.
Moreover, about 36 % of U.S. citizens have Bbasic^ or Bbelow basic^
health literacy – they can use simple texts with minimal medical or sci-
entific jargon. Thus, this study sought to study the readability and quality
of information for Lynch syndrome provided by the NIH and CDC on
four websites: the Genetics Home Reference (GHR), Genetics and Rare
Disease Information Center (GARD), the National Cancer Institute
(NCI), and the Centers for Disease Control and Prevention (CDC). All
sites were assessed on March 3–4, 2015 and judged readability with the
Flesch-Kincaid Reading Ease (FKRE), which estimates text complexity
on a 0–100 scale, and the SMOG, which estimates the years of education
needed to understand a text and is widely used to assess health texts.
Scores of 60–70 and 8.0, respectively, are considered generally accessi-
ble. Website quality was assessed using the DISCERN-Genetics tool.
Scores of 60–80 % are of adequate quality. Content was not written at
or below the 8th grade level for any site. The sites rated as follows:
GARD (FKRE: 45.1, SMOG: 12.7), GHR (FKRE: 44; SMOG: 14),
CDC (FKRE: 22.5, SMOG: 17.4), and the NCI (FKRE: 18.9, SMOG:
18.5). Website quality was rarely >60 %. The sites rated as follows: NCI
(61 %), GARD (56 %), GHR (53 %), and the CDC (45 %). Although no
site had optimal measures, GARD is the most accessible and is of similar
quality to the NCI. Genetic counselors should be mindful of literacy
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burden, proofread resources when possible, and potentially adapt and
draft material from these sites using plain language as described in the
free NIH Plain Language modules.
Development of a Knowledge-Based Survey Tool to Assess
Comprehension of Genetic Counseling for Advanced Maternal Age
C. Dreyer1, K. Hines2, K. Spoonamore3, A. Patil1
1. Indiana University School of Medicine
2. Indiana University Health
3. Krannert Institute. of Cardiology, Department of Medicine, Indiana
University School of Medicine
Introduction: As of 2005, nearly 1 in 7 pregnant women in the U.S.
satisfied criteria for advanced maternal age (AMA). Despite the need
for genetic counseling services for this population, there is currently no
method to assess comprehension of counseling on AMA. We created and
validated a survey tool to assess comprehension of genetic counseling for
AMA. Survey Development: The 2011 American Board of Genetic
Counseling Practice Analysis was reviewed and used to generate a bank
of knowledge-based questions regarding genetic risks of AMA by seven
certified prenatal genetic counselors. The questions were consolidated
based on content similarity and distributed to local (Indiana Network of
Genetic Counselors) and national (NSGC) prenatal genetic counselors for
review. These content experts were asked to rate each question on a scale
of Bessential^, Buseful, but not essential^, and Bnot necessary^ in the
context of genetic information they wish to convey in a counseling ses-
sion for AMA. A total of 74 responses were used to calculate a content
validity ratio (CVR) for validation of individual survey items. The CVR
was then compared to levels required for statistical significance for a two-
tailed test with p=0.05. Of 19 items reviewed by prenatal genetic counsel-
ing content experts, 14 met significance and were included in the survey.
Survey items underwent final expert review by a maternal-fetal medicine
specialist and two prenatal genetic counselors for relevance to counseling
goals and construction including format, verbiage, and response choices.
Future Implications: We have developed and validated a knowledge-
based assessment tool for genetic counseling for AMA in clinical settings.
We plan to utilize this tool to characterize the results of genetic counseling
for AMA and identify individuals who may need additional resources.
Another goal is to compare comprehension of counseling in individual vs.
group settings that may be used in low-resource environments.
An Effective Lesbian, Gay, Bisexual, and Transgender Cultural
Competency Curriculum for Genetic Counseling Students
K. Gallagher1, T. Ward1, A. Gamma1, A. Greb1
1. Sarah Lawrence College
The purpose of this study was to develop, implement and assess a repli-
cable lesbian, gay, bisexual, and transgender (LGBT) cultural competen-
cy curriculum for genetic counseling programs. As research focuses on
health care disparities and the unique needs of the LGBT population,
professional training programs should respond with appropriate educa-
tion to address these needs. The goal of our curriculum was to provide
students with skills and attitudes to create an environment that promotes
patient disclosure of sexual orientation and gender identity and knowl-
edge to respond sensitively to this information. Learning objectives were
created within four main themes: attention to relationship and family
structure, inclusive and respectful communication, self-awareness and
professional development. The themes were based on issues described
in the literature, and published guidelines and competencies in fields
similar to genetic counseling. Nine discreet curricular modules were cre-
ated, which can be integrated into existing curricula or taught
independently. Twenty-one second year genetic counseling students in
the Joan H. Marks Graduate Program in Human Genetics at Sarah Law-
rence College participated in the curriculum in the format of two work-
shops 1 week apart. Pre and post workshop measurements included the
Sexual Orientation Counselor Competency Scale (SOCCS) and a knowl-
edge survey. Comparison of pre and post-workshop scores revealed a
significant increase in total SOCCS (t (20) = 5.78, p<.001), and skills (t
(20) = 7.42, p < .01) and knowledge subscales (t (20) = 5.09, p<.001).
There was no significant change in attitudinal subscale (t (20) = 0.48,
p=ns). The knowledge scores significantly increased from 78 % (SD=
0.13) before training to 87 % (SD = 0.08) after training (t (20) = 3.48,
p<.01). Student evaluations indicate overall satisfaction with content and
presentation. This study indicates that the implementation of a LGBT
curriculum improves genetic counseling students’ LGBT cultural
competency.
Genetics Literacy of Sickle Cell Disease: Assessing the Inheritance
Knowledge of Young Adults Affected with Sickle Cell Disease
C. Genetti1, D. Perry2, L. Lichten1
1. Boston University School of Medicine
2. Brigham and Women’s Hospital
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy
that affects an estimated 90,000-100,000 Americans. An additional 3
million Americans are carriers of sickle cell trait (SCT). Although SCD
and SCTare relatively common in the United States, the literature reveals
a lack of understanding of disease inheritance. Past studies have exam-
ined the knowledge of unaffected and affected adults, parents of sickle
cell carriers, and unaffected college/graduate students. However, little is
known about the genetics literacy of young adults affected with SCD.
Young adults with SCD are a vulnerable population as they transition
from pediatric to adult healthcare, and during this period of change and
maturation, they are also of childbearing age. We administered a quiz-
based questionnaire to assess the genetics knowledge of young adults
affected with SCD at Boston Medical Center in Boston, MA. The ques-
tionnaire included fundamental SCD/SCT etiology and genetics ques-
tions in addition to higher-level SCD inheritance questions. Of 20 partic-
ipants with SCD surveyed, the average percent of correct responses
across all items was 70 %. Further analysis revealed a discrepancy in
scores between the basic and advanced knowledge questions, with par-
ticipants faring significantly better with the basic questions compared to
the advanced. The results of this investigation suggest that even if affected
young adults have a basic knowledge of disease inheritance, they may be
unable to translate that knowledge into an advanced understanding of
reproductive risk. This disconnect calls for further investigation into
how to best educate the SCD population about inheritance and reproduc-
tive implications.
Shadowing of Clinical Genetic Counselors as an Admissions Criteria
for Genetic Counseling Programs
S. Gilvary1, S. Bermish-Bienfeld1, R. Kodida1, S. Kristofik1, M.
Loomer- Vandersluis 1
1. Sarah Lawrence College
Exposure to genetic counseling is a strongly recommended prerequisite
for entrance into genetic counseling programs. Shadowing a clinical ge-
netic counselor is the most commonmethod of fulfilling that requirement.
Despite this, a survey of the literature revealed no studies documenting
the benefits of this experience to either genetic counseling training pro-
grams or their trainees. This study queried both program directors and
genetic counseling students to determine the perceived value of
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shadowing and barriers to access, as well as identifying acceptable alter-
natives to shadowing. An online survey was distributed to 34 genetic
counseling program directors and ~700 current genetic counseling stu-
dents, response rates were 59 % and 33 % respectively. The majority of
students (91 %, n=208) reported shadowing a genetic counselor prior to
acceptance, though many (19 %, n=37) indicated that it was either Bnear
to impossible^ or Bvery difficult^ to get this experience. Most described
their experiences positively, with 94%, of students (n=187) reporting that
shadowing Bconfirmed their desire to pursue a career in genetic
counseling.^ A substantial minority (47 %, n=94) had alternate experi-
ences they considered Bas beneficial as shadowing.^ Most training pro-
grams (80 %, n=16) reported shadowing as a recommended, but not
required, admissions criterion. All program directors (100 %, n=20) felt
that shadowing gives applicants a better understanding of the profession.
Despite the difficulty in getting this experience, 85 % of directors (n=17)
did not feel that the recommendation limits the applicant pool. Most
program directors (83 % n=15) considered interviewing a genetic coun-
selor an acceptable alternative; a minority (25 %, n=5) looked unfavor-
ably on shadowing done exclusively in a non-clinical setting. Students
and program directors both perceive value in shadowing a clinical genetic
counselor. Given the level of difficulty in gaining this exposure, alterna-
tive experiences are also perceived to be of value to both populations.
LGBT Genetic Counseling: What do Cancer Genetic Counselors
Want to Know?
N. Harada1, T. Lepard1, P. McCarthy Veach2, N. Danylchuk1, P.
Kelly1
1. University of Arkansas for Medical Sciences
2. University of Minnesota
Roughly 3.5 % of the U.S. population identifiy as lesbian, gay,
bisexual, or transgendered (LGBT), and increasing efforts have been
made to educate healthcare providers on working effectively with
the LGBT population. However, there is scant published literature
specifically addressing the educational needs of genetic counselors
in working with said population. This study aimed to identify the
types of information genetic counselors desire regarding LGBT is-
sues in the cancer setting. Ten cancer genetic counselors participated
in semi-structured phone interviews. Interview questions addressed
personal background affecting counseling of LGBT patients, genetic
counselors’ discomforts in counseling LGBT patients, perceived
differences in counseling LGBT versus non-LGBT patients, interest
in LGBT training, perceived gaps in LGBT training, and sugges-
tions regarding LGBT training method. Inductive and cross-case
analysis of interview data yielded 6 themes: genetic counselors’
personal characteristics and experience influence their counseling
with LGBT patients; genetic counselors do not experience discom-
fort with LGBT patients; background knowledge is important but
cancer genetic counseling generally should not differ for LGBT
patients versus other patients; LGBT training is needed; the biggest
gap in LGBT training concerns education regarding the transgender
population; LGBT training should take place in graduate school and
through continuing education. Per interviewee recommendations
such trainings should involve: personal experiences shared by
LGBT individuals; information on medical and psychosocial issues
specific to LGBT patients (especially transgender patients); and
highlighting of unique issues related to different specialties. Future
research should continue the investigation of desired LGBT educa-
tion in different specialties within genetic counseling, explore trans-
gender patients’ experience in genetic counseling, and involve ge-
netic counselors who self-identify as LGBT for insightful data re-
garding the unique needs of LGBT individuals in genetic
counseling.
Genetic Counselors, Graduate Students and Upwards Evaluation
of the Supervision Experience
S. Gilvary1, M. Furgoch1, J. Mattick1, R. Sutton1
1. Sarah Lawrence College
Clinical supervisors play a vital role in the training of genetic counseling
students, yet they undergo no formal training in clinical supervision and
work without established competencies. Genetic counselors hone their
supervisory skills through a combination of trial and error, student feed-
back, consultation with colleagues, and the recollection of their own
experiences with supervisors while in training (Lindh et al. 2003). While
this may be adequate in many instances, it provides students with no
safeguards of reliability, consistency or quality control in their clinical
placements. The purpose of this study was to create a tool for the evalu-
ation of clinical supervisors based on the competencies presented by
Eubanks Higgins (2013). A preliminary version of this tool was designed
to address each of the identified areas. A survey was created to refine this
preliminary list, by assessing each in the light of three questions: 1. Is this
competency easily measured? 2. Is this competency an important skill for
supervisors to have? 3. Is students’ feedback on this competency appro-
priate? Current students at the Joan H. Marks Graduate Program in Hu-
man Genetics and the genetic counselors and geneticists who supervise
their clinical placements were invited to participate in an anonymous
online survey administered using Survey Monkey. Over 95 % of students
agreed or strongly agreed that the competencies can fairly assess a super-
visor’s abilities, and 92% of supervisors felt that students could adequate-
ly evaluate them on each competency presented. On 22 out of 25 com-
petencies, 90 % or more of students felt they could adequately evaluate
their supervisors. One competency was removed from the evaluation tool
and a new competency was created in response to students’ comments.
Most supervisors (over 80 %) described themselves as very or somewhat
comfortable performing 24/25 competencies. Supervisors reported a high
level of interest in further training. Assessment of clinical supervisors
using the tool provided student feedback with strong internal consistency.
Strategies Used by Genetic Counselors to Mitigate the Effect of Low
Patient Health Literacy
T. Haygarth1, K. Hadden2, J. Chi-Jen Chen3, M. Simonson4, N.
Danylchuk5, T. Lepard-Tassin5
1. University of Arkansas for Medical Sciences
2. Center for Health Literacy, University of Arkansas for Medical Sci-
ences Regional Programs
3. Academic Affairs Administration, University of Arkansas for Medical
Sciences
4. College of Medicine Obstetrics and Gynechology Gynecologic Oncol-
ogy, University of Arkansas for Medical Sciences
5. College of Health Professions, University of Arkansas for Medical
Sciences
Individuals with low health literacy are at risk for negative health outcomes
and less informed decision making; however, it is difficult to identify such
individuals. Health literacy mitigating strategies are recommended for use
with all patients. Publications documenting which strategies genetic coun-
selors routinely use and find helpful are lacking. In particular, the teach back
technique has shown promise in the medical field, but has been described
less in genetic counseling literature. The aims of this research study were to
1) determine which techniques genetic counselors use with patients versus
what techniques they believe are helpful and 2) determine genetic coun-
selors’ knowledge and use of the teach back technique. We hypothesized
differences exist between techniques used and techniques believed to be the
most beneficial. We surveyed 365 genetic counselors using an online
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survey with two matrices, each including the same 19 health literacy mit-
igating techniques. Participants were asked the frequency in which they use
each technique with patients and how beneficial they feel each technique is
for patients. Participants who volunteered were then contacted for inter-
views addressing knowledge of health literacy, teach back, and other tech-
niques. All techniques involving the sharing of resources with patients
showed some of the largest differences in belief of benefit versus reported
utilization of the technique. Of the survey participants who believe the teach
back technique is beneficial to patients, 77.4 % reported not using it very
often. Interestingly, interviewees reported use of the teach back technique,
but approximately half were not familiar with the label Bteach back.^ The
teach back technique is referred to by several names in general health care
literature and is typically described without a specific label in genetic
counseling literature. Genetic counselors do not appear to be using the teach
back technique in proportion to their level of perceived benefit. This could
be addressed via training concerning when and how to use the technique.
Genetics and Personalized Medicine: A Comparison of College
Students’ Perspectives
M. Helm1, L. Barcellos2, J. Youngblom1, L. Servais3, M.
Gianfrancesco2, J. Rine2, M. Goldman4
1. California State University Stanislaus
2. University of California, Berkeley
3. Color Genomics
4. San Francisco State University
Personalized medicine is an emerging practice in health care that prom-
ises improvements in disease treatment and prevention. The future of
personalized medicine, however, depends on consumers and providers
of medicine understanding its worth and becoming interested in it as a
new form of health care. In 2010, the University of California, Berkeley
(UCB) recognized this need and implemented the On the Same Page
Project. The project gave incoming freshmen and transfer students the
opportunity to have genetic testing, participate in personalized medicine-
focused seminars, and take a survey related to their experience. This
current follow-up study assessed the perspectives of those same students
4 years later and compared their perspectives to a control population of
students at San Francisco State University (SFSU). The purpose of the
studywas to assess what impact exposure to genetic testing has on interest
in and understanding of genetics and personalized medicine. A total of
701 UCB students (~13 %) and 381 SFSU (19%) students participated in
the survey. The student populations differed significantly in their knowl-
edge of and interest in personalized medicine and genetic testing even
after adjusting for covariates. The study found that after adjusting for
covariates, UCB students scored higher on the genetics knowledge scale
than SFSU students (p<0.001). However, after adjusting for covariates,
SFSU students’ reported awareness of genetic testing options and interest
in genetic testing was higher than UCB students’ reported level of aware-
ness and interest (p<0.001). The results indicate that previous exposure to
genetic testing could have an impact on genetics knowledge but does not
necessarily increase awareness of or interest in genetic testing. This study
contributes to the expanding literature on the public’s knowledge of ge-
netic testing by providing a better understanding of the factors that influ-
ence interest in genetic testing and the perspectives of educated young
adults on the emerging field of personalized medicine.
Genetic Counseling Graduate Program Websites and Their
Influence on Prospective Student Application Decisions
K. Hermann1, S. Hassed1, A. Darden1, C. Guy1
1. University of Oklahoma Health Sciences
Currently, 34 universities in the United States and Canada offer a minimum
2yearmasters-degree in genetic counseling. The purpose of this studywas to
investigate what information was most useful to genetic counseling students
when considering which programs to apply to and how program websites
affected their application decisions. Current genetic counseling students and
recent graduates completed an online survey, which asked what information
on genetic counseling program websites was most influential in deciding to
which programs to apply. Program/assistant/associate directors were also
surveyed to solicit and compare their views to student responses. Chi square
analysis and t-tests were used to determine significance of results, and a two-
sample t-test was used to compare which factors students identified as im-
portant on a 5-point Likert scale compared to those identified by directors.
Content analysis identified themes from students’ open-ended responses
about program website improvement. While directors noted limitations to
making changes to their program websites, they were interested in how
prospective students use their program website and what information they
found most useful. Students indicated there were specific programs they
chose not to apply to due to the difficulty of using that website. Students
were significantly interested in all twelve program factors they were asked
about, based on a 5-point Likert scale. A two-sample T-test showed that
students and directors differed significantly in how important they thought
information about academic requirements, application requirements, and
course descriptions were in deciding which programs to apply to. Content
analysis revealed three major themes of what students want from individual
programwebsites: easy navigation, comprehensive information, and impres-
sion of the program. This information may help individual genetic counsel-
ing graduate programs to improve the functionality of program websites for
prospective students and improve their applicant pool.
The Development of Visual Aids for Genetic Counseling
About Multi-Gene Hereditary Breast Cancer Panels
L. Higgs1, K. Valverde1, A. Forman2
1. Arcadia University
2. Fox Chase Cancer Center
Cancer genetic counselors provide patients with customized information
to assist in decision-making for genetic testing. Many counselors use
visual aids during pre-test genetic counseling in order to improve patient
understanding. A collaborative team developed visual aids tailored to the
unique counseling aspects ofmultigene breast cancer panel testing includ-
ing: review of relevant genes, associated cancer risks, genetic testing
criteria, potential test results and result implications. A survey was de-
signed to gather feedback on a subset of 10 visual aids, genetic counselor
attitudes about perceived clinical utility, and current use of visual aids and
multigene cancer panels. The survey was distributed to 540 cancer genet-
ic counselors through the NSGC Cancer Special Interest Group’s elec-
tronic listserv and 23 % responded (N=123). Participants were asked to
provide feedback suggesting ways to make the ten images easier to un-
derstand. Responses were analyzed thematically utilizing QSR NVivo 10
software. Noted themes included: adjustment of labels used in figures,
need for additional text clarifying components of images, vocabulary
choice and operational definitions of terms used, visual representation
including color choice and graphic selection, and the need to create more
visual representations of information. The proposed visual aids were
modified based on these themes and specific survey responses, and dis-
tributed for clinical use by cancer genetic counselors. As new tests are
developed in the future, genetic counseling sessions and the visual aids
utilized in themmust evolve to incorporate these changes. By understand-
ing the suggestions provided by cancer genetic counselors, future devel-
opment groups can critically edit their images and maximize their poten-
tial clinical use. Future research should evaluate these visual aids to de-
termine their impact on patient understanding in the pre-test genetic
counseling session.
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Investigation of the CommonMELASMutation in the Northwestern
Pennsylvania Amish Community: Mutation Frequency
and Effectiveness of an Educational Intervention
A. Irani1, C. Walsh Vockley2, L. Gonzalez2, J. Shaffer3, A.
Goldstein2, B. Wayburn3, J. Vockley2
1. St. Vincent Hospital
2. Children’s Hospital of Pittsburgh of UPMC, Div. of Med. Gen.
3. University of Pittsburgh, Department of Human Genetics
Mitochondrial (mt) disease affects an estimated 1 in 5,000 individuals.
Prior to diagnosis of our index patient, mtDNA mutations were not re-
ported in Amish communities. The index patient, from a Northwestern
Pennsylvania Amish community, was diagnosed with MELAS (Mito-
chondrial Encephalomyopathy, Lactic Acidosis, Stroke-like Episodes)
and carries the common MELAS mutation, m.3243A>G in MT-TL1.
Subsequently, two Amish families with different mitochondrial mutations
were identified. This prompted a study to assess the efficacy of an edu-
cational intervention to increase understanding ofMELAS andmitochon-
drial disease using pre- and post-intervention questionnaires, provide
testing to an at-risk Amish community, and provide genetic counseling
at the time of results disclosure. During a study visit to the community, an
investigator-designed educational intervention was presented along with
administration of questionnaires to assess knowledge. Samples were col-
lected from 13 adults and two children and were analyzed using high-
resolution melt profiling of the MELAS mutation. Genetic testing re-
vealed m.3243A>G in 13 participants, with tissue-specific variations in
heteroplasmy levels. Data analysis of questionnaires demonstrated limit-
ed increased understanding of educational intervention material. At a
return visit, test results and their implications were disclosed and genetic
counseling provided. Anecdotal experiences at that time support in-
creased understanding and retention of educational intervention material.
These findings suggest maternally-inherited mitochondrial disease may
be under-recognized given the lack of previous diagnosis in these 13
participants. The public health significance is the potential for similarly
unrecognized mitochondrial disease in the larger Amish community and
in the general population due to the challenges related to diagnosis. Re-
sults of efficacy analysis of an educational intervention in this community
can inform the development of educational interventions for the general
population and health care providers about mitochondrial disease.
A Molecular Laboratory Rotation for Genetic Counseling Students:
No Lab Required
B. Karczeski1
1. DNA Diagnostic Laboratory; Johns Hopkins University
Identification, assessment, facilitation, and integration of genetic testing op-
tions constitute a practice-based competency according to the Accreditation
Council for Genetic Counseling. Applicability of molecular genetics to med-
ical genetics is also named as a curriculum content area. To address this need,
the Johns Hopkins DNA Diagnostic Laboratory developed a molecular
mini-course: an intensive, in-classroom, case-based exposure to pre-test, test,
and post-test issues concerning clinical molecular diagnostic testing for
inherited disorders. Goals of the course included gaining an appreciation of
the issues faced in choosing, offering and explaining molecular tests; think-
ing about molecular labs and tests in new ways; forming a mental picture of
howmolecular testing happens and the framework of non-molecular support
surrounding the technology; and gaining experience applying new knowl-
edge and perspectives by working through clinical case examples. Over 7
cycles, 53 students took the course: 40 genetic counseling students, 6 clinical
genetics residents, and 7 other students/observers. Using a survey of 8 Likert
scale questions, we assessed whether course objectives weremet and student
satisfactionwith content, detail, format, and facility. The structure for the first
three cycles of the course was lecture with interspersed case exercises. In
response to student critiques regarding increased interaction and an emphasis
of cases over lectures, the course was restructured to be completely case-
based. This led to significant increases in student approval of course format
(p<.05) and detail of content (p<.01), and an increased ability to gain appre-
ciation of issues involved in molecular testing (p<.05). Overall student sat-
isfaction across all cycles was high (3.68+/− 0.47 out of 4.00, n=47). In
conclusion, an in-classroom, case-centric course successfully provides an
engaging student experience introducing the application ofmolecular science
to clinical practice without the need for an in-lab placement.
The Interface Between Genetic Counselors and Obstetricians:
Education Concerning Noninvasive Prenatal Screening
J. Koenig1, K. Corneliussen2,3, K. Quinn2,3, M. Decker2,3, R. Culp
Stewart1,3
1. The University of North Carolina at Greensboro
2. Wake Forest Baptist Health
3. Cone Health
Education has been suggested as a strategy to increase non-genetics pro-
fessionals’ knowledge of genetic testing and reduce potential harms. Re-
search has indicated that genetic counselors may be an appropriate source
of this education, but limited research has investigated their educational
efforts. Purpose: This exploratory study aimed to examine how genetic
counselors employed by laboratories clinically offering noninvasive pre-
natal screening (NIPS) educate obstetricians about this testing, what tools
obstetricians utilize to increase their knowledge, how well educated ob-
stetricians feel, and if obstetricians feel any aspect of their knowledge is
deficient. Methods: An anonymous survey was distributed to NSGC
members employed by laboratories offering NIPS. A second anonymous
survey was distributed to obstetrician members of North Carolina Obstet-
rical and Gynecological specialty society. Open-ended responses were
coded for themes. Quantitative data was analyzed using Fisher’s-exact,
Mann–Whitney U, and Kruskal-Wallis analyses. Results: Eighteen re-
spondents completed the genetic counselor survey. The majority of ge-
netic counselor respondents indicated they utilized one-on-one support
and presentations to educate obstetricians, and the most frequently con-
veyed information included the nature of NIPS and implementing testing.
Most participants indicated these educational efforts meet obstetricians’
needs but additional education is needed with a focus on the limitations
and non-diagnostic nature of NIPS. Nineteen obstetricians participated in
the study. Obstetricians most commonly used maternal fetal medicine
specialists and genetic counselors to increase their knowledge. The ma-
jority of participants indicated they felt moderately to completely knowl-
edgeable concerning NIPS and needed additional information to provide
adequate counseling. Discussion: Obstetrician participants’ knowledge of
NIPS may be increasing, but additional education is needed to address
obstetricians’ needs and ensure published guidelines are followed.
LEND-Genetics Fellows: Long-TermAssessment of Interdisciplinary
Skills, Service and Leadership
C. Koptiuch1, A. Greb1, R. Marion2
1. Sarah Lawrence College, Joan H Marks Human Genetics Program
2. Children’s Hospital at Montefiore
The purpose of this study was to assess the long-term outcomes of the
Leadership Education in Neurodevelopmental and Related Disabilities
Genetics (LEND-Genetics) program and the interprofessional (IP) skills
and attitudes of LEND-Genetics fellows. This is the first research involv-
ing interprofessional education (IPE) for genetic counseling (GC)
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students and the first assessment of the LEND-Genetics program. LEND-
Genetics programs provide formal IPE to associated GC programs. First,
we performed a retrospective assessment of genetics fellows nationally
using 210 archived follow-up surveys. Second, IP skills and attitudes of
former genetics fellows of the Rose F. Kennedy University Center for
Excellence in Developmental Disabilities in Bronx, NY were assessed
using the Team Skills Scale (TSS) and Attitude Toward Health Care
Teams (ATHCT) scale. The majority of fellows nationally work with
maternal child health, underserved and vulnerable populations. Most
(74 %) work in hospitals, are more likely to work for government agen-
cies and less likely to work in the private sector compared to data in
NSGC’s Professional Status Survey. Over 85 % report leadership activi-
ties, mainly in clinical or academic settings. The response rates to the
TSS/ATHCT surveys were 40 % (8/20). The mean TSS score was
79.8 % (categorized as high) and positively associated with time. The
mean ATHCT total, team efficiency and team value subscale scores were
83.2 %, 78.3 % and 84.5 % (all high). Fellows’ team skills and attitudes
toward team productivity were higher than scores reported in IPE re-
search on other disciplines. Fellows’ belief in teamwork positively
effecting patient care was only stronger than some health care profes-
sionals. Our assessment shows that, nationally, the LEND-Genetics pro-
gram is achieving its aims, and fellows’ team skills and attitudes from one
program rank highly amongst other health disciplines. IP skills are a core
competency for genetic counselors. The LEND-Genetics program can
serve as an IPE model for genetic counselor training.
Sex Education and Intellectual Disability: Perspectives and Insights
from Pediatric Genetic Counselors
C. Murphy1, S. Lincoln2, S. Meredith3, E. Cross1, D. Rintell1
1. Brandeis University
2. Boston Children’s Hospital
3. University of Kentucky
Intellectual disability with or without other anomalies is a common refer-
ral for genetic counseling. Sessions may include discussions of reproduc-
tive implications and other issues related to sex education. Patients with
intellectual disability (ID) regularly meet barriers when trying to obtain
sex education due to the beliefs and practices of unaffected individuals
such as caregivers, family members, and health care professionals. We
surveyed genetic counselors to explore the frequency with which they are
asked to provide sex education counseling and their comfort in doing so
for patients with ID ages 9–17. Caregivers and patients most frequently
asked about puberty, sex abuse prevention, and reproductive health. Ge-
netic counselors were most comfortable when they could provide sex
education counseling within the context of a particular condition or con-
stellation of features. They were least comfortable when there was a lack
of familiarity with the patient, caregiver, or the family’s culture. The most
frequently cited barriers that prevented genetic counselors from providing
sex education counseling were lack of time, lack of training, the patient’s
ID being too profound, and the thought that genetic counselors should not
be responsible for providing sex education counseling. While many re-
spondents recognized that providing sex education counseling is not con-
sidered within the scope of a genetic counselor’s practice, respondents
also acknowledged that they should be prepared for such discussions and
were interested in having access to specific online and print resource
guides specifically designed for use by genetic counselors to provide to
patients with ID and their caregivers. Genetic counselors as well as med-
ical professionals of all disciplines are encouraged to embrace the role of
advocate and broach the issue of sexual health with caregivers and pa-
tients by directing them toward educational resources, if not providing
sex education themselves to effectively serve the needs of patients and
caregivers.
Evaluation of the Impact Program, a Disability Immersion
Experience, in Genetic Counseling Education
X. Qiao1, A. Greb1
1. Sarah Lawrence College
The purpose of this study was to evaluate a disability immersion experi-
ence for genetic counseling students in the Joan H. Marks Graduate Pro-
gram in Human Genetics at Sarah Lawrence College. The Impact Pro-
gram offers an opportunity for students to spend a day with a family who
has a member with Down syndrome (DS). Genetic counseling programs
have few models to guide training on disabilities despite a practice based
competency that entry-level genetic counselors must understand the lived
experiences of people with genetic conditions. This study is an outcomes
assessment of one model. Students who participated in the Impact Pro-
gram from 2012 to 2014 were surveyed to assess the program’s effective-
ness in enhancing their confidence and skills serving the disability com-
munity. The response rate was 49 % (42/86) with the majority of respon-
dents being female (95 %) and under the age of 30 (98 %). Of those
currently practicing as genetic counselors, 73 % worked in a prenatal
setting and 45 % in pediatrics. Likert 5 point agree/disagree questions
about whether the program 1) enhanced awareness of psychosocial is-
sues, comfort level and knowledge of disability scored an average of 4.1
(agree), 2) enhanced skills counseling prenatal patients with a diagnosis
of DS scored 3.28 (neutral/agree) and, 3) enhanced skills counseling those
with a postnatal diagnosis scored 3.5 (neutral/agree). 73 % of participants
commented that seeing positive interactions among family members and
the member with DS was the most memorable part of their experience.
Suggestions for improving the program include clarification about expec-
tations, expanding diversity beyond DS and fostering long-term relation-
ships with families. This study demonstrates that the Impact Program
helps students expand their understanding about, and confidence with,
the lived experiences of individuals with DS. Disability immersions pro-
grams are important in the training of genetic counselors in order to
facilitate the provision of quality services to individuals with disabilities.
Medicine’s Future: An Education Program Designed to Improve
Genomics Practice in a Community Hospital
K. Reed1, K. Johansen Taber2, T. Ingram Nissen1, L. Dowling3
1. The Jackson Laboratory
2. American Medical Association
3. Dowling Associates
Education of practicing health professionals is likely to be one factor that
will speed appropriate integration of genomics into routine clinical prac-
tice. Yet many health professionals, including physicians, find it difficult
to keep up with the rapid pace of clinical genomic advances and are often
uncomfortable using genomic information in practice. Methods: Having
identified the genomics educational needs of physicians in a Silicon
Valley-area community hospital, we developed, implemented, and eval-
uated an educational course, entitled Medicine’s Future: Genomics for
Practicing Doctors. The course structure and approachwere based on best
practices in adult learning, including interactivity, case-based learning,
skill-focused objectives, and sequential monthly modules. The course
content included fundamental skills in risk assessment, assessing utility
and validity of genetic testing, interpreting genetic test results, and incor-
porating genetic information into management applied to a variety of
disease areas – complex disease, prenatal medicine and pediatrics, cancer,
cardiology, neurology. Results: Physicians participating in the 10-module
course demonstrated significant gains in knowledge of risk assessment
(approximately 37% increase); ordering, interpreting, and using results of
genetic tests (approximately 65 % increase); and providing education and
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guidance to patients (more than 100 % increase). Confidence in skills
related to genetic testing, referral decisions, and patient communication
also significantly improved. Six months following the course, the major-
ity of participants reported that they had changed their practice to incor-
porate skills learned during the course. We observed a correlation in
increased genetic counseling referrals in the months the course was held.
Conclusion: We believe the adult learning principles underlying the de-
velopment and delivery of Medicine’s Future were responsible for partic-
ipants’ outcomes.
Development of an Interactive Online Clinical Whole Genome
Sequencing Educational and Engagement Tool
V. Raymond1, S. Waleetorncheepsawat1, R. Maile1, K. Sherman1, L.
Nguyen1, K. Rhodes1, S. Coon1, E. Ramos1
1. Illumina
The promise of clinical whole genome sequencing (cWGS) is
overshadowed by the vast amounts of complex data, difficulty in trans-
lating data into actionable information, and the need to communicate
information in lay language. Existing websites allow genomic exploration
but are neither consumer friendly nor routinely include educational or
interactive components. We developed a free, web-based Bcommunity^
where individuals who have undergone cWGS can explore their genome
using the MyGenome application and Understand Your Genome® Com-
munity. Those who have not had cWGS can join and explore a demon-
stration genome. The goal is to create an interactive, engaging workspace
to increase individual genomic literacy and expand the personal utility of
cWGS data. Individuals learn about medical conditions, including clini-
cally significant variants and pharmacogenetic indications identified
through their screening and can link to educational web resources. Indi-
viduals can access variant information (allele frequency, gene callability,
inheritance patterns, amino acid changes). As individuals learn of variants
through academic or lay literature, they can use the chromosome browser
feature to navigate to these areas within their genome. Participant feed-
back has been positive. Website statistics demonstrate frequent and return
visits. Participants overwhelmingly request the ability to follow genomic
discoveries, research their variants, share genomic information with fam-
ily, friends and health care providers, and donate their genome to research.
Participants are also interested in networking and identifying individuals
within the community with similar genomic findings. The development
of an online educational community has been positively received by
individuals engaged in cWGS. As we continue to explore the utilization
of genomic information and struggle with the definition of Bvalue^, un-
derstanding the motivations for sharing genomic information and the
opinions on the key components and features of the application will be
important in building an actively engaged community.
Bringing Sociometrics to the Classroom
E. Sanborn1, S. Andriole1
1. Sarah Lawrence College
Literature suggests that genetic counselors should keep their feelings
from influencing a session. This expectation is introduced early in train-
ing, but we historically haven’t taken the extra step to help students
identify and reflect on personal biases. Here we introduce a structured
method to encourage students to ponder complex issues, at both the
beginning and end of their first year. Over the past 3 years, the Joan H.
Marks Graduate Program in Human Genetics has used sociometry as a
tool to evaluate values and beliefs. Sociometry, a quantitative method for
measuring social relationships, is defined as Bthe inquiry into the evolu-
tion and organization of groups and the position of individuals within
them.^We take precautions to create a safe space for students to be honest
without having to disclose their beliefs to classmates or us. Students and
instructors anonymously answer all 12 questions. Questions range from
ethical issues to personal choices to professional situations. Responses for
each question are tallied and displayed. Results indicate: (a) there has
been only one unanimous response; (b) the percentage of individuals
who believe termination for a given reason is ethical always exceeds
the percentage of individuals who would personally terminate for this
indication, (c) the trend from Fall to Spring stayed consistent across all
years for 1/3 of questions, and (d) Each year, one particular question,
about potential cultural practices, significantly changes between semes-
ters, but in differing directions. 2014–2015 was the first year students
tracked and compared their Fall and Spring results. Each student had
one to five discrepant answers between Fall 2014 and Spring 2015. To
respect confidentiality we are not able to assess these individual changes
further. In our experience this exercise not only forces individuals to be
mindful of their own value system; it also demonstrates that even in a
small, Bhomogeneous^ field, there is a wide range of beliefs. This exer-
cise generates insightful discussion and is a valuable tool to incorporate
early in training.
Parental Perspectives of Array Comparative Genomic Hybridization
Educational Tool
C.Williams1, D. Hollenbeck1, K. Nelson1, G. McGwin1, C. Hurst1, S.
Rutledge1
1. University of Alabama at Birmingham
Array comparative genomic hybridization (arrayCGH) is the standard
genetic screening test for common pediatric referrals such as unexplained
developmental delay or multiple congenital anomalies. However,
healthcare providers often hesitate to address all possible array results
with parents before testing children due to the complex or sensitive nature
of some potential results. In an effort to better educate parents, an infor-
mational pamphlet describing arrayCGH and the possible results was
created and distributed to parents of children who had arrayCGH testing
after the test was ordered. A survey was developed to capture parental
opinions of arrayCGH and the pamphlet; in addition, after reviewing the
pamphlet, their knowledge level of arrayCGH was evaluated with a ten-
topic quiz located at the end of the survey. Results demonstrate parental
desire for pre-test knowledge of all potential results, particularly variants
of unknown significance, incidental findings, and areas of homozygosity.
Importantly, only 14–21 % of parents recalled discussing these particular
result types with their providers prior to testing. Despite this lack of
pretest counseling, the quiz questions about these respective result types
were answered correctly by 80–100 % of parents. Overall, the pamphlet
appeared to increase parental understanding of arrayCGH, improve their
comfort level with testing, and better prepare them for the different po-
tential result types.
Measuring the Effectiveness of a Genetic Counseling Supervision
Training Conference
K. Wusik1, H. He1, C. Atzinger1
1. Cincinnati Children’s Hospital Medical Center
Genetic Counselors (GC) who receive formal training report increased
confidence and competence in their supervisory roles. The effectiveness
of specific formal supervision training has not been assessed previously.
A day-long GC supervision conference was designed based on published
supervision competencies. Participants completed online pre, 1-week
post, and 6-months post-conference surveys with questions regarding
supervision experience, perceived supervisor competence and confidence
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as measured by Psychotherapy Supervisor Development Scale (PSDS),
and self-reported agreement in ability to perform 6 supervision compe-
tencies. Paired t-test was used to compare PSDS scores between pre and
post conference. McNemar’s Chi-squared test was used to determine if
the conference meeting had an effect on GC supervision competencies.
36 participants completed the pre-conference survey, 32 the 1-week post-
conference survey, and 19 the 6-month post-conference survey. PSDS
scores were significantly increased 1 week (p<0.001) and 6 months
(p<0.001) following the conference. For three supervision competencies,
attendees were more likely to agree they were able to perform them after
the conference than before. These competencies included: Bprovide a
balance of challenge and support appropriate to student developmental
level and experience^ (p=0.013), Buse supervisory methods appropriate
to students’ level of conceptual development, training, and experience^
(p=0.003), and Bdeal with student resistance in productive ways^
(p<0.001). These effects remained significant 6 months later. For the three
remaining competencies, the majority of supervisors agreed they could
perform these before the conference; therefore, no change was found.
This conference increased the perceived confidence and competence of
the supervisors who attended and increased their self-reported ability to
perform certain supervision competencies. We recommend additional su-
pervision training be provided to supervisors based on theGC supervision
competencies with which supervisors are least comfortable.
VII. ELSI
Potential Clinical Use of APOE Testing in the Population at Risk
for Traumatic Brain Injury: A Survey of National Collegiate Athletic
Association Student-Athletes
M. Caudle1, D. Matviychuk2, M. Herzog3, J. Griffin1, J. Tidwell4, L.
Hercher1
1. Sarah Lawrence College
2. Kingston General Hospital
3. UCLA David Geffen School of Medicine
4. Saddleback Memorial Care
Routine use of APOE genotyping, with its association to increased risk of
late-onset Alzheimer’s disease (LOAD), is controversial and has been
discouraged by professional organizations, in part because predictive in-
formation on LOAD is not clinically useful. Recent studies indicate that
APOE genotype is also associated with the risk of a poor recovery from
traumatic brain injury (TBI) suggesting that APOE genotyping may have
clinical value for athletes, either in determining the level of risk associated
with participation in high TBI incidence sports, or in personalizing treat-
ment of TBI and making decisions around return-to-play. This study
examined the interest of National Collegiate Athletic Association
(NCAA) student-athletes in APOE genotyping, the barriers to testing,
and their perception of the potential ramifications of APOE genotyping.
A survey of 843 Division I, II and III NCAA athletes indicated wide-
spread interest in APOE genotyping. The vast majority (92.5 %, n=780)
were willing to test if it was required by the school, however most indi-
cated that they would test if it were voluntary (75.9 %, n=639). Student-
athletes seemed largely unconcerned with potential ramifications of test-
ing, and indicated that they would tell their coaches (75.7%, n=638), their
parents (86.1 %, n=725) and their doctors (86.0 %, n=725). Students
suggested that they did not expect testing to impact their behavior
(59.4 %, n=500) or their style of play (67.4 %, n=568). Students were
interested in learning more about their risk for LOAD and few indicated
this made them less likely to test (12.4 %, n=104). Despite this apparent
lack of concern, most students indicated that they would prefer having the
option of genetic counseling (51.5 %, n=434) and the majority expressed
an interest in meeting with a genetic counselor to discuss their results
(62.5 %, n=527). Study findings suggest a need to consider the appropri-
ate use of APOE genotyping in this setting, and the role that genetic
counselors might play in ensuring that athletes are adequately informed
of all potential harms and benefits.
Development of Recommendations for Ordering Clinicians
with Minimal Genetics Background from the ClinGen Consortium
Cconsent and Disclosure Recommendations Committee
W. A. Faucett1, M. Rashkin1, K. Brothers2, C. Coughlin3, L.
Hercher4, L. Hudgins5, S. Jamal6, H. Levy7, H. Peay8, M. Roche9,
M. Stosic10, M. Smith11, W. Uhlmann12, K. Wain13, K. Ormond5
1. Geisinger Health System
2. University of Louisville
3. University of Colorado School of Medicine
4. Sarah Lawrence College
5. Stanford University
6. Hospital for Sick Kids Genome Diagnostics Laboratory
7. Johns Hopkins University
8. RTI International
9. University of North Carolina
10. Natera, Inc.
11. Northwestern University Feinberg School of Medicine
12. University of Michigan, Division of Molecular Medicine
13. Mayo Clinic, Division of Laboratory Genetics
Introduction: Molecular genetic testing is increasingly ordered by medical
providers in a variety of specialties. Guidelines and recommendations to
strike a balance between ensuring high quality pre- and post-test counseling
and unnecessarily restricting access are lacking for ordering clinicians who
lack expertise in genetics. We recruited stakeholders representing viewpoints
of genetic counselors, MD geneticists, ethicists, pediatricians, policy experts,
and patient advocates to join the Consent and Disclosure of Results
(CADRe) committee, a working group of the National Institutes of Health’s
ClinGen consortium, to explore possible solutions to this quandary. Purpose:
Summarize ethical, legal, social, medical, logistical issues (ELSIPlus) stake-
holders deemed critical in ensuring high-quality genetic counseling when
non-genetics providers order molecular tests. Methods: We will present re-
sults from the completed phase 1 of our project, during which we convened
three conference calls between October and December, 2014. Discussion
wasminimally guided by the study’s Primary Investigators to generate initial
topics for consideration. Calls were transcribed and analyzed for themes
using framework analysis. Results: Participants (n = 14) enumerated many
topics to consider, including: test and disease characteristics, provider/patient
misinterpretation, growing cultural awareness of genetic testing in the gen-
eral public, patient preferences, varying quality and availability of education-
al materials, necessity for a follow-up plan, cascade testing, context of test-
ing, emotional burden, lab and clinician reporting methods. Conclusion:
Thus far, the CADRe committee has developed a list of ELSIPlus topics to
consider in pre-and post-test counseling when ordering genetic testing, and
are pursuing development of recommendations suitable to incorporate into
ClinGen guidelines for actionability and as an aid to clinical practice for non-
geneticists.
A Qualitative Study of Adolescents’ Understanding of Biobanks
and Their Attitudes Towards Participation, Re-Contact and Data
Sharing
A. Murad1, M. Myers1, S. Thompson2, R. Fisher1, A. Matheny
Antommaria1
1. Cincinnati Children’s Hospital Medical Center
2. University of Cincinnati Department of Pediatrics
Background: While biobanks are important resources for advancing per-
sonalizedmedicine, there are many ethical concerns about them including
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consent, re-contact and data sharing. These concerns are more pro-
nounced when children and adolescents are included. Despite
biobanks’ increasing prevalence, little is known about adolescents’
familiarity with biobanks and their views of key governance issues.
Methods: Qualitative methods were utilized due to the limited
existing data. An investigator conducted semi-structured interviews
with adolescents between 15 and 17 years old. All interviews were
audiotaped and transcribed. Two investigators analyzed transcripts
and resolved discrepancies through consensus. Results: We con-
ducted 18 interviews before reaching data saturation. Four partici-
pants (22.2 %) had previously heard of a biobank. Many partici-
pants had misunderstandings about biobanks, some of which
persisted after education. Participants believed that participating
in a biobank would benefit others through scientific research.
Many participants were unable to identify risks of participation
and few were concerned about loss of privacy. Thirteen partici-
pants (72.2 %) were willing to enroll in a biobank, 1 (5.6 %)
was not and 4 (22 %) wanted more time to consider enrollment.
Participants believed that, if they were unable to provide assent
when enrolled, they should be re-contacted at the age of majority
and their data should not be shared until this time. Participants
emphasized the importance of being aware of enrollment and the
possibility of disagreeing with their parents. Conclusions: Partici-
pants’ misunderstanding of biobanks suggests that assent may not
be adequately informed without additional education. While the
adolescents had positive attitudes towards biobanks, they empha-
sized the importance of awareness and involvement in the decision
to participate. Nonhuman subjects approaches may risk the loss of
trust when individuals become aware of their participation.
Directiveness in Genetic Counseling: Adapting to Increasingly
Complex Tests
M. McDaniel1, R. Brown1, T. York1, T. Causey1, J. Quillin1
1. Virginia Commonwealth University
A key ethos of genetic counseling is to be non-directive and to promote
patient autonomy by illuminating all relevant choices and outcomes. The
goal of this study was to discover the extent that patients prefer genetic
counselors to be non-directive regarding genetic testing options. Patients
and genetic counselors at four hospitals near Richmond, Virginia were
recruited to complete a brief survey concerning their preferences regard-
ing autonomy. Surveys measured patient decision-making preferences
prior to their appointment and matched post appointment surveys, which
measured how they felt decisions were made. Prenatal genetic counselors
were asked to complete a similar questionnaire after the appointment
asking about their perceptions of how decisions were made. A sample
of 32 patients and 5 genetic counselors was collected. The majority of
patients, 41.9 %, wanted decisions about genetic testing to be made on an
equal basis with genetic counselors while 38.7 % wanted to make the
decision with some input from the genetic counselor. When patients’
expectations did not match the outcome, it was more commonly noted
that patients preferred the genetic counselor to be directive or to make
decisions on an equal basis with them, but felt the session was non-
directive. This finding was noted in 20.7 % of participants. Surveys from
genetic counselors were compared to those that patients completed after
their appointment. Discordance was found between patient and genetic
counselor perceptions of when a directive technique was used. All coun-
selors surveyed reported the patient was the primary decision maker for
genetic testing. 83.9% of counselors felt they had no input on the decision
while only 13.3 % of patients answered that they made the decision
independently (p<0.001). The decision-making preferences of prenatal
genetic counseling patients tend to vary. There is substantial discordance
between stated decision-making roles of counselors and their patients.
This discordance requires further investigation so genetic counselors
can provide the best care for their patients.
Developing an Abbreviated Consent for Broad Data Sharing
in the Clinical Setting
A. Niehaus1, D. R. Azzariti2, Y. Vaydylevich1, E. Ramos1, C.Martin3,
H. Rehm4, E. Riggs3
1. National Human Genome Research Institute
2. Partners HealthCare Personalized Medicine
3. Geisinger Health System
4. Harvard Medical School
Genomic data sharing between clinicians, clinical and research laborato-
ries, and patients is essential for improvements in genomic medicine. The
need for broad access to data must, however, be balanced with the need to
respect patient autonomy and privacy, and consent should be obtained
before sharing individual-level data. While obtaining consent for data
sharing in the traditional research setting is clear, obtaining consent for
data sharing in the clinical setting has been hindered by lack of time and
resources at both ends of the clinical encounter (clinician and clinical
laboratory). To address this need, the National Institutes of Health’s
(NIH) Clinical Genome Resource (ClinGen) has developed a one-page
consent form for broad data sharing in the clinical setting, facilitating the
deposition of de-identified genetic information into case-level reposito-
ries. This consent form is intentionally a single page in length to allow for
quick initial review in the clinical setting, with supplemental online con-
tent detailing key topics, such aswhat constitutes de-identification and the
risks and benefits of data sharing. The consent is consistent with the intent
of the NIH Genomic Data Sharing Policy and includes all applicable
components recommended by the National Human Genome Research
Institute’s Informed Consent Resource. Clinical laboratories and clinics
will be encouraged to use this form as a guide to facilitate their data
sharing efforts, and to incorporate the language as provided, or with
appropriate modifications, into existing clinical consent forms for testing
and treatment. Prior to public dissemination, ClinGen intends to review
this form for acceptability and feasibility with focus groups of clinicians,
clinical laboratories, and a newly created community engagement board,
composed mostly of patients and patient advocacy representatives.
ClinGen hopes this consent form will be widely disseminated and incor-
porated into the clinical care process – providing patients a straightfor-
ward way to share their genetic and health information for both research
and clinical use.
Enriching the Clinical Ethics Education for Genetic Counseling
Graduate Students Through Team-Based Learning
S. J. Noblin1
1. UT Health
We report on the use of team-based learning (TBL) to enrich the clinical
ethics education for genetic counseling graduate students. TBL is a
uniquely powerful form of small group learning that focuses on student
preparation outside of class and application of knowledge in class, thus
providing a flipped classroom experience. Genetic counseling training
programs must address ethical issues in genetics to comply with accred-
itation standards published by the Accreditation Council for Genetic
Counseling (ACGC). At the University of Texas Genetic Counseling
Program (UT GCP), the ethics requirement has traditionally been met
by a graduate school course that uses a lecture format followed by small
group discussions. As the majority of students taking this course are PhD
students, it is geared towards laboratory ethics, with topics such as, the
humane care and use of animals in the laboratory. Historically, in course
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evaluations, the UTGCP students have consistently commented on how a
lot of the material in the course is inapplicable to the practice of genetic
counseling, with comments such as, Bit just isn’t relevant!^ In 2014, the
graduate school moved to a core curriculum model and the UT GCP
reformatted the ethics course to integrate more relevant clinical ethics
training. Using a TBL approach with four 90 minute sessions, case ex-
amples, and the newly published text, Ethical Dilemmas in Genetics and
Genetic Counseling by Janice Berliner, we discussed relevant ethical
issues to the clinical practice of genetic counseling. At the conclusion
of the course, the students had overwhelmingly positive responses for
the new class format. They enjoyed and appreciated the TBL format,
the cases examples and the ethics textbook. In conclusion, we are pleased
with the outcome and will continue to explore additional opportunities,
such as TBL, to enhance the ethical training of our students.
Counseling Close to Home: Genetic Counselors’ Experiences
Providing Genetic Counseling to Their Own Family Members
L. Otto1, C. Reiser1, E. Petty1
1. University of Wisconsin
Genetic counselors are trained to provide counseling and communicate
personalized genetic information to clients and their families. When re-
quests for counseling comes from the counselor’s own family member
outside the clinic, should that counselor still provide such services?
Ninety-nine percent of physicians have been asked to provide medical
advice to family members and the majority has provided medical advice.
Similar studies exploring this issue among genetic counselors have not
been reported. The purpose of this study was to examine perceptions and
experiences of our genetic counseling colleagues, to encourage a discus-
sion about this issue among the profession. In the present study, 423
genetic counselors and genetic counseling students completed a 70-item
web-based survey exploring genetic counselors thoughts and experiences
counseling family members. Qualitative data were thematically coded
and statistical analyses of both qualitative and quantitative data was per-
formed to look for significant trends. Seventy-three percent (n=301/410)
of respondents have been asked to provide genetic counseling and 57 %
(n=257/423) have actually provided counseling, personalized genetic in-
formation or risk assessment to family members to outside of a clinic
setting. Only a small fraction of respondents (11 %; n=45/420) have
received training or discussed this issue with mentors; those who reported
they have were less likely to have provided genetic counseling to a family
member (p= 0.0459). Respondents who have provided genetic counsel-
ing to family members were more likely to think their colleagues would
also provide counseling while those who have not were more likely to
think their colleagues would refer to an unrelated genetic counselor
(p<0.0001). Based on the diverse opinions obtained and lack of consen-
sus, we believe that further discussion of this topic may help guide how
genetic counselors might respond to requests from family counseling
outside of a clinical setting.
Patient Education and Informed Decision-Making: An Assessment
of Consent Documents for Noninvasive Prenatal Genetic Screening
R. Ryan1, M. Michie1, S. Alessi2, M. Allyse3, M. Minear4
1. University of California, San Francisco
2. Stanford University Center for Biomedical Ethics
3. Mayo Clinic Department of Bioethics
4. Duke University Science & Society
Ethical concerns have highlighted the need to strengthen informed
decision-making for noninvasive prenatal genetic screening
(NIPGS). Widespread and unregulated uptake, aggressive
commercial marketing, misrepresentation as a diagnostic test, low
procedural risk, and routinization have all contributed to diminished
rigor in the consent process for NIPGS. There is a pressing need for
adequate patient education, given the rapidly transforming land-
scape of NIPGS and increasing patient preference for noninvasive
procedures. In this study, we evaluated informed consent documents
(IC) provided to patients. Here we (1) describe the content of cur-
rently existing IC; and (2) based on this assessment, offer recom-
mendations for such documents. We collected written patient edu-
cation and consent documents created by laboratories and clinics by
searching online and soliciting from genetic counselors and other
clinicians. IC (n=32) were assessed for readability, attention to ele-
ments of informed consent, and completeness of information about
the test and the conditions potentially detected. About half of IC
failed to include phenotypic descriptions of the conditions screened.
53 percent mentioned the possibility of false positives. 56 percent
discussed post-test genetic counseling. Commercial IC (n=22) were
longer and written at higher reading levels than non-commercial IC
(n=10) and less often stated that NIPGS only screens for certain
conditions. Based on our findings, we recommend that women be
offered a consent form that is separate from the lab order form and
offered a copy to take home. IC should be written at an appropriate
reading level and include information on the benefits and risks of
NIPGS and the conditions screened. Limitations and alternatives to
NIPGS should be clearly stated, including the option to decline all
prenatal screening. Finally, the rapid evolution of NIPGS means that
IC likely need to be updated frequently and should always be ac-
companied by verbal counseling by a qualified health provider.
Exploring the Importance of Guardianship for Individuals Coming
of Age with 22q11.2 Deletion Syndrome
C. Troyer1, K. Schoch2, V. Shashi2, N. Callanan1
1. University of North Carolina at Greensboro
2. Duke University
22q11.2 deletion syndrome (22q11DS) is the most commonly occurring
microdeletion syndrome, and has wide phenotypic variability among af-
fected individuals. In addition to medical manifestations symptoms often
encompass an array of behavioral, psychological, and cognitive difficul-
ties. Individuals with 22q11DS tend to have a unique cognitive profile,
with specific deficits in executive functioning and social cognition that
may impact reasoning and decision-making, as well as make them more
vulnerable in social contexts. In addition to this, many studies have dem-
onstrated a significantly increased risk for major psychiatric illness in
individuals with 22q11DS. Guardianship is a legal process designed to
protect the best interests of uniquely vulnerable individuals in adulthood.
Accordingly, pursuing guardianship may be a worthwhile consideration
for some parents of adolescents with 22q11DS. Nonetheless, there is an
absence of such information routinely accessible to parents in the context
of this specific clinical population. The goal of this project was to address
this need by conducting a primary literature review on both 22q11DS and
legal guardianship. Subsequently, a novel informational resource targeted
for parents of adolescents with 22q11DS was developed in the form of a
tri-fold brochure. The brochure was modified for readability and sugges-
tions were sought from several parents of individuals with 22q11DS,
family and disability attorneys, and a social worker. These suggestions
were incorporated into a final revision of the brochure. The brochure
provides an overview of guardianship and its potential relevance for in-
dividuals with 22q11DS, offers guidance for families considering this
decision, and directs parents to further resources. Ultimately, tailored
guardianships may be an appropriate source of protection for some fam-
ilies of adolescents with 22q11DS to consider. While the brochure
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produced is targeted for our specific clinic population, our hope is that this
resource can be modified to suit similar clinic populations in the future.
Views of Genetic Counselors on the Use of Preimplantation Genetic
Diagnosis for Social Sex Selection Purposes
B.L. Yu1, L. Hercher1
1. Sarah Lawrence College
Introduction: Preimplanatation genetic diagnosis (PGD), a technology
that allows genetic testing of an embryo before implantation into the
uterus, was first used to select for embryos at risk for X-linked diseases.
Use and indications have expanded greatly in the past two decades. In
some instances, prospective parents are using this technology to select for
male or female children for purely social purposes. Purpose: This study
aims to examine the views of genetic counselors on the use of PGD for
social sex selection. Methods: A survey was conducted using the online
website survey monkey’s platform and sent to members of NSGC
through an eblast. A total of 342 responses were received with a response
rate of 11%. Results: Amajority of respondents (64 %, n=130) expressed
concerns about the future use of PGD for social sex selection, but were
highly supportive of a woman’s right to choose regardless of their views
on sex selection (63%, n=129). Respondents expressed concerns that sex
selection may create a male–female population imbalance in other coun-
tries (53 %, n=108), that sex selection reflects prejudice against women in
other cultures (63 %, n=127), and that sex selection might lead to other,
more offensive types of trait selection (70 %, n=142). Most believed that
the use of reproductive technology to select traits is likely to becomemore
commonplace over time (72 %, n=148).
Conclusion: Genetic counselors are conflicted as regards current practice
in social sex selection. They express strong personal discomfort with sex
selection for non-medical purposes, but believe in the right of the patient
to terminate a pregnancy for any reason.
VIII. Genetic/Genomic Testing
Parental Reasons for Participation and Reactions Toward Return
of CYP2D6 Research Results
S. Adelsperger1,2, C. Prows1, M. Myers1,2, J. Lynch2
1. Cincinnati Children’s Hospital Medical Center
2. University of Cincinnati
CYP2D6 contributes to the metabolism of more than 25 % of drugs
prescribed in a clinical setting and pharmacogenetic testing for CYP2D6
can inform drug selection and dosing. Knowledge of parental reasons for
participation in CYP2D6 pharmacogenetic testing and reactions to the
return of results could inform decisions about returning incidental geno-
mic results relevant to drug response. The goal of this study was to assess
parental reasons for participating in research involving the return of their
child’s CYP2D6 research results and reactions to the receipt of results.
Following the return of CYP2D6 pharmacogenetic research results, we
conducted qualitative interviews with a subset of 61 parents enrolled in
the eMERGE study at Cincinnati Children’s Hospital Medical Center. All
interviews were recorded and transcribed verbatim. Transcripts were cod-
ed and analyzed for major themes and subthemes. Thirty-one parents of
children who were naïve to opioids and 30 parents of children with pre-
vious opioid exposure participated in the qualitative interviews. No top-
ical differences were seen between the two groups. The majority of par-
ents identified helping their child or learning about their child’s health as a
reason for participating. Some parents discussed more altruistic reasons.
In the parents’ reactions to results, two themes emerged. One theme was
Bperceived normality,^ which consisted of the subthemes that the Bchild
is medically normal^ and that the Bchild is socio-culturally normal.^ The
second theme, Bemotional appraisal filtered through expectations,^
consisted of a range of emotional reactions to the results (e.g. Bresult
was interesting^; Bresult was surprising^; etc.). Overall our findings sug-
gest that parents participate in pharmacogenetic research because they
perceive benefits for the child or themselves. Our findings suggest that
CYP2D6 research results will not affect parental interactions with chil-
dren and that Bgenetic essentialism^ is not a concern because parents do
not regard their child differently.
Evaluating Changes in Patient Anxiety Regarding Classic Cancer
Genetic Testing Versus ExpandedMultiplex Cancer Genetic Testing:
Pilot Study
A. Alfonso1, P. Walker1, C. Hill-Chapman2, W. Dobek1
1. University of South Carolina School of Medicine
2. Francis Marion University
Introduction: Five to ten percent of breast cancer cases are caused by an
inherited germline mutation. BRCA1/2 genes are associated with a he-
reditary predisposition to breast cancer. Other causative genes without
clear screening guidelines are being analyzed. Healthcare providers
now decide whether testing of the two single genes or multiplex testing
is most appropriate for patients. Consideration of possible anxiety regard-
ing poorly defined risks and absence of guidelines has not been studied.
Methods: Individuals diagnosed with breast cancer undergoing genetic
testing were invited to participate. Participants completed a baseline
State-Trait Anxiety (STAI) questionnaire at their pre-test genetic counsel-
ing session, and completed the same STAI questionnaire and a Multidi-
mensional Impact of Cancer Risk Assessment (MICRA) questionnaire
after the post-results discussion. Anxiety scores were analyzed using
paired sample t-test, Kruskal-Wallis, and Mann–Whitney U-test. Results:
Of twenty individuals who agreed to participate, nine completed all ques-
tionnaires. Results showed five with negative results, two with positive,
and twowith variants of uncertain signigificance (VUS). Participants with
positive and VUS results showed non-significantly increased mean anx-
iety scores by STAI. Differences in anxiety between those with positive
results and those with negative results trended toward significance. Two
individuals with positive mutations in genes other than BRCA1/2 showed
higher post-results anxiety levels on the MICRA scale than did two par-
ticipants with VUS results. Conclusion: We were unable to explore dif-
ferences in anxiety between those who underwent classic BRCA1/2 test-
ing versus those who pursued multiplex cancer gene testing due to small
cohort size. The gene in which a mutation or VUS was found appeared to
affect overall changes in anxiety as differences approached significance
even at small sample size. A larger population may elucidate what factors
influence changes in anxiety between patients with negative, positive, or
VUS test results including the gene in which a finding is made.
ACMG Incidental Findings: Genetic Counselors’ Views
on Disclosure
S.M. Ancheta1, R. Kragenbring2, L. Hercher1
1. Sarah Lawrence College
2. Sanford Health, Sioux Falls
The utilization of whole exome sequencing (WES) is increasing in the
clinical setting. WES technology often generates incidental findings (IF),
which are findings that are not relevant to a diagnostic indication for
which the test was ordered. The American College of Medical Genetics
and Genomics (ACMG) has identified mutations in 56 genes that they
recommend searching for when labs conduct WES. This group of 56
genes, termed the minimum list, includes mutations associated with 24
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medical conditions. This study investigated genetic counselors’ views on
disclosure of IF’s on theminimum list. A surveywas sent to 3,209 genetic
counselors through an e-blast to the membership of the NSGC; 88 re-
sponses were received. Most participants (74 %, n=51) indicated an ex-
pectation that patient preferences would be established by the lab prior to
testing. This finding implies that respondents believe the duty of informed
consent should fall primarily on the lab rather than the clinician. This
view is in direct contrast to the ACMG recommendations, which place
the burden of obtaining informed consent on the clinician. In fact, labs are
not capable of obtaining informed consent; they can only document what
was obtained by the clinician. Once results are reported, 81 % of coun-
selors (n=57) reported feeling an obligation to disclose any pathogenic
mutations of genes on the ACMG’s minimum list, and 65 % (n=45)
would disclose even if patient preferences are unknown. Although only
7 % of respondents (n=5) received a report with an IF that they felt was
inappropriate to return, 27 % of genetic counselors (n=19) feel that there
are circumstances in which disclosure is inappropriate. Additionally,
75 % of genetic counselors (n=51) expressed great concern about storing
undisclosed IF’s in EMR’s since another clinician may disclose unwanted
information. These scenarios are likely to surface more often as WES
becomes more common in clinical practice. This study suggests the clin-
ical genetics community could benefit from guidelines onmanagement of
undisclosed IF’s and from the development of infrastructure to support
that process.
11p13 Microdeletion Involving Partial Deletion of ELP4
in a Newborn Patient Without Aniridia
A. Bandholz1, C.Williams2, R. Pedersen3, V. Mehta1, M. Pronold1, J.
Song1, Z. Powis1, C. Alamillo1, C. Gau1
1. Ambry Genetics
2. Joint Base Pearl Harbor Hickam Pediatric Clinic
3. Tripler Army Medical Center
Here we describe a newborn male patient born via prolonged vaginal
delivery with possible right parietal fracture, seizures, respiratory distress,
and hypoxic-ischemic encephalopathy. Chromosome microarray analysis
(CMA) was ordered due to suspected talipes equinovarus and mildly
distinctive physical features. CMA detected a heterozygous deletion at
chromosome 11p13 of ~532 kilobases (kb) in size and involving 4 genes,
DCDC1, DNAJC24, IMMP1L, and exons 1–3 of ELP4. Overlapping
microdeletions with similar gene content have been observed in sporadic
and familial aniridia patients, but have included additional ELP4 exons
with proximal breakpoints closer to the 3’ end of PAX6. Aniridia is a
congenital ocular malformation characterized by iris hypoplasia and as-
sociated ocular abnormalities. Mutations in the PAX6 gene are the most
common genetic etiology of isolated aniridia. However, the ELP4 gene,
which is downstream from the 3’ end of PAX6, contains regulatory ele-
ments for PAX6 expression. Thus, deletions involving ELP4 but preserv-
ing PAX6 have the potential to disrupt PAX6 expression, and have been
reported in patients with aniridia. Ophthalmology exam identified retinal
hemorrhage and possible macular hemorrhage but no signs of aniridia.
Following parental FISH analysis, the 11p13 microdeletion was found to
be inherited from the mother, with no reported health, developmental, or
vision abnormalities. To our knowledge, this patient’s proximal
breakpoint, ~222 kb from the 3’ end of PAX6, is the most distal of the
overlapping deletions defined by CMA in current literature. The absence
of aniridia in this patient suggests that the regulatory elements for PAX6
were not impacted by this microdeletion overlapping ELP4. This case
report adds to existing literature regarding the association between partial
deletions of ELP4 and aniridia, and emphasizes the importance of not
only evaluating existing literature for overlapping gene content but con-
sidering additional molecular mechanisms when counseling patients with
a copy number change detected by CMA.
Twins and Triplets and Quads, Oh My! A Review of MaterniT21
PLUS® Assay Results in Multifetal Pregnancies
T. Boomer1, E. Almasri1, J. Wardrop1, N. Dharajiya1, T. Monroe1,
W. Paxton1, D. Farkas1, S. Boshes1, R. McCullough1
1. Sequenom Laboratories
Introduction: Since the 2011 introduction of noninvasive prenatal testing
(NIPT), >400,000 clinical samples have been analyzed. Nearly 18,000
(~4 %) were from high risk multifetal gestations. The increased risk for
pregnancy complications with invasive testing in this population makes
NIPTa valuable screening alternative. Here we describe our clinical assay
findings in a multifetal cohort. Methods: Maternal plasma samples were
subjected to DNA extraction and library preparation followed by mas-
sively parallel sequencing as described by Jensen et al. Sequencing data
were analyzed to detect autosomal trisomies and other subchromosomal
events as described by Chen et al. Fetal fraction requirements were ad-
justed in proportion to fetal number. Outcome datawere collected through
provider solicitation. Results: The predominant indication for testing was
maternal age, followed by abnormal ultrasound and serum screening.
Overall positivity rates for trisomy 21 (1.5 %), 18 (0.6 %) and 13
(0.3 %) were aligned with those found in our much larger singleton
pregnancy cohort of over 400,000 patient samples (1.4 %, 0.4 % and
0.2 %). Additionally, a total of 10 events associated with the Enhanced
Sequencing Series (trisomy 16 and 22 and selected microdeletions) were
reported in the multifetal cohort. Average turnaround time was ~5 calen-
dar days. The non-reportable rate in this multifetal cohort was ~6 %,
largely due to insufficient DNA, which is higher than our singleton cohort
average of 1.6 %. Conclusion: MaterniT21 PLUS® testing in high-risk
multifetal gestations has demonstrated positivity rates for trisomy 21, 18,
and 13 mirroring those found in much larger cohort of singleton gesta-
tions, suggesting that the performance of the assay inmultifetal gestations
is comparable to that in singleton gestations, except for a higher non-
reportable rate due to insufficient fetal DNA. Clinical performance con-
curs with expectations from the original validation studies.
Isochromosome Formation as a Rare, Recurrent Mechanism
for the Occurrence of Isolated Trisomy 10p
C. Campbell1, J. Fan2, L. Lewis-Bunch3, A. Szymanski4, J. Chen5, A.
Gleason6, D. Matalon 7, N. Spinner8, E. Zackai1, L. Conlin1
1. The Children’s Hospital of Philadelphia
Introduction: Trisomy 10p has been reported in over 60 cases, with the
majority of cases resulting from unbalanced translocation. Cases of iso-
lated trisomy 10p are rare, with most resulting from translocation of the
10p arm to an acrocentric chromosome. Isochromosome 10p with trans-
location of 10q to chromosome 14p has been reported in one case with a
proposed mechanism involving an exchange between chromosome 14
and the long arm of chromosome 10, followed by 10p isochromosome
formation. Case Report: We report on a newborn female evaluated by
genetics for multiple congenital anomalies. Prenatal ultrasounds demon-
strated bilateral club feet, bilateral persistence of the superior vena cava,
single umbilical artery, polyhydramnios, and possible intrauterine growth
restriction. Neonatal examination was significant for sloping forehead
with high anterior hairline, widely open posterior fontanelle, prominent
maxilla with micrognathia, simple and slightly protuberant right ear, left
ear with flattened helix and prominent antitragus, small mouth, thin upper
lip with midline dip, redundant nuchal skin, right hand with a fourth digit
that is wide at the base and tapers, left hand with an apparently duplicated
second finger and 3–4 syndactyly, and bilateral talipes equinovarus.
Chromosome analysis demonstrated a karyotype of 46,XX,i(10) (p10),
der(14) t(10;14) (q10;p10). Chromosomal single nucleotide
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polymorphism (SNP) array demonstrated trisomy 10p with no copy num-
ber loss detected on chromosome 10q or chromosome 14, confirming the
isolated trisomy 10p. Discussion: Isolated trisomy 10p is a relatively rare
chromosomal anomaly that can arise due to various mechanisms. We
report a second case in which translocation of the 10q arm to chromosome
14 and formation of a 10p isochromosome gives rise to isolated trisomy
10p. This provides evidence supporting the previously proposed mecha-
nism of chromosomal translocation followed by isochromosome forma-
tion and demonstrates that this is a recurrent, rare mechanism of chromo-
somal aneuploidy.
Lack of Standardization in Laboratory Reporting of Variants
Outside the Coding Region: A Case Report
S. Cohen1, R. Covington2
1. St. Vincent hospital
2. The West Clinic Cancer Center
A 47-year-old woman with endometrial cancer was identified as being at-
risk for Lynch syndrome due to absent MSH2/MSH6 protein expression
as part of universal immunohistochemical (IHC) screening. Family his-
tory was significant for ovarian cancer in her mother diagnosed at age 58.
Genetic testing of the MSH2 and MSH6 genes by next-generation se-
quencing (NGS) technology was reported as normal by Laboratory A. At
approximately the same time, her mother had genetic testing at another
institution with a 25-gene NGS panel that indicated a variant of uncertain
significance (VUS) in an intervening sequence (IVS), 12 base pairs (bp)
downstream of exon 14 in the MSH2 gene by Laboratory B. When
contacted, Laboratory A confirmed that the proband carried this same
VUS in the MSH2 gene, but that it was outside the reportable range of
10 bp on either side of exon-intron boundary. A third laboratory was
contacted, and it was learned that they report variants within 5 bp on
either side of exon-intron boundaries. There are currently no standards
for laboratories performing NGS testing with regard to reportable ranges
for variants identified within an IVS. This case highlights the lack of
laboratory standardization in variant reporting within the IVS region, as
well as the importance of communication between families and genetic
counselors to ensure appropriate interpretation. Understanding different
laboratory reporting practices is crucial to providing patients with the
most accurate information, particularly in families with seemingly dis-
crepant test results. Genetic counselors should be aware of differences in
variant reporting and become familiar with the policies of frequently used
laboratories.
Comparing Gene Panel and Augmented Exome Tests Using
a BGold-Standard^ Dataset
G. Chandratillake1, G. Bartha1, D. Church1, A. Patwardhan1, S.
Garcia1, J. West1, R. Chen1
1. Personalis, Inc.
Assessing the sensitivity and specificity of next-generation sequencing
(NGS) based tests poses a challenge as it requires reference samples with
known variants in all genomic regions that are included in the assay. Such
Bgold-standard^ datasets have only recently been available for a subset of
the genome. The Genetic Testing Reference Materials Coordination Pro-
gram (GeT-RM) is a Centers for Disease Control initiative that aims to
improve the availability of appropriate and characterized reference mate-
rials for genetic testing. These materials can be used by the genetic testing
community for quality control, proficiency testing, test development and
validation, as well as for research. In an effort to characterize the variants
in reference samples, several clinical testing labs have run clinical gene
panel tests on these samples and contributed their variant data to the
GeT-RM. Together with data from the National Institutes of Science
and Technology Genomes in a Bottle Consortium (GIAB), this data con-
stitutes high-quality variant datasets that labs developing new NGS tests
can use to assess analytical validity. We compared the gene panel test data
submitted to the GeT-RM by clinical labs for reference sample NA12878,
to the Bgold-standard^ data produced for this sample by GIAB. We also
compared the results to those achieved with an augmented exome assay
developed by our lab: the ACE Clinical Exome Test. Most of the panels
are 100 % covered by ACE capture regions and nearly all of the remain-
ing panels are also covered. Taken together, we found that the sensitivity
and specificity of the ACE Clinical Exome Test was comparable to most
gene panel tests for those genes specifically targeted in the panels. In
many instances, the number of false positives and false negatives obtained
was lower with the ACE Clinical Exome Test than obtained with gene
panel tests. Increased standardization and transparency in reporting accu-
racy data for NGS tests will facilitate test selection by healthcare pro-
viders and therefore ultimately benefit patients.
Isolated Retinitis Pigmentosa and Usher Syndrome Within a Single
Family
I. Cuperus1, L. Mighion1, L. Bean1, M. Hegde1, J. Alexander1
1. Emory Genetics Laboratory
Pathogenic variants in the USH2A gene can cause isolated autosomal
recessive retinitis pigmentosa (RP) or Usher syndrome type 2 (USH2).
Retinitis pigmentosa is characterized by pigment deposition in the fundus,
progressive visual field loss, night blindness, and abnormal or non-
recordable electroretinogram. USH2 is a disorder consisting of mild to
severe pre-lingual hearing loss with intact vestibular function and adoles-
cent or adult onset RP. An individual (the proband) with a personal history
of retinitis pigmentosa without hearing loss was referred to Emory Ge-
netics Laboratory (EGL) for the comprehensive eye disorders panel. The
proband’s two children, child B and child C, were reported to have clin-
ical diagnoses of Usher syndrome. The molecular results identified a
pathogenic missense and a likely pathogenic splice variant in the USH2A
gene of the proband. Information provided to the laboratory included
previous molecular studies performed at a different diagnostic center for
the proband, the proband’s partner, and their children (B and C). Se-
quence and deletion/duplication analysis of child B identified the likely
pathogenic splice variant (seen in the proband) and also a pathogenic
truncating variant in the USH2A gene. Additional targeted analysis for
the variants identified in individual B determined that the variants segre-
gatedwith disease in child C andwere found to be in trans after testing the
proband and the proband’s partner. The combined results showed that
three different pathogenic/likely pathogenic variants were found in the
same gene in a single family that in turn gave rise to different phenotypes.
Initially, the proband was suspected to have dominant RP; however, it
was not until further comprehensive molecular testing was performed at
EGL, including the USH2A gene, that the likely cause of the proband’s
RP was identified.
Genetic Testing Strategies for Patients with Epilepsy
and Neurodevelopmental Disorders
A. Decker1, K. Retterer1, J. Juusola1, T. Brandt1, G. Richard1, S.
Suchy1, D. McKnight1
1. GeneDx
Guidance is frequently requested concerning testing strategies for patients
with epilepsy, given the increasing complexity of testing options. The
objective of this study was to compare the positive yield of multi-gene
panels for epilepsy to that of whole exome sequencing (WES). Over 5,
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000 patients were tested using targeted gene panels that included next
generation sequencing and exon-level deletion/duplication testing by ar-
ray CGH. The panels included genes associated with both benign seizures
and epilepsy with neurodevelopmental disabilities (NDD) along with
subpanels for age of onset (i.e., infantile panel). WES was completed in
529 patients with epilepsy and NDD, with either just the proband (WES-
Proband), or the proband and both parents simultaneously sequenced and
analyzed (WES-Trio). The overall clinical sensitivity of the targeted
panels was 16 % with the highest positive rate for the infantile panel
(21 %, n=1,620). WES-Trio testing for patients with epilepsy and NDD
had a positive rate of 38 % (n=450), which was considerably higher than
the positive rate for WES-Proband, 23 % (n=79). The majority of auto-
somal dominant and X-linked disorders diagnosed by WES (83 % and
69 %, respectively) were caused by de novo mutations; a finding that
largely accounts for the increased yield of WES-Trio compared to
WES-Proband. Patients who had reflex testing to WES after a negative
panel had a positive diagnostic rate of 22% (n=166). Hence, reflex testing
toWES-trio after a negative panel is expected to have a combined yield of
greater than 40%. These data indicate that when only a single genetic test
can be ordered, WES-Trio has a considerably higher yield than a targeted
panel. However, the highest clinical sensitivity could be obtained by
ordering a targeted panel, with reflex testing to WES-Trio. These data
may assist clinicians in determining the most effective testing strategy for
a patient with epilepsy and NDD.
Mutations in SPATA5 are Associated with a Novel Autosomal
Recessive Disorder of Microcephaly, Intellectual Disability, Seizures,
and Hearing Loss
S. DeWard1, A. Tanaka2, M. Cho1, C. Joshi3, D. Niyazov4, A.
Granica5, E. Gratz6, M. Deardorff7, A. Wilkins7, X. Ortiz-Gonzalez8,
9, K. Mathews3, K. Panzer10, E. Brilstra11, C. M. L. Volker-Touw11,
A. Hamosh12, W. Chung13
1. GeneDx
2. Department of Pediatrics, Columbia University Medical Center
3. Departments of Pediatrics and Neurology, University of Iowa Chil-
dren’s Hospital
4. Department of Pediatrics, Division of Medical Genetics, Ochsner
Health System
5. Arkansas Children’s Hospital
6. Gratz & Shafrir, M.D., Child Neurology
7. Department of Pediatrics, Division of Human Genetics, Children’s
Hospital of Philadelphia
8. Departments of Pediatrics and Neurology, Children’s Hospital of
Philadelphia
9. University of Pennsylvania School of Medicine
10. Department of Pediatrics, University of Iowa Children’s Hospital
11. Department of Medical Genetics, University Medical Center Utrecht
12. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins
University
13. Departments of Pediatrics and Medicine, Columbia University Med-
ical Center
Using whole exome sequencing, we identified 14 individuals from ten
independent families who have compound heterozygous or homozygous
rare or novel predicted pathogenic variants in Spermatogenesis-
Associated Protein 5 (SPATA5). Common features in these patients in-
clude microcephaly (12/13), developmental delay (14/14), seizures (13/
14), hypotonia (13/14), spasticity (9/14), sensorineural hearing loss (14/
14), and visual impairment (14/14, cortical in 9). Patients range from 2 to
19 years of age and have moderate to severe intellectual disability. Ab-
normalities on brain MRI are present in 7 out of 12 patients and include
diffuse atrophy, thin corpus callosum, and hypomyelination. Short stature
is present in two patients, failure to thrive in six, and immunodeficiency in
four. Two patients had muscle biopsies that revealed a possible mitochon-
drial disorder; one patient had enlarged and abnormally shaped mitochon-
dria and the other patient had a mild increase in subsarcolemmal and
intermyofibrillar mitochondria and reduced electron transport chain ac-
tivity. Generally, the patients are not reported to have dysmorphic fea-
tures. SPATA5 is a ubiquitously expressed member of the ATPase associ-
ated with diverse activities (AAA)-protein family and is involved in mi-
tochondrial morphogenesis during early spermatogenesis, and may also
play a role in post-translational modification during cell differentiation in
neuronal development. Variants in SPATA5may affect brain development
and function, resulting in the microcephaly, developmental delay and
intellectual disability. Fifteen different pathogenic variants in SPATA5
were detected in the group, including missense (9), nonsense (1), frame-
shift (3), splice site (1), and in-frame deletion (1) mutations. An autoso-
mal recessive inheritance pattern is further supported by testing which
indicates the unaffected parents and siblings to be heterozygous carriers
or wild type. We present the first case series of patients with pathogenic
variants in SPATA5, with phenotypic details to guide genetic counseling
of families with a new diagnosis.
Expanding the Mutation Spectrum for Noonan-Like Syndrome
with Loose Anagen Hair
M. Dillon1, H. Mason-Suares1
1. Laboratory for Molecular Medicine
Background: Noonan-like syndrome with loose anagen hair (NS/LAH) is
characterized by classic Noonan syndrome features such as short stature,
facial dysmorphism, pectus deformities, and variable cognitive impair-
ment in addition to more specific features including mitral valve dyspla-
sia, darkly pigmented skin with eczema, and easily pluckable and sparse,
loose anagen hair. To date, the only variant associated with NS/LAH is
the recurring c.4A>G (p.Ser2Gly) variant in SHOC2; however, not all
individuals with NS/LAH carry the p.Ser2Gly variant suggesting there is
another molecular etiology. Methods: DNA samples from 39 individuals
referred to our laboratory for NS/LAH were tested by either oligonucle-
otide hybridization-based DNA sequencing of the coding regions and
splice sites of PTPN11, SOS1, RAF1, KRAS, BRAF, MAP2K1, MAP2K2,
HRAS, and SHOC2 exon 02 or next generation sequencing of these genes
in addition to CBL and SPRED1. All variants were confirmed by Sanger
sequencing. Physician-reported clinical features and molecular results of
individuals with NS/LAH were compared. Results: Genetic testing iden-
tified 17 individuals (43.6 %) with NS/LAH with the recurring pathogen-
ic p.Ser2Gly SHOC2 variant. Interestingly, 56.4 % (22/39) of individuals
tested did not carry the SHOC2 variant and of those, 7/22 (31.8%) carried
a different established pathogenic variant in PTPN11, KRAS, RAF1, or
HRAS. Furthermore, the pathogenic p.Asn308Thr variant in PTPN11 and
the p.Val14Ile variant inKRASwere each identified in two probands with
NS/LAH. Conclusion: Pathogenic variants in SHOC2, PTPN11, KRAS,
RAF1, and HRAS have been identified by our laboratory in individuals
with NS/LAH suggesting that NS/LAHmay be part of the Noonan spec-
trum and not a separate disorder. Supporting this, an individual with NS/
LAH, who was negative for the recurrent SHOC2 variant, carried a path-
ogenicMAP2K2 variant consistent with Cardiofaciocutaneous syndrome.
In addition, two individuals with Costello syndrome and loose anagen
hair were found to carry a pathogenic HRAS variant.
Mutations in CASK: Challenging the Genotype-Phenotype
Correlations
H. Dubbs, MS, LCGC1, L. Medne, MS, LCGC1, E. Marsh, MD,
PhD1
1. The Children’s Hospital of Philadelphia
Presented Abstracts from the Thirty Fourth Annual Education 1105
Mutations in CASK, an X-linked gene that plays a role in brain develop-
ment and synaptic function, are the cause of both microcephaly with
pontine and cerebellar hypoplasia (MICPCH), and X-linked intellectual
disability (XLID) with or without nystagmus. MICPCH is caused by loss
of function CASK mutations, typically affects females, and is associated
with moderate to severe intellectual disability (ID). Only a few affected
males have been reported; all have had profound developmental disabil-
ity. The XLID phenotype is typically caused by missense mutations and
most often manifests in males; carrier females are mildly affected or
unaffected. We report 7 patients with CASK mutations that expand these
phenotypes and challenge the reported genotype-phenotype correlations.
Cases 1 and 2 are unrelated females with loss-of-function CASK muta-
tions who display a classic MICPCH phenotype. Case 3 is a female who
also displayed a classic MICPCH phenotype, but was found to have a de
novo missense mutation. Case 4 is a female with a de novo frameshift
mutation. She has microcephaly with mild hypoplasia of the cerebellar
vermis only identified retrospectively. She has ID but at age 8 can form
complete sentences, expanding the mild end of the MICPH phenotype.
Case 5 is a male with a de novo nonsense mutation who showed the
severe male phenotype with intractable myoclonic seizures. He had pro-
foundly delayed development and died at 12months of age. Cases 6 and 7
are brothers with a maternally inherited nonsense mutation, who present-
ed with an XLID phenotype. Brain MRI is normal in both brothers. Both
are severely delayed and nonverbal. However, the oldest was walking
independently at age 3 ½. Their mother is unaffected, representing the
first known case of an unaffected female with a nonsense mutation. In
summary, these 7 cases highlight and expand the phenotypic spectrum
associated withCASKmutations and challenge the previously established
genotype-phenotype correlations, which will impact genetic counseling
for CASK-related disorders.
Exploring Attitudes of Adopted Individuals on the Utility and Value
of Universal Carrier Screening
S. Ewing1, S. Spencer2, S. O’Neill1, K. Calcagno1
1. Northwestern University
2. NMH Prentice Women’s Hospital
A complete and accurate family medical history is a valuable tool to
provide a thorough risk assessment. Many adoptees may not have access
to this information. Carrier screening is an important aspect of reproduc-
tive risk assessment and was historically offered based on family history
and ethnicity. Universal carrier screening (UCS) screens for approximate-
ly 90 genetic conditions regardless of family history or ethnicity. The
study aimed to provide healthcare professionals with a better understand-
ing of the opinions of adoptees on UCS and its potential uses. Adult
adoptees were recruited through adoption organizations using an online
survey. Of the 139 adoptees attempting the survey, 89 participants
(75.4 %) responded they would want UCS. Participants indicated they
would use results to make personal reproductive decisions (n=63), or to
inform biological relatives of their risks (n=62). Many reported wanting
UCS because they are curious to know their carrier status (n=76). Adopt-
ee total household income was moderately correlated with the amount
they would pay for UCS ( =.327, p=0.001). There was a statistically
significant difference between adoptees of differing education levels
and the amount they would pay for UCS (p=0.004). In addition to pro-
viding insight into the adoptee perspective on UCS, this study also iden-
tified an important area for improvement in the delivery of carrier screen-
ing to this population. One hundred and eight participants indicated they
had never been offered carrier screening (91.5 %), although the majority
of adoptees would want UCS if offered. Genetic counselors are well-
suited to provide UCS services to adoptees, as supported by an additional
finding of the study; the majority of survey participants (84.8 %) felt a
genetics professional would be helpful in undergoing UCS.
Expanded Carrier Screening is Vital in Appropriately Screening
the Ashkenazi Jewish Population
S. Farner1, B. Swope1, C. Settler1
1. Progenity, Inc.
Current guidelines for individuals of Ashkenazi Jewish (AJ) descent from
the AmericanCollege ofMedical Genetics andGenomics (ACMG, 2008)
and the American Congress of Obstetricians and Gynecologists (ACOG,
2009) recommend carrier screening for 9 and 4 heritable conditions,
respectively. Additional clinically severe conditions occur more frequent-
ly in the AJ population and many laboratories offer expanded AJ panels.
We sought to evaluate the clinical yield of an expanded panel for persons
of AJ descent and to determine the yield of enzyme analysis versus
targeted mutation analysis in carrier screening for Tay-Sachs disease.
Individuals underwent preconception screening at synagogues and col-
leges across the western U.S. in 2014 and 2015. Carrier screening was
offered for those who self-identified as having at least ¼ AJ ancestry, in
accordance with guidelines. The panel included all of the recommended
ACOG/ACMG conditions. Screening for Tay-Sachs disease was done via
enzyme and targeted DNAmutation analysis. Participants were provided
pre-test information by a genetic counselor and informed consent was
obtained prior to testing. Positive results were called to patients by a
genetic counselor. Six hundred sixteen individuals had screening for at
least 19 conditions. 27.3 % of individuals were identified as carriers of at
least one of the disorders tested. Thirty eight tested positive for more than
one condition. In total 197 mutations were found. The 4 disorders recom-
mended by ACOG and 9 disorders recommended by ACMG accounted
for 40.6 % (80/197) and 69.5 % (137/197) of the mutations discovered
respectively. Thirty three carriers of Tay-Sachs disease were identified.
24.2 % of these were abnormal by hexosaminidase A enzyme analysis
alone. Expanded carrier screening for individuals of AJ descent will iden-
tify more carriers than testing only for those disorders recommended by
ACMG/ACOG. Additionally, patients who self-identify as AJ should
have carrier screening for Tay-Sachs disease by both enzyme analysis
and targeted DNA testing as DNA testing alone may miss at-risk patients.
A Patient-Centered Online Resource for Segregation
and Reclassification of Variants of Uncertain Significance
L. Garrett1, A. Jacobson1, N. Hickman1, B. Shirts1
1. University of Washington, Department of Laboratory Medicine,
Genetics
Multi-gene cancer panels often identify variants of uncertain clinical sig-
nificance (VUS), which pose a challenge to genetic providers in manag-
ing patient’s cancer risk. Family segregation studies can yield powerful
data to classify VUS (as either benign or pathogenic), but resources to
coordinate these studies are limited. A potential solution is to engage
patients and their families in pedigree building for segregation analysis
to evaluate their own VUS. For most patients including extended family
members will allow VUS classification. Online genealogy and social
networking tools can facilitate identifying and contacting distant relatives.
We have developed an online patient-driven toolkit that teaches individ-
uals to better understand their VUS, use available genealogy and net-
working resources to trace how their VUS segregates in their families,
and participate meaningfully with clinical laboratories in classifying their
VUS. The toolkit available at FindMyVariant.Org walks patients step-by-
step through the process of classifying their variant. Modules include: 1.)
What is a VUS? 2.) Co-segregation analysis for variant classification. 3.)
Talking with your immediate family about your variant. 4.) Identifying
ancestors. 5.) Finding and connecting with distant relatives. 6.) Labora-
tory testing and asking relatives to participate in VUS classification. The
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free toolkit will be available to patients who have received VUS results
(regardless of laboratory used) to assist them in gathering information
needed to further classify their VUS. Genetics providers seek ways to
make genetic information meaningful to their patients, by pointing them
towards resources. We present this innovative toolkit as a resource for
genetic providers to offer to motivated families. The implications of this
project for the practice of genetic counseling include: expanding the
availability of human genotype-phenotype correlations for rare variants
in cancer risk genes and helping genetic providers empower patients to
have a more active role in their genetic health.
Selecting the Best Specimen Type for Genetic Testing: A Survey
of the Experience, Knowledge and Practices of Genetic Counselors
S. Geisler1, L.Mullineaux2, K. Swisshelm3, R. Blumhagen4, K. Wolfe
Schneider1
1. University of Colorado Anschutz Medical Campus
2. GeneDx
3. Colorado Genetics Laboratory
4. Colorado School of Public Health
Although peripheral blood is often considered the gold standard for ge-
netic testing, a blood sample could give false or inappropriate testing
results in several situations. For example, if an individual has an active
hematopoietic malignancy or has received an allogeneic bone marrow
transplantation or blood transfusion, using a blood specimen for genetic
testing may result in analyzing the oncologic or donor cells instead of the
intended germline cells. In order to explore whether genetic counselors
recognize the importance of establishing patients’ hematopoietic malig-
nancy, bone marrow transplantation, and blood transfusion status prior to
genetic testing, a web-based survey was sent to NSGCmembers. Respon-
dents (n=122) were asked if they have seen patients with the
abovementioned histories and if they have a process in place to elicit this
information. Knowledge was assessed via several scenario- and theory-
based questions. More than half of respondents reported seeing patients
who had been diagnosed with a hematopoietic malignancy (n=88), or
who had received a blood transfusion (n=84) or bone marrow transplan-
tation from a donor (n=65). Up to 57 % (n=70) of respondents either did
not, or did not know, if they have a process in place to elicit this infor-
mation. Up to 20 % (n=24) of respondents did not know which specimen
type to select in the various clinical scenarios. Approximately 17 %
(n=16) of respondents were unable to correctly identify that DNA is
contained in white blood cells only. This exploratory study targeted pro-
viders who are expected to be among the most informed regarding ap-
propriate specimen selection for genetic testing. Gaps in knowledge, and
a lack of consensus for approaching individuals with clinical histories that
require non-peripheral blood specimens for genetic testing, were evident.
Performing genetic testing on inappropriate specimens could lead to in-
accurate genetic test results with significant psychosocial and medical
implications.
Evidence of Aneuploid Rescue as Revealed by Circulating Cell Free
DNATesting
J. Helgeson1, J.Wardrop1, T. Monroe1, J. Rafalko2, K. Donahue3, R.
McCullough1
1. Sequenom
2. New Jersey Perinatal
3. Western Pennsylvania Alleghany Health System
Introduction:
Rescue of an aneuploidy to restore the euploid state in early embryonic
development is a well-documented explanation for confined placental
mosaicism (CPM). Historically, case reports have focused on the rescue
of a complete trisomy or monosomy. Since the advent of prenatal chro-
mosomal microarray, segmental CPM has also been reported, suggestive
of the rescue of a partial monosomy or trisomy. Tests using circulating
cell-free DNA (ccfDNA), likely derived from cells of the placenta, have
demonstrated CPM as a cause for discrepancies between ccfDNA results
and fetal karyotype. Case Reports: Here we report a case of a pregnancy
complicated by intrauterine growth restriction (IUGR), short long bones,
and abnormal serum screening, which had a normal noninvasive prenatal
testing result for 21, 18, 13, X and Y. Karyotype on amniocytes was 46,
XY,inv (2) (p11.2q13) and subsequent single nucleotide polymorphism
(SNP)-based array showedmaternal uniparental heteroisodisomy of chro-
mosome 2, suggestive of a rescue event in the placenta. Evaluation of
ccfDNA sequencing traces of chromosome 2 was also suggestive of
trisomy 2, consistent with a trisomy rescue in the placenta. We also report
the suspected rescue of a 1p36 microdeletion in a patient who had
ccfDNA testing and a follow-up amniocentesis which demonstrated com-
plete homozygosity along the region originally detected by ccfDNA to
contain a deletion. This pregnancy was further complicated by premature
rupture of the membranes at 23 weeks gestation and birth of a premature
infant with features of Goldenhar syndrome at 25 weeks gestation. Dis-
cussion: These cases may represent a complete trisomy rescue as well as a
segmental monosomy rescue event detectable by ccfDNA. CPM of an
aneuploidy can lead to complications in pregnancy, including IUGR and
premature delivery. There is not enough data to determine whether a
similar effect can be caused by CPM of a segmental rescue. Additionally,
aneuploidy rescue and segmental rescue can lead to uniparental disomy
(UPD) or partial UPD, in some cases causing an imprinting error in the
fetus.
The Usage of Existing Practice Guidelines may miss Half
of Pathogenic Mutations in Hereditary Cancer
L. Hellwig1, B. Biesecker1, J. Geurts2
1. John Hopkins University/National Human Genome Research Institute,
National Institutes of Health
2. Medical College of Wisconsin
Background: Genetic Counselors have expertise in identifying pheno-
types associated with known hereditary cancer syndromes. Existing prac-
tice guidelines from the American College of Medical Genetics and Ge-
nomics, NSGC, National Comprehensive Cancer Network, and the Am-
sterdam Criteria inform genetic testing strategy. With the recent wide-
spread uptake of clinical next-generation sequencing (NGS), laboratories
analyze dozens of hereditary genes simultaneously using ‘panel testing.’
Objective: The goal of this study was to determine whether the existing
practice guidelines are adequate to guide clinical genetic testing by
assessing results from 16month’s experience with hereditary cancer panel
testing at the Medical College of Wisconsin. Methods: We undertook a
retrospective analysis of the results from panel testing from 321 patients.
Results: Half (18/36) of the pathogenic mutations detected would have
been missed if single gene testing was done as recommended in current
practice guidelines using phenotype. Of those patients found to have a
pathogenic mutationwhomet hereditary breast and ovarian cancer testing
criteria, only 53 % (9/17) had a BRCA1 or BRCA2 gene mutation. Con-
versely, 47 % (8/17) of those who had a pathogenic mutation and met
testing criteria had mutations in genes other thanBRCA1 andBRCA2, and
would have been missed if panel testing had not been done. Conclusion:
Our results suggest that the current model of phenotype driven single
gene testing based on practice guidelines is insufficient to obtain a genetic
diagnosis in hereditary cancer. The use of comprehensive panel testing
nearly doubles the identification of pathogenic mutations. The existing
definitions of some hereditary cancer syndromes require re-consideration
as the use of panel testing has led to the discovery of a broader phenotypic
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spectrum. Our findings contribute to further understanding of the utility of
panel testing in cancer genetics and provide evidence to guide genetic
counseling practice in the offering of expanded genetic testing.
APOE Genotyping: Are We Ready for Clinical Use? A Survey
of Physicians
M. Herzog1, M. Caudle2, D. Matviychuk3, J. Griffin2, J. Tidwell4, L.
Hercher1
1. University of California, Los Angeles David Geffen School of Medicine
2. Sarah Lawrence College
3. Kingston General Hospital
4. Saddleback Memorial Care
Research on the effects of traumatic brain injury (TBI) has drawn a spot-
light to the issue of TBI among athletes. APOE genotype is a risk factor
for poor recovery from TBI, and may be useful to athletes considering
participation in sports with a high incidence of TBI, or for doctors in care
of TBI. Clinical use of APOE genotyping is often discussed in relation to
its associationwith risk for late-onset Alzheimer disease (LOAD). Testing
is generally discouraged, in part because the information is not medically
actionable. Personalizing the risk of poor recovery from TBI has more
clinical value; however, it may also raise the risk of genetic discrimina-
tion. In order to explore the perceived clinical value of APOE genotyping
for this purpose and the obstacles to its use, we surveyed 233 physicians
involved in the treatment of athletes with TBI contacted through the list
serve of the American Medical Society for Sports Medicine. Results
suggest that they are open to using APOE testing, with 62.2 % (n=148)
saying that they would always or frequently offer a test that could predict
poor recovery from TBI to athletes interested in participating in sports
with a high incidence of TBI, and 37.8 % (n=89) saying they would
always or frequently order such a test when making a plan for return-to-
play. However, they are apprehensive about offering APOE testing, and
most likely to identify the risk that the results might interfere with their
patient’s athletic career as the issue of presumed greatest concern to their
patients (60.9 %, n=145), and the biggest obstacle to clinical use in their
practice (53.2 %, n=126). Physicians expressed concern about their read-
iness to counsel patients for the genetic risks associated with LOAD, and
37.4 % (n=89) described themselves as Bnot familiar^ with the relation-
ship between APOE and LOAD. Given a choice of methods for educating
patients, the majority chose the option of genetic counseling (51.3 %,
n=122) andmost (64.3%, n=153) said they would bemore likely to order
genetic testing if they could refer their patient to a genetic counselor.
Assessing Test Quality in a Rapidly Changing Genetic Testing
Landscape
G. Hooker1, M. Goodenberger2, J. Riley3, M. Landon4, A.
Bandholz5, V. Mehta5, J. Cohen6, C. Hess7
1. NextGxDx
2. Mayo Clinic
3. Cleveland Clinic
4. Myriad Genetics
5. Ambry Genetics
6. Kennedy Krieger Institute
7. Detroit Medical Center University Laboratories
In recent years, across clinical subspecialties of genetic counseling, options
for genetic testing have grown at an unprecedented rate. Evaluating and
comparing genetic tests has become an increasingly time consuming and
complex part of genetic counseling practice. One of the most complicated
aspects of this process lies in assessing the quality of the testing and accom-
panying services provided by laboratories. Quality of testing can be assessed
in a number of ways, ranging from laboratory certifications to variant level
analytic and clinical validity data. These data are currently presented by
laboratories in a variety of ways and test sensitivity is represented differently
by various laboratories across different types of tests. Quality of services
includes attributes such as meeting the stated turn-around time, expertise of
laboratory staff, reporting and documentation process and accessibility of
customer service personnel to ordering clinicians. While genetic counselors
frequently cite quality of services as a major factor in choosing a laboratory,
this concept can be challenging to address objectively. Our working group of
clinical and laboratory genetic counselors, formed in response to a lack of
clear guidelines on this topic by members the Test Utilization Subcommittee
of the Industry SIG, will present our taxonomic framework and discussion
points for assessing laboratory quality and identifying high quality tests for
patients. Genetic counselors have a strong history of serving on the front
lines of evolving and growing fields. Laboratory and test selection is an area
of increasing complexity and it is critical that genetic counselors take a
leadership role in this rapidly changing landscape.
Ophthalmologists’ Perspectives on and Utilization of Genetic Testing
M. Jacobs1, K. Branham1, B. Yashar1, W. Uhlmann1
1. University of Michigan
Genetic testing (GT) has the potential to benefit patients with inherited
ophthalmic conditions, however our understanding of its use by ophthal-
mologists is limited. This exploratory study examined providers’ perspec-
tives on ophthalmic GT. Based on previous research on GT in other
medical specialties, we developed a 46-item on-line survey examining
demographics and GT-related variables included experiences, knowl-
edge, comfort with the process, perceived utility, and barriers/facilitators
to ordering GTs. Participants included ophthalmologists (MDs) who were
either alumni of our academic medical center or members of the National
Eye Institute eyeGENE consortium. Having experience or no experience
ordering GT was used to dichotomize respondents. Group differences
related to the variables were analyzed using either chi-square or t-tests.
Significant variables were entered into a logistic regression using GT
experience as the binary outcome. Seventy-two MDs responded to the
survey, 52.7 % had ordered GT. Significant differences (p<=0.05) be-
tween groups were found based on clinical specialty, work setting, train-
ing, patient race, patients seen per year, perceived utility of GT, self-
reported knowledge of genetics, and comfort with the process. In the
regression, personally having had GT done (p=0.015), patients asking
about GT (p=0.004), and comfort with the GT process (p=0.002) were
each positively associated with ordering GT. These results highlight the
fact that the reasons ophthalmologists use GT may be driven by non-
medical physician- or patient-related factors rather than clinical utility.
Ophthalmologists consistently ranked diagnostic use of GT as more im-
portant than other uses including determining inheritance, prognosis, and
use for potential clinical trial enrollment. This ranking of perceived GT
value suggests that ophthalmologists have limited recognition of the ex-
tent to which it can benefit patients. Our study is generally consistent with
previous work examining other groups of physicians, with the novel
finding that personal experience with GT can impact its utilization.
SNPArray: Valuable Tool to Guide Targeted/Accurate/Cost
Effective Diagnosis of Autosomal Recessive Conditions
G. Jervis1, S. Gellatly1, R. Ortega1, P. Callea1, S. Smith1, L. Harris1,
A. Robinson1, J. Shi1, Y. Chang1, M. Sutcliffe1
1. All Children’s Hopital
Microarray analysis is the first tier genetic test for patients with unex-
plained intellectual disability and/or multiple congenital anomalies.
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Single nucleotide polymorphism (SNP) arrays detect imbalance and copy
neutral loss of heterozygosity (LOH), providing information about uni-
parental disomy (UPD) and consanguinity. Targeted strategies for molec-
ular testing, guided by SNP array results, are illustrated by 4 patients
diagnosed with autosomal recessive (AR) disorders. Case 1: Neonate
with situs inversus totalis, cough, congestion, respiratory distress; SNP
array revealed 781Mb of LOH, coefficient of inbreeding (F) = 0.25, first
degree consanguinity. 10 genes associated with situs inversus within
LOH regions included 6 genes for primary cililary dyskinesia (PCD).
Abbreviated 6 gene PCD panel detected homozygous DNAAF2 patho-
genic variant, PCD type 10. Case 2: 14 year male, abnormal electromy-
ography, consistent with demyelinating neuropathy. 341 Mb LOH found
by SNP array, F = 0.109, second degree parental relationship. 191 AR
conditions within LOH regions included a demyelinating neuropathy,
Charcot Marie Tooth disease, type 4C (CMT4C), caused by variants in
SH3TC gene. Molecular analysis of SH3TC (instead of full CMT panel)
demonstrated homozygous pathogenic variant. Case 3 and Case 4 both
had LOH with F = 0.0126, fifth degree parental relationship. Case 3:
Neonate with status epilepticus, intractable epilepsy, responsive to
pyridoxal-5 phosphate (form of vitamin B). SNP array showed 40Mb
of LOH including PNPO gene associated with pyridoxamine 5’-phos-
phate oxidase deficiency. Molecular analysis of PNPO (instead of full
epilepsy panel) identified homozygous pathogenic variant. Case 4: Neo-
nate, with zero Screening Test for SCID: T-cell Receptor Excision Circles
(TREC) on newborn screen; diagnosed with T-, B+, NK+ severe com-
bined immunodeficiency (SCID). SNP array detected 51Mb of LOH,
including IL7R gene associated with this same type of SCID. Homozy-
gous pathogenic variant in IL7R was identified and absent IL7R expres-
sion by protein function confirmed diagnosis. SNP analysis is an effective
tool enabling cost effective, targeted molecular testing and expediting
diagnosis.
A Case of Salt-Wasting Congenital Adrenal Hyperplasia Resulting
from Two De Novo Mutational Events in CYP21A2 in Two
Generations
M. Kluge1, S. Grebe1, K. Kotzer1, L. Hansen1, A. Algeciras-
Schimnich1
1. Department of Laboratory Medicine and Pathology, Mayo Clinic
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency
is an autosomal recessive condition caused bymutations in the CYP21A2
gene. 21-hydroxylase deficiency is the most common form of CAH and
can be subdivided into three forms, the most severe of which is salt-
wasting (SW) CAH. A significant proportion of CAH mutations result
from recombination events between CYP21A2 and a highly homologous
pseudogene (CYP21A1P) located 30kb upstream. These recombination
events, and a de novo rate of about 1 %, present unique challenges for
genetic testing laboratories. In order to provide a more accurate and com-
prehensive analysis of this complex region, it is important to perform
copy number analysis of CYP21A2, CYP21A1P and the hybrid alleles
formed due to recombination events, along with full gene Sanger se-
quencing ofCYP21A2 and of potentially active hybrid alleles. We present
the case of a Saudi Arabian child affected with SW CAH and no known
family history. Analysis revealed two copies each of CYP21A2 and
CYP21A1P. Sequencing of CYP21A2 revealed three SW mutations:
p.I236N, p.V237E, p.M239K and a novel frameshift mutation,
c.558_562delCTTAA, p.L186AfsX107. The first three mutations are
commonly inherited in cis and referred to as the exon 6 cluster. Parental
studies revealed the exon 6 cluster was paternally inherited and
p.L186AfsX107 resulted from a de novo event. Full gene sequencing
and segregation analysis of multiple benign variants confirmed that the
de novo event occurred on the proband’s maternally inherited allele.
Studies of the proband’s paternal grandparents revealed the exon 6 cluster
occurred as a de novo event on the proband’s father’s maternally inherited
allele. This report demonstrates how two de novo events in one family
resulted in a case of SWCAH, and illustrates the usefulness of combining
parental studies and full gene sequencing in cases of de novo CYP21A2
mutations. This case also supports the use of full gene sequencing rather
than targeted analysis of common mutations, which would have missed
the de novo frameshift mutation.
Genetic Testing Outcomes for Hearing Loss in a Multidisciplinary
Hearing Clinic Setting
K. Kocsis1
1. Children’s Hospital Colorado/University of Colorado
Congenital hearing loss occurs in 2–3 per 1,000 babies in the United
States. It is estimated 50 % of congenital hearing loss (HL) is genetic
and when genetic, is highly heterogenous. Previously, genetic testing was
limited to single gene testing, namely GJB2/GJB6. However, with the
advent of next generation sequencing platforms, conditions like HL are
prime targets for maximizing the full diagnostic potential of this technol-
ogy. In the state of Colorado, there are two multidisciplinary clinics fo-
cused solely on hearing loss. Specialties participating in these clinics
include audiology, otolaryngology, genetics, speech pathology, develop-
mental specialist, and family support. Since multigene panels became
available, 152 individuals pursued this testing through these clinics and
the general genetics clinics. Testing was offered to all children with con-
genital or childhood onset hearing loss that was bilateral in nature. Ma-
jority of individuals had no other health or developmental concerns sep-
arate from their hearing loss. Genetic counseling was provided before
sample collection and againwhen results were reported out. Two different
panels were offered to families: OtoSCOPE® from Univeristy of Iowa
(66–116 genes) and OtoGenome® from Harvard-affialiated Laboratory
(71 genes). Of the 152 individuals who pursued testing, results are avail-
able for 140 to date. A genetic etiology was identified in 52% (73) and no
etiology was identified in the remaining 48 % (67). Positive results in-
cluded: 50%DFNB1, 12 %DFNB16, 10 % Usher, 10%DFNA17, 12 %
miscellaneous AR genes, and 6 % miscellaneous AD genes. Previous
testing strategies using single gene testing yielded a positive result in
about 5-10 % of cases. These data argue that the use of multigene panels
allow for significantly improved detection rates in congenital and child-
hood onset hearing loss which in turn results in better prognostic infor-
mation and directed improved medical management guidelines for these
families.
Whole Exome Sequencing Identifies the first PANX1 Germline
Mutation in an Individual with Intellectual Disability, Hearing Loss,
Endocrine Dysfunction, and Skeletal Abnormalities
K. Levine1, Q. Shao2, K. Lindstrom3, R. Shi4, J. Kelly2, A.
Schroeder5, J. Juusola1, J. Esseltine2, S. Penuela2, M. Jackson4, D.
Laird2
1. GeneDx
2. Department of Anatomy & Cell Biology, University of Western Ontario
3. Division of Genetics and Metabolism, Phoenix Children’s Hospital
4. Department of Pharmacology & Therapeutics, University of Manitoba
5. Division of Genetics, University of Rochester Medical Center
A 17-year-old female patient was referred for clinical genetic testing due
to a suspected diagnosis of Perrault syndrome. She exhibited intellectual
disability, sensorineural hearing loss, premature ovarian failure, and skel-
etal abnormalities including delayed bone age, short stature, and kypho-
sis. Utilizing a whole exome sequencing platform, targeted analysis of
five genes associated with Perrault syndrome (CLPP, LARS2, HARS2,
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HSD17B4) and Woodhouse-Sakati syndrome (DCAF17) was performed.
When no pathogenic variants were identified in these five genes, analysis
of the whole exome was performed using the previously generated data,
and a homozygous missense mutation (c.650G>A) in PANX1 was iden-
tified. This mutation results in a conservative amino acid substitution of
arginine to histidine at position 217 (p.R217H) of the protein. The par-
ents, who were reported to be first cousins, were both heterozygous for
the R217Hmutation. PANX1 encodes pannexin1, an ATP release channel
with both structural and functional similarities to the connexin gap junc-
tion proteins. PANX1 is highly conserved across species and is ubiqui-
tously expressed, with robust expression in many regions of the brain,
including the cochlea. Dye uptake, ATP release, and electrophysiological
measurements revealed R217H to be a loss-of-function mutation. This is
the first report of a human germline PANX1 pathogenic mutation, impli-
cating PANX1 in this newly described form of syndromic hearing loss,
and underscoring the efficacy of whole exome sequencing in the identi-
fication of novel disease-associated genes.
A Rigorous Approach for Evaluating the Importance of Sanger
Confirmation of Next-Generation Sequencing Findings: A Call
for Collaboration
S. Lincoln1, S. Yang1, M. Hogue1, M. Rabideau1, K. Vikstrom1, R.
Kurz1, M. Ghent1, M. Kennemer1, A. Rosendorff1, J. Zook2, S.
Aradhya1
1. Invitae
2. National Institute for Standards and Technology
Many laboratories use next-generation sequencing (NGS) to detect clin-
ically significant germline variants. Positive test results can lead to sub-
stantial medical decisions, and it is imperative that genetic tests have high
specificity and PPV (positive predictive value). Thus, high-quality clini-
cal labs, including our own, confirm NGS findings using a second, or-
thogonal method, such as Sanger sequencing.
While some NGS methods have high false-positive rates, improvements
in sequencing chemistry and bioinformatics can provide excellent speci-
ficity without sacrificing sensitivity. We examined all 3,105 variants de-
tected by NGS in our lab to date that (a) passed stringent NGS quality
control, and (b) had orthogonal data available. All 3,105 were confirmed
with zero false positives. Nevertheless we continue confirmations, which
of course add turn-around time and cost. Other NGS laboratories have
also made similar observations. We propose a rigorous framework for
evaluating the importance of confirmation in different cases, separating
situations where it is even possibly beneficial (e.g., around many indels)
from situations where a substantial data set clearly demonstrates that
confirmation adds little value. We assign statistically meaningful Bworst
case^ estimates to false positive rates, which may aid in careful decision
making on this subject. Genetic counselors must become intimately in-
volved in this conversation. Patient safety is critical, as is patient and
provider confidence in genetic test results. In question here is (a) how
much data would be enough to change both practices and perceptions
regarding confirmatory testing; (b) what specific criteria distinguish labs
whichmeet a strongNGS performance standard from those which do not;
(c) how do we best explain these considerations to patients and non-
genetics professionals. Our data suggest, but certainly do not determine
answers which can only come from ongoing dialog and leadership within
the clinical GC community.
Pan-Ethnic Carrier Screening for Cystic Fibrosis: A Call
for a Standardized Expanded Mutation Panel
C. Marks1, S. Rodriguez1, N. Kumar1, W. Field1, K. Chung2, K.
Bendikson2
1. Recombine
2. USC Keck School of Medicine
Introduction: Carrier screening for cystic fibrosis (CF) is recommended
for all individuals regardless of ethnicity. The American College of Med-
ical Genetics and Genomics recommends a 23-mutation panel, which has
limited detection rates outside of the European population. Thus, expand-
ed screening for additional mutations has become more common. To
determine the clinical utility of expanded CF screening, we assessed the
rates of CF carriers across ethnicities and across varying panels. Methods:
Informed consent was obtained to use genetic data from expanded carrier
screening results for 5,272 patients. Inclusion was limited to patients who
reported a single ethnicity. 108 CF mutations were tested in this assay.
Heterozygous calls for each mutation were tallied by ethnic group, and
respective carrier rates were determined. Carrier rates were also calculated
for each ethnic group using only data from the ACMG recommended 23-
mutation panel as well as the commonly used 32- and 97-mutation panels.
Data were compared across ethnicities and across panels. Results: A total
of 16, 19, 35, and 41 mutations were identified in our patients out of the
23, 32, 97, and 108 possible mutations. It was determined that 23 %,
21 %, and 7% of carriers were missed by the 23-, 32-, and 97-mutation
panels when compared to the 108-mutation panel. As expected, carrier
frequencies seen across ethnicities increase gradually with the size of the
panel. Carrier rates in the two smaller panels are highly comparable across
ethnic groups, with the exception of Middle Eastern individuals, which
increased from 1/92 to 1/46. The same is true of the larger panels, with the
exception of Asian individuals, which increased from 1/135 to 1/45.
Conclusions: Our results show that the currently recommended 23-
mutation panel missed 23% of carriers identified within our patient pop-
ulation, indicating this panel may not be appropriate for pan-ethnic CF
carrier screening. Given this, implementation of a standard expanded CF
panel incorporating mutations common in non-European individuals
should be considered in order to provide comprehensive patient care.
A Unique Finding of Somatic Mosaicism for a Novel Mutation
in the Already Rare X-Linked Joubert Syndrome
M. McDaniel1, J. Propst1, R. Lewandowski1
1. Virginia Commonwealth University
Joubert syndrome is a disorder characterized by the cardinal features
including a distinctive cerebellar and brain stem malformation known
as the molar tooth sign, hypotonia, and developmental delays. There have
been 19 genes identified to be associated with this condition. Included is
the gene OFD1, which is associated with a rare X-linked recessive form
of Joubert, with only three families reported in the current literature.
Affected males with reported OFD1 mutations had variable phenotypes
including the classic features as well as postaxial polydactyly, retinal
disease, renal cystic disease, hydrocephalus, and occipital encephalocele.
We introduce a 3-year old %Caucasian male who presented to genetics
with overall delays and MRI revealing a molar-tooth sign. He had hypo-
tonia, noted since birth. He was macrocephalic with his head measure-
ment greater than the ninety-seventh percentile. Birth and pregnancy
history were reported to be normal. At age 3 he could walk approximately
3–4 steps independently with a wide-based gait. He had a normal renal
ultrasound. Molecular testing using a Joubert gene panel identified a
variant of uncertain clinical significance in the X-linked OFD1 gene. This
variant, c.533T>C, is predicted to result in the amino acid substitution
p.Leu178Pro. This variant has not been reported in the medical literature;
whereas all other pathogenic changes in OFD1 noted to cause Joubert
syndrome are frameshift, nonsense, or splice site mutations. This patient’s
genetic change is a missense mutation. Also unique to this case is that his
mutation was only present in about 15% of the blood cells sequenced. To
further investigate, a different cell line was analyzed; targeted analysis on
buccal cells again showed mosaicism for the same variant seen in the
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blood. The patient’s mother was tested and she was found to be negative,
suggesting this de novo mutation is pathogenic for disease, and occurred
postzygotically leading to somatic mosaicism. To our knowledge, this is
the first report of such an occurrence in X-linked Joubert syndrome.
Anticipation, Ancestry, Anxiety and Autonomy: Adoptive Mothers’
Views on Genetic Testing of Their International Adoptees
O. Michel1, P. McCarthy Veach1, B. LeRoy1, M. Ahrens2
1. University of Minnesota
2. University of Minnesota Health
Families with adopted children present unique challenges for genetics
professionals. Family history is often missing for adopted children, thus
limiting information on inherited genetic risks. Genetic testing presents as
an opportunity for adoptive families to answer family history and ancestry
questions. Little is known, however, about adopted parents’ views on
genetic testing. This study aimed to explore reasons parents of adopted
children choose or do not choose genetic testing, as well as their percep-
tions of benefits, limitations, and uses of genetic testing. Seventeen par-
ents, recruited from two international adoption support groups, completed
a survey containing questions about their history of genetic testing. Of
these, seven parents (all from different families) participated in semi-
structured, phone interviews exploring their views and opinions of genet-
ic testing of adopted children. Two parents had chosen genetic testing for
their children; five had not. Inductive analysis yielded several themes.
Reasons for testing one’s children (n=2 parents) included: current medical
need, and desire for ancestry information. Reasons for not choosing test-
ing (n=5 parents) included: no current medical need, maintaining child’s
autonomy, and unforeseen consequences of testing. Across the sample,
perceptions of benefits and uses of genetic testing results in adoptive
families included: understanding the child’s medical concerns, informing
the child’s identity, connecting with biological relatives, predicting future
disease, and helping the child/family prepare for their medical future.
Perceptions of limitations included: cost, anxiety/worry, unforeseen con-
sequences, and sacrificing the child’s autonomy. Implications of the find-
ings for genetic counseling practice (e.g., suggestions regarding content
of discussions about genetic testing with adoptive families) and recom-
mendations for future research are discussed, especially in regards to
predictive testing. This study adds to the growing literature on genetic
testing in adoptive families.
Increasing the Diagnostic Yield from an Eye Disorders Panel: What
can Clinical Genetics Professionals Do to Get the most for Their
Patient
L. Mighion1, Y. Cuperus1, S. Shankar1, S. Richards1, M. Hegde1, J.
Alexander1
1. Emory University, Department of Human Genetics
The comprehensive eye disorders panel at Emory Genetics Laboratory is an
analysis of almost all clinically relevant genes associatedwith syndromic and
non-syndromic inherited retinal and choroidal dystrophies. There is a wide
range of genetic and phenotypic heterogeneity in these disorders and molec-
ular studies may aid in establishing a clinical diagnosis. The following two
cases offer examples of how the diagnostic yield can be increased. The first
case describes an individual with retinal detachment, pigmentary retinal
changes, and a clinical suspicion of Wagner syndrome. Initial sequence
analysis was inconclusive with 3 variants of unknown significance detected
in genes unrelated to the phenotype. Subsequent deletion/duplication analy-
sis of the genes on the panel identified a deletion of exon 8 in the VCAN
gene. To our knowledge, this is the first single exon deletion described in the
VCAN gene. Previously Wagner syndrome had only been attributed to
splice variants that give rise to loss of exons 7 and/or 8. This case expands
the reported mutational spectrum of Wagner syndrome and highlights the
importance of utilizing deletion/duplication studies following a negative se-
quencing panel, even when a whole/multiple exon deletion or duplication
has not been previously described. The second case describes an individual
referred for optic atrophy. An apparently homozygous variant in the WFS1
gene was identified which had previously been reported but with insufficient
evidence to classify as pathogenic/likely pathogenic. Additional clinical in-
formation was provided by the referring physician which included specific
features seen inWolfram syndrome in the individual. As a result, given all of
the evidence, including the current case, theWFS1 variant was classified as
likely pathogenic. This case highlights the importance of providing compre-
hensive clinical information, even if it is not believed to be relevant to the
initial clinical suspicion. These cases demonstrate two ways in which addi-
tional analysis or clinical information helped increase the diagnostic yield.
Zero to Four: How many AGG Interruptions are Commonly Seen
in FMR1 Intermediate and Premutation Alleles?
S.Mundy1, E. Repass1,M.Westemeyer1, K.Merrion2, J. Saucier3, A.
Anderson2, E. Mitchen2, M. Lloyd2, B. Pettersen1
1. Natera, Inc.
2. Asuragen, Inc.
Objective: Report the number of AGG interruptions (AGGs) in FMR1
intermediate and premutation alleles in a general female carrier screening
population. Purpose: Assess the overall likelihood for a change in risk for
FMR1 allele expansion based on the number of AGGs. Methods: Retro-
spective review of 13,478 Fragile X carrier screening samples received at
a lab for analysis. FMR1 CGG repeat testing was performed using a PCR
based method. 357 samples (273 with intermediate and 84 with
premutation alleles) were sent to a second lab for reflex testing performed
via a Clinical Laboratory Improvement Amendments (CLIA)-validated
test that utilizes AmplideX® GC-rich PCR chemistry in a novel amplifi-
cation format to reveal the number and position of AGG interspersions
and deduce the comprehensive FMR1 genotype. For cases with
premutation alleles, analysis was performed to determine the change in
risk for expansion to a full mutation as compared to prior published
studies. Results: The number of AGGs in intermediate and premutation
alleles ranged from 0 to 4: 23 (6.4 %) had 0 AGGs; 106 (29.7 %) had 1
AGG; 206 (57.7%) had 2 AGGs; 10 (2.8 %) had 3 AGGs; 12 (3.4%) had
4 AGGs. Of 22 samples with 3 or 4 AGGs, only one was associated with
a premutation allele. Of all samples with premutation alleles: 73 (86.9%)
had at least 1 AGG; 80% had reduction in ris %k for expansion to a full
mutation (ranging from 1.3 to 30 %); 19 % had increase in risk for
expansion to a full mutation (ranging from 0.3 to 36%); 1% had un-
changed risk for expansion. Conclusions: Intermediate and premutation
FMR1 alleles largely had 1 or 2 AGGs. Intermediate alleles had a higher
average number of AGGs compared to premutation alleles, which may
explain their stability during transmission to offspring. 99% of cases with
a premutation allele had a change in risk for expansion to a full mutation
based on AGG results. This data underscores the importance of AGG
interruption testing for refining risk for FMR1 allele expansion.
Parental Testing for Variants of Unknown Significance: Is it worth
it?
A. Narravula1, L. Mighion1, M. Hegde1, L. Bean1
1. Emory Genetics Laboratory, Department of Human Genetics, Emory
University
Genetic testing using large gene panels has become the norm. Panels can
range from having as few as three genes to having over one hundred
Presented Abstracts from the Thirty Fourth Annual Education 1111
genes. A frequent concern is the burden of detecting variants of unknown
significance (VOUSs). Parental testing is often recommended to help
determine the clinical significance of VOUSs. This study examines the
impact of parental testing on reclassification of variants. Using data avail-
able from Emory Genetics Laboratory, we performed a pilot study to
determine how often testing parental samples allowed reclassification of
a variant. A comparison of 144 neurology panel (50 genes) cases and 144
autism panel cases from 2014 was performed. Interestingly, 14 neurology
and 53 autism cases were negative with no variant being reported. There
were 14 neurology cases with a pathogenic variant of which the variant
was diagnostic in 10 and 11 autism cases that had at least one pathogenic
variant with the variant being diagnostic in 6 cases. In cases where
VOUSs were identified, parental testing was performed in 41/116 neu-
rology cases and 21/80 autism cases. Of those with parental testing, 7/41
neurology cases and 7/80 autism cases had variants that were
recla %ssified.
Of the reclassified cases, 4/7 neurology had VOUSs that were reclassified
to likely pathogenic compared to 2/7 amongst the autism cases. There
were 4 neurology and 1 autism case in which parental testing allowed
reclassification to pathogenic after sample identity testing. In 3/7 neurol-
ogy and 5/7 autism cases, a variant was reclassified as likely benign after
parental testing. This pilot study revealed the impact of parental testing on
reclassification of variants. By looking at a larger number of cases and
other panels we will determine the utility of parental testing based on
well-defined versus non-specific phenotype; whether variants are in
genes for autosomal recessive, autosomal dominant or X-linked disor-
ders; or is gene-specific.
Rare and Novel Cystic Fibrosis Variants are Prevalent in Pan-Ethnic
Populations
D. Neitzel1, C. Perreault-Micale1, J. Davie1, T. Mullen1
1. Good Start Genetics, Inc.
Objective: To assess the types and frequency of CFTR variants in a pan-
ethnic population using next-generation sequencing (NGS). Design:
NGS-based carrier screening was used to screen for the presence of path-
ogenic CFTR variants. Materials and Methods: The CFTR coding region
and intron-exon borders were sequenced by NGS in a pan-ethic popula-
tion of 53,396 individuals referred for carrier screening from fertility
centers across the U.S. Both previously known and novel truncating
variants were considered pathogenic. Self-reported ethnicity data were
collected. Results: Out of 53,396 patients, 1,834 carriers of 136 unique
CFTR variants were identified, resulting in an overall carrier frequency of
1/29. The carrier frequency in males was higher than in females (1/23
versus 1/31), likely due to a high rate of infertile males (CAVD) in our
dataset. 1,049 patients were carriers of delF508. Of the remaining 135
unique variants, 74 were identified in only one individual each,
representing 8 ethnicity demographics, including ethnicity not provided.
Additionally, 11 of these 74 were novel truncating variants, detectable
only by sequencing. Conclusions: In pan-ethnic populations, there is a
high frequency of rare and novel pathogenic variants. Even for a well-
characterized disorder like cystic fibrosis, traditional carrier screening via
genotyping would have missed ~50 % of the variants we detected by
NGS. Cystic fibrosis screening by NGS will identify more carriers than
traditional genotyping across all ethnicities.
Next-Generation DNA Sequencing: Improving the Accuracy
of Routine Carrier Screening
D. Neitzel1, C. Perreault-Micale1, J. Davie1, N. Faulkner1
1. Good Start Genetics Inc.
Objective: To evaluate the efficacy of next-generation sequencing
(NGS) versus traditional genotyping for routine carrier screening
for guideline recommended disorders based on the frequency of car-
riers that would not have been identified by genotyping alone. De-
sign: An increasing number of physicians screen all patients, regard-
less of ethnicity, for the same disorders because it is difficult to
ascertain a patient’s ethnicity to offer appropriate ethnicity-based
carrier screening. Up to 13 Ashkenazi Jewish (AJ) tests are frequent-
ly ordered in patients who do not identify as AJ. Consequently, many
low-risk patients receive genotype-based screening with low or un-
known detection rates. In contrast, since NGS captures a larger var-
iant set, carrier status should be more accurately determined, even in
low-risk patients. Materials and Methods: Using NGS, carrier status
was evaluated for up to 13 society-recommended AJ genetic disor-
ders in fertility centers in the U.S. Cystic fibrosis was excluded from
this analysis because screening is recommended for all patients re-
gardless of ethnicity. Results: 64,584 patients from a wide range of
ethnicities had screening. 1,012 carriers (of 259 distinct variants)
were detected. In this population, 1 in 64 patients were identified as
a carrier of at least one disorder tested. 30 % of carriers would have
been missed by traditional genotyping assays. Of the 1,012 carriers,
only 16 % identified as high-risk (i.e., AJ). Of the 84 % of carriers
who did not identify as the Bhigh-risk^, 471 identified as low-risk and
378 did not provide an ethnicity. Had traditional genotyping been
used, 37 % (175) of carriers would have been missed in the low-
risk group, 35 % (131) in the group that did not provide ethnicity,
and 1.2 % (2) in the high-risk group. Conclusions: Carrier screening
with traditional genotyping misses a significant number of carriers, in
both high- and low-risk populations. NGS more thoroughly evaluates
carrier status, regardless of patient ethnicity.
Benign Variants in HEXA Account for Enzyme Positive Results
for Tay-Sachs Disease Carrier Screening in African Americans
D. Neitzel1, E. Tsung1, K. Robinson1, V. Greger1, A. Indap1
1. Good Start Genetics, Inc.
Tay-Sachs disease (OMIM 272800) is an autosomal recessive disor-
der caused by pathogenic mutations in the HEXA gene. Carrier
screening for Tay-Sachs disease is recommended for the Ashkenazi
Jewish population and certain other high-risk ethnic groups. Screen-
ing consists of HexA enzyme analysis and/or DNA analysis of the
HEXA gene. According to professional societies (including the
American College of Obstetricians and Gynecologists), enzyme
analysis should be used to screen individuals in low-risk popula-
tions, as their mutations are less likely to be included on targeted
DNA genotyping panels. Using our high-throughput Next Genera-
tion sequencing platform, it is possible to efficiently sequence the
HEXA gene and identify common founder mutations, as well as rare
and novel alleles. Here we present an in-depth comparison of DNA
sequencing and enzyme-based carrier screening of Tay-Sachs dis-
ease in 8,148 individuals of various ethnicities. Our findings show
that mean percent HexA enzyme values are lower in African Amer-
ican (AA) individuals as compared to non-AA populations.
Enzyme-based screening yields more AA carriers than would be
predicted by the incidence of Tay-Sachs in the AA population,
strongly suggesting false positive enzyme results. Next we show
that two benign variants, prevalent in AA populations, are associat-
ed with reduced enzyme activity in African Americans. Over half of
enzyme positive, DNA negative AA samples in our dataset are het-
erozygous or homozygous for at least one of these variants. These
results strongly suggest that carrier screening via enzyme analysis is
of limited utility in AA populations. Therefore carrier screening by
DNA sequencing, with a more comprehensive panel of mutations
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(versus genotyping), is expected to be the most accurate means to
determine carrier status.
Genetic Counselors’ Current Practices, Challenges and Needs
for Support with Clinical Exome and Genome Sequencing
K. Newell1, A. Cirino2, S. Ziniel3, S. Savage3
1. Boston University School of Medicine
2. Brigham and Women’s Hospital
3. Boston Children’s Hospital
Exome and whole genome sequencing (ES/WGS) have become increas-
ingly incorporated into clinical practice as useful diagnostic tools for
patients who have not had success with traditional genetic testing
methods. At many institutions, genetic counselors (GCs) play a central
role in ordering and disclosing results from genomic tests and are unique-
ly qualified to address some of the inherent challenges that have accom-
panied the rapid emergence of genomic technologies. An anonymous
online survey was conducted to investigate these challenges and elucidate
specific areas where support is needed. The survey was distributed
through the American Board of Genetic Counseling and the National
Society of Genetic Counselors. 220 GCs submitted surveys for analysis,
of whom 77 % currently utilize ES/WGS in clinical care. In general,
complexity of informed consent, results disclosure, and needs for support
are all greater for ES/WGS than for other types of genetic testing. GCs
who had been utilizing ES/WGS for less than 2.5 years were more likely
to rate all three as ‘significantly more’ complex (p<0.05). GCs reported
needing the greatest amount of support with variant interpretation and
medical management related to both primary and secondary results.
Those not yet involved with ES/WGS anticipated significantly higher
needs for support than individuals who currently use it (p<0.05), except
with regard to interpretation and medical management of primary results.
Coding of qualitative data from open-ended items revealed trends related
to unequal access to ES/WGS as a result of lack of insurance coverage,
differences in provider thresholds for ordering testing, and lack of
established eligibility criteria. Institutional support services related to as-
sessment of candidate patients, variant interpretation, and education of
non-genetics providers would improve equality of patient access to test-
ing and consistency in patient care. Ultimately, this would be beneficial
for GCs and other providers involved in ES/WGS as its scope and utili-
zation across specialties continues to increase.
The Integration of the American College of Medical Genetics
and Genomics Interpretation of Sequence Variants Guidelines
in Clinical Variant Analysis and Interpretation Processes: A Model
for Diagnostic Standardization and Classification
K. Nykamp1, Y. Kobayashi1, S. Yang1, S. Lincoln1, S. Gandomi1, M.
Anderson1, M. Powers1, S. Topper1
1. Invitae
Recently, the American College of Medical Genetics and Genomics
(ACMG) published updated guidelines for the interpretation of sequence
variants (ISV), which represent a major step towards the standardization
of evidence assessment and variant classification among diagnostic labs.
Since variant classification plays a critical role in patient counseling and
decision-making processes, as well as in treatment and management pro-
tocols, the published guidelines aim to provide genetic counselors and
physicians with consistent and high-quality clinical laboratory services.
Here we present BSherloc,^ a weighted, score-based classification system
based on the elements described in the 2013 draft ISV guidelines. It has
been refined over 2 years of use and optimized for accuracy, efficiency,
and reproducibility. Sherloc adds greater resolution to broad ISV rules
that encompass various use cases, adds dependencies between rules to
reduce redundant use of evidence, and incorporates detailed usage notes
for various evidence types. To evaluate the concordance of this classifi-
cation system with current community standards, we compared classifi-
cations of more than 800 variants to a consensus classification derived
from ClinVar submissions. Sherloc classifications were very often
(92.2 %) in the consensus majority; indeed, more so than ClinVar sub-
missions from other diagnostic labs when benchmarked equivalently
(85.7 %). Most differences between Sherloc interpretations and the con-
sensus were modest (e.g., between likely pathogenic and pathogenic or
between likely benign and benign). We selected 42 variants for which
Sherloc-based interpretations were discordant with the consensus and re-
interpreted them using a different internal analyst who was blinded to the
original interpretation. Although these variants were enriched for
Bdifficult-to-interpret^ cases, a high percentage (92.5 %) resulted in the
same classification by a new scientist, demonstrating remarkable repro-
ducibility. Our implementation of Sherloc illustrates the practical appli-
cation and evolution of ISV criteria in a highly scalable clinical molecular
lab setting.
Clinically Significant Variants Detected Via Whole Genome
Sequencing and Reported in a Large Healthy Adult Cohort: Clinical
Utility and Pre-Test Counseling Implications
D. Perry1, J. Kakishita1, A. Khouzam1, E. Ramos1, V. Raymond1, A.
Livengood1, S. Chowdhury1, T. Hambuch1
1. Illumina
Background: Since May 2012, the Illumina Clinical Services Laboratory
(ICSL) has performed clinical whole genome sequencing (cWGS) on 538
healthy adults for predisposition and carrier screening.
Methods: Individuals were evaluated as part of a cWGS test that included
1,600 genes associated with 1,221 monogenic conditions (n=443) or as
part of an expanded test that encompasses 1,691 genes associated with 1,
232 monogenic conditions (n=95). Evidence was evaluated by a team of
geneticists and genetic counselors and variants were classified according
to the American College of Medical Genetics and Genomics guidelines.
Clinical reports were issued to the ordering physician in accordance with
CLIA/CAP regulations. Results: Of the 538 adults sequenced, 189 (35%)
had variants classified as pathogenic or likely pathogenic and expected to
be clinically significant (heterozygous for a dominant condition, homo-
zygous or compound heterozygous for a recessive condition). One hun-
dred and five (20 %) had no pathogenic or likely pathogenic variants, but
had a variant in a disease-associated gene classified as a suspicious variant
of uncertain significance (VUS-S), which includes variants of uncertain
significance in which there is suggestive evidence of disease causation.
These VUS-S variants were found in a heterozygous state for a dominant
condition and thus could be clinically significant. Regarding heterozy-
gous carriers for recessive conditions, 471 (88 %) had variants classified
as pathogenic or likely pathogenic and 36 (7 %) had VUS-S variants.
Implications: Over one half of healthy individuals who underwent cWGS
for the purpose of predisposition screening were found to have clinically
significant variants with potential personal health implications. These
data provide a general outline for what a predominantly healthy adult
might expect from having a cWGS test based on the processes within
ICSL, which may be useful in providing pre-test counseling for patients
considering a cWGS test.
Germline Mosaicism Detection with Family-Centered Exome
Sequencing: More Common than Previously Recognized?
Z. Powis1, K. Farwell1, L. Shahmirzadi1, D. El-Khechen1, S. Tang1
1. Ambry Genetics
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When analyzing family histories, observing multiple similarly affected
offspring without relevant family history is generally considered a strong
indicator for autosomal and/or X-linked recessive disorders. Although
germline mosaicism (GM) has significant implications for genetic
counseling, statistics are limited and rates vary. Family-centered diagnos-
tic exome sequencing (DES) is integral to enhanced diagnostic yield and
discovering GM. Among a cohort of 510 consecutive unselected DES
cases, we analyzed the diagnostic yield and origin of detected mutations
in the first 50 families with healthy parents but at least two affected
offspring. There was no difference (p=0.86) in diagnostic yields among
the 50 cases when compared to the total cohort of remaining 460 cases
(34.0 % and 35.2 %, respectively), indicating that the observation of
multiple affected siblings is not a positive predictor for receiving a diag-
nosis. Among these 50 cases, 15 (24.0 %), were positive/likely positive
for findings in characterized genes, 2 (4.0 %) with novel genetic etiolo-
gies, 3 (6.0 %) uncertain, and 30 (60 %) negative. Among the 15 positive/
likely positive findings in characterized genes, 12 (66.7 %) are related to
autosomal or X-linked recessive inheritance patterns, respectively. As
expected, these two ratios (80.0 %) are significantly higher compared to
the remaining 460 cases (31.6 %, p< 0.001). Perhaps the most interesting
finding from this cohort was identification of autosomal dominant con-
ditions arising from GM in 3 families: p.R257H in ACTG2, p.R209H in
GNAO1, and p.E1799K in MTOR. These alterations were heterozygous
in both the proband and an affected sibling, but absent in unaffected
parents (reported biological relationships confirmed). The results of this
study indicate that GM is seen in 6 % of DES families with multiple
affected offspring and accounts for 20 % of positive finding, which is
more common than previously documented. Discovering or ruling out
GM has tremendous genetic counseling implications in regards to recur-
rence risk, family planning, and testing options.
Attitudes Toward Informed Consent Regarding Incidental Findings
Among Parents of Children Undergoing Clinical Exome Sequencing
K. Ray1, J. Cohen2, K. Maloney1, N. Ambulos1, S. Dixon1
1. University of Maryland Baltimore
2. Kennedy Krieger Institute
Many laboratories currently offer whole exome sequencing (WES) as a
diagnostic tool and its use will continue to increase as more diagnoses are
made. Discussing the potential for discovering incidental (secondary)
findings (IFs) during WES and the ability to opt out of receiving these
findings are crucial parts of the informed consent process. Much research
has focused on determining patient preferences for which IFs they would
like the option of receiving. Additionally, many studies have evaluated
provider experiences and attitudes toward informed consent and the re-
turn of IFs. The purpose of this study was to investigate parent attitudes
toward informed consent regarding IFs and determine ways in which that
process could be improved. Parents or guardians of children who
underwent WES at the Kennedy Krieger Institute were invited to partic-
ipate and 47 parents or guardians completed a survey that assessed their
experience of providing informed consent for incidental findings inWES.
All respondents recall having the informed consent discussion regarding
WES, and the majority (61.5 %) reported the discussion was very helpful
in aiding them in their decision whether or not to receive IFs. All respon-
dents (n=12) who reported receiving IFs indicated they felt prepared to
receive the results based on the informed consent discussion. Many re-
spondents expressed their appreciation for the genetic counselor answer-
ing their questions and explaining WES. Some respondents commented
on their gratitude for WES, but most of these individuals received a
diagnosis from WES; others revealed their disappointment with WES
and many of these individuals did not receive a diagnosis from WES.
This study provides initial insight into patient perspectives of informed
consent regarding incidental findings, but further study is warranted.
The Importance of Laboratory Genetic Counselor Review of BRCA
Test Orders at LabCorp
C. Riordan1, A. Tatar1, B. Rush1
1. LabCorp
Genetic testing for inherited cancer can be complex and expensive. Ge-
netic counselors play a critical role in proper test candidate identification
and test selection. Unfortunately, not every medical center has access to a
genetic counselor. For this reason, a laboratory genetic counselor can be a
valuable asset when used to screen incoming test orders. At LabCorp, a
genetic counselor reviews all BRCA test orders, clarifying comprehen-
sive orders when a known familial variant is reported and targeted test
orders when no variant information is provided.We reviewed 391 BRCA
targeted analysis test orders received between December 2013 and Feb-
ruary 2015. It was found that 153 (39%) of these orders required updating
when reviewed by a laboratory genetic counselor. While a negative fa-
milial variant result may warrant further testing by comprehensive anal-
ysis (depending on family history), a positive result would not. We found
that 62 (40%) of the orders updated from comprehensive to targeted were
positive, representing a cost savings of around $148,490 by updating to
targeted testing. In addition to financial benefit for the positive results, full
gene sequencing can lead to finding variants of uncertain significance.
More testing is not always better and could leave the patient feeling
unsure about their risk even when negative for a familial pathogenic
variant. Out of 238 BRCA samples ordered correctly, 112 (47 %) were
through a clinical genetic counselor or nurse in genetics, while 126 (53%)
had no genetic counselor involvement prior to arrival at LabCorp. There-
fore, combining the updated orders and those with no genetic counseling
before arrival, 279 of the 391 (71%) specimens in the studywould benefit
from laboratory genetic counselor review. This process could lead to
significant healthcare savings and reduce unnecessary testing for patients
who have not seen a genetic counselor, possibly reducing patient anxiety
and uncertainty.
Marfan Syndrome or Not? AnUnexpected Finding onWhole Exome
Sequencing
V. Roberts Sanders1, J. Charrow1
1. Ann & Robert H. Lurie Children’s Hospital of Chicago
Patient AQ presented to our Genetics clinic at 2 years for evaluation of
dysmorphic features, macrocephaly, developmental delay, anemia and
subdural hematomas. There were no findings suggestive of a connective
tissue disorder. Initial work-up was unrevealing. Whole exome sequenc-
ing (WES) was therefore obtained and did not identify a cause of this
patient’s phenotype. However, an incidental finding in the FBN1 gene
[c.4270 C>G (P1424A)] was identified in this patient and his mother.
This missense change has previously been reported in multiple patients
with Marfan syndrome, and the reference laboratory classified it as a
known pathogenic variant. FBN1 testing of additional family members
was pursued. AQ’s brother and maternal aunt carry the same FBN1 var-
iant. Echocardiograms and ophthalmology exams were obtained on AQ,
his brother, and his maternal aunt and were normal.
None of the family members with FBN1 mutations have any features of
Marfan syndrome.WhileAQand his brother are still young,AQ’s 14 year
old maternal aunt and 20 year old mother report no features of Marfan
syndrome. Neither maternal grandparent reports any symptoms either.
Furthermore, the P1424A change has an allele frequency of 0.0005 in
11,576 alleles from a Latino population sequenced in ExomeAggregation
Consortium, and 0.0005 in 8,588 alleles sequenced in Caucasian Amer-
icans in Natinal Heart, Lund and Blood Insitute’s GO Exome Sequencing
Project. Given the lack of symptoms in this family and the allele
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frequency in different populations, we question whether this variant really
confers disease and this family really has Marfan syndrome or will de-
velop symptoms in the future. With such ambiguity, the necessary course
is screening the family as though they have Marfan syndrome. In the
meantime we are increasing the family’s stress and potentially ordering
tests and spending additional health care dollars on screening that might
not actually be necessary. This case illustrates the complexities and man-
agement challenges ofWES and the presence of incidental findings in the
absence of previous clinical suspicion.
Diversity Within: The Complexities of Genetic Heritage in the Latin
American Population
E. Shehan1, R. Shraga1, S. Bristow1, S. Rodriguez1,M. Barrionuevo2,
S. Munne3
1. Recombine
2. IVF Florida
3. Reprogenetics
Introduction: The genetic pool is becoming increasingly homoge-
nized and historically isolated cultures are now more genetically
admixed. The Latin American population is one in which the com-
plexities of genetic heritage are often overlooked. We aimed to
understand these complexities by studying the predicted genetic
ethnicity of individuals reporting Latin American ancestry and eval-
uating founder mutations identified in these individuals. Methods:
Expanded carrier screening was performed for >1,500 subjects. Mu-
tations with a >50 % detection rate were obtained, which typically
imply a founder effect in 1 population and are thus less frequently
expected in others. Patients identifying with 1 ethnic group were
included. Carriers were identified for the founder mutations and
categorized by reported ethnicity. Genetic ancestry was predicted
by a statistical model based on 672 SNPs validated using the 1000
Genomes Project. Documented informed consent was obtained. Re-
sults: Individuals reporting Latin American ancestry were frequently
identified as carriers of founder mutations associated with other
populations. Mutations were associated with diseases such as ataxia
telangiectasia, Bardet-Biedl syndrome, and Gaucher disease. Anal-
ysis of genetic ancestry demonstrated a high degree of genetic ad-
mixture within Latin American individuals. The 3 highest contrib-
uting ancestral groups were European (0.509±0.126), Native Amer-
ican (0.234±0.185), and African (0.101±0.183). Discussion: Results
show that the Latin American population is genetically admixed,
with a significant proportion of these patients identified as carriers
for mutations associated with other ancestries. Findings highlight: 1)
the disadvantages of conducting ethnicity-based carrier screening in
populations with ethnic admixture, 2) the challenges of relying on
patient-reported ancestries, and 3) the underestimation of reproduc-
tive risk for partners if carrier status is not identified. Thus, provid-
ing panethnic carrier screening for all patients is more clinically
responsible, regardless of reported ethnicity.
Three Cases of Familial Pseudodominance in Pompe Disease: Are
Current Practices Missing Diagnostic and Treatment Opportunities?
J. Sullivan1, L. Bailey1, C. Bailey2, S. Austin1, D. Viskochil2, P.
Kishnani1
1. Duke University Medical Center
2. University of Utah
Pompe disease (glycogen storage disease type II, acid maltase deficiency)
has a broad spectrum of phenotype ranging from the classic infantile
presentation with severe hypotonia and cardiomyopathy to a late onset
form with a limb girdle muscular dystrophy and respiratory insufficiency.
The U.S. Food and Drug Adminstration approved alglucosidase alfa en-
zyme replacement therapy (ERT) for Pompe disease in 2006. Clinical
studies indicate that treatment with ERT results in improved clinical out-
comes. We present three families with multigenerational, phenotypically
variable Pompe disease. Case 1: In 2014 a proband presented with mo-
lecularly confirmed infantile Pompe disease. In 2015 her mother was
molecularly confirmed to have late onset Pompe Disease (LOPD). Test-
ing in the proband’s full siblings determined that two, ages 4 and 6 years
have LOPD. Case 2: A proband was enzymatically confirmed to have
infantile onset Pompe in 1997. In 2008 her mother was molecularly
confirmed to have LOPD. Case 3: In 1994 an adult sib-pair were enzy-
matically confirmed to have LOPD. In 2002 a first cousin twice removed
presented with infantile disease. Molecular testing confirmed a common
disease allele shared by these family members. Three additional cases of
pseudo dominance in Pompe disease have been published previously –
one parent–child pair and two grandparent-child pairs. In 2015, the Unit-
ed States Secretary of Health and Human Services added Pompe disease
as a core condition to the Recommended Uniform Screening Panel for
state newborn screening (NBS). Published data from NBS programs in
Taiwan, Austria, and the state ofMissouri, have all demonstrated a carrier
frequency of Pompe disease higher than the previous estimate of 1/100. In
a mixed U.S. based population, the carrier frequency for Pompe disease
may be as high as 1/37. Careful consideration of family history or symp-
toms may warrant diagnostic evaluation for family members instead of
targeted mutation testing.
Experience with Global Panethnic Genetic Carrier Screening
in a Diverse Preconception Patient Population in Texas
B. Swope1, T. Niemchak1, L. Dohany1, J. DaRe1, C. Holland1, J.
Tazelaar1, C. Settler1
1. Progenity, Inc.
Current professional guidelines recommend offering carrier screening
based on ethnicity, however a recently published joint commentary by
genetic professionals and obstetricians noted the limitations of this strat-
egy in an increasingly ethnically diverse population. Limited data has
been published on the results of global carrier screening panels in multi-
ethnic populations. We analyzed the results of a panethnic panel per-
formed on an ethnically diverse patient population at a large reproductive
medicine practice in Texas. Two hundred eighty-six preconception indi-
viduals underwent testing. The panel included testing for hemoglobinop-
athies, Fragile X (FX), and 20 disorders common in Ashkenazi Jewish
populations (including cystic fibrosis (CF) and spinal muscular atrophy
(SMA)). Testing included targeted mutation analysis for each condition,
as well as hexosaminidase A (HexA) enzyme analysis, partial CBC, and
hemoglobin fractionation. The majority (90 %) of the participants were
female, with a high proportion of Hispanic individuals (36 %). Positive
results were identified for 51 participants (18 %), with three individuals
positive for two conditions. The most common positive result was the
presence of an alpha-thalassemia deletion (12 patients - 6 of whom had
normal MCVs and hemoglobin fractionations). Eight individuals were
found to be carriers of Tay-Sachs disease, with the majority (75 %) iden-
tified as carriers through HexA analysis only. Thirty individuals were
found to be carriers of SMA (9), CF (9), FX (8), or a variant hemoglo-
binopathy (4). Lastly, four patients were found to be carriers of the fol-
lowing disorders: Niemann-Pick disease (2), glycogen storage disease,
and Gaucher disease. Results of this study suggest that global panels will
likely identify carriers that may be missed through traditional ethnicity-
based screening paradigms. Additionally, a dual method of carrier screen-
ing (i.e., DNA analysis in conjunction with enzyme or hemoglobin
screening) for specific disorders increases the likelihood of identifying
carriers.
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Mosaic Tetrasomy 18p: Discordant Results Between Noninvasive
Prenatal Screening and Fetal Karyotyping
B. Tucker1, D. Hennerich2, S. Toomey2, K. Montgomery3, M. Haag2,
D. Minka2, P. Hulac4, K. Liechty1, M. Schneider3, M. Zaretsky5, D.
Manchester4
1. Colorado Fetal Care Center
2. Colorado Genetics Laboratory
3. Rocky Mountain Perinatology
4. Children’s Hospital Colorado
5. Colorado Institute for Maternal and Fetal Health
Abnormal results of noninvasive prenatal screening (NIPS) require con-
firmation by chorionic villus sampling or amniocentesis. We report an
unusual cytogenetic disorder presenting as trisomy 18 by NIPS. The
follow-up genetic amniocentesis for a 36-year-old woman showed two
signals for chromosome 18 centromeric FISH probes. Because the signal
for the centromere of chromosome 18 was polymorphic and therefore
difficult to score in this patient’s sample, additional FISH targeting 18q
was performed. Two copies of 18q21 were observed by FISH. However,
the final prenatal karyotype revealed an isochromosome 18p, tetrasomy
18p, in eight of fifteen colonies. Genetic counseling included a discussion
about the likely de novo nature of the cytogenetic finding, but also noted
recurrences of tetrasomy 18p reported in the literature. The variability
associated with mosaicism was carefully reviewed as well as common
characteristics such as developmental and cognitive delays. Parental
karyotyping was offered and declined by the patient. The father was
unavailable for testing. A second-trimester ultrasound and fetal echocar-
diogram were normal. The patient elected to continue the pregnancy to
term and the baby was delivered at 39weeks’ gestation. The newborn had
good tone and good suck reflex, was breastfeeding well, and was not
dysmorphic. Karyotype in the newborn period confirmed mosaic
tetrasomy 18p: 47,XY,+i(18) (p10) [3]/46,XY [42]. Discussion: This case
illustrates the importance of fetal karyotyping in response to a positive
NIPS result. Mosaic tetrasomy 18p was identified by prenatal karyotype
analysis pursued in response to a positive NIPS for trisomy 18. This is a
rare occurrence that adds to the literature regarding low-level mosaicism
for tetrasomy 18p with an apparently normal phenotype at birth.
Analysis of Incidental Findings and Patient Preferences
Regarding Return of Results in Medical Exome Sequencing
K. Wiens1, P. McCarthy Veach2, B. LeRoy1, B. Thyagarajan1, M.
Bower3
1. University of Minnesota
2. University of Minnesota Department of Clinical Psychology
3. University of Minnesota-Fairview
As whole exome (WES) and whole genome sequencing are adopted as
clinical diagnostic tools, identifying and reporting incidental findings is
salient. The estimated chance of identifying a highly penetrant, pathogen-
ic clinically actionable incidental finding is 1–5 % in individuals seeking
WES. The purposes of this study were to elicit patient preferences regard-
ing return of incidental findings and develop efficient methods for ana-
lyzing and identifying such findings in 41 patients with unexplained
cerebellar ataxia undergoing partial medical exome sequencing. 26 pa-
tient samples were sequenced on an Illumina Hiseq 2500. Raw variants
were filtered in Illumina VariantStudio to identify high-quality, rare, and
functional variants in 3 curated lists of medically or reproductively sig-
nificant genes. All candidate variants underwent manual review with data
obtained from CLINVAR, HGMD, LOVD, and review of medical liter-
ature. Frequency of pathogenic variants from the list of 56 genes recom-
mended by the American College of Medical Genetics was 3.8 % (n=1);
frequency of carrier status for mutations in genes contained within
Natera’s Horizon Multi-Disease Carrier Screening panel was 19.2 %
(n=5). Patient preferences regarding return of incidental findings were
elicited via a consent form. Consistent with prior studies, nearly everyone
(n=40) desired medically actionable incidental findings. The Fisher’s ex-
act test revealed patients’ aged < 50 (n=15) were significantly more likely
to prefer receipt of variants of uncertain clinical significance (p=0.023)
and whole genome information (p=0.015) than those aged > 50 (n=26).
This study is among the first to evaluate preferences regarding return of
results in adults with neurologic disease. Moreover, scant published data
exist regarding return of non-medically actionable incidental findings and
variants of uncertain significance. Descriptions of the implementation of
effective strategies for identifying and analyzing reportable incidental
findings fromwhole exome sequencing in a research setting are provided.
De novo Pathogenic Variants in DDX3X are a Novel Cause
of Intellectual Disability in Females
L. Williams1, M. Cho1, K. Retterer1, M. Natowicz2, Q. Stein3, K.
Strauss4,5, K. Brigatti4, K. Kim6, K. Keating6, J. Norman7, A.
Foster-Barber8, A. Kimball9, E. Zackai10, M. Harr10, K.M. Haude11,
J. McLaughlin12, W. Chung13
1. GeneDx
2. Pathology & Laboratory Medicine and Genomic Medicine Institute
3. Sanford Children’s Specialty Clinic
4. Clinic for Special Children
5. Franklin & Marshall College
6. Ann & Robert H. Lurie Children’s Hospital Of Chicago
7. Integris Pediatric Neurology
8. University of California San Francisco Benioff Children’s Hospital
9. The Harvey Institute for Human Genetics, Greater Baltimore Medical
Center
10. Children’s Hospital of Philadelphia
11. University of Rochester Medical Center
12. Division of Medical Genetics, North Shore-LIJ
13. Departments of Pediatrics &Medicine, Columbia University Medical
Center
Developmental delay and intellectual disability (ID) are heterogeneous
disorders, and a genetic etiology is often not identifiable after standard
karyotype, Fragile X, and microarray testing. Whole exome sequencing
(WES) is an effective diagnostic tool, and it is especially powerful in
identifying de novo variants using a trio approach that compares data
from the affected proband and both parents. Through WES, we have
identified 11 females from unrelated families who have novel predicted
pathogenic heterozygous variants in DDX3X, a gene located on the X-
chromosome. Ten variants were de novo, and parental samples were
unavailable for the remaining case. DDX3X encodes a highly conserved
DEAD-box RNA helicase that plays an important role in RNA metabo-
lism; however, little is understood about human phenotypes associated
with pathogenic variants in this gene. All 11 female patients (ages 1 to
18 years) harboring pathogenic DDX3X variants have ID ranging from
mild to severe. Other common clinical features include hypotonia (10/11),
structural brain abnormalities (8/11), dysmorphic features (8/11), behav-
ioral problems (7/9), poor weight gain (7/11), abnormal sleep patterns
(4/9), and microcephaly (4/11). Six patients had missense variants while
5 had variants that introduce a premature stop codon; however, there was
no discernible difference in the nature or severity of their symptoms. Of
414 unique female probands with unexplained ID who underwent WES
at our center, 2.9 % were found to have a predicted pathogenic variant in
DDX3X. We describe a novel disorder characterized by ID and other
variable neurological abnormalities in females, thereby providing a diag-
nosis and recurrence risk information for a large number of patients for
whom a diagnosis has previously been elusive. Functional studies are
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indicated to further determine the function of DDX3X on neural
development.
Test Sequentially or Test Concurrently? An Analysis of Clinical
Approaches to Expanded Carrier Screening
S. Yarnall1, N. Paolino1, E. Shehan1, N. Kumar1, J. Batzofin2
1. Recombine
2. New York Fertility Services
Introduction: Patients are now increasingly offered carrier screening via
expanded panels of over 100 diseases. Recent statements by professional
societies provide guidance on how to approach the clinical use of such
panels, including potential benefits of concurrent versus sequential
screening for partners. Our aim was to understand approaches to expand-
ed carrier screening in our population. Methods: Our initial analysis in-
cludes 64 patients referred for screening via an expanded panel. Patients
received post-test genetic counseling; information regarding partner test-
ing status and intention was gathered during the consults. Results: Of
patients who had partners, 30% underwent carrier screening concurrently
and 70 % underwent screening sequentially. Among the patients who
underwent screening sequentially, only 16 % of this group indicated that
they would or were likely to pursue testing for the second partner, regard-
less of the first partner’s carrier status. Discussion: Our analysis indicates
the majority of couples undergoing expanded genetic carrier screening
approach testing sequentially. While this may provide a cost savings,
disadvantages include increased turnaround time and patient anxiety, par-
ticularly in the event of a positive screen during pregnancy. Results dem-
onstrated the majority (84 %) of partners who approached screening
sequentially were not planning to pursue testing for the second partner,
regardless of carrier status. This presents a disadvantage as reproductive
risks may be missed; additionally, the second partner is not able to learn
meaningful information about their genetic health. Consideration should
be given to recommendations regarding an appropriate approach to ex-
panded carrier screening in order for couples to obtain the full benefits.
IX. Pediatrics
Whole Exome Sequencing Identifies POGZMutations as a Cause
of Neurodevelopmental Disorders and Microcephaly
N. Alexander1, Y. Ye1, M. Cho1, K. Retterer1, T. Ben-Omran2, I.
Christian3, P. Wheeler3, C. Crain3, D. Zand4, V. Weinstein4, H.
Vernon5, R. McClellan5, V. Krishnamurthy6, F. Millan1, W. Chung7,
P. Vitazka1
1. GeneDx
2. Hamad Medical Corporation
3. Nemours Children’s Hospital
4. Children’s National Medical Center
5. Kennedy Krieger Institute
6. Pediatrics & Genetics, Alpharetta, GA
7. Columbia University Medical Center
De novo muta t ions p lay an impor tan t ro le in sporad ic
neurodevelopmental disorders due to the deleterious effect on reproduc-
tive fitness. For genetically heterogeneous disorders such as developmen-
tal delay and intellectual disability, whole exome sequencing (WES) can
identify a genetic etiology in up to 30 % of cases when chromosomal
array and fragile X testing are normal. WES testing using a trio approach
that compares data from the affected proband and both parents can iden-
tify de novo variants in individuals with neurodevelopmental disorders.
Of 2,415 patients referred for clinical WES for neurodevelopmental dis-
orders, seven unrelated patients were found to have heterozygous changes
that introduce premature stop codons in the POGZgene, whichwe predict
result in haploinsufficiency of the POGZ protein. Identified changes in-
clude nonsense and frameshift variants as well as one partial gene dele-
tion. Six patients have de novo changes while the inheritance of the
seventh patient could not be determined because parental samples were
not available. All seven patients are developmentally delayed, and six
patients whose cognitive status was known have intellectual disabilities.
Four patients are microcephalic, with an additional patient having relative
microcephaly. Additional features present in the majority of reported
individuals include hypotonia, facial dysmorphism, and hands with broad
and/or adducted thumbs and syndactyly. The POGZ gene is involved in
normal kinetochore assembly and mitotic sister chromatid cohesion and
mitotic chromosome segregation. The role of POGZ in mitosis suggests a
possible role in regulating neuronal proliferation and could explain why
patients withPOGZmutations are microcephalic and dysmorphic, includ-
ing anomalies with craniofacial and limb development. WES is an effec-
tive diagnostic tool used to identify mutations among the large number of
genes associated with neurodevelopmental disorders. Providing a molec-
ular genetic diagnosis is important for accurate assessment of prognosis,
risk of recurrence, and effective treatment options.
Investigation of Speech and Language Dsorders in Patients
with 1p36 Deletion Syndrome
C. Bac1, J. Marshall1, A. Brazil1, A. Kummer1, R. Hopkin1
1. Cincinnati Children’s Hospital Medical Center
Background: 1p36 deletion syndrome is a chromosomal terminal deletion
syndrome, with an incidence ranging from 1/5,000–1/10,000. Speech
impairment is considered to be almost universal among individuals with
1p36 deletion syndrome; however, there are no previous studies that
clinically characterize the specific speech-language patterns and abilities
within this population. The purpose of this study was to assess the com-
munication abilities, as well as to describe the types of speech and lan-
guage problems identified within this population. Methods: Formal
speech-language evaluations were performed by certified speech-
language pathologists on twenty-eight individuals (aged 1–17) with
1p36 deletion syndrome. Evaluations focused on assessment of the fol-
lowing domains: verbal ability, expressive language, and receptive lan-
guage. Results: 54 % of participants (n=15) were verbal; specific verbal
ability ranged from mildly to severely impaired. None of the participants
were found to have age appropriate receptive or expressive language. 14
participants (50 %) showed signs characteristic of apraxia of speech. Of
significance, only 5 of these individuals reported a previous clinical di-
agnosis of apraxia. Conclusions: Over half of our study population dem-
onstrated verbal communication abilities, which directly contrasts with
previous findings of absent expressive language in the majority of people
with 1p36 deletion syndrome. In addition, our results illustrate a high
prevalence of apraxia characteristics in the speech of individuals with
1p36 deletion syndrome. This information has the potential to impact
the type of treatment recommended for these individuals as well as the
counseling provided to families at the time of diagnosis. Further investi-
gation into the specific speech and language skills of individuals with this
deletion syndrome is warranted with a larger patient population.
Retrospective Study of Obesity in Children with Down Syndrome
J. Basil1, S. Santoro3,4, L. Martin2,5, K. Wusik Healy2,5, H. Saal2,5
1. University of Cincinnati
2. Cincinnati Children’s Hospital Medical Center
3. Nationwide Children’s Hospital
4. The Ohio State University
5. University of Cincinnati, College of Medicine
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Background: Down syndrome is the most common live-born chromo-
some aneuploidy condition, and many features associated with this syn-
drome increase the risk for obesity. Few studies have conducted an in-
depth review of children with Down syndrome with regard to obesity
prevalence and health risk factors associated with obesity. Objectives:
To characterize the obesity burden in children with Down syndrome by
developing a trajectory of obesity throughout childhood and comparing
the prevalence of obesity in our study population with the general pedi-
atric population. We hypothesized that children with Down syndrome
would have a higher prevalence of obesity, and those who are obese
would have a higher co-occurrence of obstructive sleep apnea (OSA).
Methods: This was a retrospective chart review that included children
ages of 2 through 18 who have a diagnosis of Down syndrome. All
children had been seen at Cincinnati Children’s Hospital Medical Center
with at least three height and weight measurements. The rate of obesity
was compared to a local control cohort using contingency tables. Change
in obesity rate through time was determined with mixed models. Impact
of obesity on OSA risk was determined with contingency tables. Results:
Of the 303 individuals evaluated, 47.8 % were obese (BMI>=95th per-
centile). This was significantly higher than the general pediatric popula-
tion, of whom 12.1 % were obese (p<0.0001). BMI z-scores did not
change markedly over time, indicating that those who were obese at
young ages remained obese and those who were not obese at young ages
remained non-obese. A majority of children with Down syndrome also
had OSA, however, OSA risk was increased in obese children (RR=2.5,
p=0.0005). Conclusions: Our data indicate that children with Down syn-
drome are at a substantial risk for obesity and OSA. These findings
support the need for more aggressive weight management in early child-
hood and throughout the lifespan. Further studies of metabolism and
growth are needed to determine the caloric requirements for children with
Down syndrome.
The Path to Inclusion: Parent Perspectives on the Transition of Their
Children with Down Syndrome into an Inclusion Classroom
E. Bryant1, T. Toler2, A. Lombardo3, J. Heffernan4, E. Cross1, J.
Rosenfield5
1. Brandeis University
2. Washington University School of Medicine in St. Louis
3. Boston Children’s Hospital
4. Understanding Our Differences
5. South Shore Hospital
Many studies have been done on the benefits of inclusion for children
with Down syndrome and their typically functioning classmates. The
purpose of this study is to gain a greater understanding of the parent
experience as their child transitions from Early Intervention or special
education classes into an inclusion classroom. An online, anonymous
survey was hosted byQualtrics and distributed through theMassachusetts
General Hospital and Boston Children’s Hospital Down syndrome pro-
grams’ Facebook groups. The survey contained multiple choice ques-
tions, Likert scale questions, and open-responses questions. We found
that parents acted as advocates for their child in finding the people and
resources that would best help their child be successful in the inclusion
setting. Using chi square tests, we explored the relationship between birth
order and perceived helpfulness of educational staff members and found
no statistically significant differences between those who were the youn-
gest or the middle child in their family and those who were the oldest or
only child in their family. We also explored the relationship between
income level and availability of resources and support and found no
statistically significant differences between income levels. Every child
with Down syndrome is unique and therefore their experiences with in-
clusion varied accordingly. However, parents’ hopes for their child are the
same as for any other child; they want them to be successful, have
friendships, and become integral members of the school community. Ge-
netic counselors need to make themselves aware of the issues faced by
families who are raising children with Down syndrome. By understand-
ing the challenges faced by families transitioning to an inclusion class-
room, genetic counselors can align themselves with their patients and
families to provide needed support.
Autism is not Always Present in Individuals with ADNPMutations:
Expanding the Helsmoortel-van der Aa Syndrome Phenotype
G. Cowing1, M. Szybowska1, C. Li1
1. McMaster Children’s Hospital
Helsmoortel-van derAa syndrome (HVDAS) (OMIM#615873) results from
mutations in the ADNP gene and has recently been described as a cause of
intellectual disability and syndromic autism. ADNP interacts directly with
essential components of the BAF complexes, the functional eukaryotic
equivalent of the SWI/SNF complex in yeast that is involved in gene expres-
sion. BAF complexes have critical functions in multiple aspects of neural
development. Disorders caused by mutations in these complexes are some-
times referred to as SWI/SNF-related intellectual disability syndromes. To
date, there have only been ten patients reported with HVDAS which limits
the natural history and phenotypic information available. These ten patients
were ascertained through a study looking at the prevalence of ADNP muta-
tions in cohorts of patients with intellectual disability, autism spectrum dis-
order (ASD), and facial dysmorphisms. All ten patients had intellectual
disability and ASD. Other features reported in these individuals with ADNP
mutations include: short stature, obesity, congenital heart defects, feeding
difficulties, joint laxity, small hands, hypotonia, seizures, and recurrent in-
fections. Here we report on a 12-year-old male patient in whom whole
exome sequencing revealed a de novo ADNPmutation. This same mutation
was identified in two of the ten patients described by Helsmoortel et al. Our
patient has several features in common with the ten patients, including:
global developmental delay and intellectual disability, dysmorphic facial
features, obesity, joint laxity, and hypotonia. Unlike the previously described
patients, however, our patient does not have a diagnosis of ASD. Our patient
also has several features not previously reported in individuals with ADNP
mutations, including: strabismus, cryptorchidism, hidradenitis suppurativa,
systolic hypertension, and hypothyroidism. Our patient is the eleventh pa-
tient described with an ADNP mutation. This case helps expand the pheno-
type associated with ADNPmutations and suggests that autism is not always
present in these individuals.
Novel Discriminant Functions Based on Brain MRI Extra-Axial
Fluid Measurements Allows Differentiation Between Glutaric
Acidemia Type 1 and Benign Enlargement of the Subarachnoid
Spaces of Infancy
C. Faig1, S. Scrivner2, C. Kucera2, R. Gallagher3, C. Walton2, N.
Stence2
1. University of Colorado Health Sciences Center
2. Children’s Hospital Colorado
3. University of California, San Francisco
4. University of Colorado Anschutz Medical Campus
Glutaric acidemia, type 1 (GA1) can cause irreversible neurologic injury
in an encephalopathic crisis. Early diagnosis and treatment have been
shown to decrease morbidity and mortality by reducing the buildup of
toxic metabolites. Characteristic findings on brain MRI can be seen in
individuals that haven’t had a crisis, which include enlargement of the
perisylvian fissures, interhemispheric space, and spaces anterior to the
temporal lobes. These spaces may also be increased in benign enlarge-
ment of the subarachnoid spaces of infancy (BESSI). Distinguishing
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these diagnoses is critical, as failure to recognize and treat GA1 risks
severe neurologic injury. A retrospective study of MRIs was performed
for 3 groups: 10 individuals with GA1 and 30 age-matched individuals,
20 with normal brain MRIs and 10 with BESSI. Two raters measured
seven extra-axial fluid spaces of each participant. These measurements
were used to create three linear discriminant functions, whichwere able to
discriminate among the three groups with reasonable accuracy. All con-
trol participants were classified correctly in the resubstitution and cross-
validation studies. In the resubstitution analysis, 90 % of the BESSI and
80 % of GA1 groups were classified correctly; while 70 % of both the
BESSI and GA1 groups were classified correctly in the cross-validation
analysis. These results support the potential value of extra-axial fluid
space measurements when considering GA1, though the functions should
be validated in a larger cohort, as well as in low excretors and heterozy-
gotes. Better distinction between individuals with GA1 and BESSI may
help promptly identify affected individuals, while lessening unnecessary
evaluation for GA1. This information may aid in genetic counseling for
children whose genetic, enzymatic, and biochemical testing has not been
diagnostic. Identification of characteristic MRI findings in an individual
with a suspected diagnosis of GA1, while not diagnostic, may help pro-
viders and family recognize the ismportance of ongoing evaluation for an
unconfirmed, but likely diagnosis.
Education of Children with Sanfilippo Syndrome: Identification
of Needs, Challenges and Services Required for Children
with Sanfilippo Syndrome by Their Parents
L. Gotsell1, S. Harris2, M. Campion1, L. Calderwood1
1. Boston University School of Medicine
2. Brigham and Women’s Hospital
Mucopolysaccharidosis type III (Sanfilippo syndrome) is a progressive,
life-limiting, inherited metabolic disease characterized by severe behav-
ioral manifestations and medical complications. Sanfilippo syndrome is
often categorized into three stages of disease progression. The first stage
is characterized by developmental delay, after a period of seemingly nor-
mal development. The second stage begins in early childhood and in-
cludes severe behavior problems and progressive mental deterioration.
Specifically, children with Sanfilippo syndrome struggle with destructive,
impulsive, and aggressive behaviors. The third stage is defined by motor
deterioration and further neurological decline, ultimately leading to death.
The behavioral manifestations and progressive nature of Sanfilippo syn-
drome are unique, thus traditional educational models for children with
special needs may not be applicable. This study investigated the educa-
tional needs of children with Sanfilippo syndrome through parent inter-
views. Our results showed the difficulties parents of children with
Sanfilippo syndrome face when choosing a school setting, and the need
for an educational setting where the professionals have knowledge of the
disease. The trajectory for developmental regression was also noted as a
major challenge; however participants spoke of the positive impact of
traditional services like physical, occupational, and speech therapy, as
well as alternative therapies. Our results provide educators with a better
understanding of the needs and services for children with Sanfilippo
syndrome, as well as other children with behavior manifestations and
developmental regression.
Adolescent-Centered Transition Program for Adolescents and Young
Adults with Sickle Cell Disease
B. Harrison1, S. Nouraie2, Z. Segunmaru2, A. Mason2, O. Owoyemi2,
A. Rock2, N. Kalu2, P. Oneal2
1. Howard University
2. Howard University Center for Sickle Cell Disease
Purpose: Pediatric genetic counselors often witness the difficult process
families experience as their children age, and the challenges presented
when navigating a new system of health care delivery. Young adults with
sickle cell disease (SCD) are plagued with higher rates of morbidity and
mortality than their pediatric counterparts. Our newly developed Adult
Transition Program (ATP) at Howard University Center for Sickle Cell
Disease (HUCSCD) provides a unique approach to this problem, as we
are intimately familiar with the challenges new patients face when enter-
ing adult care. Methods: The ATP focuses on meeting the individual
patient’s and family’s needs by assessing knowledge, willingness to tran-
sition, self-efficacy, psychosocial and executive performance, and pre-
senting educational workshops throughout a year-long program. A case
manager and patient navigator team enlist resources to manage multiple
hospitalizations, social and psychological adjustments, and lifestyle be-
havior choices. Workshops provide education on managing healthcare
and insurance, financial impacts, and genetics and reproductive issues.
Exit interviews access changes in knowledge base, satisfaction, and will-
ingness to transition. Results: To date, we have recruited 42 participants
(48 % female) throughout the D.C. area. After year 1, analysis revealed
that 74 % had at least one hospitalization per year, 38 % did not have a
transition plan, and 42 % reported no discussion regarding adult care. In
22 followed-up participants, the following had improved from baseline to
exit: knowledge (72 % vs. 100 %); readiness (32 % vs. 54 %); and
efficacy (77 % vs. 79 %). Of note, parents’ knowledge (5 % vs. 14 %)
and readiness (5% vs. 7 %) were poorer at baseline and exit, respectively.
Conclusion: Our ATP is an effective model, providing education and
empowerment to patients, while supporting for parents as they Blet go^
of their adult children. As a result, it ensures better health outcomes by
facilitating a pathway to better healthcare management.
Online Cognitive Assessment of 15q11.2 Deletion Carriers Reveals
Domain Specific Impairments
P. Hemati1,2, Y. J.Woo1, L. Hercher2, B. Abrahams1, J. Kirschen1, R.
Nebel1, T. Wang1
1. Albert Einstein College of Medicine
2. Sarah Lawrence College
Background: The 15q11.2 deletion has been implicated in a number of
neurodevelopmental disorders, including developmental delay, schizo-
phrenia, epilepsy, dyslexia, and dyscalculia. However, carriers with no
associated phenotype have also been observed. The heterogeneity of pre-
sentation complicates genetic counseling and it can be difficult to inter-
pret findings of 15q11.2 deletion for patients and families. Finding and
categorizing a possible intermediate or associated phenotype in 15q11.2
deletion carriers would provide important insight into the neurobiology
associated with the deletion, and aid clinicians in the challenging task of
providing patients and families with a clearer understanding of the poten-
tial range of outcomes. Methods: To investigate cognitive function in
15q11.2 deletion carriers, we used an online platform called Lumosity,
which employs well-established neuropsychology tests to look at cogni-
tive functions including memory, speed, attention, flexibility, problem
solving, and logical reasoning. A cohort of 27 15q11.2 deletion carriers
participated in a series of internet-based video games designed by
Lumosity. We matched each deletion carrier with 100 controls based on
gender, age, and level of education. Controls were assumed to not carry
the 15q11.2 deletion, which has a population prevalence of 1/500. Results
of their tests were obtained from Lumosity. Results: We compared each
subject’s score to a mean score for the cohort of 100 matched controls.
Subjects were compared to controls for 10 different tasks. Although on
average deletion carriers scored lower and performed slower in all the
tasks, the results were significant for Grammatical Reasoning and Wordy
Equation tasks, with P values of 0.00187 and 0.00144 respectively. Dis-
cussion: Results suggest that individuals with 15q11.2 deletion who
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function within the norm in the general population, perform significantly
worse than the general population in tasks that involve arithmetic problem
solving and logical reasoning, providing evidence for the presence of an
intermediate phenotype.
Two Siblings with a New Form of Spondyloepimetaphyseal
Dysplasia: No Closer to a Diagnosis After Negative Whole Exome
Sequencing
K. Langley1, S. Schrier Vergano
1. Children’s Hospital of The King’s Daughters
2. Division of Medical Genetics, Children’s Hospital of The King’s
Daughters
Spondyloepimetaphyseal dysplasias (SEMD) are a heterogeneous group
of disorders characterized by radiographic abnormalities of the spine,
epiphyses and metaphyses of the long bones. There are currently 13
described OMIM types with 7 known genes. Here we present siblings
with an unknown type of SEMD for whom whole exome sequencing
(WES) has been uninformative. Proband 1 is a term male African Amer-
ican born after a pregnancy complicated by polyhydramnios and poor
fetal growth. Prenatal U/S demonstrated spinal curvature, rhizomelia,
and a small bell-shaped thorax. Amniocentesis revealed a normal 46,
XY karyotype. Skeletal surveys performed both at 2 days and at 8 months
of age showed a hypoplastic maxilla, increased mandibular angle,
hypertelorism, thoracolumbar kyphosis with wedged and beaked L1,
and flattened acetabular angles with a champagne-glass configuration of
the bony pelvis. The metaphyses were broad and smooth with small
epiphyses. All metacarpal and metatarsal bones and phalanges were short
and thick. Expert review of the films confirmed SEMD, unclassified type.
Labs revealed normal urine oligosaccharides and glycan screening, a
single nucleotide polymorphism (SNP) microarray with multiple
inherited copy number variants (CNV) of unknown significance and nor-
mal blood FGFR3 and TRPV4 sequencing. Proband 2 is the female sib-
ling to proband 1, born at 36-2/7 weeks gestation. The pregnancy was
complicated by poor fetal growth and shortened long bones. Skeletal
surveys performed after birth showed dolichocephaly, multiple vertebral
bodies with beaking and other similar findings to her brother. A SNP
microarray revealed the previously detected inherited CNVs of unknown
significance. WES was sent and found no clinically relevant changes. As
the children carry multiple inherited CNVs; these are unlikely to contrib-
ute to the phenotype. We hypothesize there is a mutation in an unidenti-
fied gene, either inherited autosomal recessively or a germline mutation,
responsible for the children’s phenotype.
Carey-Fineman-Ziter Syndrome can be Caused by Mutations
in TUBB3
E. Leo1, A. Gunter1, O. Abdul-Rahman1
1. University of Mississippi Medical Center
Carey-Fineman-Ziter Syndrome (CFZS; OMIM# 254940) is a disorder
characterized by a congenital, non-progressive myopathy combined with
Moebius Sequence, Pierre-Robin sequence, and growth delay. The first
case was described by Carey et al. in 1982 in a brother and sister with
these features. Since that time twelve cases of suspected or diagnosed
CFZS have been reported. To date, no genetic etiology has been identi-
fied. We report a case of CFZ syndrome in a 5 year old who was found to
have a likely causative mutation upon whole exome sequencing (WES).
At birth (36 weeks gestation), patient was noted to have micrognathia
with cleft palate, frontal bossing with sunken eyes and cortical thumbs.
Newborn complications included respiratory distress and stridor second-
ary to true vocal cord paralysis. He also had facial nerve palsy and
subsequent feeding difficulties, which necessitated gastrostomy tube
placement. Initial diagnoses were Moebius and Pierre-Robin sequences,
although his symptoms went beyond theMoebius-Robin spectrum. Gross
motor delays in the first year prompted a diagnosis of hypotonia. EMG
and muscle biopsy results suggested congenital, non-progressive neuro-
genic myopathy. His features in conjunction with his myopathy were felt
to be consistent with Carey-Fineman-Ziter Syndrome. WES identified a
de novomissense mutation in exon 4 of TUBB3, mutations in which have
previously been described as causative for congenital fibrosis of the
extraocular muscles type 3 (CFEOM3). TUBB3 plays a major role in
axonal migration and microtubule stability, which could explain the fea-
tures of Moebius and Pierre-Robin sequences as well as the myopathy in
Carey-Fineman-Ziter Syndrome. Based on these findings, we suggest that
Carey-Fineman-Ziter syndrome is allelic to CFEOM3 and feel that addi-
tional testing of known CFZS patients for TUBB3mutations is warranted.
Additionally, for at least a subset of CFZS patients, the inheritance pattern
may actually be a new dominant disorder as opposed to an autosomal
recessive condition.
Parents’ Information-Seeking Journeys Related to Their Child’s
Rare Disorder: A Qualitative Study
S. Lozinsky1, S. Morrow1, J. Palumbos1
1. University of Utah
Background: Previous research demonstrates that parents of childrenwith
chronic health conditions are dissatisfied with the quality and quantity of
information received from healthcare providers (HCPs), as well as the
manner of delivery. However, the majority of parental health information-
seeking studies center on relatively common chronic childhood condi-
tions, such as cancer, kidney disease, and congenital heart defects. There-
fore, parents of children with rare disorders face greater challenges ac-
quiring information related to their child’s disorder because of the limited
knowledge about rare conditions. The purpose of this study is to explore
parents’ journey in seeking information related to their child’s rare disor-
der, and document their recommendations to HCPs and similar parents.
Methods: We use a qualitative methodology utilizing data from inter-
views and focus groups, analyzed in a thematic framework. Here, partic-
ipants consist of parents or primary caregivers of an individual with a rare
genetic disorder. Results: Parents face difficulty gathering information
from HCPs and the healthcare system, motivating them to seek informa-
tion on their own. This process often forces parents to become experts of
their child’s condition, as well as educators of their child’s HCPs. Parents
recommend that HCPs provide more resources when first disclosing their
child’s condition, and help disseminate the knowledge parents accumu-
late during their information-seeking journey. Our participants advise
rare-disorder parents to become informed, share their knowledge with
HCPs, and interact with other affected families. Conclusion: A parent’s
information-seeking process goes beyond just wanting more information
from HCPs: parents want to be incorporated into the process of creating
and disseminating information. HCPs can learn from thewealth of knowl-
edge that parents accumulate on their journey, partnering with them to
share this information and improve their healthcare experience.
Exome Sequencing Identifies a Rare Case of Birk-Barel Syndrome
Caused by a Mutation in the Paternally Imprinted KCNK9 Gene
A. Nesbitt1, D. Elizabeth1,W. Alisha1, Q. Guan1, E. Dechene1, Z. Yu1,
K. Pechter1, M. Thiess1, K. McDonald Gibson1, N. Spinner1,2, M.
Deardorff1,2, A. Santani1,2
1. Children’s Hospital of Philadelphia
2. University of Pennsylvania
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Introduction: Birk-Barel mental retardation dysmorphism syndrome is
characterized by moderate to severe mental retardation, hypotonia, cleft
palate, micrognathia, dysphagia and reduced facial movement. Dysmor-
phic features include a narrow, elongated face and flared, bushy eye-
brows. The syndrome is caused by a pathogenic variant in the KCNK9
gene, located at 8q24.3. The gene falls within an imprinted region
resulting in expression of the maternal allele and silencing of the paternal
allele. Case Report: We report on a male evaluated by genetics in the
neonatal period due to cleft palate, micrognathia, hypotonia, leg length
discrepancy and phymosis. A diagnosis of Prader-Willi syndrome (PWS)
was considered, however both a genomewide single nucleotide polymor-
phism (SNP) array and methylation analysis of the PWS critical region
were normal. The proband was evaluated in genetics clinic for a follow-
up appointment at 7 months of age. A hypotonic face with a thin upper
lip, reverse cupids bow of the lower lip, thick gums, and retrognathia was
noted. Exome sequencing of the proband and both parents was pursued
through our laboratory. We identified a de novo pathogenic variant within
KCNK9 that had been previously described in the first and only case
report on Birk-Barel syndrome. Proximity with an inherited polymor-
phism allowed us to determine phase by examining the next generation
sequencing reads from the proband and each parent. The de novo patho-
genic variant was in cis with a polymorphism inherited from the mother,
thus proving a diagnosis of Birk-Barel syndrome. The diagnosis led to the
discovery of other affected families via social media, as well as informa-
tion regarding potential drug therapies. Discussion: Birk-Barel syndrome
is a rare genetic form of intellectual disability due to maternally inherited
pathogenic variants in the KCNK9 gene. Exome sequencing led to a
diagnosis of Birk-Barel syndrome, which affected medical management
and recurrence risk counseling for the proband and his family.
CHOPS Syndrome: A Novel Genetic Diagnosis Characterized
by Cognitive Impairment and Coarse Facial Features, Heart Defects,
Obesity, Pulmonary Involvement, Short Stature and Skeletal
Dysplasia
S. Noon1, K. Izumi2, A. Edmondson1, M. Kaur1, E. Zackai1, Z.
Zhang1, K. Shirahige2, I. Krantz1
1. The Children’s Hospital of Philadelphia
2. Research Center for Epigenetic Disease, The University of Toronto
Three unrelated probands have been followed in the Center for Cornelia
de Lange syndrome and Related Diagnoses at The Children’s Hospital of
Philadelphia (CHOP) for a combined 12-year period who were all initial-
ly referred due to a suspected diagnosis of Cornelia de Lange syndrome
(CdLS). All three probands had features overlapping those seen in CdLS
including developmental and speech delays, intellectual disability, and
short stature with small hands and feet. However, all three probands
had several distinct features not associated with CdLS including obesity,
vertebral anomalies, bracydactyly and respiratory findings such as
laryngomalacia, tracheostomy and chronic lung disease making a diag-
nosis of CdLS unlikely. Additionally, though they had dysmorphic fea-
tures including synophrys and arched eyebrows (which is seen in CdLS),
they had distinct coarse facies with a round face which is not typically
observed in CdLS. Extensive testing throughout the course of their care
was negative including screening by single nucleotide polymorphisms
(SNP) array, multi-gene panel analyses, and biochemical disorder screen-
ing including mucopolysaccharadisoses. The underlying genetic etiology
remained unknown until exome sequencing through research efforts at
CHOP identified a de novo missense mutation in the AFF4 gene in all
three probands.AFF4 plays an important role in regulating transcriptional
elongation which is a critical mechanism by which gene expression is
regulated during development. Somatic mutations in genes that control
transcriptional elongation have been previously described in cancers but
to our knowledge this is the first human developmental disorder caused
by a germline mutation. Developmental diagnoses caused by disruption
of normal transcriptional processes are collectively termed
Btranscriptomopathies^. This new diagnosis has been named CHOPS
syndrome (C for Cognitive impairment and Coarse facies, H for Heart
defects, O for Obesity, P for Pulmonary involvement and S for Short
stature and Skeletal dysplasia). The clinical features and natural history
of CHOPS syndrome will be presented.
Investigation into Inherited Metabolic Disease Clinic Practices
for Follow Up of Positive Very Long Chain acyl-CoADehydrogenase
Deficiency Newborn Screen Results
I. Novikova1, G. Bentz-Pino2
1. University of Colorado Anschutz Medical Campus
2. Mayo Clinic
Background: Very long chain acyl-CoA dehydrogenase deficiency
(VLCADD) is a fatty acid oxidation disorder included on every state
newborn screen (NBS). Age of onset and severity are variable and pen-
etrance is incomplete. Symptoms include hypoglycemia, lethargy, muscle
weakness, liver abnormalities, and life-threatening heart problems. Trig-
gers include periods of fasting, illness, and exercise. Diagnosis relies on
documenting a substantial reduction in VLCAD enzyme activity or pres-
ence of two pathogenic mutations in the ACADVL gene. In some cases,
biochemical and genetic results make it difficult to distinguish affected
from unaffected individuals, impacting management and genetic counsel-
ing for these families. The purpose of this study was to ascertain how
metabolic physicians diagnose and follow children with an unclear
VLCADD diagnosis. Methods: Study subjects were recruited through
Metab-l listserv via an email which contained a description of the study
and a link to an anonymous survey. Statistical analyses were performed to
evaluate differences in responses based on geographic location and num-
ber of years of newborn screen follow-up experience. Results: A total of
19 individuals participated. There was no consistent follow-up protocol
among metabolic physicians for a child positive for VLCADD on new-
born screen. No differences in responses were observed based on geo-
graphical area of practice (U.S. versus non-U.S.) or provider experience.
More than half of the respondents indicated that they perform literature
review for updates in classification of reported variants of uncertain sig-
nificance. Discussion: This exploratory study found that variability exists
in metabolic physicians’ clinical approach to a newborn with an unclear
diagnosis of VLCADD. The reasons for this variability are unknown. It is
important for genetic counselors to be familiar with the variability in
VLCADD presentation and medical management approach in order to
help families understand and cope with the uncertainty of the diagnosis.
TheMyelin Disorders Bioregistry Project: A Bioregistry for Patients
with Known and Unsolved Genetic Disorders of the White Matter
A. Pizzino1, G. Helman1, R. Taft2, C. Simons3, L. Caldovic1, N.
Ulrick1, J. Devaney1, S. Hofherr1, J. Schmidt4, A. Vanderver1
1. Children’s National Health System
2. Illumina, Inc.
3. University of Queensland
4. Westside Genetic Counseling
Introduction: Leukodystrophies are a heterogeneous group of heritable
disorders characterized by abnormal signal of the white matter on brain
magnetic resonance imaging (MRI). Common clinical symptoms include
delayed milestones, spasticity, dystonia, and ocular movement abnormal-
ities. Pattern recognition on MRI can aid in reaching a diagnosis; how-
ever, historically nearly 50 % of cases remain unsolved. We ascertained
the current rate of molecularly confirmed leukodystrophies within a
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research cohort. Purpose: The Myelin Disorders Bioregistry Project (-
MDBP) is a bioregistry that aims to develop diagnostic and therapeutic
approaches for leukodystrophies and provide support opportunities for
families living with these rare conditions. Methods: Families and/or phy-
sicians reach out to the MDBP team for inclusion. Medical records and
blood samples are collected. Patients with known leukodystrophies are
included for future studies on therapeutics of the disorder and patients
with an unknown genetic diagnosis may undergo next generation se-
quencing (NGS) technologies to identify known and novel conditions.
Results: The MDBP has enrolled 569 participants. Participants without a
complete file were excluded from analysis (n=104) for a total of 465
active cases. 150 families were unsolved from this group (32%). Of those
150, 22 % (n=34) underwent NGS but no known or likely pathogenic
variants were identified. New disease entities have been described and
known disorders have been clinically expanded. Four family conferences
have allowed families to connect and further characterize these disorders.
One clinical drug trial is currently under review. A diagnosis was
achieved or known in 76 % of cases over 10 years of recruitment. Con-
clusions: TheMDBP hosts a group of genetically diverse leukodystrophy
patients. MRI pattern recognition and NGS technologies may provide an
effective methodology for diagnosis in the leukodystrophies, with a pre-
dicted decrease of unresolved cases to 20 %. A specific diagnosis may
decrease the disease burden of an unsolved leukodystrophy by permitting
targeted disease management and support.
Pilot Study of Attention Deficit Hyperactivity Disorder-Related
Behaviors in a Pediatric Ehlers-Danlos Syndrome-Hypermobility
Type Population
C. Reinert1,2, J. Johnson2, X. Zhang2, J. Epstein2, D. Neilson2
1. University of Cincinnati
2. Cincinnati Children’s Hospital Medical Center
Introduction: Clinical observation in the Cincinnati Children’s Hospital
Medical Center (CCHMC) Connective Tissue Clinic (CTC) as well as
recently published research suggests a link between joint hypermobility
and attention deficit hyperactivity disorder (ADHD). However, existing
studies are few in number and of limited clinical utility. The primary goal
of this pilot study was to examine the relationship between Ehlers-Danlos
syndrome-Hypermobility type (EDS-HT) and attention-related behaviors
in order to assess whether further studies might be warranted. Methods:
The parents of 12 children with EDS-HT seen in the CCHMC CTC
(cases) and 7 non-hypermobile children (controls) seen in a local pediatric
office completed the Child Behavior Checklist (CBCL) to rate the partic-
ipants on a variety of behaviors. The CBCL contains multiple scales, of
which we examined sixteen. Comparisons of t-scores for each CBCL
scale were performed using Wilcoxon rank-sum test. T-scores were also
dichotomized and proportions of borderline/clinical range scores (t-score
>= 65) were compared between cases and controls using Fisher’s exact
test. Results: Compared with controls, cases showed significantly higher
t-scores on the Sluggish Cognitive Tempo (SCT) scale (p=0.006). Scores
on the SCTscale correlated highly with scores on the Attention Problems
syndrome scale (R=0.83) and ADHD Problems DSM-oriented scale
(R=0.70). When scores were dichotomized, the two attention-related
CBCL scales were among the scales that showed the largest difference
in proportion of cases with t-scores >= 65 (ADHD Problems DSM-
oriented scale, p=0.147).
A Patient with PTEN-Associated Macrocephaly and Autism
Presenting with Thyroid Follicular Adenomas (Cowden Syndrome)
V. Roberts1, J. Charrow1
1. Ann & Robert H. Lurie Children’s Hospital of Chicago
Patient was evaluated by a pediatric neurologist at 15 years of age fol-
lowing a single seizure in presence of an afebrile illness. She had a history
of macrocephaly with an arachnoid cyst and pervasive developmental
disorder diagnosed in the first few years of life. Given her history, diag-
nostic studies were obtained and included urine organic acid analysis,
plasma lactate, Fragile X testing and array comparative genomic hybrid-
ization (aCGH), all of which were normal. Plasma amino acids were also
obtained, and revealed elevated plasma free-homocystine, undetectable
cystathionine, and normal methionine. She was therefore referred to Ge-
netics for evaluation of elevated homocystine. She subsequently had an
extensive evaluation for persistent hyperhomocystinemia which was
unrevealing.
At 19 years of age, she developed hyperthyroidism and underwent thy-
roidectomy. Thyroid tissue pathology revealed multiple follicular adeno-
mas, suggestive of Cowden syndrome. PTEN sequencing was performed
and revealed a previously reported pathogenic mutation (c.407 G>A;
C136Y). This finding also explains her history of macrocephaly and
pervasive developmental disorder. Parents were tested and the mutation
was not identified in either parent. Current recommendations call for
PTEN testing in the presence of macrocephaly and autism, even in the
absence of other features. This patient presented in her first years of life
with autism spectrum disorder and macrocephaly. She was born before
macrocephaly and autism were known to be associated with PTEN mu-
tations, and she was only diagnosed with a PTENmutation after findings
of follicular adenomas on resected thyroid tissue. This case highlights the
increased risk of cancer in patients with PTEN mutations who originally
present with only macrocephaly and autism spectrum disorder, and con-
firms the need for cancer screening in those patients, even while still
teenagers.
A Model for a Multidisciplinary Epilepsy Genetics Program
B. Rosen-Sheidley1, L. Smith1, H. Olson1, A. Poduri1
1. Boston Children’s Hospital
It is estimated that 3 million Americans and 65 million people worldwide
live with epilepsy, a condition characterized by recurrent unprovoked
seizures that leads to significant morbidity and mortality. Epilepsy may
be caused by a variety of factors, and increasingly genetic factors have
been recognized as a major contributor. Since the first epilepsy gene was
identified in 1994, there have been dozens of novel epilepsy gene discov-
eries, particularly among patients with early onset, intractable epilepsy
accompanied by neurodevelopmental disability. There are already several
examples of treatment recommendations that can be made based on mo-
lecular diagnoses, and small-scale precision-treatment trials are underway
The Epilepsy Genetics Program (EGP) at Boston Children’s Hospital,
founded in 2011, is the first multidisciplinary program that provides clin-
ical consultation to families of children with known or suspected genetic
epilepsy syndromes, as well as conducting translational research to ad-
vance genetic knowledge and treatment outcomes. The Program is staffed
by 2 pediatric epileptologists and 2 licensed genetic counselors as well as
several laboratory researchers. Our weekly clinical service is devoted to
addressing diagnostic, genetic counseling and treatment related issues.
Patients with known molecular diagnoses have the option of participating
in gene-specific protocols such as the PDH19-Related Epilepsy Patient
Registry. For patients in whom currently available clinical testing yields
no diagnosis, the Program offers enrollment into research protocols that
incorporate expert review of variant pathogenicity, such as the Epilepsy
Genetics Initiative. Finally, the EGP’s laboratory facilities and collabora-
tions enable functional assessment of epilepsy gene variants using animal
models and pluripotent stem cell protocols to assess both variant patho-
genicity and drug response. Ultimately the findings from these ap-
proaches will lead to additional precision-treatment clinical trials for pa-
tients with epilepsy.
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Genotype-Phenotype Correlation for NF1A Gene as Part
of Microdeletion 1p32.1p31.3 Syndrome
L. Schultz1, C. Li1
1. McMaster Children’s Hospital
The NFI family of genes encodes transcription and replication proteins in
adenovirus and eukaryotic cells in vitro. In vivo studies on homozygous
Nfia −/− and heterozygous Nfia +/− mice show that a lack of gene prod-
uct is associated with hydrocephalus, agenesis of the corpus callosum and
urinary tract defects. The 1p32p31 microdeletion syndrome in humans
(OMIM #613735), which encompass the NFIA gene (OMIM 600727),
has been associated with similar central nervous system malformations as
well as macrocephaly, developmental delay and dysmorphic features, in
conjunction with urinary tract abnormalities. To date, only seven patients
with 1p32p31 microdeletion syndrome, along with two patients with
translocation-mediated disruption of the NF1A gene, have been reported.
We report a case of a de novo 1.936Mb deletion of chromosome
1p32.1p31.3 which includes the NFIA gene and two other genes
TM2D1 and INADL. The patient is a 9 year-old boy who, to date, does
not have developmental delay despite central nervous system malforma-
tion in the form of dysgenesis of the corpus callosum and
ventriculomegaly. He is also non-dysmorphic and does not have urinary
tract malformations. Furthermore, unlike the previously described pa-
tients he has the unique features of hyperopia, esotropia and amblyopia
in the left eye. While it is not clear whether his ocular findings are directly
associated with the microdeletion per se, the absence of developmental
delay, dysmorphic features and urinary tract malformation argue that
haplo-insufficiency of the NF1A gene is necessary, but not sufficient, in
itself, to cause cognitive impairment, craniofacial dysmorphism and uri-
nary tract defects. Other modifier gene(s) and environmental factors may
also play a role in phenotypic outcome.
Review of 33 Cases of Clitoromegaly: Causes and Outcomes
M. Setzer1, M. Ferguson2, A. Kimball2, S. Helou2, M. Pane2, H.
Birenbaum2, A. Kline2
1. Johns Hopkins/ National Human Genome Research Institute, National
Institutes of Health
2. Greater Baltimore Medical Center
Newborns presenting with ambiguous genitalia can lead to counseling
sessions that often include uncertainty about the prognosis of the child.
We conducted a retrospective chart review of newborn patients seen at
Greater Baltimore Medical Center presenting with enlarged clitoris over
the past 25 years. There were a total of 33 females with clitoromegaly. For
members of our cohort who had hormonal studies, 24 % had elevated
testosterone and 18 % elevated 17-OH-progesterone. In addition, 9 % of
mothers had self-reported a larger than average clitoral size, and 6 % of
sisters and/or aunts, for 15 % with a maternal family history. Notably,
12 % of the newborns were the result of an in vitro fertilization (IVF)
pregnancy and 24 % were exposed to progesterone, both of which are
elevated over population rates. All patients had normal XX chromo-
somes. There was variability in outcomes and identified etiologies. Twen-
ty six (79 %) had a spontaneous resolution of the enlarged clitoris and
seven (21 %) had continued growth. Three (10 %) were found to have a
known genetic condition – two had 21-hydroxylase deficiency (CAH)
and one had Beckwith-Weidemann syndrome. An additional four were
identified as having an unknown genetic disorder. Additionally, five
(13 %) of the patients had developmental delay. While endocrine disor-
ders such as CAH are reported in the literature as the most frequent cause
of enlarged clitoris, it was the etiology for only two (6 %) members of our
cohort. These data illustrate that there are multiple etiologies and that
clitoromegaly may resolve over time. Our findings can be used to shape
medical management and counseling of families with newborn presenting
with clitoromegaly. For parents of newborns our data introduce more
ambiguity into early diagnoses but also provide more hope for resolution
without apparent consequence. Future research may explore larger co-
horts and longer-term outcomes of newborns with this malformation and
the potential relationship with IVF pregnancies.
Twenty-Year Follow-Up of Newborn Screening for Patients
with Muscular Dystrophy
A. L. Smith1, J. Chung1, S. C. Hughes1, G. Niizawa1, H. Z. Abdel-
Hamid2, E. W. Naylor3, T. Hughes4, P. R. Clemens1,5
1. Department of Neurology, University of Pittsburgh
2. Department of Pediatrics, University of Pittsburgh
3. Medical University of South Carolina
4. Department of Internal Medicine, School of Medicine, Wake Forest
University
5. Neurology Service, Department of Veterans Affairs Medical Center
Introduction: Consideration of including muscular dystrophy in newborn
screening (NBS) panels is highly relevant to the families affected by
muscular dystrophy and their physicians. A unique population of young
men entering adulthood who received a diagnosis of Duchenne muscular
dystrophy (DMD) or Becker muscular dystrophy (BMD) during a pilot
NBS program in Pittsburgh, Pennsylvania from 1987 to 1995 provides an
exceptional opportunity to obtain insight into the patient and family ex-
perience with NBS for these disorders and resulting attitudes towards
NBS. Methods: To assess these experiences with and attitudes towards
NBS,we surveyed families with sons affected byDMDor BMD and born
during the pilot NBS program, stratifying into 2 groups: those identified
by NBS (sons n=8; parents: n=10) and those identified by the traditional
diagnostic process that generally occurs after symptom onset (sons: n=7;
parents: n=15). Results: All parents in the NBS cohort and 14 of 15
(93.3 %) parents in the non-NBS cohort supported NBS for DMD and
BMD. All NBS and non-NBS patients supported NBS for DMD and
BMD. The non-NBS parent cohort felt that NBS would cause increased
anxiety; however, this was not a concern in the NBS parent cohort. Dis-
cussion: There was strong support for NBS for DMD and BMD in both
groups of patients and parents regardless of whether diagnosis was by
NBS or after symptom onset. Parents who received the diagnosis of DMD
or BMD for their son by NBS indicated a preference for this means of
early diagnosis even in the absence of available pre-symptomatic
treatment.
Very Small Familial Microdeletion of 15q11.2 Results in an Atypical
Prader-Willi Syndrome Phenotype
J. Stone1, J. Kass2, L. Melchiorre Jr.3, R. Schnur2
1. Cooper University Healthcare
2. Cooper Medical School of Rowan University
3. Our Lady of Lourdes Medical Center
We present a family with atypical Prader Willi Syndrome (PWS) caused
by an unusually small 106 Kb deletion of 15q11.2. Initial testing found
the typical abnormal PWS methylation pattern in the absence of a detect-
able deletion by FISH. Subsequent microarray verified a deletion that
includes only a portion of the 3’ end of the SNRPN gene and the 5’ end
of the snoRNAgene cluster, proximal to SNORD116. Our family includes
at least two affected full siblings, one male, one female, ages 15 and 13,
respectively. They meet clinical criteria for PWS, but their phenotype is
mild and some facial and neurologic features are unique to the sib pair.
Only the brother had early feeding issues with relatively late onset of mild
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hyperphagia. The sister never had early feeding problems, but had poor
weight gain in early childhood. Now, weights are normal for age, but
increased for height, with hyperphagia relatively well-controlled. Both
have short stature and hypogonadism, obstructive sleep apnea, small
hands and feet, mild intellectual disability, and behavior problems. The
sister has cataplexy, and now has developed intention tremor and
dysmetria of as yet uncertain etiology. Although common paternity was
initially denied, chromosomemicroarray confirmed that both siblings and
their father carry the familial deletion. This family further refines the
critical region for the PWS phenotype and illustrates that very small,
paternally-inherited 15q11.2 deletions may be associated with a more
limited, atypical form of PWS.
Anxiety in Adolescents with Neurofibromatosis Type 1
K.Weinand1, N. Cantor2, D. Viskochil1, S. Latimer, Mstat3, K. Dent1
1. University of Utah
2. Primary Children’s Hospital
3. University of Utah College of Nursing
Neurofibromatosis type 1 (NF1) is a common genetic condition char-
acterized by both physical (café-au-lait spots, neurofibromas, skeletal
abnormalities) and neurodevelopmental manifestations (learning dis-
abilities and attention deficit disorders). During adolescence, both
aspects of the condition may become more evident to affected indi-
viduals as well as their peers. In the general population, approximate-
ly 8 % of adolescents have anxiety and fewer than 20 % of these
individuals receive care for the disorder. We hypothesize that anxiety
is more common in adolescents with NF1 and that they are more
likely to experience anxiety than their unaffected siblings. We invited
adolescents with NF1 and their unaffected siblings to participate in
an online survey. Participants were either members of the Utah
Chapter of the Children’s Tumor Foundation or the NF Registry. This
survey assessed manifestations of NF1, family history of the condi-
tion, co-morbid conditions, school performance, use of medications,
and the possibility of anxiety based on assessment by the Screen for
Anxiety Related Disorders (SCARED) assessment. Analysis includ-
ed 38 adolescents from the Utah Chapter of the Children’s Tumor
Foundation and 10 adolescents from the NF Registry. Overall, 38
(78 %) adolescents had NF1 and 11 (22 %) adolescents were unaf-
fected siblings. Our results indicate no statistically significant corre-
lation between anxiety and NF1 status; however, 40 % of the affected
survey respondents indicated significant predictors of anxiety on the
SCARED assessment (five times greater than the average rate report-
ed in adolescents). We identified a statistically significant correlation
between rarer manifestations of NF1 (plexiform neurofibromas, tibial
bowing, and scoliosis) and higher levels of anxiety in affected study
participants. Self-reported below-average performance in language
arts positively correlated with anxiety as was use of anxiety/
depression medication. As part of anticipatory guidance in NF
Clinics, discussion of potential anxiety risks for adolescents is
appropriate.
Mutations in ARID2 are Associated with Syndromic Intellectual
Disabilities
R. Willaert1, L. Sang2, M. Cho1, K. Retterer1, L. Folk1, J.
Humberson3, L. Rohena4, A. Sidhu5, S. Saliganan5, A. Iglesias2, P.
Vitazka1, J. Juusola1, W. Chung1,6
1. GeneDx
2. Department of Pediatrics, Columbia University Medical Center
3. Department of Pediatrics, Division of Genetics and Metabolism, Uni-
versity of Virginia
4. Department of Pediatrics, Division of Genetics, San Antonio Military
Medical Center
5. Department of Pediatrics and Human Development, Michigan State
University
6. Department of Medicine, Columbia University Medical Center
The etiology of syndromic intellectual disabilities (ID) remains unknown
for the majority of patients. Due to reduced reproductive fitness in many
individuals with ID, de novo mutations account for a significant portion
of severe ID. In this study, we used clinical whole exome sequencing
(WES) in proband-parent-trios to identify the etiology of syndromic ID.
We identified four independent, novel, loss of function variants in the
ARID2 gene in four patients, three of which were confirmed to be de
novo. ARID2 is an intrinsic component of Polybromo-associated BAF
(PBAF), which is part of the SWI/SNF subcomplex. The ATP-
dependent SWI/SNF chromatin modifier has previously been linked with
neurodevelopmental disorders including ID and autism. All four novel
variants are predicted to lead to a premature termination with the loss of
the two conservative zinc finger motifs. The patients all have ID and share
other clinical characteristics including attention deficit hyperactivity dis-
order, short stature, Wormian bones and dysmorphic facial features such
as plagiocephaly, retrognathia, micrognathia and low set, posteriorly ro-
tated ears. Other features found in some but not all affected individuals
include macrocephaly, highly arched palate, and cleft palate associated
with Pierre Robin sequence. This is the first report of mutations in ARID2
associated with developmental delay and syndromic ID. In the quest to
provide a molecular genetic diagnosis for heterogeneous disorders such
as syndromic ID, whole exome sequencing (WES) is an effective diag-
nostic tool for exploring the genetic etiology of these disorders and offers
an opportunity to provide families with a prognosis, risk of recurrence,
and potentially, a network of other families with similarly affected
members.
Two Cases of 2p16.3 Microdeletion Including MSH6 and FBXO11:
Are Developmental Delays and Other Clinical Features Related?
K. Wolfe Schneider1, K. Kocsis1, A. Larson1, M. Saenz1, C. Tsai2, B.
Tucker3, C. Porter 1
1. University of Colorado Denver
2. Children’s Hospital Colorado
3. Colorado Institute for Maternal & Fetal Health
Chromosomal microarray analyses revealed 2p16.3 microdeletions in-
cluding the MSH6 and FBXO11 genes in two unrelated children.
MSH6 haploinsufficiency causes Lynch syndrome, an adult onset hered-
itary cancer syndrome. FBXO11 is associated with ubiquination and
transforming growth factor β signaling, but the clinical phenotype of
germline haploinsufficiency is currently unknown. Both children were
referred for cancer genetic counseling based on the MSH6 deletion. One
is a 12-year-old male who was born at 34 weeks’ gestation and had
respiratory failure in the neonatal period. He has tracheo-esophageal fis-
tula, chronic lung disease, developmental delay, and seizures. Oligo mi-
croarray detected a 0.5 Mb loss (hg18 coordinates: 47,381,791–47,887,
705) later found to be maternally inherited. The family did not pursue
recommended cancer genetic counseling until after his mother was diag-
nosed with stage IV colorectal cancer at 48 years of age. Family history is
also significant for esophageal cancer diagnosed in a maternal uncle at
age 40. The second child is a 4-year-old male with developmental delay
and dysmorphic facial features. He was born at 39 weeks’ gestation and
was admitted to the NICU for feeding and breathing support for 3 weeks.
He also has truncal hypotonia. Audiology evaluation due to expressive
language delay showed moderate unilateral conductive hearing loss, and
he required placement of typanostomy tubes. Single nucleotide polymor-
phism microarray showed 0.18 Mb loss (hg18 coordinates: 47,884,950-
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48,060,992) later found to be maternally inherited. Family history is
significant for mild intellectual disability in his sister and mother. In both
cases, results from other genetic and biochemical tests have been non-
diagnostic. Ethical considerations must be considered in that these anal-
yses identified an adult onset condition in the pediatric population. Addi-
tionally, the association of intellectual disability with similar small dele-
tions in two families may implicate the contiguous genes MSH6 and
FBXO11 in patients with both Lynch syndrome and intellectual disability.
X. Pre- and Perinatal
Diagnosis of an Unbalanced Fetal Translocation Following
Abnormal Cell-Free DNA Screening
L. Bagby1, C. Settler1, L. Dohany1
1. Progenity, Inc
Introduction: Noninvasive prenatal screening (NIPS) analyzes circulating
cell-free (ccf) fetal DNA derived from maternal plasma for common fetal
aneuploidies. This testing was originally validated for the identification of
trisomies 13, 18 and 21; however, massively parallel shotgun sequencing
(MPSS) analysis of ccf DNA looks for over- or under-representation of
genomic material, and therefore has the potential to identify smaller copy
number variants as well. We present a case of abnormal cfDNA screening
results leading to the diagnosis of an unbalanced fetal translocation. Case
Report: A 29-year-old woman was referred to specialist care following the
identification of a suspected fetal brain anomaly on ultrasound. After genetic
counseling and maternal-fetal medicine evaluation, the patient elected
cfDNAscreening.Abnormal results revealed an underrepresentation of chro-
mosome 18, suspicious for either partial or full monosomy 18. Karyotyping
of amniocytes revealed an abnormal karyotype consistent with a deletion of
chromosome 18 (46,XY,del (18) (q21.3)). Results of microarray analysis
revealed an apparently unbalanced translocation, consisting of a 29.3 Mb
terminal deletion of chromosome 18q21.2-qter and a 14.1 Mb terminal du-
plication of 20pter-p12.1. The pregnancy was terminated. Parental chromo-
some studies revealed a maternal 18;20 balanced translocation. Discussion:
This case report demonstrates the potential for cfDNA screening to inciden-
tally but accurately identify copy number variants when utilizing MPSS
methodologies. These findings have significant clinical impact for patients
and can provide important information regarding reproductive risks and
options for the future. Incidental findings are not novel to cfDNA analysis;
however cases like this reinforce the need for adequate pre- and post-test
counseling and follow-up, as supported by the American College of Obste-
tricians and Gynecologists/Society for Maternal-Fetal Medicine joint com-
mittee opinion.
The Impact of Cystic Fibrosis on Women’s Reproductive
Decision-Making
L. Bokovitz1, A. Matthews1, A. Mitchell2, A. Goldenberg1, R.
Darrah1
1. Case Western Reserve University
2. University Hospitals Case Medical Center
As women with cystic fibrosis (CF) live into their reproductive years with
better health, the number ofwomen considering pregnancy is also increasing.
Research has shown that women with CF recognize that they lack adequate
information about the effects of pregnancy on their health. Because pregnan-
cy in any woman with a chronic illness can be complicated, having accessi-
ble information about how other women have made often conflicted deci-
sions about pregnancy may benefit women with CF as well. The purpose of
this study was to determine what factors impact the decision to try or not to
try to become pregnant and how decisional conflict and cystic fibrosis-
related quality of life relates to those factors. Women with CF over the age
of 18 were recruited through various social media sites and completed an
online survey that utilized two previously validated scales to assess decision-
al conflict and CF-related quality of life, as well as a scale that assessed the
importance of various factors. Forty-three women between the ages of 20
and 59 completed the survey. Overall, major concerns included how preg-
nancy would impact their health and what impact their disease would have
on their children. Several women (4/41) mentioned that having a negative
carrier test for their partner reduced their anxiety about having an affected
child and made them more likely to try to become pregnant. Analysis dem-
onstrated no statistically significant differences of decisional conflict between
women who decided to become pregnant, those who were undecided or
decided not to get pregnant. Interestingly, two women who decided not to
become pregnant had higher perceived quality of life and lower decisional
conflict. By providing information about how others have made decisions,
genetic counselors may promote informed decision-making to women with
CFwho are considering pregnancy and optimize both their health and quality
of life.
How do Women Make Decisions About Preimplantation Genetic
Screening? Sacrifices made and Factors Considered
S. Cochrane1, E. Thorpe2, M. Campion1, K. Krepkovich3
1. Boston University School of Medicine
2. Center for Fetal & Prenatal Genetics, Brigham and Women’s Hospital
3. Fetal Treatment Center, Akron Children’s Hospital
Pre-implantation genetic testing is a field in which research and techniques
are advancing and uptake is increasing. Preimplantation genetic screening
(PGS), in contrast to its counterpart, preimplantation genetic diagnosis
(PGD), is a process by which embryos are screened for chromosomal aneu-
ploidies prior to implantation into a woman’s uterus for development. Im-
plementation of ever-advancing technologies to screen embryos for chromo-
some aberrations through PGS has been shown to potentially increase preg-
nancy rates. Most research investigating decision-making related to preim-
plantation genetic testing has been focused on decisions regarding PGD (for
families who are at risk for having a child with a specific genetic condition).
Also, existing research focuses on couples who can easily access the tech-
nology (those of higher socioeconomic groups). The goal of this studywas to
assess women’s opinions about PGS and the associated decisions made by
women from a broader range of backgrounds, especially from varied socio-
economic (SES) groups. Fifty women, recruited through an infertility sup-
port group, completed surveys. Possibility of avoiding termination was rated
as the strongest factor playing into decisions, but cost was consistently cited
as a barrier to PGS. Thematic analysis was performed,which yielded 3major
themes: 1.) We’ll try anything, 2.) Knowledge is power, and 3.) If we could
afford it, we would do it. The majority of the women in this study indicated
clearly that any technology that could increase the possibility of a euploid
(and therefore, more likely healthy) pregnancy is worth pursuing, but that
there are major barriers to the utilization of PGS technology. IVF/PGS was
found to be financially inaccessible to women across a wide range of socio-
economic groups, including those of lower SES.
Efficacy of Genetic Testing in Cases of Ambiguous Genitalia
Detected on Prenatal Ultrasound
E. Crawford1, L. Rippel2, S. Debanne3, N. Lazebnik4, A. Parikh5, A.
Matthews3
1. Ambry Genetics
2. University Hospitals
3. Case Western Reserve University
4. Case Western Reserve University School of Medicine
5. University Hospitals Case Medical Ceneter
Presented Abstracts from the Thirty Fourth Annual Education 1125
This study assessed the accuracy of genetic testing in identifying a pre-
natal diagnosis for ambiguous genitalia through a systematic review of
published case studies and prenatal ambiguous genitalia identified cases
from University Hospitals (UH) ultrasound database. Nine-thousand,
three hundred and eighty-two articles were flagged for potential review.
A total of 28 articles (2006–2014) met inclusion criteria. The 28 articles
contained 89 case studies for review. The UH chart review yielded 39
cases from 2006 to 2014. Cases analyzed from the literature demonstrated
that, regardless of which protocol was used, a prenatal diagnosis of am-
biguous genitalia was correctly diagnosed in 60 % of cases. From these
data, an algorithmic testing guideline was generated. Cases from the chart
review that had prenatal and postnatal records were used to assess the
efficiency of the proposed algorithm of identifying the correct diagnosis
and was successful in 10 of 15 cases (66.6 %), with 5 cases being unclear
as to whether a diagnosis could be reached using the proposed algorithm.
The Value and Impact of Genetic Counseling Risk Assessment
D. Cutillo1, K. Fissell1, A. Cronister1, A. Donnenfeld1, D. Ramsey1
1. Integrated Genetics
Referrals for reproductive/preconception Genetic counseling (GC)
to Integrated Genetics were analyzed for the time period March 1,
2013 thru March 1, 2015. During this time, 17,926 patients were
referred by a physician for a family history of a genetic disease,
birth defect or intellectual disability. Risk was assessed for all pa-
tients based on relevant family history information, medical records
and review of genetic testing results. 4,632 patients were seen for a
family history of a chromosome abnormality. 829 of these patients
(17.9 %) were found to have no increased risk for a fetus with a
chromosome abnormality based on the GC risk assessment. 8,994
patients were seen for a family history of a genetic disease. GC
determined that 342 patients (3.8 %) did not have an increased risk
for the genetic disease listed as the reason for referral. 3,433 patients
were seen for a family history of physical birth defects. GC deter-
mined that 523 (15.2 %) of patients did not have an increased risk
for the birth defect indicated in the genetic counseling referral. 867
patients were seen for a family history of intellectual disability. 407
patients (47.3 %) did not have an increased risk for intellectual
disability based on the risk assessment. Genetic testing for the dis-
order identified as the referral indication was offered when an in-
creased risk was identified. Genetic counseling risk assessment was
more likely to identify an increased risk to patient’s offspring when
the referral was for a specific genetic disease, and was less likely to
identify an increased risk when the referral indication was more
general, such as intellectual disability. Genetic counseling improved
accuracy of risk identification compared to physician referral indi-
cation (r=−0.1519). This study of data from a large genetic counsel-
ing program illuminates the value of genetic counseling in the pro-
vision of personalized genetic risk assessment and the identification
of appropriate genetic testing.
Newborn Screening Education in the Prenatal Period: New Parent
Experiences and Desires
M. Dreon1, S. Rosendahl1, P. Constant1, A. Eames2, B. Roby1, M.
McCann1
1. Minnesota Department of Health Newborn Screening Program
2. Icahn School of Medicine at Mt. Sinai
Newborn screening (NBS) has a history of occurring routinely without
significant discussion or consent. The Minnesota NBS Program has re-
cently begun to recognize the importance of early education to allow
parents to absorb information before the hectic hours after delivery. These
internal motivations to educate early were compounded by a state legis-
lative mandate directing the NBS Program to provide prenatal providers
NBS educational materials for use in the prenatal timeframe. We
embarked on a new initiative to discover what expectant parents want
to know and learn before screening occurs so we could tailor efforts.
During the summer of 2014 we received 1,170 responses from new par-
ents when asking about their recent experiences and desired experiences
regarding newborn screening education in the prenatal period. Reported
awareness of NBS prior to receiving the survey was high (89 %), but we
found significant gaps between actual and desired educational experi-
ences on the topic of screening. About half of expectant parents (51 %)
reported learning about NBS from a nurse, although a majority of parents
reported wanting to hear this from higher level practitioners, such as
obstetricians/gynecologists and family physicians (68 % and 24 % re-
spectively). Parents most frequently reported receiving information about
NBS during labor and delivery (63 %), but nearly all reported wanting
this information prenatally (93 %), especially during the 3rd trimester
(64 %) of pregnancy. A majority (70 %) reported wanting to have a
conversation about NBS with their provider, but only 61 % reported
having that conversation with their provider. Lastly, we found that the
content of current discussions about NBS lack key pieces of information
that parents report are important to them. This includes how parents get
results (76 % desired, 27 % received) and what happens when a result is
abnormal (75 % desired, 26 % received). Overall, data suggests parents
are not receiving the education they desire. These findings have implica-
tions for future medical practice regarding NBS education.
A False Positive Noninvasive Prenatal Screening Result Leads to an
Incidental Finding of Translocated Yq Material in a Phenotypically
Normal Female
A. Essendrup1, C. Marcou1, J. Buescher1, K. N. Drewianka1, N.
Hoppman1
1. Department of Laboratory Medicine and Pathology, Mayo Clinic
Noninvasive prenatal screening (NIPS) has become an increasingly pop-
ular tool for the screening of autosomal aneuploidy, sex chromosome
aneuploidy, and recently, a limited number of microdeletion syndromes.
These tests rely heavily on bioinformatics for interpretation and can pro-
vide seemingly inconsistent or equivocal results in comparison to diag-
nostic cytogenetic testing. In some cases, diagnostic cytogenetic testing
may lead to the identification of a complex incidental finding.
Here, we report a case in which a pregnancy was screened via NIPS
through two separate laboratories. Both NIPS reported findings sugges-
tive of Klinefelter syndrome with greater than 99 % accuracy. However,
ultrasound findings throughout the pregnancy were suggestive of a fe-
male fetus, and at birth, the newborn appeared to be a phenotypically
normal female. Baby girl was reported to be healthy, non-dysmorphic,
and was released from the hospital at the typical time. Chromosome
studies were performed to confirm the sex chromosome content. Karyo-
type performed on peripheral blood revealed a derivative chromosome 22
with Yq material present on the short arm. Further discussions with the
NIPS laboratories revealed that the amount of Y material detected was
reportedly less than is seen in a true positive Klinefelter syndrome case.
This case report emphasizes the importance of correlation of additional
phenotypic findings and necessity of diagnostic chromosome studies to
confirm NIPS results. Furthermore, while aneuploidies due to transloca-
tions are less common, provision of accurate data suggesting an unbal-
anced translocation will allow tailored counseling and discussion to occur
upfront with the patient and their family. It also highlights the need for
improvement of biostatistical analysis tools to discern partial aneuploidies
from full aneuploidies.
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A Crossroads: Noninvasive Prenatal Screening Microdeletion
Syndromes Identified in Products of Conception Samples
M. Maisenbacher1, K. Merrion1, S. Sigurjonsson1, K. Paik1, M.
Young1, M. Dodd1, B. Pettersen1
1. Natera
Objective: Report incidence of microdeletion syndromes screened for by
noninvasive prenatal screening (NIPT) in a cohort of 17,424 products of
conception (POC) samples. Purpose: No prior studies have examined the
rate of syndromic microdeletions (1p36 del, Cri du Chat, Angelman,
PraderWilli and 22q11.2 del) inmiscarriage. In order, published live birth
rates for these conditions are: 1/5000; 1/20,000; 1/12,000; 1/10,000;
1/2000. Methods: Retrospective review of 17,424 fresh POC samples
shipped with maternal blood samples to a reference lab for analysis.
Genotyping was performed using Illumina CytoSNP-12b microarrays
with bioinformatics. Results: 14,824 cases (84 %) had fetal results, of
these, 31 (0.2 %) had one of the above microdeletion syndromes; some
had additional findings (AF) which may be related to the cause of the loss
or incidental: 1p36 del (6 cases, 3 had AF, incidence 1/2470); Cri du Chat
(12 cases, 6 had AF, incidence 1/1235), Angelman (2 cases, 2 had AF,
incidence 1/7412), Prader Willi (3 cases, 2 had AF, incidence 1/4941);
22q11.2 del (8 cases, 2 had AF, incidence 1/1853). Median gestational
age for these cases was 7 weeks. Conclusions: Higher incidences of
syndromic microdeletions were found in this study of POC samples com-
pared to reported live birth rates. Research into syndromic phenotypic
variability by gestational age and relationship to causality of miscarriage
is needed. This data may allow better recurrence risk counseling for
families with a pregnancy affected with one of these syndromes, some
of which carry significant recurrence risk based on potential parental
chromosome anomalies or rearrangements. Future studies can compare
these rates to other gestational age samples from NIPT, done as early as
9 weeks, and prenatal diagnosis offered later in gestation.
Obstetrician and Gynecologist Utilization of the Noninvasive
Prenatal Testing Expanded Testing Option
S. Mayes1, J. Czerwinski2, S. Hashmi2, M. Turrentine3, S. Darilek4,
L. Friel2
1. UT Health
2. UT Health at Houston
3. Kelsey Seybold Clinic, Houston, Texas
4. Baylor College of Medicine
Noninvasive prenatal testing (NIPT) enables the detection of common
fetal aneuploidies such as trisomy 21, trisomy 18, trisomy 13, and sex
chromosome abnormalities via analysis of cell-free fetal DNA circulating
in maternal serum. Although the accuracy of NIPT for fetal aneuploidy is
expected to be higher than that of currently available alternative maternal
serum screening options, the implications of results are not straight for-
ward. In October 2013, the option to screen for additional trisomies and
select microdeletion syndromes, such as 22q11.2 deletion syndrome and
5 p- syndrome, became clinically available. Due to this rapidly evolving
prenatal screening technology, clinicians must make a conscious effort to
keep abreast of the current options; however, the complexity of the testing
methods, oftentimes unclear clinical utility of results, and current lack of
professional guidelines for its use renders this task challenging. To assess
physicians’ awareness of, utilization of, and attitudes toward the expand-
ed NIPToption, 85 Houston, Texas area Obstetrician/Gynecologists (Ob/
Gyns) were surveyed.While all respondents indicated they were aware of
NIPT in its traditional form, 75 % were aware of the expanded testing
option. Of these respondents, 17 % report having elected the expanded
testing option when ordering NIPT. Thirty-nine percent of those surveyed
indicated they would feel at least somewhat uncomfortable explaining the
expanded testing option to a patient and, accordingly, 91% expressed that
practitioners needmore information regarding the screen. The responding
Ob/Gyns indicated that this new screening option will be increasingly
applicable to their future practice, with 28 % indicating that they plan to
incorporate the NIPT expanded testing option into their practice in the
future. Based on these findings and the quickly evolving landscape of
prenatal screening, education and reeducation of healthcare professionals
is imperative to ensure responsible patient counseling, informed consent,
and appropriate management following test results.
Correlation of Occult Maternal Colon Cancer with Serial
Noninvasive Prenatal Test Screening Evaluations
K. Murray1
1. Women’s Care
Noninvasive prenatal testing (NIPT) is a revolutionary technique to
screen pregnancies for common trisomies. The low false positive rate
and very high detection rate has resulted in widespread use. This case
illustrates the possibility that the unique nature of NIPT screening (ge-
nome wide copy number variants) may be associated with the genetic
instability seen in cancer cells. Initially, the discordant NIPT and fetal
karyotype results were likely to be explained by an expected mechanism
such as confined placental mosaicism. However, this was ruled out. Ap-
proximately 10 months later, her colon cancer was diagnosed. Two more
samples were obtained before and after her cancer treatment. Extensive
bioinformatics analysis revealed more extensive copy number variation
and the eventual return to normal after the treatment was completed.
Occult maternal cancer may, 1 day, be found to be a possible explanation
of discordant results.
Transitioning Cell Free DNATesting for Aneuploidy to a General
Pregnancy Population: Preliminary Results of the Rhode Island
Experience
G. Palomaki1, E. Kloza1, B. O’Brien1,2, E. Eklund1, G. Messerlian1
1. Women & Infants Hospital of Rhode Island
2. Department of Obstetrics and Gynecology, Alpert Medical School of
Brown University
Introduction: Cell free (cf) DNA testing for aneuploidy in high-risk set-
tings has been validated by comparison with fetal karyotype. Professional
societies now seek evidence of effectiveness in a general risk setting.
Purpose: To introduce cfDNA testing through primary care obstetrical
providers and document patient knowledge and decision-making in a
subset of 3,000 women screened. We address provider and patient edu-
cation and whether information was understood. We also developed a
plan to manage DNA test failures. Methods: Targeted educational mate-
rials were created and validated. A protocol (DNAFirst) was implemented
to offer cfDNA to all pregnant women, reflexing to serum screening and
repeat cfDNA options for DNA test failures. Patients chose whether to
include testing for sex chromosome aneuploidies. In September, 2014,
following office education, DNAFirst was offered through providers at no
charge to the patient or her insurance (via Natera, Inc., San Carlos, CA).
Results: Through April 2015, 14 practices were approached, 12 were
trained and 11 offered DNAFirst through 58 providers without additional
office resources. Of the 1,904 women tested, 62 % were drawn at 11–
12 weeks and 78 % were <35 years of age. Most women (91 %) opted to
include sex chromosome aneuploidy testing. The cfDNA positive rate
was 1 %(19/1914): six T21 (4 true positive (TP), 1 false positive (FP),
1 pending), two T18 (1 TP, 1 pending), three T13 (1 TP, 1 FP, one
probable), five sex chromosome aneuploidy (2 confirmed, 3 pending),
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and three triploidy/twin (3 twins [2 vanished, 1 not previously known]).
There were 1,779 negative results and 106 DNA failures (5.5 %). Among
failures, 68 had a normal repeat DNA or serum result, yielding a revised
rate of 1.8 % (some results pending). Conclusions: General primary care
obstetrical providers are capable of offering cfDNA testing given proper
education. Sample drawing and handling do not pose significant logistic
issues. False positive rates are low, with very few women recommended
for diagnostic testing, and positive predictive value high (82%, excluding
twins and pending cases).
Genetic Conditions in Congenital Diaphragmatic Hernia
and Recommendations for Prenatal Testing
E. Partack1, R. Hopkin1, M. Baric1, F. Lim1, T. Burns1, A.B. Ross1
1. Cincinnati Children’s Hospital Medical Center
Introduction: Congenital diaphragmatic hernia (CDH) occurs in 1 in
3,000 pregnancies and causes significant neonatal morbidity and
mortality. In approximately 40 % of cases there is an additional
malformation, and in 10-15 % of cases there is an associated genetic
syndrome. Identification of a genetic syndrome is important in
counseling about expected prognosis. Methods: We retrospectively
reviewed 97 cases of prenatally diagnosed CDH. All had an addi-
tional malformation and/or genetic condition. We assessed the types
of syndromes, method of diagnosis, and outcome. Results: Chromo-
some abnormalities were present in 14/97 (14 %), which were very
variable. Two were 15q26 deletions, and one was ring chromosome
15. A single-gene condition was identified in 9/97 (9 %) cases,
either through molecular confirmation or clinical suspicion. Corne-
lia de Lange was identified in three cases. Other syndromes includ-
ed Goltz, Fryns, Beckwith-Wiedemann, and Donnai-Barrow. Heart
defects were present in 50 cases, and complex heart disease was a
poor prognostic indicator. Other malformations included
omphalocele (8), limb defects (6), renal abnormalities (6), and uro-
genital abnormalities (4). Discussion: There are a variety of genetic
conditions to consider when providing prenatal genetic counseling
for CDH. In our series, only 3 of the 14 chromosomal abnormalities
would be detected using cell free fetal DNA testing. Additionally,
some of the chromosomal abnormalities that were identified can be
missed on routine chromosomal analysis. Amniocentesis with high
resolution chromosomal microarray (CMA) is recommended. Many
single-gene genetic conditions were seen with Cornelia de Lange as
the most frequent. This condition should be considered if chromo-
somes and CMA are normal, especially if there is IUGR. Although
Fryns syndrome and Donnai-Barrow syndrome have strong associ-
ations with CDH, these two conditions are very rare and they were
not the most frequent syndrome reported in our series.
Amniocentesis does not Increase the Risk of Miscarriage in a Screen
Positive Population when Performed by an Experienced Practitioner
M. Randall1, L. Becerra1, A. Randall2, L. Cowan1, C. Archie1
1. Linda S. Cowan, MD & Associates
2. California State University-Stanislaus
Objective: In order to provide more appropriate counseling to wom-
en with a prenatal screen positive result regarding the risk of mis-
carriage after amniocentesis, we compared the rate of pregnancy
loss in women that elected amniocentesis (14–24 weeks GA) to
women who declined diagnostic testing. Study Design: Patients with
a screen positive result from the California Prenatal Screening Pro-
gram are offered referral to a Prenatal Diagnosis Center, where
follow-up services include genetic counseling with a detailed
ultrasound and amniocentesis by an experienced practitioner, if in-
dicated. Pregnancy outcomes/losses were ascertained by postpartum
surveys sent to providers of screen positive patients. Cases with
confirmed chromosome abnormalities or birth defects were exclud-
ed, as were cases that were screen positive for neural tube defects
based on the difference in amniocentesis acceptance rates in this
group. The outcomes of women with singleton pregnancies electing
amniocentesis were compared with those that declined. Two-sided
confidence intervals for the loss rates in the two groups were cal-
culated. Results: After exclusions, there were 11,478 amniocenteses
and 14,475 declines that were screened between April 2009 and
December 2012. In the amniocentesis group, there were 80 fetal
losses (0.70 %, 95 % CI 0.54–0.85 %). In the decline group, there
were 117 fetal losses (0.81 %, 95 % CI 0.66–0.95 %). These rates
were not significantly different (p=0.84). Conclusion: Screen posi-
tive women who had amniocentesis with an experienced practitioner
were not at increased risk for miscarriage/fetal loss compared to
women who declined the procedure. The risk after amniocentesis
is also lower than what most counselors describe to patients. This
population is at increased risk for adverse outcome related to abnor-
mal maternal serum analyte levels and counseling should address
this risk more so than the risk of miscarriage from amniocentesis.
In our study, there is no evidence that amniocentesis by an experi-
enced practitioner increases the risk of fetal loss.
Women’s Assessment of Benefit in Pre-Test Genetic Counseling
for Noninvasive Prenatal Testing
C. Rao1, H. Kershberg1, M. Constantine2, S. Alessi3, M. Michie4, M.
Allyse5
1. Kaiser Permanente
2. University of Minnesota
3. Stanford Center for Biomedical Ethics
4. UCSF Institute for Health & Aging
5. Mayo Clinic
Objectives: Kaiser Permanente Southern California currently offers non-
invasive prenatal testing (NIPT) as a screen in all high-risk pregnancies.
Prior to screening, patients receive a one-hour, individual consult on
screening and diagnostic options. To assess the value of this resource-
intense model, this study tests women’s evaluation of benefit in extended,
pre-test genetic counseling. Method: Self-administered survey methods
were used for data collection with pregnant women eligible for NIPT
referred to one of two genetic counseling practices in Southern California.
Women were asked to complete surveys after their genetic counseling
session. Results: The average age of 336 respondents was 37 years and
11.5 weeks gestation; response rate was 76.4 %. Almost all women re-
ported that pre-test genetic counseling was ‘extremely’ or ‘very’ helpful
(93 %) in deciding whether or not to have NIPT. Semantic differential
formatting of 1 (very clear) to 7 (very confusing) found that over 73 % of
women reported pre-test counseling made their options ‘very clear’. On a
similar rating, 76.5 % of women reported counseling made them feel
more calm than anxious. Of the 64 % of women who reported only a
little or no understanding of NIPT prior to counseling, almost 86 % re-
ported that the consult helped their understanding of NIPT ‘a lot’. 80% of
women reported little or no understanding of conditions tested for by
NIPT prior to counseling and said that the consult helped their under-
standing ‘a lot’. Post counseling, women overwhelmingly reported feel-
ing more certain about what they would do next if their NIPT results were
returned as normal (96 %) or abnormal (93 %) respectively. Conclusion:
Women found extensive, pre-test genetic counseling useful in their
decision-making around NIPT, suggesting that that this model should
remain the gold standard in counseling for NIPT.
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Newborn Screening Education in the Prenatal Period: Provider
Practices and Desired Assistance
S. Rosendahl1, M. Dreon1, P. Constant1, A. Eames2, B. Roby1, M.
McCann1
1. Minnesota Department of Health
2. Icahn School of Medicine at Mt. Sinai
Since its inception more than 50 years ago, newborn screening (NBS) has
been a routine standard of care. Yet while screening happens routinely, it is
imperative that parents are informed about this life-saving process. In 2014,
the Minnesota Legislature passed a law mandating the Newborn Screening
Program to provide education materials to prenatal providers for use in
educating about NBS. In order to assess what providers truly want and need
from the Program, we surveyed prenatal care providers and received re-
sponses from 396 providers about their current educational practices and
any additional needs for outreach and/ormaterials theymay have.Our results
showed that labor/delivery and postpartum are the most frequently reported
timeframes for educating patients about NBS (85 %), and that a small mi-
nority of providers report never discussing NBS with their patients (6 %). A
significant number of respondents (35 %) report that they do not feel suffi-
ciently informed about NBS and that this poses a barrier to educating their
patients about the topic. When asked what additional provider-specific re-
sources would aid in patient education, providers indicated that they desired:
written materials (54.8 %), website links (43.9 %), pocket cards (39.9 %),
and phone applications (33.8 %). When asked what patient-specific re-
sources would aid education efforts, providers indicated that they desired:
written materials (78.3 %), tear-off fact sheets (53.0 %), a short video
(46.0 %), and website links (45.2 %). These findings suggest that while
prenatal providers report education is occurring for most patients, a signifi-
cant number of providers do not feel sufficiently informed about NBS, and
there are a number of resources health departments can develop to better
assist their medical partners in educating expectant parents about NBS.
These findings have important implications for future health department
practices regarding intentional development of materials for prenatal provid-
er audiences.
Cerebellar Hypoplasia Associated with Mutations in the EIF2B2
Gene
R. Silver1, J. Pierre-Louis2, S. Goobie2, J. Schmidt2, D. Chitayat1,3
1. Mount Sinai Hospital
2. London Health Sciences Centre
3. The Hospital for Sick Children
Prenatal diagnosis of cerebellar hypoplasia (CH) is a relatively common,
but non-specific neuroimaging finding. The etiological spectrum of CH is
wide and includes both primary (malformative) and secondary
(disruptive) conditions. Primary conditions include chromosomal (e.g.,
trisomy 13, 18), metabolic disorders (e.g., molybdenum cofactor defi-
ciency, Smith-Lemli-Opitz), genetic syndromes (e.g., Joubert,
CHARGE), and brain malformations (primary posterior fossa
malformations or global brain malformations). Secondary conditions in-
clude prenatal infections, teratogens, and prematurity. We report on a
couple with two pregnancies with CH presenting in the second trimester.
Their first pregnancy was complicated by oligohydramnios, microcephaly,
CH, mega cisterna magna, single umbilical artery, and intrauterine growth
restriction (IUGR). The couple terminated the pregnancy. Amnio showed a
normal karyotype (46,XY); autopsy was declined. In a second affected preg-
nancy, Integrated Prenatal Screening was positive for trisomy 18. Detailed
fetal ultrasound at 18.5 weeks showed oligohydramnios, IUGR, CH and
prominent cisterna magna. MRI at 21 weeks showed a small cerebellum
and disproportionately large cisterna magna. The couple terminated the
pregnancy. Whole exome sequencing on DNA from the second affected
fetus identified compound heterozygote mutations in the EIF2B2 gene; each
parent was heterozygote for a mutation. A healthy sib was heterozygous for
the paternal mutation. Mutations in the five EIF2B subunits (including
EIF2B2) have been described in association with a group of
leukoencephalopathies that includes the CACH syndrome (ChildhoodAtax-
ia with Central nervous system Hypomyelination) or Vanishing White Mat-
ter, with mutations in the EIF2B5 gene being the most common. A wide
clinical spectrum exists within this group, from severe, lethal infantile forms
to adult-onset forms with slow progression. To the best of our knowledge,
this is the first reported case of prenatal presentation within the EIF2B
leukoencephalopathies, and provides insight into the prenatal phenotype
associated with mutations in EIF2B2.
Clinical Experience with a Single Nucleotide Polymorphism (SNP)
-Based Noninvasive Prenatal Test for 22q11.2 Deletion Syndrome
M. Stosic1, S. Gross1, A. Norvez1, R. Dhamankar1, K. Jinnett1, Z.
Demko1, P. Benn2
1. Natera, Inc.
2. University of Connecticut Health Center
Introduction: The occurrence of 22q11.2 microdeletions (associated with
DiGeorge syndrome) is independent of maternal age. Because of their
small size, these deletions are more difficult to detect by noninvasive
prenatal testing (NIPT). Purpose: To report on the clinical experiencewith
our single nucleotide polymorphism (SNP)-based NIPT for this
microdeletion. Methods: 20,776 consecutive, eligible, maternal blood
samples were received between February and August 2014. A unique
set of PCR primers amplified 672 SNPs in the 2.91 Mb DNA segment
commonly deleted in this syndrome. Sequencing and analysis of the
SNPs allowed determination of fetal and maternal copy number at the
interrogated region. 19,237 cases received a high-risk or low-risk call for
the presence of this deletion. Follow-up information was sought for all
high-risk cases. Results: 95 (0.5 %) pregnancies were found to be high
risk for a 22q11.2 deletion. In two additional cases, the mother was
suspected to have the deletion; one of these was confirmed and one likely
based on family history. Diagnostic testing was obtained for the fetus in
61 high-risk cases: 11 were true positives and 50 were false positives,
resulting in a positive predictive value (PPV) of 18.0 %. Re-sequencing
89 high-risk samples at a higher depth of read (i.e., reflex testing) im-
proved the PPV to 42.3% (11/26). Invasive testing decisions were known
for 84 cases: 57.1 % (48/84) had invasive testing and 42.9 % (36/84)
declined. Ultrasound anomalies were present for 81.8 % of true positives
and 18.0 % of false positives. The PPV for cases without known ultra-
sound findings prior to NIPTwas 5.1 %; this increased to 16.7 % follow-
ing reflex testing. Conclusions: Screening for 22q11.2 deletion syndrome
with this SNP-based NIPT resulted in a 0.5 % rate for high-risk calls with
a PPVof 18.0 %. Early therapeutic interventions exist and can substan-
tially improve the quality of life for the affected child. The routine provi-
sion of prenatal screening for 22q11.2 microdeletions should be consid-
ered for women already undergoing NIPT for fetal aneuploidy.
Exploring Birthparent’s Experiences of Creating an Adoption Plan
for Their Children with Down Syndrome
S. Tawde1, V. A. Vincent2, K. Berrier3, S. Thompson4
1. University of South CarolinaSchool of Mmedicine
2. University Specialty Clinics, University of South Carolina School of
Medicine
3. Duke University Medical Genetics
4. National Down Syndrome Adoption Network
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Introduction: Very little peer-reviewed information is available regarding
the experience and needs of families who create an adoption plan for
children with disabilities. The purpose of this study was to learn more
about the experiences of birthparents who created an adoption plan for
their child with Down syndrome (DS) in order to understand their infor-
mational and emotional needs for decision-making and throughout the
adoption process. Methods: Birthparents were invited to participate in the
study by membership emails from the National Down Syndrome Adop-
tion Network (NDSAN). Information about the study was also made
available on the organization’s website. Semi-structured telephone inter-
views were conducted with five birthmothers who had created adoption
plans for their children with DS. Conventional content analysis methods
were used for systematic coding and identification of emergent themes.
The interviews focused on three major areas: (1) families’ reasons for
creating an adoption plan, (2) informational and emotional needs of these
families, and (3) messages to other birthparents and medical health pro-
fessionals about special needs adoption. Results: All five birthmothers
were Caucasian, over 35 years of age, and all but one were married with
previous children. Various reasons for creating an adoption plan included
unplanned pregnancy, feeling unprepared to raise a child with DS, and
religious or personal beliefs regarding pregnancy termination. Finding the
Bright^ adoptive family was identified as an instrumental factor for final-
izing the adoption plan. Emotional and informational needs included
support from their partners, acceptance from others, informational re-
sources about the process and the opportunity to connect with other
birthparents who had been through the same situation. Conclusion: Con-
sideration of these results may help genetic counselors and healthcare
providers to facilitate informed decision-making and may also bring
greater ease during the discussion about adoption with families who
may have not otherwise considered adoption.
Whose Y is it Anyway? Transplantation as a Biological Cause
of Noninvasive Prenatal Testing Gender Discrepancies
J. Wardrop1, N. Dharajiya1, T. Monroe1, T. Boomer1, R.
Mccullough1
1. Sequenom Laboratories
Introduction: Since the introduction of noninvasive prenatal testing
(NIPT) in 2011, more than 400,000 clinical samples have been run in
Sequenom Laboratories. Discrepant results often have biological expla-
nations, including confined placental mosaicism, maternal mosaicism,
co-twin demise, and maternal neoplasm. As cell-free DNA is comprised
of maternal and trophoblastic placental DNA, tissue from foreign organs
can contribute its DNA to the pool. Here we describe three cases of NIPT
fetal sex discrepancies in patients who had undergone bone marrow and
liver transplants. Methods: Maternal blood samples submitted to
Sequenom Laboratories for ccfDNA testing were subjected to DNA ex-
traction, library preparation, and whole genome massively parallel se-
quencing as described by Jensen et al. Sequencing data were analyzed
using a novel algorithm to detect certain aneuploidies and microdeletions
as described by Chen et al. Case#1: NIPT result: Male, negative for
aneuploidies. Provider informed us that ultrasound was consistent with
a female fetus. Second aliquot of sample was run. Both samples showed a
strong Y signal. Provider later informed the lab that the patient had a liver
transplant due to Wilson’s disease 16 years prior, from a male donor.
Case#2: NIPT result: Male, negative for aneuploidies. Provider informed
us that ultrasound was consistent with a female fetus. Provider later in-
formed the lab that the patient had a bone marrow transplant from her
brother in 1985. Normal female anatomy at birth. Case #3: NIPT result:
Male, negative for aneuploidies. Provider informed us that ultrasound
was consistent with a female fetus and that the patient had a bone marrow
transplant from her brother in 2002 due to aplastic anemia. In reviewing
the data, the sample showed a strong Y signal. Conclusion: Obtaining a
detailed clinical history in cases of NIPT discrepancy can provide unex-
pected and valuable clues toward resolution and understanding. As NIPT
becomes increasingly available to all populations, pre-test counseling
about maternal conditions is essential.
Professional Issues
An Exploration of the Roles and Satisfaction Level of Genetic
Counselors Working with Newborn Screening
S. Bradley1, B. Vogel1
1. New York State Department of Health
Introduction: Newborn screening (NBS) is a public health service admin-
istered by Newborn Screening Programs in all 50 states, as well as many
international locations. Through this screening, newborns at risk for seri-
ous conditions are identified, evaluated, and those with confirmed disease
receive timely treatment. Genetic counselors (GCs) may be involved with
NBS through direct work with a Program, designated evaluation and
treatment centers, or via other means. The purpose of this study was to
elucidate the roles of these counselors, and their satisfaction with this
work. Results: A 29-question survey was distributed via email to the
Association of Public Health Laboratories (APHL) Newborn Screening
Technical Assistance and Evaluation Program (NewSTEPS) listserv as
well as an international listserv administered by the National Newborn
Screening and Global Resource Center. In total, 69 GCs responded, of
which 97%were female, 71%were ages 25–44, and 49% had graduated
from their training program within the last 10 years. In their NBS roles,
25%were the first GC in that position, 39%worked in role for 1–5 years,
and 78% had a clinical role prior to NBSwork. In their NBS role, 77% of
respondents had face-to-face patient contact, 97 % had telephone contact
with patients, and 69% have been involved in education via presentations
and/or material production. The majority of respondents worked with the
Inherited Metabolic Disorders (79 %) and/or Cystic Fibrosis (71 %), and
28% have supervision responsibilities in their NBS role. 84 % of respon-
dents said they were moderately or completely satisfied with their NBS
role, and 95 % said they would recommend this work to other GCs.
Individual factors such as work schedule, respect from co-workers, utili-
zation of GC skills, and intellectual stimulation rated highest satisfaction
levels; opportunities for advancement had the lowest rate. Conclusions:
Genetic counselors working with newborn screening have high rates of
satisfaction with this work.
Misconceptions and Psychosocial Issues Raised by Linkage Analysis
Completed in 1987: A Case Report
C. Bruha1, J. Kelsay2, J. Vengoechea2
1. University of South Florida
2. University of Arkansas for Medical Sciences
We report the case of a patient who presented with a striking family
history of breast cancer. The family history was notable for four out of
her five brothers having died from an unknownmuscular dystrophy (ages
of death ranged from 19 to 43). All were confined to wheelchairs, did not
have use of their legs, and were never given a diagnosis. The family had
linkage testing performed in 1987 that was inconclusive suggesting link-
age to the DMD locus. However, the family had an incorrect impression
that the test was conclusive and identified the carriers and non-carriers in
the family. The proband was diagnosed with cardiomyopathy. The
family’s pedigree suggests an x-linked muscular dystrophy with symp-
tomatic carriers. Due to the concern about the possibility that the proband
could be a symptomatic carrier, genetic testing was ordered for the pro-
band. Intricate psychosocial issues were raised by the family’s impression
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of a ‘conclusive’ test. We educated the family about the limitations of the
previous testing done and explained the implications an X-linked muscu-
lar dystrophy could have for carriers. This case exemplifies the impor-
tance of pre- and post-test counseling and demonstrates the massive
strides genetic counseling has made since 1987. Genetic counseling
helped clarify this family’s medical history, genetic testing misconcep-
tions, and integrated this family into their own medical care.
Seekers, Finders, Settlers, and Stumblers: Identifying the Career
Path for Males in the Genetic Counseling Profession
A. Chen1, P. McCarthy Veach1, C. Schoonveld1, H. Zierhut1
1. University of Minnesota
Introduction: Genetic counseling is a female-dominated profession, as
96 % of counselors self-identify as female. Prior studies suggest gender
diversification benefits both members of a profession and populations
they serve. The aims of this study were to explore men’s reasons for
choosing a genetic counseling career, and associations between career
entry dynamics and career satisfaction. Methods: Twenty-five male coun-
selors (with 0–5, 6–14, or >15 years experience) and 8 male genetic
counseling students, recruited through NSGC and program directors, par-
ticipated in semi-structured phone interviews. Inductive and cross-case
analysis of interview data was informed by Simpson’s BSeekers, Finders,
and Settlers^ theory about men in non-traditional careers. Results: Four-
teen interviewees (42 %) were seekers, who actively chose a non-
traditional career; 10 (30 %) were settlers, who tried various traditional
jobs with limited satisfaction before settling into genetic counseling; and
two (6 %) were finders, who discovered genetic counseling while making
career decisions and had no desirable alternative. Seven men (21 %) fit a
new category, we termed stumblers, who were already pursuing another
career path before hearing of genetic counseling, at which point they
actively pursued it. Prevalent career entry dynamics included: desire for
a multidisciplinary career; lack of knowledge of different genetic coun-
selor roles; and initial exposure to the profession following graduation
from college. Many individuals chose genetic counseling as they did not
find Bthe right fit^ in medical school or laboratory research. Career satis-
faction was high across cohorts and regardless of how one entered the
field. Discussion: Few males actively sought a genetic counseling career,
suggesting a need for exposure to the profession earlier in one’s educa-
tion, and more detailed descriptions of multidisciplinary aspects of the
career.
The Evaluation of the Molecular Basis of Disease (EMBoDy)
in Clinical Reporting: What Genetic Counselors Need to Know
for Counseling and Return of Novel Genetic Etiology Results
Identified via Diagnostic Exome Sequencing
K. Farwell Hagman1, Z. Powis1, D. El-Khechen1, L. Shahmirzadi1,
D. Shinde1, E. Chao1, S. Tang1
1. Ambry Genetics
Exome sequencing serves a dual role as a diagnostic and a discovery tool,
and case reports of patients in whom a novel genetic etiology is identified
on a clinical basis are becoming abundant. A novel genetic etiology is a
newly described gene-disease relationship. In our laboratory, a novel
genetic etiology is reported in ~10 % of patients. The analysis and assess-
ment criteria used to evaluate novel genetic etiologies for clinical
reporting are markedly different than those used for a clinically charac-
terized gene. Given the implications for genetic counseling, it is important
for genetic counselors to be aware of these differences. Overall, the evi-
dence criteria used to report a novel genetic etiology is much more strin-
gent than a characterized gene finding. For alterations in characterized
genes in which the patient’s phenotype is consistent with the known
clinical and molecular spectrum, the reportable findings are categorized
as positive, likely positive, or uncertain. Because no previous patients
have been reported for novel genetic etiologies, a unique set of scientific
criteria are used to make the case for the gene’s potential implication in
the patient’s phenotype. Evaluated evidence includes relevant human
microdeletion syndromes, gene function and expression profiles, co-lo-
calization/interaction with gene products known to cause similar presen-
tations, animal models, gene family/pathway information, and possible
mutational mechanism inferred from distribution of variants in control
populations. If there is sufficient, high quality evidence, findings are
reported out as either likely or possibly positive. The remaining novel
gene findings with insufficient available evidence are provided in a sup-
plemental list in the patient’s report. These are not negative findings, and
the possibility exists for sufficient scientific evidence to emerge in the
future. Therefore, it is important for the genetic counselor to remain in
contact with the laboratory to gain new information, to perhaps find
additional patients with alterations in the same gene.
An Exploration of the Nuances of Common Legal Documents
Commonly Encountered in Industry-Based Employment Settings
S. Gandomi1, R. Stanton1
1. Invitae
The Supreme Court’s decision that naturally occurring genetic material
cannot be patented removed a longstanding hurdle to innovation in and
expansion of clinical genetics. This, in turn, is fueling the growth of the
genetic counseling profession, which is rapidly forging paths beyond the
clinic, opening exciting opportunities as well as unique challenges for the
profession. In particular, an increasing number of genetic counselors are
accepting positions in private industry. Here we present an overview of
issues that are not often taught in genetic counseling training programs
and often not appreciated by professionals before accepting positions in
industry. While there are clearly exciting opportunities in industry, there
are important issues that run the gamut from restrictive clauses in em-
ployment contracts, such as non-competes and confidentiality, to at-will
employment, conflicts of interest, and up front promises to transfer own-
ership of intellectual property. Education on these topics is essential for
genetic counselors to better appreciate how best to uphold a high standard
of practice while adhering to industry norms, and exploring new disci-
plines. Understanding the nuances of the legal documents is an important
step for genetic counselors as more companies in industry are relying on
their expertise as a key strategic element to commercial success. It is
mutually beneficial if the profession is as savvy about best practices
and obligations to the workplace as they are prepared to uphold their high
standards of practice. Genetic counselors should increase awareness of
their obligations to both their profession as well as their employer in terms
of details outlined in employment documents. By providing genetic coun-
selors with a neutral, fact-focused overview of the legal requirements
upon hire, it is our goal to provide them with educational resources and
tools for which they can approach these commitments with a better over-
all understanding, in turn leading to an informed career path.
Measuring Awareness and Perceptions of Genetic Counseling
in Three Groups: General Population, a Disability Community,
and a New Parent Community
D. Goldberg1, M. Bocian1, K. Singh1, K. Osann1, W. Grody2, J.
Austin3
1. University of California Irvine
2. University of California Los Angeles
3. University of British Columbia
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Background: Understanding awareness and perceptions of genetic
counseling (GC) among different groups is important in order to identify
and overcome potential barriers to GC services. However, there are rela-
tively little empirical data regarding awareness and perceptions of GC
among US-based populations. Methods: To address this gap within the
state of California, we attended community events for the general public,
disability community, and new parents, and recruited people to participate
in a survey-based study comprising demographic questions, closed-ended
knowledge-based and awareness questions, and open text sections. We
applied descriptive statistics to responses about: demographics, whether
the individual had heard of GC, and perceptions of what a genetic coun-
selor does. Open text responses to a question about participants’ first
associations with the phrase Bgenetic counseling^ were analyzed for
themes. Responses to 18 items about the possible purposes of GC were
used to generate a total Bknowledge score^. Results: In total, 320 people
participated, including 69 from the general public, 209 from the disability
community, and 42 from a new parent community. Slightly more than
half of all respondents (n=173, 54 %) had heard of GC. Risk assessment
and counseling were amongst the most frequently cited activities attrib-
uted to genetic counselors, but a small number felt that GC was related to
eugenics. Many respondents thought that GC aims to prevent genetic
diseases and abnormalities (n=82, 74 %), help people find their ethnic
origins and understand their ancestry (n=176, 55 %), advise people about
whether to have children (n=140, 44 %), and help couples have children
with desirable characteristics (n=126, 39 %). The mean knowledge score
was 12/18 for all groups combined, and scores were not significantly
different between communities or any demographic groups. Conclusions:
These data reveal gaps in awareness of GC and misperceptions about its
purpose. These data could be used to develop targeted interventions to
improve awareness and dispel misconceptions.
Spanish-Speaking Medical Interpreters’ Understanding of and
Attitudes Towards Genetics and Genetic Counseling
A. Henshaw1, P. Reitnauer1,2, G. Namihira-Alfaro2, R. Stewart1
1. University of North Carolina at Greensboro
2. Cone Health
Background: The need for spanish-speaking medical interpreters can be
demonstrated ethically, statistically, and legally. While many studies have
researched interpreters in other medical specialties, there is a lack of
literature regarding interpreters in genetics and genetic counseling ses-
sions. Purpose: This exploratory project aimed to address the following
research questions: What do interpreters know about genetics and genetic
counseling, andwhere do they obtain this education?What do interpreters
understand about the importance of genetics and genetic counseling?
What attitudes do interpreters have about genetics and genetic counsel-
ing? Methods: This study was conducted through telephone interviews
with spanish-speaking medical interpreters recruited through three inter-
preter organizations in the Triad region of North Carolina. Nine partici-
pants completed telephone interviews. Interview responseswere analyzed
qualitatively by thematic analysis. Results: Participants reported that ge-
netic counseling is important because of patient education, psychological
counseling, follow-up care, and patient decision-making. The most com-
mon perceived barriers to nondirectiveness included patient education
level and health care provider characteristics. Terminology was the most
frequently reported challenge for interpreting in genetic counseling ses-
sions. Sources of genetic counseling knowledge included previous sci-
ence classes, previous interpreting experiences in genetic counseling, the
Internet, and interpreter training. Discussion: Interpreters demonstrated a
general knowledge and understanding of genetic counseling and its im-
portance, but most lacked knowledge of the intricacies of the profession.
The majority of participants discussed the importance of interpreter edu-
cation in genetics and genetic counseling, and many expressed interest in
training courses. All participants reported that genetic counseling was
enjoyable and/or an important service. This information can be used to
promote educational efforts for interpreters working with genetic
counselors.
The GC on TV: The Absence of a Genetic Counseling Professional
in Popular Medical Television Storylines and What we can do
About it
D. Goldberg1, M. Bocian1, K. Singh1, K. Osann1, W. Grody2, J.
Austin3
1. University of California Irvine
2. UCLA School of Medicine
3. University of British Columbia
Background: Entertainment education is a means of informing the public
about a social issue or concern that involves incorporating an educational
message into popular entertainment content. TV is one vehicle for enter-
tainment education that has the potential to reach millions of viewers at a
time. Studies have shown that TVeducation entertainment can be used to
raise awareness, increase knowledge, create favorable attitudes, and even
motivate people to take health related actions. But there are no published
data regarding representation of genetic counselors (GCs) in TV shows.
Methods: First, we explored representation of GCs in mainstream TV
shows that incorporate clinical genetics scenarios. Second, to establish
interest in and preferences regarding a hypothetical genetic counseling
themed TV show amongst potential audiences, we surveyed 320 individ-
uals from three different groups: a disability community, a new parent
community, and the general public. We asked respondents about how
they consume their media, and what type(s) of programming they would
prefer for a hypothetical genetic counseling themed TV show. Specifical-
ly, participants used a 5 point likert scale to rate their interest in watching
(would definitely watch to would definitely not watch) hypothetical ge-
netic counseling TV shows of the following types: talk show, reality,
comedy, documentary, or medical drama/thriller. Results: We reviewed
various clips from popular TV shows that incorporate clinical genetics
and identified 6 specific instances in which a GC character could have
been involved or written into a scene. However, to date, to our knowl-
edge, no GCs have ever been portrayed or written into a TV show. Our
survey data showed that the majority of participants in all groups pre-
ferred to watch a medical thriller followed by documentary series, and all
groups rated the comedy the lowest. Conclusion: These data could be
used to illustrate a niche content need to TV producers, and to inform
the development of a show to teach the public about genetic health and
the roles of GCs.
Exploring the Impact of Multiplex Cancer Gene Panels on Genetic
Counselors: BI really didn’t See this One Coming^
C. Kielczewski1, R. Mueller2, A. Weinberg1, L. Kessler1
1. Arcadia University
2. Baer Research Center for BRCA, University of Pennsylvania
Since 2012, advances in technology and research have led to the intro-
duction of multiplex gene testing for cancer susceptibility in clinical set-
tings. While this introduction has been viewed as a cost effective and
efficient approach to testing, it has also yielded an increased number of
unexpected results with unknown consequences for patients and pro-
viders. The goal of this study is to describe counselors’ early experiences
with multiplex cancer panels and to identify the needs of the counselors
based on these experience. Semi-structured telephone interviews were
conducted with members of the National Society of Genetic Counselors
(NSGC) who specialize in cancer genetics about their most memorable
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experience involving multiplex cancer gene panels; counselors were also
asked about their experience receiving and interpreting multiplex gene
panel results. Fourteen genetic counselors were interviewed. All of the
counselor’s memorable cases involving multiplex cancer gene panels
were memorable due to an unexpected result. We categorized the coun-
selors’ reactions into three main types: frustration (expressed by 87.5 %
of counselors), anxiety (71.4 %) and excitement (35.7 %). In this small
study, it was found that the majority of counselors are ordering cancer
gene panels regardless of their overall experience. Despite numerous
challenges, when asked to sum up their experience with multiplex cancer
gene panels, the majority of cancer genetic counselors view multiplex
gene panels as a positive advancement to the field.
Responsibilities, Competencies, andResources of Genetic Counselors
in Management Positions
B. Lubben1, L. Williams2, E. Balkite3, N. Callanan1
1. University of North Carolina at Greensboro
2. GeneDx
3. Genetics Education Consultant, Durham, NC
Background: According to the Professional Status Survey produced by the
National Society of Genetic Counselors (NSGC), the number of genetic
counselors that holdmanagerial positions has increased over the past 4 years.
While genetic counselors continue to expand into managerial positions, little
is known about the responsibilities, competencies, or resources of these
genetic counselors. Goals: The goals of this exploratory study were to 1)
describe the responsibilities of genetic counselors in management positions;
2) evaluate the importance and frequency of use of Accreditation Council for
Genetic Counseling (ACGC) Practice-Based Competencies (PBC) and se-
lect managerial competencies by genetic counselors in management posi-
tions; and 3) identify additional resources genetic counselors use to build
their management skills. We hypothesized that genetic counselors use the
core competencies they already possess when they transition to management
roles. Methods: Online anonymous survey methods and semi-structured
telephone interview methods were used to survey genetic counselors self-
identified as holding management positions. Results: The 113 genetic coun-
selors in managerial positions who completed the survey rated all ACGC
PBC and all given managerial competencies above a rating of 2 (with 3
being the highest), indicating they are important and frequently used in their
current positions. Mentorship and personal communication with other man-
agers was rated as being themost valuable resource to participants in gaining
managerial skills. Although the majority (64 %) of participants received on-
the-job training in management skills, 83 % would have liked additional
resources and/or opportunities for management training prior to beginning
their current position. Conclusions: Genetic counselors report using their
genetic counseling skills in their current managerial position, although they
desire more resources and training in the area of management. A special
interest group (SIG) through the NSGC may be one way managers can
connect with mentors, gather resources, and identify additional training
opportunities.
Provision of Genetic Services: Is it Time to Embrace Social Media?
R. Moore1, A. Matthews1, S. McCandless1,2, A. Goldenberg1,3, L.
Cohen1,2
1. Department of Genetics and Genome Sciences, Case Western Reserve
University
2. Center for HumanGenetics, University Hospitals CaseMedical Center
3. Department of Bioethics, Case Western Reserve University
Social media is changing the way people interact with each other, includ-
ing the manner in which healthcare providers interact with their patients.
Technological advances are being made exponentially in all areas of
healthcare and, to date, there have not been any published studies inves-
tigating patient-provider interactions between genetic counselors and
their patients. The purpose of this descriptive study was to define current
social media usage and interest in social media in the provision of genetic
counseling services. The study aimed to 1) assess genetic counselors’ use
of, interest in, and challenges regarding using social media to interact with
patients and other professionals; 2) assess patients’ use of, interest in, and
challenges regarding using social media to interact with clinical genetics
professionals; and 3) compare use of social media, interest in using social
media for clinical genetics services, and challenges associated with using
social media for patient-provider interactions between the two groups.
Genetic counselors who are members of NSGC (n=223) and genetics
patients at University Hospitals (n=106) were surveyed on their current
use of social media, interest in using social media for patient-provider
interactions, and concerns and challenges for using social media in this
way. This study found that 54 % of the patient population, compared to
only 33 % of the genetic counselor population, reported interest in
patient-provider on social media. The ability to maintain patients’ privacy
and confidentiality was ranked as a high level of concern by both groups.
In addition, 55 % of genetic counselors thought it was somewhat or very
important for NSGC to develop a policy statement addressing social
media interactions with colleagues, and 89 % thought it was somewhat
important for NSGC to develop a policy statement regarding social media
interactions with patients. As both personal and professional interactions
on social media continue to increase, genetic counselors will need guid-
ance on how to respond to social media interactions from patients.
Incidental Misidentification of Constitutional Mismatch Repair
Deficiency via Whole Exome Sequencing and its Impact
on Management
R. Noss1, T. Moss1, E. Mundt2
1. Cleveland Clinic
2. Myriad Genetic Laboratories
Introduction: The following case report illustrates whole exome sequenc-
ing’s potential to identify incidental findings with substantial unforeseen
clinical impact. It also describes the technical limitations of whole exome
sequencing (WES), and how correct result interpretation greatly impacts
appropriate patient care. Case report: JS was a 2 year old male whose
family pursued WES at our clinic due to his history of seizures, GI
dysmotility, laryngomalacia, and hypotonia. WES did not identify a di-
agnosis for the above symptoms, but reported a homozygous mutation in
PMS2. This established the diagnosis of Constitutional Mismatch Repair
Deficiency (CMMRD), which is associated with brain tumors, leukemia,
lymphoma, small bowel and colorectal cancers. Prior toWES the person-
al or family history was not suspicious for CMMRD, but its identification
indicated the need for an intensive screening protocol for JS. The testing
facility did not disclose the mechanism of inheritance, but did not identify
UPD or a PMS2 deletion. Parental testing identified a mutation in JS’s
mother, which established the diagnosis of Lynch syndrome for her. How-
ever, JS’s father did not have a PMS2mutation. JS was retested by a local
genetics department using a separate facility, which identified the pres-
ence of a heterozygousPMS2mutation. This changed JS’s diagnosis from
CMMRD to Lynch syndrome, which is allows his cancer screening to be
delayed until age 20. Discussion: This case illustrates WES’s ability to
identify incidental findings, and demonstrates the need for informed con-
sent prior to testing regarding this potential. Through the reporting of
these incidental findings JS and his family have the ability to receive
tailored screening not evident by the personal and family history. Addi-
tionally, this case illustrates the need to counsel families of the limitations
to the technology utilized by WES.
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The Role of a Genetic Counselor as Coordinator and Clinical
Recruiter in a Study of Hereditary Susceptibility to Lung Cancer
A. Salkowski1, A. Schwartz1
1. Wayne State University SOM/Karmanos Cancer Institute
A Genetic Counselor’s (GC) experience and training provide the unique
skills needed for coordination and recruitment of medical oncology pa-
tients into genetic research studies. For successful recruitment, the coor-
dinator must possess: knowledge of cancer genetics, the ability to collect
family health histories, and from those histories, determine on which
family members to collect medical records and biospecimens for genetic
analysis. Incorporating a GC for recruitment of patients into the Genetic
Epidemiology of Lung Cancer Consortium (GELCC) study from the
Lung Cancer Multidisciplinary Clinic at the Karmanos Cancer Institute/
Wayne State University School of Medicine during a visit with their
oncologist proved to be highly beneficial. Lung cancer patients reporting
a family history of lung cancer were asked for permission to meet with a
GC Study Coordinator at the conclusion of their visit with an Oncologist.
Approximately 90 % of patients approached in this way by the GC were
receptive to discussing the study during their visit. The GC conducted the
consenting process and coordinated biospecimen collection from the pa-
tient (probands) and their family members. During the recruitment period
(1998–2012), about 80 families of the 600 total families collected at our
site originated from clinical recruitment. The biospecimens collected have
been a tremendous resource for linkage analysis, genome-wide associa-
tion studies, and whole exome sequencing analysis, in addition, data have
been provided to the National Institutes of Health bio-repository. As the
recruitment phase ends, there continues to be a need for the skills of a GC
to maintain data, manage medical histories, and facilitate the inclusion of
this unique study population into behavioral and other relevant studies. In
conclusion, the recruitment of participants by a trained GC in the setting
of a Multidisciplinary Lung Cancer clinic proved to be highly effective.
Addressing Employer Needs byMeeting Employee Needs: Successful
Integration of Teleworkers
A. Studinski1, G. Pino1, A. White1, L. Zetzsche1
1. Mayo Clinic
Historically, the Biochemical Genetics Lab (BGL) at Mayo Clinic was
supported by a team of onsite genetic counselors (GCs). In response to
continued institutional growth and typical turnover, compounded by
growing demands for GCs nationally, teleworker use was evaluated. To
assess feasibility, the responsibilities of the BGL GCs were categorized
into three primary groups of tasks that: 1) could be accomplished offsite,
2) could not or would pose difficulty, or 3) would require additional
discussion. In addition, potential barriers and onsite:teleworker ratios
were considered. After evaluating the daily team responsibilities, initial
concerns were raised regarding the number of items which could not be
performed by a teleworker. However, after extensive review of how
duties were performed it was found that the majority could be done with
minor modifications. Those remaining were primarily team building or
professional enhancement activities. The times and reasons a teleworker
would need to physically be at the laboratory were anticipated. The larg-
est onsite time commitment was for training. The structure of these visits
varied depending upon previous laboratory experience. Multiple trips
were required which allowed new GCs to gain specific skills and put
them into practice at their offsite work locations. The hiring of two
teleworkers provided an impetus for reviewing processes. The majority
of anticipated barriers were overcome easily by streamlining activities,
using existing resources, and implementing new tools. Communication is
enhanced through instant messaging and daily team meetings.
Limitations posed by the employer provided hardware are still under
consideration. Currently, BGL is supported by a team of four GCs, with
two working onsite and two remotely. Advance planning provided a
smooth transition for incorporating teleworkers and continued evaluation
contributes to ongoing success. Team structure is similar to when all
employees were onsite with GCs contributing to daily activities and
enjoying task and project diversity.
Effectiveness of Telephone Genetic Counseling for Parkinson Disease
and Association with Disease Status and Genotype
J. Verbrugge1, L. Cushman1, D. Smith1, L.Wetherill1, J. Jackson1, C.
Halter1, K. Sims2, W. Xin2, V. Arnedo3, S. Lasch4, K. Marek4, T.
Foroud1
1. Indiana University, Dept of Medical and Molecular Genetics
2. Massachusetts General Hospital, Department of Neurology
3. Michael J. Fox Foundation
4. Institute for Neurodegenerative Disorders
Introduction: While numerous studies have demonstrated the effective-
ness of telephone genetic counseling, there is currently a lack of published
data regarding its use in counseling for complex disorders and the poten-
tial associations between knowledge retention and patient characteristics.
This study evaluated the effectiveness of telephone genetic counseling for
Parkinson disease (PD) in individuals tested for the LRRK2G2019S gene
mutation, which is associated with a 30 % risk of developing PD by age
80. Methods: After testing, telephone genetic counseling was performed
by a single genetic counselor. Following the counseling session, partici-
pants were asked to complete an online survey that assessed their under-
standing of the information provided during the session. Knowledge re-
tention was compared between study groups defined by PD status (affect-
ed vs. unaffected) and LRRK2 test results. Results: Of 653 eligible par-
ticipants, 359 completed the survey (55.0 %). The average number of
correct responses was 9.5 out of 11 (86.4 %), with no significant differ-
ence among study groups. However, when questions were analyzed in-
dividually, significant group differences were detected. LRRK2 carriers
were more likely to respond correctly to a question regarding segregation
of the LRRK2 mutation (>=90.0 % vs. <=61.4 % in LRRK2-negative;
p=0.001), while LRRK2-negative individuals were more likely to respond
correctly to 2 questions regarding the risk of PD in a non-carrier
(>=89.1 % vs. <=75.0 %, p=0.003; >=91.2 % vs. <=86.7 %, p=0.03).
When asked about PD risk and aging, individuals with PD were more
likely to respond correctly than unaffected subjects, regardless of geno-
type (>=95.9 % versus <=79.2 %; p=0.005). Conclusions: This study
demonstrates the effectiveness of telephone genetic counseling for a com-
plex disorder and suggests that the specific information retained may
correlate with an individual’s disease status and gene test results. These
findings may have implications for the use of telephone genetic counsel-
ing in patients with PD or other multifactorial conditions.
Systematic Processes to Formalize andOptimize Patient Engagement
in a Large Healthcare System
J. Williams1, A. Rahm1, D. Davis1
1. Geisinger Health System
Since the early 2000s, initiatives organized under two related con-
cepts have sought to alter the landscape of health care delivery and
health care research: (1) patient-centered care is a philosophy and a
practice that privilege the perspectives, needs, values, and prefer-
ences of patients in everything from the design of hospital units to
models of decision making and (2) in the domain of research and
discovery, patient engagement entails similar strategies and aims,
Yashar et al.1134
with the overall goal of optimizing the outcomes and translation of a
range of activities, from quality improvement to clinical trials. In
early 2014, research leadership at the Geisinger Health System
launched a revision of the system’s research strategic plan with
the recognition that the voice of patients in planning and executing
research was non-existent. In response, the revised strategic plan
included recommendations to make patient engagement the
Bdefault^ – rather than the exception – in Geisinger research and
discovery and to establish mechanisms for achieving this goal.
Those mechanisms include the establishment of a standing patient
and family engagement working group with specified tasks and
timeframes and the development of a conceptual framework for
patient and family engagement to guide investigators in their efforts
to enlist participants in the design and conduct of research, especial-
ly research involving definitions and measures of patient outcomes.
We will present the strategies developed by the Geisinger working
group and share materials employed to encourage measurable pa-
tient engagement in all aspects and phases of research and discov-
ery. We will discuss the role played by genetic counselors in the
Geisinger working group and suggest roles for broad professional
investment in promoting patient engagement strategies.
Certified Genetic Counselors in Japan: Current Status 2014
Y. Yamanouchi1, H. Murakami2, N. Tanabe3, E. Utsuno4, N.
Nakagawa5
1. Kawasaki University of Medical Welfare Graduate School
2. Clinical Genetics Unit, Kyoto University Hospital
3. Kitasato University School of Pharmacy
4. Chiba University Hospital
5. Tottori University Hospital
Introduction: We report the current status of certified genetic coun-
selors in Japan. The Japanese certification program for genetic
counselors began in 2005. In this program, a certified genetic coun-
selor is described as Ban expert that assists clients suffering from
genetic problems in conjunction with clinical genetic specialists and
protects their rights to facilitate the provision of high-quality clinical
genetic medical care.^ The Japanese Association of Certified Genet-
ic Counselors conducted this survey of their members. In Japan, all
of the certified genetic counselors belong to this association. Mate-
rials and Methods: The subjects were 161 certified genetic coun-
selors in Japan. This survey was carried out using a self-
administered anonymous questionnaire (for confirmation of the re-
sponses, we requested them to write their names if they did not
mind). The questionnaire was distributed by attaching it to emails
to the certified genetic counselors in our mailing list, or postal mail
delivery, and collected by email or postal mail delivery. The ques-
tionnaire contains 20 questions regarding their basic attributes and
statuses (e.g., work situation, specialty, work details, and income)
before and acquiring their certification as a genetic counselor, as
well as any issues that they may have currently. Results: One hun-
dred and twenty subjects responded (response rate: 72 %). All of the
respondents were employed after acquiring their certification. Over
90 % of the certified genetic counselors were female. Their ages
widely ranged from twenties to fifties. Medical institutions
accounted for the highest percentage as work places, where they
belong to various specialty departments. Many of them felt that
there are problems in their employment conditions. More than half
of them have participated in a seminar required for continuation of
their qualification during their vacation time. Following more de-
tailed analyses, we will report the current status of certified genetic
counselors in Japan.
Genetic Test Utilization Review: Moving it Upstream
L. Zetzsche1, G. Bentz Pino1, A. Studinski1, A. White1, S. Vitek1, M.
Erath1, E. Winters1
1. Mayo Clinic
Many large healthcare organizations have instituted genetic test utiliza-
tion management (UM) programs to help address the growing number
and cost of genetic tests ordered, which due to the complexity and large
array of available testing options, are particularly prone to errors. Mayo
Clinic implemented a UM program for review of sendout genetic testing
that is connected to its large referral catalog through Mayo Medical Lab-
oratories (MML). In the initial phase of this UM program, test orders were
reviewed by a genetic counselor team for potential errors and appropri-
ateness of testing at the point of sendout through the MML Referrals
department. This included a review of the medical record, test paperwork,
and whether or not the test was currently in theMML referral catalog. The
second phase of the program centered upon genetic sendout tests for
which DNA extraction/cryopreservation services were performed by the
MayoClinicMolecular Genetics Laboratory. Test requests were reviewed
after insurance preauthorization was obtained but before the specimen
and test request were forwarded to the MML Referrals team. The UM
program then evolved to move the review process upstream, closer to the
time of order entry. The Mayo Clinic Department of Medical Genetics
collaborated with the genetic counselor UM team to review sendout ge-
netic test orders on the day of order entry, prior to the initiation of insur-
ance review and precertification. A review of the data from the different
phases of the genetic sendout UM program at Mayo Clinic demonstrate
that by moving the review process upstream, resources of both time and
dollars are conserved. Other benefits include redundancy reductions, in-
creased discussions with ordering providers closer to the time the patient
was seen, and education regarding testing trends and preferred referral
laboratories.
XI. Professional Issues/Professional Roles
Genetic Counselor Workforce Issues: A Survey of Genetic
Counselors Licensed in the State of Indiana
S. Cohen1, P. Delk2, M. Tucker3
1. St. Vincent Hospital
2. Indiana University
3. Indiana State University
We have observed the movement of genetic counselors (GCs) out of
clinical positions in the state of Indiana. The aim of this study is to
identify reasons for this movement and factors that might help employers
retain board-certified GCs in clinical positions. Although there are some
publications on access to GCs, the changing landscape of genetic ser-
vices, and professional satisfaction among GCs, no studies have ad-
dressed this apparent recent shift away from clinical roles or why GCs
change jobs. Methods: An anonymous on-line survey of GCs ever li-
censed in the state of Indiana was conducted. Subjects were recruited
from the Indiana Network of Genetic Counselors (n=48) and the Indiana
Professional Licensing Agency (n=85); invitees were encouraged to for-
ward the invitation to previous co-workers. Results: There were 42 re-
sponses from GCs, most of who reside and are actively licensed in Indi-
ana. Of these, 29 % reported they work for a laboratory or in industry and
71% for a hospital. Thirty-seven percent of respondents reportedworking
in their current position for less than 1 year and 26 % reported thinking
about leaving their current position at least monthly. Of the 17 GCs
(40 %) who reported changing jobs within the past 2 years, 94 % were
previously working in a hospital clinic setting and 53 % reported current-
ly working in a laboratory or industry position. Salary and flexibility were
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most often reported as reasons for changing jobs. Additional analysis to
identify factors associated with dissatisfaction and free-text comments
will be analyzed for common themes. Conclusions: This is the first doc-
umentation of the movement of GCs out of clinical roles into industry
positions. This changing landscape may impact the access to clinical
services and the training of genetic counseling students. This data will
provide employers with data to help attract and retain GCs in clinical
roles.
What do Genetic Counselors who Work at Fetal Centers do?
M. Dudek1, S. Reichert2
1. Vanderbilt University
2. Children’s Hospital of Philadelphia
Introduction: When a fetal abnormality is suspected in pregnancy, referral
to a multidisciplinary Fetal Center is evolving to be the standard of care.
The roles and responsibilities of genetic counselors (GCs) in this setting
has not been characterized. Purpose: The purpose of this study was to
assess the roles and responsibilities of genetic counselors in Fetal Centers.
All GCs working in a Fetal Center were eligible. GCs were identified by
two separate methods. 1) GCs had previously been ascertained by a
demographic survey about Fetal Centers and were emailed directly. 2)
GCs were recruited to participate on the NSGC Prenatal Special Interest
Group (SIG) message board. Methods: An online survey was created and
administered via REDCap, a secure web application for building and
managing online surveys and databases. Questions were compiled from
a review of the literature on defining GCs roles. Survey responses were
tabulated using descriptive statistics. Results: From January to March of
2015, 68 GCs completed the survey. Of the GCs whowere emailed, 54%
participated. One-fifth of respondents were recruited from the NSGC SIG
post. GCs from 24 states were represented and demographics were com-
parable to the NSGC membership. All respondents indicated that they
provided direct patient care, ordered tests and managed results. The ma-
jority of GCs also obtain insurance authorizations (88 %), provide case
management (79 %), and perform administrative tasks like scheduling
(71 %). While GCs were involve with teaching (63 %) and research
(22 %), their average effort was less than 10 % for these tasks. Direct
patient care required >50 % of the GCs’ effort on average. Conclusions:
Genetic counselors’ skills in patient care and expertise in genetic testing
are utilized in the Fetal Center setting. These skills are core competencies
for GCs. New graduates from genetic counseling programs or GCs
looking for a new opportunity should pursue or create a Fetal Center
position.
Comparing Pharmacy and Genetic Counseling: Education Related
to Pharmacogenomics and Attitudes about Roles and Collaboration
in Clinical Pharmacogenomics
C. Gilliland1, C. Wicklund2, S. Johnson3, S. Aufox2
1. Northwestern Genetic Counseling Program
2. Northwestern University, Feinberg School of Medicine
3. Kaiser Permanente Colorado, Skaggs School of Pharmacy
Background: Genetic counselors (GC’s) and pharmacists have been pro-
posed as an ideal team to help provide clinical pharmacogenomic ser-
vices. Due to this topic’s limited research, this study sought to assess
their interest in collaborating, level of preparedness to discuss
pharmacogenomics, and barriers to professional involvement and roles
in clinical implementation. Methods: Third/fourth year pharmacy stu-
dents, second year GC students, and recent GC alumni from fifteen uni-
versities with coexisting pharmacy and GC programs were sent an email
invitation to participate in an online survey. The survey was developed by
the primary investigator, piloted on GC students, and revised based on
feedback.
Results: 103 individuals responded to the survey. The majority were inter-
ested in collaborating with either a pharmacist (n=75, 80.6 %) or a genetic
counselor (n=72, 84.7 %), and saw a role for both professions (n=94/96) in
clinical pharmacogenomics. Participants did not feel adequately prepared to
speak to physicians or patients about pharmacogenomic information and
indicated a need for further training. GC alumni were more likely to agree,
than other participant groups, that the following acted as barriers to becoming
involved in clinical pharmacogenomics: their role in clinical
pharmacogenomics is uncertain (p=0.001), and their lack of personal interest
is a barrier to their involvement (p=0.011). While most participants elected
pharmacogenomic roles that would traditionally align with their profession,
there was some overlap of anticipated roles between professions. Discussion:
While respondents expressed interest in collaborating and saw a role for both
professions, most did not feel adequately prepared to discuss
pharmacogenomics. This suggests a need for additional pharmacogenomics
education during training and continuing education. Since GC alumni per-
ceived more barriers to becoming involved in clinical pharmacogenomics,
we suggest collaborative efforts begin at the student level.
The Evolving Partnership Between the Clinical and Laboratory
Genetic Counselor
S. Stasi1, J. Conta1, D. Sternen1, K. Golden-Grant2
1. Seattle Children’s Hospital and the Pediatric Laboratory Utilization
Guidance Services
2. Genetic Medicine, Seattle Children’s Hospital
Opportunities for and responsibilities of laboratory genetic counselors
(GC) are evolving. This ongoing growth has an impact on the traditional
scope of the clinical genetic counselors’ role. In this report, we present the
evolution of both roles at Seattle Children’s Hospital and the division of
responsibility at each step of the genetics evaluation. Historically, the
clinical genetic counselor has been involved in all aspects of the patient’s
pediatric genetic testing experience, including intake, evaluation, test se-
lection, pre- and post-test counseling, and test coordination. With the
rapid expansion of test options, the addition of the lab GC’s expertise
regarding genetic testing methodologies provides positive support to the
clinical GC in the effort to select the most appropriate test for each patient.
The laboratory GC can more efficiently recommend reference laborato-
ries based on internal lab-defined variables such as institutional contracts,
reducing the rework of order triage. The labGC also has a unique window
into institution-wide practices and in consultation with the clinical GC
can partner to direct patient referral to genetics clinic when non-genetics
specialists request guidance for genetic test orders. The authors highlight
the opportunities for a collaborative and supportive relationship of the lab
and clinical GC and their contribution to the successful implementation of
genetic services. This partnership results in improved patient care and
genetic counselor satisfaction.
Psychiatry/Neurology
The Changing Age of Individuals Seeking Presymptomatic Genetic
Testing for Huntington Disease
M. Beyer1, J. Quillin2, T. York3, C. Testa4, A. Rosen5, V. W. Norris4
1. Virginia Commonwealth University
2. Virginia Commonwealth University Massey Cancer Center
3. Virginia Institute for Psychiatric and Behavioral Genetics
4. Virginia Commonwealth University Parkinson’s and Movement Disor-
ders Center
5. Emory University School of Medicine
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Huntington disease (HD) is a progressive neurological disorder with on-
set typically later in life. Presymptomatic genetic testing is available for
at-risk individuals to clarify their HD status. By defining the characteris-
tics and motivations of individuals who seek presymptomatic genetic
testing for HD, genetic counselors can provide comprehensive and per-
sonalized care. The aims of this study were to: 1) determine whether or
not the average agewhen individuals seek presymptomatic genetic testing
for HD has decreased over time, 2) define motivations for seeking testing
and correlate them with age at testing, and 3) explore genetic counselors’
perceptions of the shift in age. A small but statistically significant de-
crease in age was observed (p=0.045). The relationship between age at
testing and year of testing is modified bywhether or not an individual was
in a committed relationship at the time of testing (p=0.03). A survey of
individuals at risk for HD was also administered to elucidate the most
frequently cited motivations for testing and correlate them with age at
testing. Three motivations showed a significant correlation with age at
testing; individuals who were tested at younger ages were significantly
more likely to cite BTo learn whether or not you would develop HD^ and
BTo make choices about further education or a career^ (p<0.05). BTo give
children a better idea of their risk^ was more frequently cited as a moti-
vation for testing by older individuals (p<0.002). Finally, a survey was
given to genetic counselors to determine their perception of a change in
age. Sixteen percent of genetic counselors surveyed perceived a change in
age of testing. All of these respondents felt the age at testing has de-
creased, and have provided presymptomatic testing for ten or more years.
The findings from this study can be used by genetic counselors to help
provide more personalized counseling based on the age of the individual
seeking testing, and provide a starting point for more research into the
relationship between age at testing and motivations for testing.
Detection of Causative Variants Using Multigene Panels
in a Pediatric Population with Epilepsy
C. Campbell1, E. Partack1, V. Pilipenko1, K. Holland1, T. Burrow1,
H. Greiner1
1. Cincinnati Children’s Hospital Medical Center
Guidelines for ordering genetic testing for epilepsy have not been devel-
oped and there is little information available on the yield of multigene
panels for epilepsy. The purpose of this study was to determine the yield
of epilepsy multigene panels among a pediatric population, as well as to
identify potential clinical predictors of obtaining a causative genetic var-
iant using epilepsy multigene panels. This retrospective medical record
review examined the data of 117 pediatric epilepsy patients at a large
tertiary referral center who had at least one epilepsy multigene panel of
any type ordered between January 1st, 2009 and December 31st, 2013.
The association of clinical predictors with causative results was analyzed
using the chi-square test, Fisher’s exact test, andWilcoxon rank-sum test.
Of 124 epilepsy panels ordered, 17 (14 %) received a causative result.
Tonic or atonic seizures detected on EEG were significantly associated
with causative results (p=0.04). A higher proportion of children with
myoclonic seizures on EEG had a causative variant identified (p=0.06).
Microcephaly, age of onset of epilepsy, developmental delay, drug resis-
tant epilepsy, and abnormal brain MRI results were not significant. There
was no significant relationship between number of genes on multigene
panels and panel results. This is the largest study examining yield and
clinical characteristics of patients with causative variants from epilepsy
multigene panels. The overall yield in a pediatric population was compa-
rable to other studies. This study identified that certain seizure types (tonic
or atonic seizures on EEG) are clinical predictors of causative multigene
panel results, however further studies are needed to confirm these clinical
predictors and clarify the utility of various ordering practices for genetic
testing in epilepsy.
Complexities of Genetic Counseling for Amyotrophic Lateral
Sclerosis: A Case of Two Distinct Mutations in a Single Patient
K. Dent1, M. Bromberg2, J. Downie3, K. Figueroa2, S. Pulst2, L.
Jorde3, S. Gibson2
1. Department of Pediatrics, University of Utah
2. Department of Neurology, University of Utah
3. Department of Human Genetics, University of Utah
Amyotrophic lateral sclerosis (ALS) is a degenerative disease of the mo-
tor neurons occurring in ~2 per 100,000 individuals. The disease is pro-
gressive leading to limb paralysis and death from respiratory failure with
2–4 years median survival. In ~10 % of ALS cases, the disease is
inherited in an autosomal dominant pattern (AD-ALS) and penetrance
is age-dependent. Approximately two-thirds of AD-ALS can be ex-
plained bymutations in any one of four genes:C9orf72, SOD1, TARDBP,
and FUS. However, mutations in several other genes have also been
associated with AD-ALS including ANG, OPTN, and VCP.
We report the identification of two disease-causing mutations in the
SOD1 and ANG genes in an individual with AD-ALS. Onset of symp-
toms was at 60 years with weakness in the right upper limb. Cognition
was normal. The patient’s ancestry was Irish and Scottish. Disease
progressed rapidly with death occurring 2 years after diagnosis. The pa-
tient’s mother and maternal grandfather also had ALS. Genetic testing
identified an I113T missense mutation in the SOD1 gene and a K41I
missense mutation in the ANG gene. Mutations in SOD1 are associated
with AD-ALS and the penetrance of the I113T mutation is reported to be
reduced. Missense mutations of the ANG gene have been associated with
ALS in the British Isle populations. The K41I mutation is rare and pre-
dicted to be deleterious. The patient’s parents were not available for
testing so from which parent(s) each mutation was inherited could not
be determined. It is unclear to what extent either or both mutations con-
tributed to disease in this case but both are likely contributing. ANG
mutations are more common in this patient’s ancestry and consistent with
rapid disease progression. However, recurrence risk counseling for her
offspring is complicated as either mutation can cause AD-ALS albeit with
varying penetrance and expressivity.
An Investigation of Neurologists’ Perceptions of the Value of Genetic
Counselors in the Neurology Clinic
G. Egar1, J. Dalton1, P. McCarthy Veach1, H. Zierhut1
1. University of Minnesota
Introduction: Genetic counseling outcomes research focuses on the
impact of clinical genetic counseling services on patient care. Mea-
suring genetic counseling outcomes involves examining the roles
genetic counselors play, the value added by their services, and the
resulting patient outcomes. Other healthcare professionals who work
in close association with genetic counselors are in ideal positions to
provide one perspective on the value of genetic counselors. The
purpose of this qualitative study was to assess perceptions of genetic
counselors’ roles, value added, and resulting patient outcomes from
the perspective of neurologists. Methods: Clinical neurologists or
neurogeneticists currently working in the United States with genetic
counselors were recruited through emails to 56 genetic counselors
that indicated a specialty in neurology on the NSGC website. Of the
42 identified neurologists, 10 from various U.S. regions participated
in semi-structured audio-recorded phone interviews and 7 rated the
value of specific genetic counselor duties. Inductive and cross case
analysis methods yielded several prevalent themes. Results: Neurol-
ogists indicated genetic counselors’ most valuable contributions are
genetic expertise and specialized training, especially in genetic
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testing. They unanimously agreed that genetic counselors are very
valuable to their neurology practice in terms of explaining genetic
etiology and risk to patients, facilitating the genetic testing process,
and providing psychosocial support and resources to patients. They
also indicated genetic counselors have an important role in clinic
coordination. Barriers to genetic counselors included lack of
funding and limited availability. Discussion: This study indirectly
measured genetic counseling outcomes through the eyes of their
physician counterparts in the neurology setting. The results charac-
terize valued roles for clinical genetic counselors in a multidisciplin-
ary team, identify their unique contributions to patient care, and
support the importance of their contributions to patient outcomes.
Perceptions and Utilization of Genetic Counseling by Adults
with Charcot-Marie-Tooth
E. Francisco1, J. Caress2, M. Berry2, N. Callanan1
1. University of North Carolina at Greensboro
2. Wake Forest Baptist Health
Background: Charcot-Marie-Tooth disease (CMT) is a hereditary
motor and sensory neuropathy affecting one in 2,500 people glob-
ally. Objective: The purpose of this study was to assess the percep-
tions, experiences, and utilization of genetic counseling services by
adults with CMT. Methods: Data was collected using an online
anonymous survey distributed through the Hereditary Neuropathy
Foundation Results: The survey had 724 total respondents, not all
of whom answered every question. Overall, 49 % of participants had
received genetic counseling, from a neurologist (54 %), genetic
counselor or medical geneticist (37 %) or other provider (9 %). Of
236 respondents, 72.4 % (186) indicated they had never been of-
fered an appointment with a genetic counselor. Of 535 respondents ,
51.4 % (275) indicated that they would be interested in being re-
ferred to a genetic counselor. Participants who have not had genetic
counseling (N=186) were more likely to identify receiving support
as a potential benefit of this service than those who had genetic
counseling. They were also more likely to be concerned about po-
tential negatives such as discrimination and cost, compared to those
who had genetic counseling. Of 652 respondents, 52.6 % indicated
that they had been offered genetic testing, 79.6 % chose to pursue
this service, and 92.5 % of those that received testing were happy
with their decision. Of those who were not offered or did not pursue
testing, 71.6 % (227) indicated they were interested in pursuing
genetic testing. Discussion: The results of this study suggest that
many people with CMT are not being referred for genetic counsel-
ing and testing. Genetic counselors can work to eliminate this bar-
rier by educating neurologists about benefits of pre and posttest
genetic counseling for CMT patients. Genetic counselors should
also consider spending more time focusing on support needs for
these patients, as it is highly desired in this population.
Planning, Implementation, and Evaluation of a New Clinical
Simulation: Psychiatric Disease Case
B. Fuller1, L. Holt1, D. Taylor Peterson1, C. Hurst1, J. Austin2
1. University of Alabama at Birmingham
2. Departments of Psychiatry and Medical Genetics University of British
Columbia
Psychiatric illnesses are common and have complex etiologies with
genetic and environmental factors. Despite the fact that genetic
counseling can benefit individuals and family members affected by
psychiatric illness, genetic counselors often feel unprepared or
unqualified to address these conditions. Training opportunities to
address the needs of individuals with a psychiatric illness are limit-
ed in the clinical setting since few patients are seen by genetic
counselors for the primary indication of psychiatric illness. Howev-
er, many of the patients seen by genetic counselors are affected by
some form of psychiatric disorder, either as part of a larger genetic
diagnosis or as an isolated issue. Without deliberate training, genetic
counselors may continue to feel unprepared and patient’s needs may
continue to be unmet. To introduce more psychiatric illness content
into genetic counseling clinical training, a clinical simulation was
developed, implemented, and evaluated at the University of Ala-
bama at Birmingham (UAB) Genetic Counseling program. The sim-
ulation scenario lasted 90 minutes, including pre and post briefing
and evaluation. The scenario required genetic counseling students
(n=11) to address disease etiology and recurrence risk with a stan-
dardized patient with bipolar disorder. Participation was required by
the UAB curriculum, but all students consented to their data being
used for research purposes. Participants’ responses were evaluated
to determine if the simulation experience increased their content
knowledge and their comfort with providing genetic counseling
for this indication. Pre and post simulation, students used a five-
point Likert scale to self-rate their comfort level with providing
psychiatric genetic counseling. Content knowledge was measured
by open responses to questions concerning specific vignettes. While
content knowledge showed no change post-simulation, comfort lev-
el increased by 65.9 %. Our findings suggest that the simulation
could potentially encourage students to engage with an underserved
population.
Exploring Physician Perceptions of Psychiatric Genetic Counseling
and Conceptual Barriers to Referrals
E. Leach1, E. Morris2, H. White3, A. Inglis2, J. Austin2
1. University of British Columbia - Vancouver
2. University of British Columbia
3. California State University-Stanislaus
Background: The world’s first specialist psychiatric genetic counseling
(PGC) service of its kind was founded in Vancouver in 2012, and the
discipline is emerging as a specialty within the genetic counseling pro-
fession. While clear benefits of PGC services have been demonstrated,
experience in Vancouver reveals that many physicians do not regularly
refer to the clinic. Understanding the barriers that obstruct physicians
from making referrals to PGC will allow the development of mitigating
strategies. Methods: Using a grounded theory approach, telephone inter-
views were conducted with 12 physicians from Vancouver who were
aware of a local PGC clinic with the aim to understand the process by
which physicians make decisions about referring patients for PGC. Inter-
views were recorded, transcribed verbatim, coded, and a constant com-
parative analysis of emergent themes was conducted. Results: Patient
cues and physicians’ perceptions about the purpose of PGC inform their
referral practices. Physicians perceive PGC to be an information-focused
intervention, and consider referral when patients express desire for infor-
mation about recurrence risk or etiology that they feel unable to address
themselves. Even when physicians are able to identify the psychothera-
peutic benefits of PGC, patient psychotherapeutic needs are not perceived
as cues for referral to PGC. Implications: These data suggest that further
work is necessary to position PGC in physicians’ minds as a service that
could potentially benefit most individuals with psychiatric disorders and
their families. In particular, it will be important to increase physicians’
awareness of: a) the importance of psychotherapeutically-oriented
counseling around issues of risk and etiology, and b) the role that genetic
counselors can play in this domain, in a manner that is complementary to
and supportive of the role of the physician.
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Compound Heterozygosity of Two MECP2 Deletions with Paternal
Inheritance of a Late-TruncatingMutation in a Female with Atypical
Rett Syndrome
A. Lindy1, M. Rumple2, M. Morrow2, A. Shanmugham1, D. Stolar1,
T. Zach2, D. McKnight1
1. GeneDx
2. Banner Children’s Specialists
Introduction: Rett syndrome (RS) is an X-linked dominant
neurodevelopmental disorder caused by mutations inMECP2 that predom-
inantly affects females. RS is characterized by a period of apparently normal
development until 6–18 months of age, followed by gradual loss of motor
and communication skills. The majority of cases are sporadic, with only a
few maternally-inherited mutations described. Rarely, males with RS due to
a mosaic point mutation or hemizygosity for a late-truncating mutation have
been described. Purpose: To expand the current knowledge of familial Rett
syndrome, we describe a case of a paternally-inherited late-truncating muta-
tion and a maternally-inherited variant of unknown significance (VUS) in
MECP2 in a female with atypical RS. Methods: Next generation sequencing
of a 51-gene panel for epilepsy was completed and two MECP2 variants
were identified in the proband. Confirmations and subsequent parental test-
ing were performed by Sanger sequencing. Results: We identified two novel
deletions in exon 4. A maternally-inherited deletion of 2 amino acids
(c.1101_1106delCCACCA) and a paternally-inherited deletion of 70 nucle-
otides (c.1129_1198del70) resulting in late protein truncation. In-frame de-
letions within this region of exon 4 have been described previously and are
considered of unclear clinical significance. The paternal frameshift mutation
is likely pathogenic, consistent with rare reports of late-truncating mutations
in affected males and carrier mothers. Conclusions: Here we report a case of
a female with atypical RS who inherited a late-truncating mutation from her
symptomatic father and a VUS from her mother with learning disabilities.
Males with late truncating mutations similar to the c.1129_1198del70 muta-
tion have been described with intellectual disability and atypical RS. This
family represents the first report of paternal transmission of one of these
variants. It is unclear if the more severe phenotype of the proband reflects
the phenotypic variability of late-truncating mutations and/or can be attrib-
uted to the maternal VUS.
Training to Provide Psychiatric Genetic Counseling: How does it
Impact Recent Graduates’ and Current Students’Attitudes Towards
Individuals with Psychiatric Illness and Their Readiness to Provide
Genetic Counseling for this Population?
A. Low1, C. Hippman2, S. Dixon1, A. Higgs1, J. Joines1
1. University of Maryland School of Medicine
2. University of British Columbia, Department of Psychiatry
Background: Mental illness (MI) is pervasive in the general population
and genetic counselors (GCs) frequently see patients with MI as either a
primary indication or incidentally. GCs report discomfort in providing
psychiatric genetic counseling (PGC), suggesting the need for a critical
look at current training in this area. This study aimed to investigate PGC
training and its impact on perceived preparedness to provide PGC (pre-
paredness). Methods: Current students and recent graduates (graduation
year 2009–2014) were eligible to complete an anonymous survey, sent
via the NSGC listserv between Oct-Nov 2014. The survey included de-
mographic questions and questions characterizing PGC training and out-
comes (open- and closed-ended). Bivariate correlations (p<.10) identified
variables for inclusion in a logistic regression model to predict prepared-
ness. Data were checked for assumptions underlying logistic regression.
Results: Of 1,167 eligible NSGC members, 286 completed the survey
(response rate: 24.5%; 33.9 % students, 46.8 %with a personal history of
MI). The logistic regression model χ2 (8)=84.87, p<.001) explained be-
tween 37.1 % (Cox & Snell R2) and 49.7 % (Nagelkerke R2) of the
variance in preparedness scores. More frequent PGC instruction
(OR=5.13), more active methods for practicing risk assessment
(OR=4.43), and education on providing resources for MI (OR=4.99)
made uniquely significant contributions to the model (p<.001). Re-
sponses to open-ended questions revealed an overwhelming interest in
further PGC training, particularly enabling ‘hands on’ experience, and the
sentiment that current PGC training is inadequate. Discussion: This ex-
ploratory study suggests that enriching PGC training by offering more
frequent instruction on PGC and more active opportunities to practice
PGC skills will support students in feeling more prepared to provide
PGC after graduation. GC training programs are in an ideal position to
improve outcomes for future students by evaluating their current ap-
proach to PGC training and exploring new interventions designed to
improve preparedness.
Perspectives on Genetics Among Individuals with Trichotillomania
L. Nassereddine1, J. Picker2, H. Andrighetti3, E. Cross1, B. Rosen
Sheidley2
1. Brandeis University
2. Boston Children’s Hospital
3. Translational Psychiatric Genetics Group
An estimated 3.7 million people in the United States struggle with Tricho-
tillomania (TTM), a psychiatric disorder involving chronic or compulsive
hair-pulling, leading to excessive hair loss frequently involving pro-
nounced functional impairment, and often associated with depression,
anxiety, low self-esteem and impaired quality of life. TTM twin and
family studies indicate that genetic factors contribute significantly, with
heritability of 76 % and recurrence rates among first-degree relatives of
approximately 11 %. Inheritance of TTM is likely to be complex and no
molecular testing is available currently. The purpose of this study was to
explore beliefs, experiences and attitudes of individuals with TTM about
the potential roles of: 1) heritability in causation, 2) genetic testing, and 3)
genetic counseling in this disorder. We recruited individuals with a self-
reported history of TTM through online TTM support groups to partici-
pate in an online, anonymous survey consisting of 40 multiple choice and
open-ended questions. Among the 299 respondents who completed the
survey, 31 % reported having a first-degree relative who also has TTM.
Approximately one-third (35 %) indicated that they were uncertain of the
recurrence risk of TTM, 29% believed there was an up to 50% chance of
recurrence, and the remaining 37 % believed there was less than a 25 %
chance of having a child with TTM. Many (63 %) were interested in
hypothetical genetic testing for TTM and 43 % indicated interest in ge-
netic counseling. While 48 % did not see direct benefits to receiving
genetic counseling others saw pursuing genetic testing as a public educa-
tion benefit. Only 7 participants reported meeting with a genetic counsel-
or, with two reporting the meeting as unhelpful. Our findings suggest the
recurrence risk for TTM may be higher than previously estimated. They
also highlight variable interest in and understanding of genetic testing and
counseling.
Novel In-Frame Deletion in GRIA3: A Case Report
H. Newman1, M. Taylor2, J. Jirikowic2, A. Bergner1
1. Ambry Genetics
2. University of Colorado School of Medicine
X-linked intellectual disability (XLID) is a collection of genetically het-
erogeneous disorders thought to explain approximately 16 % of all intel-
lectual disability in males. More than 90 genes on the X chromosome
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have been implicated in XLID thus far. One such gene, GRIA3, encodes
glutamate receptor 3, and is located on chromosome Xq25. Although
clinical and functional data on GRIA3 in the literature is limited, several
reports have shown mutations in GRIA3 to be associated with varying
degrees of intellectual disability, behavioral problems, autistic features,
seizures, poor muscle bulk, short stature, and dysmorphic features. Here,
we present a novel GRIA3 in-frame deletion located in a functional do-
main of coding exon 13 (c.2167_2175delGCCCGAGTG), which was
identified in a male proband with severe intellectual disability, behavior
problems, hypothyroidism, and dysmorphic features. The variant was
shown to segregate with disease in all affected male members of this
individual’s family, allowing the alteration to be reclassified from a var-
iant of uncertain significance to a variant that is likely to be pathogenic.
Previous testing in this proband and his family members detected two
translocations [t(4q;10p) and t(6;9)] that did not segregate with disease in
the family. The data presented here not only contributes additional phe-
notypic information regarding GRIA3 alterations to the currently limited
literature, but also highlights the importance of family studies in variant
reclassification efforts.
An Extension of our Assessment: Addressing Psychiatric Concerns
in Prenatal Genetic Counseling
R. Peralta1, K. Steinhaus French1, J. Toohey1, M. Bocian1
1. UC Irvine
There is a broad range of psychiatric disorders that can present within the
prenatal setting, including depression and anxiety. The relative high fre-
quency of mental health disorders in pregnancy and the potential for
adverse outcomes indicates that there would be benefit in identifying a
history of mental health disorders during pregnancy so that appropriate
referrals can be made. This study was designed to determine if any spe-
cific demographic or historical factors could be correlatedwith depression
and anxiety among patients being seen for prenatal genetic counseling.
Prior to seeing the GC, participants were given an anonymous 32-
question survey which assessed demographics, pregnancy history, genet-
ic counseling referral indication, mental health history, and two 8-
question PROMIS screens: one for depression, and one for anxiety. In
total, 122 women participated in the study. Overall 14.8 % of participants
screened positive for depression and 24.6 % of participants screened
positive for anxiety. We were able to determine 7 factors which correlated
with current depression status along with 7 factors which correlated with
anxiety status. The only two factors which were statistically significant
for both a positive depression and anxiety screen were the historical
questions assessing if there was a personal history of a mental health
disorder. This study supports the idea that a mental health history assess-
ment is an extension of the risk assessment which is already performed
within the prenatal counseling session. We believe GCs have the proper
counseling and risk assessment skills to be particularly useful identifying
these patients. As the roles of genetic counselors expand, we recognize
that mental health disorders will continue to be a part of genetic counsel-
ing sessions. With the information gleaned from this study, we have
supported the idea that there is value to assessing mental health in preg-
nancy, and that GCs have a particularly unique opportunity to become
part of an interdisciplinary team to better assess and assist our patients.
Next-Generation Panel Testing for Neuromuscular Disorders Gives
a High Diagnostic Yield in a Clinic-Based Population
J. Roggenbuck1, A. Puski2, S. Iyadurai1, J. Kissel1
1. Ohio State University Medical Center
2. Ohio State University
The genetic diagnosis of neuromuscular disorders has long been a signif-
icant clinical challenge. The high genetic heterogeneity and phenotypic
overlap between disorders make molecular confirmation laborious and
expensive. Published diagnostic algorithms to guide genetic evaluation
are complex, involve multiple testing steps, and may involve invasive
procedures such as muscle biopsy. Patients and clinicians often elect to
stop testing before a genetic diagnosis is acheived. The advent of next-
generation sequencing (NGS) technology has reduced the price of DNA
sequencing to such an extent that it is no longer necessary to priorize
individual genes for testing. In the last year, several commerical NGS
multigene panels for neuromuscular disorders have become available.
The application of such panels has the potential to revolutionize the ge-
netic diagnosis of patients with neuromuscular disorders.
We present our experience to date with the use of NGS multigene panel
testing for neuromuscular disorders in a clinic-based population. Of 26
total NGS neuromuscular panels sent, 14 (53.8 %) were positive for a
genetic diagnosis, 10 (38.5%) reported variants of uncertain significance,
and 2 (7.7 %) were negative. The positive diagnostic yield was found to
vary widely depending on the specific test indication: genetic diagnosis
was achieved in 7/12 (46 %) cases of limb-girdle muscular dystrophy, 6/7
(86 %) cases of non-dystrophic myotonia, 0/2 (0 %) cases of ‘other
myopathy’, 0/3 cases of cramping/pain syndromes, and 1/2 cases of other
neuromuscular disorders. The high frequency of variants of uncertain
significance encountered in this testing complicated test interpretation
and was frustrating to patients and clinicians. We will present our ap-
proach to variant interpretation and use specific case examples to illustrate
both the power and limitations of this new technology.
Clinical Experiences with a PCDH19-Related Epilepsy Cohort
L. Smith1, B. Rosen Sheidley1, H. Olson1,2, A. Poduri1,2
1. Epilepsy Genetics Program, Department of Neurology, Boston Chil-
dren’s Hospital
2. Neurogenetics Program, Department of Neurology, Boston Children’s
Hospital
Mutations in the PCDH19 gene cause PCDH19-Related Epilepsy, a rel-
atively newly recognized disorder characterized by early-onset epilepsy,
intellectual disability, developmental delay and autism spectrum disorder.
PCDH19 is located on Xp22.1, yet there appears to be a unique sex-
limited pattern of expression in which girls manifest the phenotype while
carrier males do not. Until recently, mutations had been documented as
either de novo or transmitted from unaffected fathers to affected daugh-
ters. In the Epilepsy Genetics Program at Boston Children’s Hospital, we
follow 11 girls with variants in the PCDH19 gene, 4 of whom have
atypical presentations that present diagnostic and counseling challenges.
In this series, we report on cases in which predicted pathogenic variants
have been transmitted from seemingly unaffected mothers to affected
daughters. Since inheritance patterns are often utilized to assist in deter-
mining pathogenicity of novel variants, such findings complicate
PCDH19 variant interpretation. We also report on patients with de novo,
predicted pathogenic variants whose features are not entirely consistent
with the PCDH19 phenotype. These scenarios present diagnostic chal-
lenges and may lead to variant misinterpretation by clinicians and fami-
lies. Particularly concerning are situations in which variant re-analysis
leads to re-classification. We report on one family of a girl with a
PCDH19 variant initially reported as likely-pathogenic, who started a
support organization to fund research into PCDH19-Related Epilepsy.
The laboratory later re-classified the variant as benign, thus leading to
both retraction of the diagnosis for the patient and the loss of community
identity for the family. Our cohort of females with PCDH19 variants
suggests that there is still much to be learned about both the phenotype
and transmission pattern of this unusual X-linked condition. A PCDH19
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patient registry and functional studies are currently underway to address
these gaps in knowledge.
Yield of Clinical Genetic Testing for Amyotrophic Lateral
Sclerosis-Associated Mutations in a Tertiary Care ALS Clinic
J. Roggenbuck1, K. Wagner1, A. Puski1, S. Iyadurai1, J. Kissel1, S.
Kolb1
1. Ohio State University Medical Center
The practice of genetic testing and genetic counseling for amyotrophic
lateral sclerosis (ALS) has been transformed in recent years with the
identification of novel genes including C9orf72, the recognition of the
etiologic link between ALS and frontotemporal dementia (FTD), and the
advent of next generation sequencing technology. Little information is
available on the yield of genetic testing in clinic-based ALS populations.
We report testing outcomes of our first year of a clinic-based ALS genetic
testing program. ALS genetic testing was offered to patients with 1)
familial ALS 2) a combined ALS/FTD phenotype 3) ALS with onset
<50 years old 4) ALS who requested genetic testing and 5) asymptomatic
family members at 50 % genetic risk. Twenty-nine (29) persons had
genetic testing, including 27 ALS patients and 2 asymptomatic family
members at 50 % risk. Six (6) ALS patients had C9orf72 testing only and
21 had multigene panel testing. Genetic testing was positive in 7/27
(25.9 %) of ALS cases, negative in 15/27 (55.6 %) of ALS cases, and
identified variants of uncertain significance in 5/27 (18.5 %) of ALS
cases. Among patients with familial ALS, 7/11 (63.6 %) tested positive,
2/11 (18.2 %) were found to have a variant of uncertain significance on
panel testing, and 2/11 (18.2 %) tested negative on panel testing. No
patients in the other testing categories tested positive; one patient with
an ALS/FTD phenotype was found to a have an intermediate C9orf72
repeat expansion of uncertain significance. Of patients identified with
mutations, 4/7 (57.1 %) had pathogenic expansions in C9orf72, and 1/7
had mutations each in SOD1, FUS, and ERBB4. Our early data concur
with published literature reporting that ALS mutations are found in two-
thirds of familial cases. We advocate offering C9orf72 testing to all pa-
tients with ALS, with reflex to panel testing for patients with a positive
family history.
Understanding Psychiatrists’ Preceptions Surrounding Psychiatric
Genetics and Genetic Counseling Services
H. White1, C. Thompson1, J. Youngblom1, E. Leach2, J. Kianmahd3,
J. Austin2
1. California State University-Stanislaus
2. University of British Columbia-Vancouver
3. University of California-Los Angeles
Background: Shortly after the first specialty psychiatric genetic counsel-
ing (PGC) service began in Vancouver, Canada in 2012, a private PGC
practice launched in San Francisco, CA. Though clear benefits of PGC
have been demonstrated, including increases in empowerment and self-
efficacy among individuals with mental illness, the majority of psychia-
trists were not referring patients to the private PGC practice in San
Francisco. Until now, no literature has focused on psychiatrist perceptions
of PGC services. Methods: Ten physicians recruited from a pool of 41
eligible psychiatrists in the San Francisco area participated in the study. A
qualitative study was conducted involving semi-structured telephone in-
terviews with the psychiatrists, in which their perceptions and beliefs
regarding potential challenges and benefits of PGC services for individ-
uals with mental illness were explored. Results: Analysis of interview
transcripts revealed conceptual and practical barriers that obstructed psy-
chiatrists from making referrals to the private practice PGC clinic, which
were classified into themes related to: 1) perceptions of PGC as focused
almost exclusively on discussing information related to genetics and re-
currence risk; 2) effects of the relative absence of trusting relationships
between psychiatrists and genetic counselors; and 3) the need for psychi-
atrist education to clear existing misperceptions surrounding PGC. Con-
clusion: The conceptual and practical barriers identified in this study that
obstruct psychiatrists from making referrals to PGC services provide
enlightening, novel information for development of mitigating strategies
that could be used in the San Francisco practice. These results also inform
referral generation strategies for other genetic counselors who may be
interested in setting up similar private practices.
XII. Public Health
Public Opinion of Newborn Screening for Disorders with Various
Treatment and Intervention Options
M. Bunnell1, C. Wicklund2, B. Tarini3, M. Petros4, A. Goldenberg5,
A. Arjunan6
1. Northwestern University Medical School Graduate Program in Genet-
ic Counseling
2. Northwestern University
3. University of Michigan
4. University of Illinois at Chicago
5. Case Western Reserve University
6. Ann & Robert H. Lurie Children’s Hospital of Chicago
Newborn screening (NBS) is a public health program that identifies new-
bornswith rare genetic disorders for whom early intervention or treatment
can be beneficial. As the ability to screen for new disorders through NBS
expands, attention must be paid to the characteristics of these disorders
and how the framing of treatability influences stakeholder perceptions of
the benefits of screening. This study aimed to better understand public
opinions of the benefits of screening for certain types of disorders and
how key terminology might impact these opinions. 5,840 participants in
the NUgene biobank population were electronically surveyed. For the
aims of this study, we developed and assessed twelve vignettes that de-
scribed a disorder and associated characteristics such as treatability, like-
lihood of improved outcome, and risks of intervention. For each vignette,
we randomized the use of the terms treatment and intervention between
subjects to describe potential care options for affected infants. We
assessed participants’ perceptions of the benefits of screening based upon
disorder characteristics. 555 individuals responded (response rate of
9.5 %). Participant ratings of benefit and importance were not influenced
by the use of the term treatment versus intervention. Participants were
most likely to perceive benefit in testing for a disorder if a treatment or
intervention offered a guaranteed improved outcome. Participants rated
little benefit in testing for a disorder if the treatment or intervention was
risky and promised only a minimal increase in lifespan. Females were
more likely to perceive screening benefits, as were participants with a
child with a chronic illness or disability (Mann–Whitney U test,
p<0.05). While participants perceived benefit in screening for most dis-
orders, nuances in inter-vignette ratings suggest that participants distin-
guished between disorder characteristics. These results are an important
addition to NBS policy decision-making, as they demonstrate a lack of
consensus about screening benefits in expanded disorder scenarios.
Development of Sickle Cell Trait Notification Process of Newborn
Screening Results: A Community Needs Assessment
M. Dreon1, J. Tarnowski1, N. Silva1, P. Constant1, M. McCann1
1. Minnesota Department of Health Newborn Screening Program
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In 1988, Minnesota’s Newborn Screening (NBS) Program began screen-
ing for hemoglobinopathies (HGB). The primary purpose was to identify
newborns with sickle cell disease (SCD), but the incidental finding of this
methodology yields trait (SCT) status. No active method of notification
regarding trait status occurs in Minnesota at this time which is inconsis-
tent with current medical practices of full disclosure of results. In order to
understand community perspectives and desires regarding notification of
SCT status identified through NBS, the Minnesota Department of Health
held focus groups within at-risk communities. Focus groups addressed
the importance of parents understanding the trait status of newborns,
possible process for notification, and qualities desired in a notification
process. All participants expressed the importance of parent notification
and how the current lack of notification fails to meet community expec-
tations. Through focus groups, it became clear no single notification
process would meet all individual preferences of parents; rather, a multi-
faceted approach would best meet community expectations. Participants
articulated four key qualities important for parental acceptance of trait
results, including: knowledge base of individual providing information,
personal relationship, provision of support/resources, and timeliness of
notification. Unexpectedly, participants felt the entity providing this com-
munication does not need a medical degree, rather a depth of knowledge
on this specific topic. Lastly, focus groups identified the importance for
community-based support groups and organizational efforts to increase
awareness and education of trait within the community. In summary, SCT
notification should include the following: 1) a minimum standard notifi-
cation consisting of an approach which is multifaceted, timely, and facil-
itated by individuals with a working knowledge of HGB and counseling
theories; 2) provision of sufficient resources/support; and 3) continued
efforts to increase culturally appropriate general awareness of SCT and
NBS.
Effect of Newborn Screening Collection Methods on Concentration
of Markers for Newborn Screened Disorders
J.Harashima1, K.Hart2, R. Christensen1, N. Longo3,4,M. Pasquali3,4
1. Intermountain Healthcare
2. Utah Department of Health
3. ARUP
4. University of Utah
Objective: To evaluate if samples collected from cord blood have a higher
false positive rate than samples collected from the traditional heel stick
collection method during newborn screening. Methods: We sent out 10
surveys to Neonatal Intensive Care Unit (NICU) level III NurseManagers
working in Utah (UT). We used our survey results to identify which
NICU facilities used cord blood in 2011 as compared to 2009. We then
performed a retrospective, de-identified, cumulative statistical analysis of
18 amino acids and acylcarnitines. We used 95 % confidence Intervals to
ascertain the differences in concentrations of analytes. For our analysis on
Congenital Adrenal Hyperplasia (CAH) samples, we looked at the num-
ber of abnormal first- and second-tier CAH testing in UT, age of collec-
tion for all CAH samples, overall distribution of age of collection, and
individual age of collection for each NICU. To evaluate if differences
between the ages of collection for CAH samples were significant, we
used an analysis of variance test. Results: Neonatal Intensive Care Unit
1 (NICU1) is the only facility to fully implement the use of cord blood in
2011. 95% confidence interval revealed no significant differences among
the 18 amino acids and acylcarnitines. Our CAH results revealed that
NICU1 had the highest increase in false positive results from 3 in 2009
to 39 in 2011. Conclusions: Results from the study indicate that the cord
blood collection method affects Congenital Adrenal Hyperplasia new-
born screening results by resulting it a higher false positive rate. In con-
trast, cord blood does not seem to have the same impact on amino acids
and acylcarnitines of samples collected at <1 day of age.
Who Utilizes Genetic Counseling After Direct-to-Consumer Genetic
Testing?
D. Koeller1,4, W. Uhlmann1,4, R. Green2,4, S. Roberts3,4
1. University of Michigan
2. Brigham and Women’s Hospital and Harvard Medical School
3. University of Michigan School of Public Health
4. PGEN Study Group
Introduction: Direct-to-consumer genetic testing (DTC-GT) results lead
some consumers to seek genetic counseling (GC), but little is known
about these consumers and why they seek services. Methods: We ana-
lyzed pre-test (baseline) and post-test (2-weeks and 6-months) data from a
longitudinal survey of new 23andMe and Pathway Genomics customers.
Chi-square and t-tests were used to evaluate differences between GC
users and non-users, and logistic regression to assess predictors of GC
use. Results: Of the 975 participants included in this analysis, 43 (4.4 %)
sought GC after testing, with 390 (40 %) reporting they would have used
GC had it been available. GC users were 65 % female, 93 % white, and
49 % college educated. GC users were significantly (p<0.05) more likely
to be younger (38 vs 46 years), to report poor general health (16 vs 3.7%),
to report prior use ofGC (37 vs 7%) and to report prior genetic testing (30
vs 14 %). GC users were significantly more likely to seek DTC-GT for
health reasons (83 vs 62 %), to report a positive family history of more
conditions (7.7 vs 6.6), and to report perceived elevated risk for more
conditions (4.3 vs 2.9) at baseline. After testing, GC users were signifi-
cantly more likely to report uncertainty about their test results (41 vs
27%) and to report an increase in mean disease risk perception compared
to baseline (2.8 % increase vs 20 % decrease). Each of these variables
remained significant predictors (p<0.05) in regression analyses except
family history, prior genetic testing, and baseline perceived risk. Conclu-
sions: DTC-GT consumers have high interest in GC, but low levels of
post-test use of services. GC users differed from the broader population of
DTC-GTconsumers in terms of age, self-reported health, prior use of GC
services, and reactions to test results. These insights can help GC pro-
viders better prepare for clinical discussions of DTC-GT results.
Stakeholder Views on Newborn Screening Using Whole Genome
Analysis
C. Young1, G. Joseph2, J. Harris-Wai2, F. Chen2, B. A. Koenig2
1. California State University, Stanislaus
2. University of California San Francisco
Due to advances in next-generation sequencing technology the human
genome can now be analyzed more quickly and at lower costs, a trend
likely to continue. With greater accessibility, opportunities to integrate
genomic information into public health and clinical care will expand.
One potential clinical application of whole genome analysis (WGA) is
newborn screening (NBS). Although studies have explored genomic
analysis in the context of direct-to-consumer testing, the translation of
WGA into the NBS setting is not well understood. The purpose of this
study was to examine key stakeholders’ views, perspectives, and values
regarding the potential expansion of NBS to include WGA. We conduct-
ed four focus groups in English (3) and Spanish (1) with socioeconomi-
cally and ethnically diverse pregnant women (n=30), and one focus group
with parents of children with immunodeficiency disorders (n=8). To elicit
preferences regarding return of results, we provided information about
case examples of pharmacogenomics and adult disorders such as hered-
itary breast and ovarian cancer. Focus groups were transcribed (and trans-
lated) verbatim, and a grounded theory approach was used to analyze the
data. Several themes emerged from the results, including: 1) preferences
for discussion of NBS with a physician during the prenatal period (for
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traditional or WGA NBS); 2) a struggle between sentiments of
Bknowledge is power^ and Bignorance is bliss^ resulting in differing
opinions about what WGA results participants would like returned (all
results, medically actionable, adult onset, or pharmacogenomics); 3) a
desire to storeWGA results for potential later use, with some reservations
due to potential of privacy violations, and unwanted uses by researchers,
the government or insurance companies; 4) preference for opt-in consent
rather than opt-out for NBS if WGA is implemented. These results show
that parents and pregnant women would like to be included in the NBS
process, with implications for policy development should NBS be con-
ducted with WGA.
Research Issues
Exploring the Process of Decision-Making About Participation
in Genetic Research on Mental Illness
H. Andrighetti1, A. Semaka1, J. Austin1
1. University of British Columbia
Introduction: There are several barriers to recruitment for research on
mental illness (MI), including distrust of researchers and social stigma.
Among individuals who do participate in MI research, little is known
about how and why they decide to participate. This study explored the
process of decision-making around participation in genetic research on
MI, including motivating factors and perceived benefits of participation,
and expectations regarding return of genetic research results. Methods:
This qualitative study utilized grounded theory methodology. Open-
ended interviews were conducted with 16 individuals who had either
completed participation or had recently made a decision about participa-
tion in a genetic research study on MI led by genetic counselors. Inter-
views were transcribed and analyzed using the constant comparative
method and open, axial, and theoretical coding procedures. Results: Ill-
ness acceptance and establishment of trust with the research team and
institution were foundational elements required for individuals to consid-
er participating in genetic research on MI. Main motivators for participa-
tion included perceived personal relevance, anticipated benefits, a desire
to Bgive back^, and accessible study procedures. Perceived benefits of
research participation included access to support and resources via the
research team, the opportunity to learn, and improved self-worth. Return
of personal genetic research results did not appear to be a major factor in
the decision-making process regarding participation. Conclusion: Our
data suggest that participation in genetic research on MI helps make
meaning of individuals’ illness experience and empowers them to adopt
positive health management strategies. Our results support the value of
genetic counselors in research. Genetic counselors possess a unique skill
set that enables them to build trusting relationships that facilitate recruit-
ment and retention of participants. These findings may inform strategies
that improve participation rates, decrease attrition, and maximize partic-
ipant benefits.
Expectations of False Reassurance in a Genetic Sequencing Cohort
K. Lewis1, P. Han2, L. Biesecker1, B. Biesecker1
1. National Institutes of Health
2. Maine Medical Center Research Institute
Absent, negative or uncertain genetic testing results may lead patients to
be falsely reassured about their disease risks, which may affect their
subsequent adherence to recommended screening practices. Studies of
single gene and direct-to-consumer genetic testing have found that false
reassurance occurs but does not lead to inaccurate risk perceptions or
inappropriate screening. However, genetic sequencing differs from pre-
vious genetic testing in its breadth and potential for generating uncertain
results, making it important to assess false reassurance in this context.
This study was designed to determine the magnitude and correlates of
expectations of false reassurance among 151 participants in a genome
sequencing study. Participants completed a survey assessing their expec-
tations of false reassurance and knowledge of genome sequencing. Sur-
vey respondents were 59 years old on average and the majority had a
college degree or beyond (71 %). Roughly half of the participants were
male (62 %) and non-Hispanic African Americans (49 %). Overall, only
17 % of respondents expected some false reassurance. Lower expecta-
tions of false reassurance were significantly correlated with less knowl-
edge about genome sequencing (R=−0.3926, p<0.01) and having less
than a college degree (X2 = 7.16, p=0.03). Our data suggest the impor-
tance of emphasizing the potential for false reassurance in sequencing
during the consent process, particularly when counseling participants
with less formal education. Further research is necessary to determine
whether expectations of false reassurance affect downstream outcomes,
such as adoption of recommended health behaviors, decisions to learn
results from sequencing and satisfaction with study participation.
Returning Genomic Research Results to Biobank Participants
E. Winkler1, T. Kruisselbrink1, J. Olson1, J. Cerhan1, S. Thibodeau1
1. Mayo Clinic
As highlighted by the recent announcement of the National Insti-
tutes of Health’s Precision Medicine Initiative and the call for a 1
million participant national cohort, biobanks play an important role
in genomic research to understand the biology of disease. Over
time, biobanks store and curate information on participants and have
the capacity to generate large amounts of genomic data. Some of
these data may have important health implications for participants,
raising the need to address return of results. Several recommenda-
tions have suggested researchers and biobanks have a minimum
obligation to return research results that may be clinically actionable
for participants. The Mayo Clinic Biobank is a large clinic-based
biobank of 50,000 participants recruited irrespective of disease sta-
tus and who provide health information and samples including
blood and blood derivatives. As many participants continue to re-
ceive some, if not all, of their health care at Mayo Clinic, the
Biobank has opted to return genomic research results that are: 1)
analytically valid (test methodology is valid and can be replicated);
2) clinically valid (associated risks are established and substantial
with high penetrance); and 3) clinically actionable (established ther-
apeutic or preventive interventions or other actions that may change
the clinical course of the disease are available). We will review our
process for determining which genomic research results meet the
criteria listed above. Additionally, we will describe how genetic
counselors have been utilized to return genomic research results to
biobank participants. Our experiences add a tangible example of
how a large, non-disease-focused biobank manages research results,
which may be useful for other researchers and biobanks as they
develop policies. As biobank research continues to expand, it is
important for genetic counselors to contribute to these conversations
about which results are returned, how to implement the return, and
how to facilitate necessary clinical follow up of genomic results
generated in a biobank setting.
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